Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,29905619,AUC0-12h,"The median values of AUC0-12h were 43.98 and 41.95 mcg·h/mL for MMF capsule and MMF dispersible tablet, respectively.",Pharmacokinetic Comparison of Two Mycophenolate Mofetil Formulations in Kidney Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905619/),[h·mcg] / [ml],43.98,1262,DB00864,Tacrolimus
,29905619,AUC0-12h,"The median values of AUC0-12h were 43.98 and 41.95 mcg·h/mL for MMF capsule and MMF dispersible tablet, respectively.",Pharmacokinetic Comparison of Two Mycophenolate Mofetil Formulations in Kidney Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905619/),[h·mcg] / [ml],41.95,1263,DB00864,Tacrolimus
>,18459999,trough,"The incidence of early, acute rejection episodes was higher for recipients who were younger, received a graft from an unrelated donor or failed to achieve adequate tacrolimus concentrations (trough > 10 ng/mL) in the first seven d after transplant.",Combination therapy with tacrolimus and mycophenolate mofetil: effects of early and late minimization of mycophenolate mofetil after renal transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18459999/),[ng] / [ml],10,1322,DB00864,Tacrolimus
,25707517,oral clearance,"Typical mean value of MPA oral clearance, estimated by base model (without covariates) was 0.741 L h(-1).",Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25707517/),[l] / [h],0.741,1786,DB00864,Tacrolimus
,21632965,oral clearance,"The predicted oral clearance values of the drugs investigated ranged from 8.79 to 6320 l/h for tacrolimus and simvastatin, respectively, and were overall within 3-fold of the observed data with the exception of indinavir, atorvastatin, and buspirone.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),[l] / [h],8.79 to 6320,1970,DB00864,Tacrolimus
,21632965,CLu(int),"The individual HJM CLu(int) values ranged from 17 to 14,000 μl · min(-1) · mg(-1) for atorvastatin and saquinavir, respectively, and corresponding interindividual variability in CLu(int) estimates ranged from 41 to 67%.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),[μl] / [mg·min],"17 to 14,000",1971,DB00864,Tacrolimus
,21632965,F(G),"These in vitro data resulted in predicted F(G) values ranging from 0.03 to 0.94 for simvastatin and indinavir, respectively.",Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21632965/),,0,1972,DB00864,Tacrolimus
,21910052,area under the concentration-time curve,"The area under the concentration-time curve, the time of maximum concentration, and the maximum concentration were 43.4 ng·h/mL, 0.85 h, and 8.1 ng/mL, respectively, similar to those of FK506.",Effects of water-soluble tacrolimus-PEG conjugate on insulin-dependent diabetes mellitus and systemic lupus erythematosus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21910052/),[h·ng] / [ml],43.4,2393,DB00864,Tacrolimus
,21910052,time of maximum concentration,"The area under the concentration-time curve, the time of maximum concentration, and the maximum concentration were 43.4 ng·h/mL, 0.85 h, and 8.1 ng/mL, respectively, similar to those of FK506.",Effects of water-soluble tacrolimus-PEG conjugate on insulin-dependent diabetes mellitus and systemic lupus erythematosus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21910052/),h,0.85,2394,DB00864,Tacrolimus
,21910052,maximum concentration,"The area under the concentration-time curve, the time of maximum concentration, and the maximum concentration were 43.4 ng·h/mL, 0.85 h, and 8.1 ng/mL, respectively, similar to those of FK506.",Effects of water-soluble tacrolimus-PEG conjugate on insulin-dependent diabetes mellitus and systemic lupus erythematosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21910052/),[ng] / [ml],8.1,2395,DB00864,Tacrolimus
,32858576,flow rate,"PBMCs were isolated from the whole blood of 27 Chinese renal transplant patients using Ficoll-Paque Plus solution, and cell number was determined; acetonitrile treatment for protein precipitation, and gradient elution was performed on an Agilent Eclipse XDB-C18 column (3.5 μm, 2.1 × 100 mm) with mobile phase: water and methanol (containing 2 mM ammonium formate); flow rate: 0.3 mL·min.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),min·ml,0.3,3532,DB00864,Tacrolimus
,32858576,extraction effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,70.4,3533,DB00864,Tacrolimus
,32858576,matrix effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,93,3534,DB00864,Tacrolimus
,32858576,matrix effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,72.7,3535,DB00864,Tacrolimus
,32858576,matrix effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,90.1,3536,DB00864,Tacrolimus
,32858576,relative recovery,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,90.1,3537,DB00864,Tacrolimus
,16762205,T(max),T(max) and C(max) in eye drops were (1.25 +/- 0.50) h and (15.52 +/- 2.37) ng/ml respectively; while T(max) and C(max) in subconjunctiva injection were (64.00 +/- 13.86) h and (10.16 +/- 1.37) ng/ml respectively.,[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),h,1.25,3637,DB00864,Tacrolimus
,16762205,C(max),T(max) and C(max) in eye drops were (1.25 +/- 0.50) h and (15.52 +/- 2.37) ng/ml respectively; while T(max) and C(max) in subconjunctiva injection were (64.00 +/- 13.86) h and (10.16 +/- 1.37) ng/ml respectively.,[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),[ng] / [ml],15.52,3638,DB00864,Tacrolimus
,16762205,T(max),T(max) and C(max) in eye drops were (1.25 +/- 0.50) h and (15.52 +/- 2.37) ng/ml respectively; while T(max) and C(max) in subconjunctiva injection were (64.00 +/- 13.86) h and (10.16 +/- 1.37) ng/ml respectively.,[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),h,64.00,3639,DB00864,Tacrolimus
,16762205,C(max),T(max) and C(max) in eye drops were (1.25 +/- 0.50) h and (15.52 +/- 2.37) ng/ml respectively; while T(max) and C(max) in subconjunctiva injection were (64.00 +/- 13.86) h and (10.16 +/- 1.37) ng/ml respectively.,[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),[ng] / [ml],10.16,3640,DB00864,Tacrolimus
,16762205,AUC(0-->t),Each AUC(0-->t) was (152.44 +/- 16.74) ng.ml(-1).,[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),[ng] / [ml],152.44,3641,DB00864,Tacrolimus
,16762205,Ka,h(-1) respectively; each Ka was 3.790 +/- 0.730 and 0.040 +/- 0.004 respectively; and each MRT was (8.20 +/- 1.28) h and (58.53 +/- 5.42) h respectively.,[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),,3.790,3642,DB00864,Tacrolimus
,16762205,Ka,h(-1) respectively; each Ka was 3.790 +/- 0.730 and 0.040 +/- 0.004 respectively; and each MRT was (8.20 +/- 1.28) h and (58.53 +/- 5.42) h respectively.,[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),,0.040,3643,DB00864,Tacrolimus
,16762205,MRT,h(-1) respectively; each Ka was 3.790 +/- 0.730 and 0.040 +/- 0.004 respectively; and each MRT was (8.20 +/- 1.28) h and (58.53 +/- 5.42) h respectively.,[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),h,8.20,3644,DB00864,Tacrolimus
,16762205,MRT,h(-1) respectively; each Ka was 3.790 +/- 0.730 and 0.040 +/- 0.004 respectively; and each MRT was (8.20 +/- 1.28) h and (58.53 +/- 5.42) h respectively.,[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),h,58.53,3645,DB00864,Tacrolimus
,16762205,T(max),"T(max) was 1 h and C(max) was (18.93 +/- 6.95) ng/ml in 20 microg FK506, while in 40 microg FK506 T(max) was 2h and C(max) was (28.33 +/- 1.31) ng/ml.",[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),h,1,3646,DB00864,Tacrolimus
,16762205,C(max),"T(max) was 1 h and C(max) was (18.93 +/- 6.95) ng/ml in 20 microg FK506, while in 40 microg FK506 T(max) was 2h and C(max) was (28.33 +/- 1.31) ng/ml.",[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),[ng] / [ml],18.93,3647,DB00864,Tacrolimus
,16762205,T(max),"T(max) was 1 h and C(max) was (18.93 +/- 6.95) ng/ml in 20 microg FK506, while in 40 microg FK506 T(max) was 2h and C(max) was (28.33 +/- 1.31) ng/ml.",[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),h,2,3648,DB00864,Tacrolimus
,16762205,C(max),"T(max) was 1 h and C(max) was (18.93 +/- 6.95) ng/ml in 20 microg FK506, while in 40 microg FK506 T(max) was 2h and C(max) was (28.33 +/- 1.31) ng/ml.",[The pharmacokinetics of FK506 and its nanoparticles in aqueous humor of rabbits]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16762205/),[ng] / [ml],28.33,3649,DB00864,Tacrolimus
,16430311,first-order absorption rate constant (k(a)),"For the whole blood population model, the population estimates of the first-order absorption rate constant (k(a)), apparent clearance based on whole blood concentration after oral administration (CL(B)/F) and apparent volume of distribution based on whole blood concentrations after oral administration (V(d,B)/F) were 2.08h(-1), 14.1 L/h and 217L, respectively.",Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430311/),1/[h],2.08,3797,DB00864,Tacrolimus
,16430311,apparent clearance,"For the whole blood population model, the population estimates of the first-order absorption rate constant (k(a)), apparent clearance based on whole blood concentration after oral administration (CL(B)/F) and apparent volume of distribution based on whole blood concentrations after oral administration (V(d,B)/F) were 2.08h(-1), 14.1 L/h and 217L, respectively.",Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430311/),[l] / [h],14.1,3798,DB00864,Tacrolimus
,16430311,apparent volume of distribution based on,"For the whole blood population model, the population estimates of the first-order absorption rate constant (k(a)), apparent clearance based on whole blood concentration after oral administration (CL(B)/F) and apparent volume of distribution based on whole blood concentrations after oral administration (V(d,B)/F) were 2.08h(-1), 14.1 L/h and 217L, respectively.",Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430311/),[l] / [h],14.1,3799,DB00864,Tacrolimus
,16430311,k(a),"For the plasma population model, the population estimates of the k(a), apparent clearance based on plasma concentrations after oral administration (CL(P)/F) and apparent volume of distribution based on plasma concentrations after oral administration (V(d,P)/F) were 5.21h(-1), 537 L/h and 563L, respectively.",Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430311/),1/[h],5.21,3800,DB00864,Tacrolimus
,16430311,apparent clearance,"For the plasma population model, the population estimates of the k(a), apparent clearance based on plasma concentrations after oral administration (CL(P)/F) and apparent volume of distribution based on plasma concentrations after oral administration (V(d,P)/F) were 5.21h(-1), 537 L/h and 563L, respectively.",Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430311/),1/[h],5.21,3801,DB00864,Tacrolimus
,16430311,apparent clearance,"For the plasma population model, the population estimates of the k(a), apparent clearance based on plasma concentrations after oral administration (CL(P)/F) and apparent volume of distribution based on plasma concentrations after oral administration (V(d,P)/F) were 5.21h(-1), 537 L/h and 563L, respectively.",Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430311/),[l] / [h],537,3802,DB00864,Tacrolimus
,16430311,CL(P)/F,"For the plasma population model, the population estimates of the k(a), apparent clearance based on plasma concentrations after oral administration (CL(P)/F) and apparent volume of distribution based on plasma concentrations after oral administration (V(d,P)/F) were 5.21h(-1), 537 L/h and 563L, respectively.",Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430311/),[l] / [h],537,3803,DB00864,Tacrolimus
,16430311,apparent volume of distribution based,"For the plasma population model, the population estimates of the k(a), apparent clearance based on plasma concentrations after oral administration (CL(P)/F) and apparent volume of distribution based on plasma concentrations after oral administration (V(d,P)/F) were 5.21h(-1), 537 L/h and 563L, respectively.",Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430311/),[l] / [h],537,3804,DB00864,Tacrolimus
,16430311,"V(d,P)/F","For the plasma population model, the population estimates of the k(a), apparent clearance based on plasma concentrations after oral administration (CL(P)/F) and apparent volume of distribution based on plasma concentrations after oral administration (V(d,P)/F) were 5.21h(-1), 537 L/h and 563L, respectively.",Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16430311/),l,563,3805,DB00864,Tacrolimus
,7535213,maximum blood/plasma ratio,The maximum blood/plasma ratio of tacrolimus was 55.5 +/- 26.8 (SD) and half-life averaged 12.1 +/- 4.7 hours.,Pharmacokinetics of tacrolimus in liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7535213/),,55.5,4123,DB00864,Tacrolimus
,7535213,half-life,The maximum blood/plasma ratio of tacrolimus was 55.5 +/- 26.8 (SD) and half-life averaged 12.1 +/- 4.7 hours.,Pharmacokinetics of tacrolimus in liver transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7535213/),h,12.1,4124,DB00864,Tacrolimus
,7535213,CL,"The CL and V were relatively high based on plasma concentrations (CL, 1.7 L/hr/kg; V, 30 L/kg) and low based on whole blood (CL, 54 ml/hr/kg; V, 0.9 L/kg), with moderate variability (coefficient of variation, 34% to 49%) among the patients.",Pharmacokinetics of tacrolimus in liver transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7535213/),[l] / [h·kg],1.7,4125,DB00864,Tacrolimus
,7535213,V,"The CL and V were relatively high based on plasma concentrations (CL, 1.7 L/hr/kg; V, 30 L/kg) and low based on whole blood (CL, 54 ml/hr/kg; V, 0.9 L/kg), with moderate variability (coefficient of variation, 34% to 49%) among the patients.",Pharmacokinetics of tacrolimus in liver transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7535213/),[l] / [kg],30,4126,DB00864,Tacrolimus
,7535213,CL,"The CL and V were relatively high based on plasma concentrations (CL, 1.7 L/hr/kg; V, 30 L/kg) and low based on whole blood (CL, 54 ml/hr/kg; V, 0.9 L/kg), with moderate variability (coefficient of variation, 34% to 49%) among the patients.",Pharmacokinetics of tacrolimus in liver transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7535213/),[ml] / [h·kg],54,4127,DB00864,Tacrolimus
,7535213,V,"The CL and V were relatively high based on plasma concentrations (CL, 1.7 L/hr/kg; V, 30 L/kg) and low based on whole blood (CL, 54 ml/hr/kg; V, 0.9 L/kg), with moderate variability (coefficient of variation, 34% to 49%) among the patients.",Pharmacokinetics of tacrolimus in liver transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7535213/),[l] / [kg],0.9,4128,DB00864,Tacrolimus
,7535213,maximum blood/plasma ratios,Correlations of plasma CL and V with maximum blood/plasma ratios (ranging from 13 to 114) were strong (r = 0.65 and r = 0.73).,Pharmacokinetics of tacrolimus in liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7535213/),,13 to 114,4129,DB00864,Tacrolimus
,7535213,absorption lag time (tlag,"The oral dose data for tacrolimus yielded a brief absorption lag time (tlag, 0.39 hour), a variable first-order absorption rate constant (ka, 4.5 +/- 3.0 hr-1), and consistent bioavailability (F, 25% +/- 10%).",Pharmacokinetics of tacrolimus in liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7535213/),h,0.39,4130,DB00864,Tacrolimus
,7535213,first-order absorption rate constant (ka,"The oral dose data for tacrolimus yielded a brief absorption lag time (tlag, 0.39 hour), a variable first-order absorption rate constant (ka, 4.5 +/- 3.0 hr-1), and consistent bioavailability (F, 25% +/- 10%).",Pharmacokinetics of tacrolimus in liver transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7535213/),1/[h],4.5,4131,DB00864,Tacrolimus
,7535213,bioavailability (F,"The oral dose data for tacrolimus yielded a brief absorption lag time (tlag, 0.39 hour), a variable first-order absorption rate constant (ka, 4.5 +/- 3.0 hr-1), and consistent bioavailability (F, 25% +/- 10%).",Pharmacokinetics of tacrolimus in liver transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7535213/),%,25,4132,DB00864,Tacrolimus
>,29033547,f2,The f2 values were >50 in all media.,New tablet formulation of tacrolimus with smaller interindividual variability may become a better treatment option than the conventional capsule formulation in organ transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29033547/),,50,4289,DB00864,Tacrolimus
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],46.0,5067,DB00864,Tacrolimus
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],69.0,5068,DB00864,Tacrolimus
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],25.2,5069,DB00864,Tacrolimus
,15561257,AUC,"Comparing the AUC per milligram dose, there was no significant difference between PK-1 and PK-S among TAC (46.0 +/- 24.3 ng x h/mg x mL versus 69.0 +/- 43.9 ng x h/mg x mL, P = .15 by paired t-test), but a significant difference in CsA (25.2 +/- 11.4 ng x h/mg x mL versus 45.4 +/- 12.9 ng x h/mg x mL, P = .0005 by paired t-test).",Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561257/),[h·ng] / [mg·ml],45.4,5070,DB00864,Tacrolimus
,22423577,oral bioavailability,"The oral bioavailability of tacrolimus averages 20% to 25%; however, the inter-individual variability in this parameter is large.","Relationship among changes in hematocrit, albumin and corticosteroid dose on the disposition of tacrolimus during the first six months following renal transplantation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22423577/),%,20,5435,DB00864,Tacrolimus
,22423577,oral bioavailability,"The oral bioavailability of tacrolimus averages 20% to 25%; however, the inter-individual variability in this parameter is large.","Relationship among changes in hematocrit, albumin and corticosteroid dose on the disposition of tacrolimus during the first six months following renal transplantation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22423577/),%,25,5436,DB00864,Tacrolimus
,15996252,trough level,"TAC was given at 0.14+/-0.09 mg/kg/day, resulting in a trough level of 6.3+/-2.5 ng/mL.",Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15996252/),[ng] / [ml],6.3,5583,DB00864,Tacrolimus
,25587129,dose,"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),[ml·ng] / [kg·mg],56.2,6643,DB00864,Tacrolimus
,25587129,trough concentration (C0/D),"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),[ml·ng] / [kg·mg],56.2,6644,DB00864,Tacrolimus
,25587129,trough concentration (C0/D),"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),[ml·ng] / [kg·mg],76.7,6645,DB00864,Tacrolimus
,25587129,C0/D,"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),[ml·ng] / [kg·mg],51.2,6646,DB00864,Tacrolimus
,25587129,C0/D,"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),[ml·ng] / [kg·mg],76.3,6647,DB00864,Tacrolimus
,25587129,C0/D,"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),,61.3,6648,DB00864,Tacrolimus
,25587129,C0/D,"Among the CYP3A5 expressers, the dose-adjusted trough concentration (C0/D) of tacrolimus in HSD11B1 rs846908 AA homozygous individuals was considerably lower than found in GG+GA carriers [56.2 (23.9-86.6) versus 76.7 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0204]; HSD11B1 rs846910 AA homozygotes had a lower tacrolimus C0/D compared with GG+GA carriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367]; carriers with the HSD11B1 rs4844880 AA genotype had a significantly lower tacrolimus C0/D with respect to carriers of TT+TA genotypes [61.3 (23.9-97.5) versus 77.2 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0002]; the HSD11B1 AA-AA-AA haplotype carriers had a lower tacrolimus C0/D than noncarriers [51.2 (23.9-86.6) versus 76.3 (12.6-220.0) (ng/ml)/(mg/kg), P = 0.0367].",Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25587129/),,77.2,6649,DB00864,Tacrolimus
,14621866,trough level,"In conclusion, the therapeutic dose of FK 506 should be adjusted by monitoring the trough level in whole blood, the range of which might be recommended to be 15-20 ng/ml during the early phase after transplantation.",Japanese study of kidney transplantation: 1. Results of early phase II study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14621866/),[ng] / [ml],15-20,8112,DB00864,Tacrolimus
,33786892,clearance,"The population PK parameters were as follows: clearance, 3.27 L/h; intercompartmental clearance, 9.6 L/h; volume of distribution of compartments 1 and 2, 95 and 500 L, respectively.",Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33786892/),[l] / [h],3.27,8529,DB00864,Tacrolimus
,33786892,intercompartmental clearance,"The population PK parameters were as follows: clearance, 3.27 L/h; intercompartmental clearance, 9.6 L/h; volume of distribution of compartments 1 and 2, 95 and 500 L, respectively.",Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33786892/),[l] / [h],9.6,8530,DB00864,Tacrolimus
,33786892,volume of distribution of compartments,"The population PK parameters were as follows: clearance, 3.27 L/h; intercompartmental clearance, 9.6 L/h; volume of distribution of compartments 1 and 2, 95 and 500 L, respectively.",Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33786892/),l,1,8531,DB00864,Tacrolimus
,33786892,volume of distribution of compartments,"The population PK parameters were as follows: clearance, 3.27 L/h; intercompartmental clearance, 9.6 L/h; volume of distribution of compartments 1 and 2, 95 and 500 L, respectively.",Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33786892/),l,2,8532,DB00864,Tacrolimus
,33786892,volume of distribution of compartments,"The population PK parameters were as follows: clearance, 3.27 L/h; intercompartmental clearance, 9.6 L/h; volume of distribution of compartments 1 and 2, 95 and 500 L, respectively.",Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33786892/),l,95,8533,DB00864,Tacrolimus
,33786892,volume of distribution of compartments,"The population PK parameters were as follows: clearance, 3.27 L/h; intercompartmental clearance, 9.6 L/h; volume of distribution of compartments 1 and 2, 95 and 500 L, respectively.",Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33786892/),l,500,8534,DB00864,Tacrolimus
,12200787,time to reach the peak concentration,The time to reach the peak concentration was 1 hour in all patients.,"Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12200787/),h,1,9132,DB00864,Tacrolimus
,11214772,Km,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),mM,0.31,9164,DB00864,Tacrolimus
,11214772,Km,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),mM,0.28,9165,DB00864,Tacrolimus
,11214772,Vmax,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.2,9166,DB00864,Tacrolimus
,11214772,Vmax,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],10.5,9167,DB00864,Tacrolimus
,11214772,glucuronidation rates,The MPA glucuronidation rates (mean +/- SD; nmol/min/mg) were 3.3+/-0.9 (liver; n = 10) and 7.8+/-1.5 (kidney; n = 10; P = 0.0002).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],3.3,9168,DB00864,Tacrolimus
,11214772,glucuronidation rates,The MPA glucuronidation rates (mean +/- SD; nmol/min/mg) were 3.3+/-0.9 (liver; n = 10) and 7.8+/-1.5 (kidney; n = 10; P = 0.0002).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],7.8,9169,DB00864,Tacrolimus
,11214772,rate of,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],2.0 and 5.1,9170,DB00864,Tacrolimus
,11214772,rate of,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.7 and 9.8,9171,DB00864,Tacrolimus
,11214772,glucuronidation,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],2.0 and 5.1,9172,DB00864,Tacrolimus
,11214772,glucuronidation,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.7 and 9.8,9173,DB00864,Tacrolimus
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,8,9174,DB00864,Tacrolimus
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,19,9175,DB00864,Tacrolimus
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,63,9176,DB00864,Tacrolimus
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,109,9177,DB00864,Tacrolimus
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,8,9178,DB00864,Tacrolimus
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,13,9179,DB00864,Tacrolimus
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,49,9180,DB00864,Tacrolimus
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,122,9181,DB00864,Tacrolimus
,22329639,k(a),"k(a), estimated at 1.7 h(-1) at age 8.7 years, exhibited large interindividual variability (308%).",Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329639/),1/[h],1.7,9194,DB00864,Tacrolimus
,22329639,V/F,"V/F, estimated at 64.7 l, increased about 2.3 times in children during the immediate post transplantation period.",Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329639/),l,64.7,9195,DB00864,Tacrolimus
,22329639,CL/F,CL/F was estimated at 12.7 l h(-1).,Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329639/),[l] / [h],12.7,9196,DB00864,Tacrolimus
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[μg] / [ml],11.8,9335,DB00864,Tacrolimus
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[μg] / [ml],17.8,9336,DB00864,Tacrolimus
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[ng] / [mg·ml],22.6,9337,DB00864,Tacrolimus
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[ng] / [mg·ml],33.1,9338,DB00864,Tacrolimus
,25160518,trough levels,Tacrolimus was titrated to achieve trough levels of 8-12 ng/ml.,A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160518/),[ng] / [ml],8-12,9577,DB00864,Tacrolimus
,25160518,C0,"Mean Tac C0 was 11.0 ± 2.2 and 11.3 ± 1.8 ng/ml for Tac-ER and Tac-IR, respectively.",A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160518/),[ng] / [ml],11.0,9578,DB00864,Tacrolimus
,25160518,C0,"Mean Tac C0 was 11.0 ± 2.2 and 11.3 ± 1.8 ng/ml for Tac-ER and Tac-IR, respectively.",A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160518/),[ng] / [ml],11.3,9579,DB00864,Tacrolimus
,25160518,Effective 24 h renal plasma flow (ERPF),"The mean Effective 24 h renal plasma flow (ERPF) was significantly higher with Tac-ER compared with Tac-IR (658 ± 127 vs. 610 ± 93 ml/min/1.73 m(2) , P = 0.046).",A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160518/),[1.73·min·ml] / [m(2],658,9580,DB00864,Tacrolimus
,25160518,Effective 24 h renal plasma flow (ERPF),"The mean Effective 24 h renal plasma flow (ERPF) was significantly higher with Tac-ER compared with Tac-IR (658 ± 127 vs. 610 ± 93 ml/min/1.73 m(2) , P = 0.046).",A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25160518/),[1.73·min·ml] / [m(2],610,9581,DB00864,Tacrolimus
,17488394,apparent half-life,"The mean apparent half-life of MPA was 5.3 +/- 4.3 h, (1.0-15.7).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),h,5.3,9641,DB00864,Tacrolimus
,17488394,t(max),Mean t(max) was 2.4 +/- 1.1 h (1.0-5.0).,Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),h,2.4,9642,DB00864,Tacrolimus
,17488394,area-under-curve,The mean area-under-curve was 45.3 +/- 23.1 microg-h/mL (17.3-90.0).,Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),[μg-h] / [ml],45.3,9643,DB00864,Tacrolimus
,17488394,Trough level concentrations (C(12 h)),Trough level concentrations (C(12 h)) showed large inter-individual variability (0-9.2 microg/mL).,Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),[μg] / [ml],0-9.2,9644,DB00864,Tacrolimus
,16906020,time to reach the target concentration,Patients who do not carry both Cyp3A5*3 alleles achieved lower mean dose-adjusted tacrolimus blood concentrations (p<0.001) and needed a longer time to reach the target concentration (10-12 ng/ml; p<0.001) compared to Cyp3A5*3 homozygotes.,"Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16906020/),[ng] / [ml],10-12,9681,DB00864,Tacrolimus
,19782740,fine particle fraction (FPF),Characterization of the nebulized tacrolimus dispersion for nebulization showed a fine particle fraction (FPF) of 46.1% and a mass median aerodynamic diameter (MMAD) of 4.06 microm.,Characterization and pharmacokinetic analysis of tacrolimus dispersion for nebulization in a lung transplanted rodent model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782740/),%,46.1,10456,DB00864,Tacrolimus
,19782740,mass median aerodynamic diameter (MMAD),Characterization of the nebulized tacrolimus dispersion for nebulization showed a fine particle fraction (FPF) of 46.1% and a mass median aerodynamic diameter (MMAD) of 4.06 microm.,Characterization and pharmacokinetic analysis of tacrolimus dispersion for nebulization in a lung transplanted rodent model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782740/),μm,4.06,10457,DB00864,Tacrolimus
,19782740,peak transplanted lung concentration,"After single dose administration to transplanted and non-transplanted rats, a mean peak transplanted lung concentration of 399.8+/-29.2 ng/g and mean peak blood concentration of 4.88+/-1.6 ng/mL were achieved.",Characterization and pharmacokinetic analysis of tacrolimus dispersion for nebulization in a lung transplanted rodent model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782740/),[ng] / [g],399.8,10458,DB00864,Tacrolimus
,19782740,peak blood concentration,"After single dose administration to transplanted and non-transplanted rats, a mean peak transplanted lung concentration of 399.8+/-29.2 ng/g and mean peak blood concentration of 4.88+/-1.6 ng/mL were achieved.",Characterization and pharmacokinetic analysis of tacrolimus dispersion for nebulization in a lung transplanted rodent model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19782740/),[ng] / [ml],4.88,10459,DB00864,Tacrolimus
,31843550,size,"The mean size and zeta potential measured by dynamic light scattering were 110 ± 1.3 nm and -20.56 ± 3.65 mV, respectively.",Delivery of FK506-loaded PLGA nanoparticles prolongs cardiac allograft survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31843550/),nm,110,10473,DB00864,Tacrolimus
,31843550,zeta potential,"The mean size and zeta potential measured by dynamic light scattering were 110 ± 1.3 nm and -20.56 ± 3.65 mV, respectively.",Delivery of FK506-loaded PLGA nanoparticles prolongs cardiac allograft survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31843550/),mv,-,10474,DB00864,Tacrolimus
,31843550,zeta potential,"The mean size and zeta potential measured by dynamic light scattering were 110 ± 1.3 nm and -20.56 ± 3.65 mV, respectively.",Delivery of FK506-loaded PLGA nanoparticles prolongs cardiac allograft survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31843550/),mv,20.56,10475,DB00864,Tacrolimus
,31843550,entrapment,"The FK506 entrapment and loading efficiency were 94.46 ± 1.88% and 5.38 ± 0.24%, respectively.",Delivery of FK506-loaded PLGA nanoparticles prolongs cardiac allograft survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31843550/),%,94.46,10476,DB00864,Tacrolimus
,31843550,loading efficiency,"The FK506 entrapment and loading efficiency were 94.46 ± 1.88% and 5.38 ± 0.24%, respectively.",Delivery of FK506-loaded PLGA nanoparticles prolongs cardiac allograft survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31843550/),%,5.38,10477,DB00864,Tacrolimus
,31843550,mean,"Furthermore, the immunosuppressive efficacy was evaluated in a rat heterotopic heart transplantation model, and the results showed that PLGA-FK506-NP treatment could successfully alleviate acute rejection and prolong allograft survival compared with the free FK506 treatment (mean survival time, 17.1 ± 2.0 versus 13.3 ± 1.7 days).",Delivery of FK506-loaded PLGA nanoparticles prolongs cardiac allograft survival. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31843550/),d,17.1,10478,DB00864,Tacrolimus
,31843550,survival time,"Furthermore, the immunosuppressive efficacy was evaluated in a rat heterotopic heart transplantation model, and the results showed that PLGA-FK506-NP treatment could successfully alleviate acute rejection and prolong allograft survival compared with the free FK506 treatment (mean survival time, 17.1 ± 2.0 versus 13.3 ± 1.7 days).",Delivery of FK506-loaded PLGA nanoparticles prolongs cardiac allograft survival. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31843550/),d,17.1,10479,DB00864,Tacrolimus
,31843550,survival time,"Furthermore, the immunosuppressive efficacy was evaluated in a rat heterotopic heart transplantation model, and the results showed that PLGA-FK506-NP treatment could successfully alleviate acute rejection and prolong allograft survival compared with the free FK506 treatment (mean survival time, 17.1 ± 2.0 versus 13.3 ± 1.7 days).",Delivery of FK506-loaded PLGA nanoparticles prolongs cardiac allograft survival. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31843550/),d,13.3,10480,DB00864,Tacrolimus
,9763399,blood,"After iv administration to rats, the blood and plasma clearance of L-732,531 decreased from approximately 60 ml/min/kg at 0.2 mg/kg to 30 ml/min/kg when dosed at 1 and 3 mg/kg.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),[ml] / [kg·min],60,10733,DB00864,Tacrolimus
,9763399,plasma clearance,"After iv administration to rats, the blood and plasma clearance of L-732,531 decreased from approximately 60 ml/min/kg at 0.2 mg/kg to 30 ml/min/kg when dosed at 1 and 3 mg/kg.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),[ml] / [kg·min],30,10734,DB00864,Tacrolimus
,9763399,plasma AUC,"At 1, 5, and 15 mg/kg, plasma AUC was 29, 466, and 2832 ng.hr/ml, respectively, and Cmax was 10, 129, and 304 ng/ml, respectively.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),[h·ng] / [ml],29,10735,DB00864,Tacrolimus
,9763399,plasma AUC,"At 1, 5, and 15 mg/kg, plasma AUC was 29, 466, and 2832 ng.hr/ml, respectively, and Cmax was 10, 129, and 304 ng/ml, respectively.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),[h·ng] / [ml],466,10736,DB00864,Tacrolimus
,9763399,plasma AUC,"At 1, 5, and 15 mg/kg, plasma AUC was 29, 466, and 2832 ng.hr/ml, respectively, and Cmax was 10, 129, and 304 ng/ml, respectively.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),[h·ng] / [ml],2832,10737,DB00864,Tacrolimus
,9763399,Cmax,"At 1, 5, and 15 mg/kg, plasma AUC was 29, 466, and 2832 ng.hr/ml, respectively, and Cmax was 10, 129, and 304 ng/ml, respectively.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),[ng] / [ml],10,10738,DB00864,Tacrolimus
,9763399,Cmax,"At 1, 5, and 15 mg/kg, plasma AUC was 29, 466, and 2832 ng.hr/ml, respectively, and Cmax was 10, 129, and 304 ng/ml, respectively.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),[ng] / [ml],129,10739,DB00864,Tacrolimus
,9763399,Cmax,"At 1, 5, and 15 mg/kg, plasma AUC was 29, 466, and 2832 ng.hr/ml, respectively, and Cmax was 10, 129, and 304 ng/ml, respectively.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),[ng] / [ml],304,10740,DB00864,Tacrolimus
,9763399,Bioavailability,"Bioavailability, although compromised by nonlinear kinetics, was estimated to be between 8% and 18%.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),%,8,10741,DB00864,Tacrolimus
,9763399,Bioavailability,"Bioavailability, although compromised by nonlinear kinetics, was estimated to be between 8% and 18%.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),%,18,10742,DB00864,Tacrolimus
,9763399,clearance,"In baboons, the clearance of L-732,531 was lower than that in rats, especially when calculated from blood concentrations (12 ml/min/kg at 0.2 mg/kg and 8 ml/min/kg at 1 mg/kg).","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),,12,10743,DB00864,Tacrolimus
,9763399,clearance,"In baboons, the clearance of L-732,531 was lower than that in rats, especially when calculated from blood concentrations (12 ml/min/kg at 0.2 mg/kg and 8 ml/min/kg at 1 mg/kg).","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),,8,10744,DB00864,Tacrolimus
,9763399,bioavailability,"The bioavailability of L-732,531 in baboons was estimated at 3%, 9%, and 24% when animals were dosed at 5, 15, and 26 mg/kg po, respectively.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),%,3,10745,DB00864,Tacrolimus
,9763399,bioavailability,"The bioavailability of L-732,531 in baboons was estimated at 3%, 9%, and 24% when animals were dosed at 5, 15, and 26 mg/kg po, respectively.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),%,9,10746,DB00864,Tacrolimus
,9763399,bioavailability,"The bioavailability of L-732,531 in baboons was estimated at 3%, 9%, and 24% when animals were dosed at 5, 15, and 26 mg/kg po, respectively.","Disposition of L-732,531, a potent immunosuppressant, in rats and baboons. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9763399/),%,24,10747,DB00864,Tacrolimus
,18708992,peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),[mg] / [l],15.0,12414,DB00864,Tacrolimus
,18708992,peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),[mg] / [l],16.1,12415,DB00864,Tacrolimus
,18708992,time to reach the peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),h,1.0,12416,DB00864,Tacrolimus
,18708992,time to reach the peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),h,1.2,12417,DB00864,Tacrolimus
,18443548,volume of distribution,"At the same time, the volume of distribution of the drug in the latter group was distinctly increased for the entire post-transplant year (at 6 months: 1.79+/-0.42 vs. 0.73+/-0.5 l/kg, p=0.001).",The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443548/),[l] / [kg],1.79,13631,DB00864,Tacrolimus
,18443548,volume of distribution,"At the same time, the volume of distribution of the drug in the latter group was distinctly increased for the entire post-transplant year (at 6 months: 1.79+/-0.42 vs. 0.73+/-0.5 l/kg, p=0.001).",The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18443548/),[l] / [kg],0.73,13632,DB00864,Tacrolimus
,27511886,AUC0-∞,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[h∙ng] / [ml],210·0,13881,DB00864,Tacrolimus
,27511886,AUC0-∞,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[h∙ng] / [ml],313·9,13882,DB00864,Tacrolimus
,27511886,CL/F,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[l] / [h·kg],1·16,13883,DB00864,Tacrolimus
,27511886,CL/F,"However, diplotype analysis suggested that CYP3A5 expressers with the CYP3A4*1/*1G genotype (n = 3) had significantly lower midazolam AUC0-∞ values (210·0 ± 33·5 vs. 313·9 ± 204·6 h∙ng/mL, P = 0·044) and higher CL/F values (1·16 ± 0·16 vs. 0·88 ± 0·48 L/h/kg, P = 0·005) compared to subjects with the CYP3A4*1/*1 genotype (n = 4), which is consistent with some previous studies with tacrolimus.",Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27511886/),[l] / [h·kg],0·88,13884,DB00864,Tacrolimus
,33067715,Tmax,"Following single topical administration, TAC was absorbed slowly with a Tmax of 4 h and an absolute bioavailability of 11%.",Pharmacokinetics and Biodistribution of Tacrolimus after Topical Administration: Implications for Vascularized Composite Allotransplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33067715/),h,4,14056,DB00864,Tacrolimus
,33067715,absolute bioavailability,"Following single topical administration, TAC was absorbed slowly with a Tmax of 4 h and an absolute bioavailability of 11%.",Pharmacokinetics and Biodistribution of Tacrolimus after Topical Administration: Implications for Vascularized Composite Allotransplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33067715/),%,11,14057,DB00864,Tacrolimus
,31436896,trough levels,"At Year 1, mean ± standard deviation tacrolimus trough levels were 6.6 ± 2.2 and 5.4 ± 1.6 ng/mL, and there were 2 and 7 acute rejection episodes in the PR-T and IR-T groups, respectively.",Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31436896/),[ng] / [ml],6.6,14748,DB00864,Tacrolimus
,31436896,trough levels,"At Year 1, mean ± standard deviation tacrolimus trough levels were 6.6 ± 2.2 and 5.4 ± 1.6 ng/mL, and there were 2 and 7 acute rejection episodes in the PR-T and IR-T groups, respectively.",Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31436896/),[ng] / [ml],5.4,14749,DB00864,Tacrolimus
,31436896,overall efficacy failure rate,The overall efficacy failure rate was 18.2% (PR-T n = 1; IR-T n = 7).,Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31436896/),%,18.2,14750,DB00864,Tacrolimus
,17318074,area under the curve,MPA concentration-time profiles in 21 patients showed that MPA exposure was similar with MMF or EC-MPS (mean area under the curve 39.9+/-11.6 microg x h/mL versus 43.7+/-17.4 microg x h/mL at day 14 post-conversion).,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·μg] / [ml],39.9,14993,DB00864,Tacrolimus
,17318074,area under the curve,MPA concentration-time profiles in 21 patients showed that MPA exposure was similar with MMF or EC-MPS (mean area under the curve 39.9+/-11.6 microg x h/mL versus 43.7+/-17.4 microg x h/mL at day 14 post-conversion).,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·μg] / [ml],43.7,14994,DB00864,Tacrolimus
,17318074,time to peak concentration,Median time to peak concentration was 0.5 hr with MMF and 1.5 hr with EC-MPS.,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),h,0.5,14995,DB00864,Tacrolimus
,17318074,time to peak concentration,Median time to peak concentration was 0.5 hr with MMF and 1.5 hr with EC-MPS.,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),h,1.5,14996,DB00864,Tacrolimus
,17318074,area under the enzyme activity time curve (AEC),"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·nM] / [h·mg·prot],124.2,14997,DB00864,Tacrolimus
,17318074,area under the enzyme activity time curve (AEC),"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·nM] / [h·mg·prot],130.3,14998,DB00864,Tacrolimus
,17318074,activity,"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[nM] / [h·mg],10.3,14999,DB00864,Tacrolimus
,17318074,activity,"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[nM] / [h·mg],10.9,15000,DB00864,Tacrolimus
,17495880,AUC(0-12 h),"In contrast to recipients carrying the CYP3A4*1/CYP3A5*1 or CYP3A4*1B/CYP3A5*1 genotypes, dose-corrected tacrolimus exposure almost doubled over 5 years in patients with the CYP3A4*1/ CYP3A5*3 genotype (AUC(0-12 h): from 41.7+/-18.7 to 80+/-39.2 ng h/ml/mg; P<0.05), whereas apparent oral steady-state clearance and dose requirements significantly decreased accordingly.",CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495880/),[h·ng] / [mg·ml],41.7,15063,DB00864,Tacrolimus
,17495880,AUC(0-12 h),"In contrast to recipients carrying the CYP3A4*1/CYP3A5*1 or CYP3A4*1B/CYP3A5*1 genotypes, dose-corrected tacrolimus exposure almost doubled over 5 years in patients with the CYP3A4*1/ CYP3A5*3 genotype (AUC(0-12 h): from 41.7+/-18.7 to 80+/-39.2 ng h/ml/mg; P<0.05), whereas apparent oral steady-state clearance and dose requirements significantly decreased accordingly.",CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17495880/),[h·ng] / [mg·ml],80,15064,DB00864,Tacrolimus
,14529944,C(0) MPA level,C(0) MPA level among the tacrolimus group were significantly higher than those in CsA group: 3.18 +/- 2.21 microg/mL versus 1.68 +/- 1.03 microg/mL (P </=.001).,The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529944/),[μg] / [ml],3.18,17449,DB00864,Tacrolimus
,14529944,C(0) MPA level,C(0) MPA level among the tacrolimus group were significantly higher than those in CsA group: 3.18 +/- 2.21 microg/mL versus 1.68 +/- 1.03 microg/mL (P </=.001).,The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529944/),[μg] / [ml],1.68,17450,DB00864,Tacrolimus
,30730287,apparent clearance,"The estimated apparent clearance and volume of distribution of tacrolimus were 13.7 l/h and 791 l, respectively.",Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30730287/),[l] / [h],13.7,18215,DB00864,Tacrolimus
,30730287,volume of distribution,"The estimated apparent clearance and volume of distribution of tacrolimus were 13.7 l/h and 791 l, respectively.",Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30730287/),l,791,18216,DB00864,Tacrolimus
,12403074,solubility,The solubility of cyclosporin A or tacrolimus in water dropped to 49% or 16% of the respective control in the presence of probucol.,Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403074/),%,49,18942,DB00864,Tacrolimus
,12403074,solubility,The solubility of cyclosporin A or tacrolimus in water dropped to 49% or 16% of the respective control in the presence of probucol.,Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12403074/),%,16,18943,DB00864,Tacrolimus
,31086126,AUC0-24,Mean AUC0-24 was higher and less variable on Day 3 vs. Day 1 (AUC0-24 (coefficient of variation; CV): 301 (50.8) vs. 193 (94.5) ng·h/mL).,Pharmacokinetic Profile of Prolonged-Release Tacrolimus When Administered via Nasogastric Tube in De Novo Liver Transplantation: A Sub-Study of the DIAMOND Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31086126/),[h·ng] / [ml],301,19592,DB00864,Tacrolimus
,31086126,AUC0-24,Mean AUC0-24 was higher and less variable on Day 3 vs. Day 1 (AUC0-24 (coefficient of variation; CV): 301 (50.8) vs. 193 (94.5) ng·h/mL).,Pharmacokinetic Profile of Prolonged-Release Tacrolimus When Administered via Nasogastric Tube in De Novo Liver Transplantation: A Sub-Study of the DIAMOND Trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31086126/),[h·ng] / [ml],193,19593,DB00864,Tacrolimus
,31086126,Cmax,Mean Cmax was lower and median Tmax was shorter on Day 1 vs. Day 3 (Cmax (CV): 15.1 (73.9) vs. 19.1 (47.9) ng/mL; Tmax (range): 2.0 (2.0-24.0) vs. 4.5 (0.5-24.0) h).,Pharmacokinetic Profile of Prolonged-Release Tacrolimus When Administered via Nasogastric Tube in De Novo Liver Transplantation: A Sub-Study of the DIAMOND Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31086126/),[ng] / [ml],15.1,19594,DB00864,Tacrolimus
,31086126,Cmax,Mean Cmax was lower and median Tmax was shorter on Day 1 vs. Day 3 (Cmax (CV): 15.1 (73.9) vs. 19.1 (47.9) ng/mL; Tmax (range): 2.0 (2.0-24.0) vs. 4.5 (0.5-24.0) h).,Pharmacokinetic Profile of Prolonged-Release Tacrolimus When Administered via Nasogastric Tube in De Novo Liver Transplantation: A Sub-Study of the DIAMOND Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31086126/),[ng] / [ml],19.1,19595,DB00864,Tacrolimus
,31086126,Tmax,Mean Cmax was lower and median Tmax was shorter on Day 1 vs. Day 3 (Cmax (CV): 15.1 (73.9) vs. 19.1 (47.9) ng/mL; Tmax (range): 2.0 (2.0-24.0) vs. 4.5 (0.5-24.0) h).,Pharmacokinetic Profile of Prolonged-Release Tacrolimus When Administered via Nasogastric Tube in De Novo Liver Transplantation: A Sub-Study of the DIAMOND Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31086126/),h,2.0,19596,DB00864,Tacrolimus
,31086126,Tmax,Mean Cmax was lower and median Tmax was shorter on Day 1 vs. Day 3 (Cmax (CV): 15.1 (73.9) vs. 19.1 (47.9) ng/mL; Tmax (range): 2.0 (2.0-24.0) vs. 4.5 (0.5-24.0) h).,Pharmacokinetic Profile of Prolonged-Release Tacrolimus When Administered via Nasogastric Tube in De Novo Liver Transplantation: A Sub-Study of the DIAMOND Trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31086126/),h,4.5,19597,DB00864,Tacrolimus
,31727575,AUC0-24,Fifteen patients were included and provided AUC0-24 of 202.9 ± 44.4 ng h/mL for TAC-BID (pre-conversion) and 193.0 ± 63.4 ng h/mL for TAC-OD (post-conversion) (p = 0.41).,The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31727575/),[h·ng] / [ml],202.9,19835,DB00864,Tacrolimus
,31727575,AUC0-24,Fifteen patients were included and provided AUC0-24 of 202.9 ± 44.4 ng h/mL for TAC-BID (pre-conversion) and 193.0 ± 63.4 ng h/mL for TAC-OD (post-conversion) (p = 0.41).,The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31727575/),[h·ng] / [ml],193.0,19836,DB00864,Tacrolimus
,31727575,trough blood concentration (Cmin),Mean trough blood concentration (Cmin) of TAC-BID and TAC-OD was 6.4 ± 1.4 ng/mL and 4.9 ± 1.6 ng/mL (p = 0.01).,The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31727575/),[ng] / [ml],6.4,19837,DB00864,Tacrolimus
,31727575,trough blood concentration (Cmin),Mean trough blood concentration (Cmin) of TAC-BID and TAC-OD was 6.4 ± 1.4 ng/mL and 4.9 ± 1.6 ng/mL (p = 0.01).,The association between trough blood concentration and systemic exposure of tacrolimus: Comparison between once-daily (Advagraf®) and twice-daily (Prograf®) formulation in de novo kidney transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31727575/),[ng] / [ml],4.9,19838,DB00864,Tacrolimus
,24493215,trough levels,"In this phase 2 study, adult stable liver transplant patients on tacrolimus capsules (Prograf) twice-daily were converted to tacrolimus tablets (LCP-Tacro) once-daily; patients continued on LCP-Tacro once-daily for days 8-21; target trough levels were 5-15 ng/mL; 24-hour pharmacokinetic (PK) assessments were done on days 7 (baseline pre-switch), 14, and 21.",Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24493215/),[ng] / [ml],5-15,21034,DB00864,Tacrolimus
,25659459,time from diagnosis to HCT,"The median number of previous therapies was 3 (range, 1-8) and median time from diagnosis to HCT was 32 months (range, 4.5-177.5 months).",Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25659459/),month,32,21467,DB00864,Tacrolimus
,25659459,overall survival,"Three-year progression-free and overall survival for all patients was 47.8% and 55%, respectively.",Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25659459/),,55,21468,DB00864,Tacrolimus
,12644921,C(0),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],3.46,21628,DB00864,Tacrolimus
,12644921,C(max),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],13.5,21629,DB00864,Tacrolimus
,12644921,C(max),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],63.2,21630,DB00864,Tacrolimus
,12644921,AUC (0-12),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],13.5,21631,DB00864,Tacrolimus
,12644921,AUC (0-12),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],63.2,21632,DB00864,Tacrolimus
,12644921,T(max ),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),h,1.3,21633,DB00864,Tacrolimus
>,12644921,AUC(0-12 ),"Six (30%) children were considered to have an adequate exposure (36-54 microg x h/ml) to MPA, 11 (55%) showed an AUC(0-12 )>54 microg.h/ml, and 3 (15%) showed an AUC(0-12 )<36 microg x h/ml.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],54,21634,DB00864,Tacrolimus
<,12644921,AUC(0-12 ),"Six (30%) children were considered to have an adequate exposure (36-54 microg x h/ml) to MPA, 11 (55%) showed an AUC(0-12 )>54 microg.h/ml, and 3 (15%) showed an AUC(0-12 )<36 microg x h/ml.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],36,21635,DB00864,Tacrolimus
>/=,12644921,C(max ),A C(max )>/=10 microg/ml was seen in 13 (65%) children.,Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],10,21636,DB00864,Tacrolimus
,19122342,bioavailability,"The bioavailability after intraportal and intraintestinal administration were 48.0% and 21.2%, respectively.",Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122342/),%,48.0,21662,DB00864,Tacrolimus
,19122342,bioavailability,"The bioavailability after intraportal and intraintestinal administration were 48.0% and 21.2%, respectively.",Effect of intestinal and hepatic first-pass extraction on the pharmacokinetics of everolimus in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19122342/),%,21.2,21663,DB00864,Tacrolimus
,32403135,flow-rate,"Chromatographic resolution of SAFit-1, SAFit-2 and the internal standard (warfarin) was achieved on an X-Terra phenyl column using 0.2% formic acid:acetonitrile (20:80, v/v) as an eluent, which was delivered at a flow-rate of 0.9 mL/min.",Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403135/),[ml] / [min],0.9,21744,DB00864,Tacrolimus
,32403135,m/,"The MS/MS ion transitions monitored were m/z 748.4→420.4, 803.7→384.3 and 309.2 →163.2 for SAFit-1, SAFit-2 and the internal standard, respectively.",Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403135/),,748.4,21745,DB00864,Tacrolimus
,32403135,m/,"The MS/MS ion transitions monitored were m/z 748.4→420.4, 803.7→384.3 and 309.2 →163.2 for SAFit-1, SAFit-2 and the internal standard, respectively.",Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403135/),,420.4,21746,DB00864,Tacrolimus
,32403135,m/,"The MS/MS ion transitions monitored were m/z 748.4→420.4, 803.7→384.3 and 309.2 →163.2 for SAFit-1, SAFit-2 and the internal standard, respectively.",Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403135/),,803.7,21747,DB00864,Tacrolimus
,32403135,m/,"The MS/MS ion transitions monitored were m/z 748.4→420.4, 803.7→384.3 and 309.2 →163.2 for SAFit-1, SAFit-2 and the internal standard, respectively.",Validated LC-MS/MS Method for Simultaneous Quantitation of SAFit-1 and SAFit-2 in Mice Plasma: Application to a Pharmacokinetic Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32403135/),,309.2,21748,DB00864,Tacrolimus
,22215359,area under the concentration-time curve (AUC),"The mean ± S.D. pharmacokinetic parameters for tacrolimus, normalized to a dose of 1 mg, were as follows: area under the concentration-time curve (AUC), 52.6 ± 24.8 μg · hr/L/mg; maximum concentration (C(max)), 8.0 ± 3.3 μg/L/mg; time to C(max) (t(max)), 1.8 ± 1.0 hr; and minimum concentration (C(min)), 2.6 ± 1.4 μg/L/mg.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[h·μg] / [l·mg],52.6,21832,DB00864,Tacrolimus
,22215359,maximum concentration (C(max)),"The mean ± S.D. pharmacokinetic parameters for tacrolimus, normalized to a dose of 1 mg, were as follows: area under the concentration-time curve (AUC), 52.6 ± 24.8 μg · hr/L/mg; maximum concentration (C(max)), 8.0 ± 3.3 μg/L/mg; time to C(max) (t(max)), 1.8 ± 1.0 hr; and minimum concentration (C(min)), 2.6 ± 1.4 μg/L/mg.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[μg] / [l·mg],8.0,21833,DB00864,Tacrolimus
,22215359,time to C(max) (t(max)),"The mean ± S.D. pharmacokinetic parameters for tacrolimus, normalized to a dose of 1 mg, were as follows: area under the concentration-time curve (AUC), 52.6 ± 24.8 μg · hr/L/mg; maximum concentration (C(max)), 8.0 ± 3.3 μg/L/mg; time to C(max) (t(max)), 1.8 ± 1.0 hr; and minimum concentration (C(min)), 2.6 ± 1.4 μg/L/mg.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),h,1.8,21834,DB00864,Tacrolimus
,22215359,minimum concentration (C(min)),"The mean ± S.D. pharmacokinetic parameters for tacrolimus, normalized to a dose of 1 mg, were as follows: area under the concentration-time curve (AUC), 52.6 ± 24.8 μg · hr/L/mg; maximum concentration (C(max)), 8.0 ± 3.3 μg/L/mg; time to C(max) (t(max)), 1.8 ± 1.0 hr; and minimum concentration (C(min)), 2.6 ± 1.4 μg/L/mg.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[μg] / [l·mg],2.6,21835,DB00864,Tacrolimus
,22215359,AUC,"The mean ± S.D. pharmacokinetic parameters for mycophenolic acid, normalized to a mycophenolate mofetil dose of 1 g, were AUC, 26.9 ± 13.2 μg ·hr/mL/g; C(max), 17.5 ± 5.4 μg/mL/g; t(max), 0.9 ± 0.6 hr; and C(min), 1.5 ± 1.1 μg/mL/g.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[h·μg] / [g·ml],26.9,21836,DB00864,Tacrolimus
,22215359,C(max),"The mean ± S.D. pharmacokinetic parameters for mycophenolic acid, normalized to a mycophenolate mofetil dose of 1 g, were AUC, 26.9 ± 13.2 μg ·hr/mL/g; C(max), 17.5 ± 5.4 μg/mL/g; t(max), 0.9 ± 0.6 hr; and C(min), 1.5 ± 1.1 μg/mL/g.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[μg] / [g·ml],17.5,21837,DB00864,Tacrolimus
,22215359,t(max),"The mean ± S.D. pharmacokinetic parameters for mycophenolic acid, normalized to a mycophenolate mofetil dose of 1 g, were AUC, 26.9 ± 13.2 μg ·hr/mL/g; C(max), 17.5 ± 5.4 μg/mL/g; t(max), 0.9 ± 0.6 hr; and C(min), 1.5 ± 1.1 μg/mL/g.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),h,0.9,21838,DB00864,Tacrolimus
,22215359,C(min),"The mean ± S.D. pharmacokinetic parameters for mycophenolic acid, normalized to a mycophenolate mofetil dose of 1 g, were AUC, 26.9 ± 13.2 μg ·hr/mL/g; C(max), 17.5 ± 5.4 μg/mL/g; t(max), 0.9 ± 0.6 hr; and C(min), 1.5 ± 1.1 μg/mL/g.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[μg] / [g·ml],1.5,21839,DB00864,Tacrolimus
,22215359,free fraction,The free fraction of mycophenolic acid was 1.8% ± 0.7%.,Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),%,1.8,21840,DB00864,Tacrolimus
,22215359,AUC ratios,"AUC ratios of MPAG:mycophenolic acid and AcMPAG:mycophenolic acid were 13.0 ± 5.8 and 0.1 ± 0.2, respectively.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),,13.0,21841,DB00864,Tacrolimus
,22215359,AUC ratios,"AUC ratios of MPAG:mycophenolic acid and AcMPAG:mycophenolic acid were 13.0 ± 5.8 and 0.1 ± 0.2, respectively.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),,0.1,21842,DB00864,Tacrolimus
,22461034,C/D ratio,The median C/D ratio of tacrolimus increased significantly from 172.8 (range 28.6-1110.7) to 537.5 (range 127.8-1933.3) (ng/mL)/(mg/kg) (P < 0.01) following initiation of voriconazole; the median increase was 138.8 % (range -32.0 to 685.7 %).,Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22461034/),[ml·ng] / [kg·mg],172.8,21975,DB00864,Tacrolimus
,22461034,C/D ratio,The median C/D ratio of tacrolimus increased significantly from 172.8 (range 28.6-1110.7) to 537.5 (range 127.8-1933.3) (ng/mL)/(mg/kg) (P < 0.01) following initiation of voriconazole; the median increase was 138.8 % (range -32.0 to 685.7 %).,Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22461034/),[ml·ng] / [kg·mg],537.5,21976,DB00864,Tacrolimus
,21916909,CL/F,The CL/F in subjects with CYP3A4*1/*1-CYP3A5*3/*3 was 10·3 L/h and was 48·5% in those not carrying CYP3A4*1/*1-CYP3A5*3/*3.,"Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21916909/),[l] / [h],10·3,22507,DB00864,Tacrolimus
,21916909,CL/F,The CL/F in subjects with CYP3A4*1/*1-CYP3A5*3/*3 was 10·3 L/h and was 48·5% in those not carrying CYP3A4*1/*1-CYP3A5*3/*3.,"Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21916909/),%,48·5,22508,DB00864,Tacrolimus
,19715843,trough,"Despite taking similar MMF doses, patients with delayed graft function (DGF) showed lower 12-hour trough MPA levels than patients without DGF 1.4 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P = .001).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],1.4,22770,DB00864,Tacrolimus
,19715843,trough,"Despite taking similar MMF doses, patients with delayed graft function (DGF) showed lower 12-hour trough MPA levels than patients without DGF 1.4 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P = .001).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],2.1,22771,DB00864,Tacrolimus
>,19715843,trough,Logistic regression analysis showed that creatinine clearance was a predictive factor of adequate 12-hour trough MPA levels (>1.6 microg/mL) at 7 days posttransplantation.,Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],1.6,22772,DB00864,Tacrolimus
,19715843,Twelve-hour,"Twelve-hour trough MPA levels at 7 days posttransplantation were lower among patients who developed an acute rejecton episode (1.5 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P < .001), whereas those with gastrointestinal side effects showed high levels (4.1 +/- 0.5 microg/mL).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],1.5,22773,DB00864,Tacrolimus
,19715843,Twelve-hour,"Twelve-hour trough MPA levels at 7 days posttransplantation were lower among patients who developed an acute rejecton episode (1.5 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P < .001), whereas those with gastrointestinal side effects showed high levels (4.1 +/- 0.5 microg/mL).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],2.1,22774,DB00864,Tacrolimus
,19715843,trough MPA levels,"Twelve-hour trough MPA levels at 7 days posttransplantation were lower among patients who developed an acute rejecton episode (1.5 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P < .001), whereas those with gastrointestinal side effects showed high levels (4.1 +/- 0.5 microg/mL).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],1.5,22775,DB00864,Tacrolimus
,19715843,trough MPA levels,"Twelve-hour trough MPA levels at 7 days posttransplantation were lower among patients who developed an acute rejecton episode (1.5 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P < .001), whereas those with gastrointestinal side effects showed high levels (4.1 +/- 0.5 microg/mL).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],2.1,22776,DB00864,Tacrolimus
,19715843,trough MPA levels,"Twelve-hour trough MPA levels at 7 days posttransplantation were lower among patients who developed an acute rejecton episode (1.5 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P < .001), whereas those with gastrointestinal side effects showed high levels (4.1 +/- 0.5 microg/mL).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],4.1,22777,DB00864,Tacrolimus
,18608277,concentration,A tacrolimus concentration 27 hours after her last exposure was 96.8 ng/mL (therapeutic 5 to 20 ng/mL).,Acute tacrolimus toxicity in a non-transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608277/),,96,22818,DB00864,Tacrolimus
,18608277,elimination half-life,"Her tacrolimus elimination half-life was 16.5 hours, compared to a mean half-life in healthy volunteers of 34.2 +/- 7.7 hours.",Acute tacrolimus toxicity in a non-transplant patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608277/),h,16.5,22819,DB00864,Tacrolimus
,18608277,half-life,"Her tacrolimus elimination half-life was 16.5 hours, compared to a mean half-life in healthy volunteers of 34.2 +/- 7.7 hours.",Acute tacrolimus toxicity in a non-transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18608277/),h,34.2,22820,DB00864,Tacrolimus
,16550361,trough levels,Tacrolimus trough levels were 7.8+/-1.9 ng/ml and 7.3+/-2.5 ng/ml.,The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550361/),[ng] / [ml],7.8,23121,DB00864,Tacrolimus
,16550361,trough levels,Tacrolimus trough levels were 7.8+/-1.9 ng/ml and 7.3+/-2.5 ng/ml.,The pharmacokinetics and immunosuppressive response of tacrolimus in paediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550361/),[ng] / [ml],7.3,23122,DB00864,Tacrolimus
,7527198,50% inhibitory concentration,"Furthermore, its antiviral activity against laboratory strains and against clinical isolates from geographically distinct regions in primary T4 lymphocytes and in primary monocytes (50% inhibitory concentration = 0.011 to 0.057 micrograms/ml) was demonstrated.","Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7527198/),[μg] / [ml],0.011 to 0.057,24430,DB00864,Tacrolimus
,9129559,blood/plasma ratio,"Sirolimus distribution between whole blood and plasma was concentration-independent, with a mean blood/plasma ratio (coefficient of variation) of 30.9 (48.5%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),,30.9,24920,DB00864,Tacrolimus
,9129559,terminal half-life,"Elimination was not influenced by dose, as shown by estimates of the terminal half-life of 63 hours (27.5%) and apparent oral blood clearance of 8.9 L/hr (38.2%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),h,63,24921,DB00864,Tacrolimus
,9129559,apparent oral blood clearance,"Elimination was not influenced by dose, as shown by estimates of the terminal half-life of 63 hours (27.5%) and apparent oral blood clearance of 8.9 L/hr (38.2%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),[l] / [h],8.9,24922,DB00864,Tacrolimus
,9129559,absorption lag-time,"Sirolimus was rapidly absorbed, as shown by the absorption lag-time of 0.27 hour (35.1%), and ka of 2.77 hr-1 (48.4%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),h,0.27,24923,DB00864,Tacrolimus
,9129559,ka,"Sirolimus was rapidly absorbed, as shown by the absorption lag-time of 0.27 hour (35.1%), and ka of 2.77 hr-1 (48.4%).",Population pharmacokinetics of sirolimus in kidney transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9129559/),1/[h],2.77,24924,DB00864,Tacrolimus
,16175131,AUC0-12,The mean AUC0-12 of tacrolimus was increased 250% with clotrimazole (467.0 +/- 170.0 ng.h/mL versus 188.7 +/- 50.2 ng.h/mL; P = 0.002).,Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175131/),[h·ng] / [ml],467.0,25892,DB00864,Tacrolimus
,16175131,AUC0-12,The mean AUC0-12 of tacrolimus was increased 250% with clotrimazole (467.0 +/- 170.0 ng.h/mL versus 188.7 +/- 50.2 ng.h/mL; P = 0.002).,Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175131/),[h·ng] / [ml],188.7,25893,DB00864,Tacrolimus
,16175131,blood trough concentrations,Tacrolimus blood trough concentrations also more than doubled with coadministration of clotrimazole (27.7 +/- 10.4 ng/mL versus 11.6 +/- 4.0 ng/mL; P = 0.003).,Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175131/),[ng] / [ml],27.7,25894,DB00864,Tacrolimus
,16175131,blood trough concentrations,Tacrolimus blood trough concentrations also more than doubled with coadministration of clotrimazole (27.7 +/- 10.4 ng/mL versus 11.6 +/- 4.0 ng/mL; P = 0.003).,Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175131/),[ng] / [ml],11.6,25895,DB00864,Tacrolimus
,16175131,Cmax,"Mean Cmax was significantly increased with clotrimazole (70.7 +/- 34.7 ng/mL versus 27.4 +/- 11.1 ng/mL, P = 0.01).",Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175131/),[ng] / [ml],70.7,25896,DB00864,Tacrolimus
,16175131,Cmax,"Mean Cmax was significantly increased with clotrimazole (70.7 +/- 34.7 ng/mL versus 27.4 +/- 11.1 ng/mL, P = 0.01).",Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175131/),[ng] / [ml],27.4,25897,DB00864,Tacrolimus
,16175131,Tmax,Tmax decreased from 3.2 +/- 1.6 hours to 1.9 +/- 1.0 hours (P = NS).,Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175131/),h,3.2,25898,DB00864,Tacrolimus
,16175131,Tmax,Tmax decreased from 3.2 +/- 1.6 hours to 1.9 +/- 1.0 hours (P = NS).,Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175131/),h,1.9,25899,DB00864,Tacrolimus
,16175131,oral clearance,"In addition, the apparent oral clearance decreased 60% with coadministration of clotrimazole (median oral clearance 0.16 L/h/kg versus 0.40 L/h/kg; P = 0.03).",Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175131/),[l] / [h·kg],0.16,25900,DB00864,Tacrolimus
,16175131,oral clearance,"In addition, the apparent oral clearance decreased 60% with coadministration of clotrimazole (median oral clearance 0.16 L/h/kg versus 0.40 L/h/kg; P = 0.03).",Concomitant clotrimazole therapy more than doubles the relative oral bioavailability of tacrolimus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16175131/),[l] / [h·kg],0.40,25901,DB00864,Tacrolimus
,21280190,area under the curve (AUC) from 0 to 24 hours (AUC(0-24) ),"Tacrolimus area under the curve (AUC) from 0 to 24 hours (AUC(0-24) ) at equivalent doses was approximately 50% lower for tacrolimus qd than for bid on day 1 (146 versus 264 ng · h/mL, respectively), but by day 14 was comparable between treatments (324 and 287 ng · h/mL, respectively) with higher tacrolimus qd doses.","Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280190/),[h·ng] / [ml],146,26115,DB00864,Tacrolimus
,21280190,area under the curve (AUC) from 0 to 24 hours (AUC(0-24) ),"Tacrolimus area under the curve (AUC) from 0 to 24 hours (AUC(0-24) ) at equivalent doses was approximately 50% lower for tacrolimus qd than for bid on day 1 (146 versus 264 ng · h/mL, respectively), but by day 14 was comparable between treatments (324 and 287 ng · h/mL, respectively) with higher tacrolimus qd doses.","Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280190/),[h·ng] / [ml],264,26116,DB00864,Tacrolimus
,21280190,area under the curve (AUC) from 0 to 24 hours (AUC(0-24) ),"Tacrolimus area under the curve (AUC) from 0 to 24 hours (AUC(0-24) ) at equivalent doses was approximately 50% lower for tacrolimus qd than for bid on day 1 (146 versus 264 ng · h/mL, respectively), but by day 14 was comparable between treatments (324 and 287 ng · h/mL, respectively) with higher tacrolimus qd doses.","Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280190/),[h·ng] / [ml],324,26117,DB00864,Tacrolimus
,21280190,area under the curve (AUC) from 0 to 24 hours (AUC(0-24) ),"Tacrolimus area under the curve (AUC) from 0 to 24 hours (AUC(0-24) ) at equivalent doses was approximately 50% lower for tacrolimus qd than for bid on day 1 (146 versus 264 ng · h/mL, respectively), but by day 14 was comparable between treatments (324 and 287 ng · h/mL, respectively) with higher tacrolimus qd doses.","Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21280190/),[h·ng] / [ml],287,26118,DB00864,Tacrolimus
,21088289,area under the curve,"In renal transplant recipients, MMF therapy is optimal when the area under the curve of MPA is 30 to 60 mg·h/L.",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),[h·mg] / [l],30 to 60,26320,DB00864,Tacrolimus
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,123,26321,DB00864,Tacrolimus
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,111,26322,DB00864,Tacrolimus
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,94,26323,DB00864,Tacrolimus
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,90,26324,DB00864,Tacrolimus
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,176,26325,DB00864,Tacrolimus
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,133,26326,DB00864,Tacrolimus
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,85,26327,DB00864,Tacrolimus
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,76,26328,DB00864,Tacrolimus
,15991041,CL(max),"Typical population estimates (percentage inter-individual variability) of CL(max), TCL50, and gamma and apparent distribution volumes (V) were 36 l/h (43%), 6.3 days (33%), and 4.9 l and 1870 l (49%), respectively.",Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15991041/),[l] / [h],36,27573,DB00864,Tacrolimus
,15991041,TCL50,"Typical population estimates (percentage inter-individual variability) of CL(max), TCL50, and gamma and apparent distribution volumes (V) were 36 l/h (43%), 6.3 days (33%), and 4.9 l and 1870 l (49%), respectively.",Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15991041/),d,6.3,27574,DB00864,Tacrolimus
,15991041,TCL50,"Typical population estimates (percentage inter-individual variability) of CL(max), TCL50, and gamma and apparent distribution volumes (V) were 36 l/h (43%), 6.3 days (33%), and 4.9 l and 1870 l (49%), respectively.",Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15991041/),l,4.9,27575,DB00864,Tacrolimus
,15991041,gamma,"Typical population estimates (percentage inter-individual variability) of CL(max), TCL50, and gamma and apparent distribution volumes (V) were 36 l/h (43%), 6.3 days (33%), and 4.9 l and 1870 l (49%), respectively.",Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15991041/),d,6.3,27576,DB00864,Tacrolimus
,15991041,apparent distribution volumes (V),"Typical population estimates (percentage inter-individual variability) of CL(max), TCL50, and gamma and apparent distribution volumes (V) were 36 l/h (43%), 6.3 days (33%), and 4.9 l and 1870 l (49%), respectively.",Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15991041/),l,4.9,27577,DB00864,Tacrolimus
,15991041,apparent distribution volumes (V),"Typical population estimates (percentage inter-individual variability) of CL(max), TCL50, and gamma and apparent distribution volumes (V) were 36 l/h (43%), 6.3 days (33%), and 4.9 l and 1870 l (49%), respectively.",Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15991041/),l,1870,27578,DB00864,Tacrolimus
,10071348,time to reach peak plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),h,1.8,27847,DB00864,Tacrolimus
,10071348,time to reach peak plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),h,1.0,27848,DB00864,Tacrolimus
,10071348,trough plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [ml],1.1,27849,DB00864,Tacrolimus
,10071348,trough plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [ml],1.4,27850,DB00864,Tacrolimus
,10071348,peak plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [ml],10.6,27851,DB00864,Tacrolimus
,10071348,peak plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [ml],11.1,27852,DB00864,Tacrolimus
,10071348,area under the plasma concentration-versus-time curve (AUC),"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [h·ml],40.1,27853,DB00864,Tacrolimus
,10071348,area under the plasma concentration-versus-time curve (AUC),"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [h·ml],43.2,27854,DB00864,Tacrolimus
,31840222,Maximum binding capacity,Maximum binding capacity of erythrocytes was directly proportional to hematocrit and estimated at 2700 pg/mL (95% confidence interval 1750-3835) with a dissociation constant of 0.142 pg/mL (95% confidence interval 0.087-0.195).,"Unbound Plasma, Total Plasma, and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31840222/),[pg] / [ml],2700,28010,DB00864,Tacrolimus
,31840222,dissociation constant,Maximum binding capacity of erythrocytes was directly proportional to hematocrit and estimated at 2700 pg/mL (95% confidence interval 1750-3835) with a dissociation constant of 0.142 pg/mL (95% confidence interval 0.087-0.195).,"Unbound Plasma, Total Plasma, and Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31840222/),[pg] / [ml],0.142,28011,DB00864,Tacrolimus
,17044457,clearance,"Tacrolimus clearance after the fluconazole combination was significantly reduced, compared with before the combination (14.74 vs 38.79 L/h, p = 0.001).",Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044457/),[l] / [h],14.74,28597,DB00864,Tacrolimus
,17044457,clearance,"Tacrolimus clearance after the fluconazole combination was significantly reduced, compared with before the combination (14.74 vs 38.79 L/h, p = 0.001).",Pharmacokinetic study of the combination of tacrolimus and fluconazole in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17044457/),[l] / [h],38.79,28598,DB00864,Tacrolimus
,14620947,accumulation ratio,The accumulation ratio of cerivastatin (after 3 months/ Day 1) was 1.6.,"Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14620947/),,1.6,28833,DB00864,Tacrolimus
,29888809,treatment costs,"Median treatment costs during the first year were 7.825€ (IQR 6.195-8.892€) for LCPT, 9.813€ (IQR 7.630-16.832€) for IR-Tac, and 9.838€ (IQR 7.503- 13.541€) for ER-Tac (Kruskal-Wallis test, P = .003).",Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29888809/),€,7.825,29027,DB00864,Tacrolimus
,29888809,treatment costs,"Median treatment costs during the first year were 7.825€ (IQR 6.195-8.892€) for LCPT, 9.813€ (IQR 7.630-16.832€) for IR-Tac, and 9.838€ (IQR 7.503- 13.541€) for ER-Tac (Kruskal-Wallis test, P = .003).",Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29888809/),€,9.813,29028,DB00864,Tacrolimus
,29888809,treatment costs,"Median treatment costs during the first year were 7.825€ (IQR 6.195-8.892€) for LCPT, 9.813€ (IQR 7.630-16.832€) for IR-Tac, and 9.838€ (IQR 7.503- 13.541€) for ER-Tac (Kruskal-Wallis test, P = .003).",Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29888809/),€,9.838,29029,DB00864,Tacrolimus
,9987705,clearance,Coadministration of rifampin significantly increased tacrolimus clearance (36.0 +/- 8.1 ml/hr/kg vs. 52.8 +/- 9.6 ml/hr/kg; p = 0.03) and decreased tacrolimus bioavailability (14.4% +/- 5.7% vs. 7.0% +/- 2.7%; p = 0.03).,Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987705/),[ml] / [h·kg],36.0,29878,DB00864,Tacrolimus
,9987705,clearance,Coadministration of rifampin significantly increased tacrolimus clearance (36.0 +/- 8.1 ml/hr/kg vs. 52.8 +/- 9.6 ml/hr/kg; p = 0.03) and decreased tacrolimus bioavailability (14.4% +/- 5.7% vs. 7.0% +/- 2.7%; p = 0.03).,Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987705/),[ml] / [h·kg],52.8,29879,DB00864,Tacrolimus
,9987705,bioavailability,Coadministration of rifampin significantly increased tacrolimus clearance (36.0 +/- 8.1 ml/hr/kg vs. 52.8 +/- 9.6 ml/hr/kg; p = 0.03) and decreased tacrolimus bioavailability (14.4% +/- 5.7% vs. 7.0% +/- 2.7%; p = 0.03).,Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987705/),%,14.4,29880,DB00864,Tacrolimus
,9987705,bioavailability,Coadministration of rifampin significantly increased tacrolimus clearance (36.0 +/- 8.1 ml/hr/kg vs. 52.8 +/- 9.6 ml/hr/kg; p = 0.03) and decreased tacrolimus bioavailability (14.4% +/- 5.7% vs. 7.0% +/- 2.7%; p = 0.03).,Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9987705/),%,7.0,29881,DB00864,Tacrolimus
,10823378,t(max),"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),h,1 to 2,30721,DB00864,Tacrolimus
,10823378,systemic availability (F,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),%,14,30722,DB00864,Tacrolimus
,10823378,partitioning into,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),,36,30723,DB00864,Tacrolimus
,10823378,B/P,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),,36,30724,DB00864,Tacrolimus
,10823378,apparent volume of distribution,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),[l] / [kg],1.7,30725,DB00864,Tacrolimus
,10823378,terminal half-life,"Pharmacokinetic studies in adult renal transplant patients have shown that sirolimus may be characterized as a drug with rapid absorption (t(max) = 1 to 2 hours), low systemic availability (F = 14%), linear dose proportionality (2 to 24 mg), extensive partitioning into formed blood elements (B/P = 36), large apparent volume of distribution (1.7 L/kg), prolonged terminal half-life (62 hours), and large intersubject (CV = 52%) and intrasubject (CV = 26%) variability in oral-dose clearance.",Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),h,62,30726,DB00864,Tacrolimus
,10823378,therapeutic window,A whole-blood sirolimus therapeutic window of 5 to 15 ng/mL (measured by microparticle enzyme immunoassay) is recommended for patients at standard risk of rejection.,Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10823378/),,5 to 15,30727,DB00864,Tacrolimus
,19307937,area under the concentration-time curves (AUCs),MPA area under the concentration-time curves (AUCs) ranged from 31.8 to 102.1 (median: 52.9) mg.h(-1).,Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19307937/),[mg] / [h],52.9,30923,DB00864,Tacrolimus
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],25.8,30938,DB00864,Tacrolimus
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],33.8,30939,DB00864,Tacrolimus
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],45.2,30940,DB00864,Tacrolimus
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],26.2,30941,DB00864,Tacrolimus
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],34.4,30942,DB00864,Tacrolimus
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],45.3,30943,DB00864,Tacrolimus
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],39.6,30944,DB00864,Tacrolimus
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],56.4,30945,DB00864,Tacrolimus
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],40.5,30946,DB00864,Tacrolimus
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],56.0,30947,DB00864,Tacrolimus
,19214147,AUCs,Both LC-MS/MS and the enzymatic methods revealed a tendency toward lower AUCs and predose levels in patients with biopsy-proven acute rejection (BPAR) (day 10 median: 0.9 mg/L with BPAR and 1.7 mg/L without BPAR).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[mg] / [l],0.9,30948,DB00864,Tacrolimus
,19214147,AUCs,Both LC-MS/MS and the enzymatic methods revealed a tendency toward lower AUCs and predose levels in patients with biopsy-proven acute rejection (BPAR) (day 10 median: 0.9 mg/L with BPAR and 1.7 mg/L without BPAR).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[mg] / [l],1.7,30949,DB00864,Tacrolimus
,21572388,area under the concentration-time curve from 0 to 12 hours (AUC0-12),Routine therapeutic drug monitoring of mycophenolic acid (MPA) is generally performed using the area under the concentration-time curve from 0 to 12 hours (AUC0-12) with recommended values between 30 and 60 μg·h/mL.,Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21572388/),[h·μg] / [ml],30 and 60,31127,DB00864,Tacrolimus
<,21572388,AUC0-12,"Recipients with MPA AUC0-12 levels<30 μg·h/mL on day 28 and 1 year after transplantation had an MPA C0 of <2.0 μg/mL, with a sensitivity of 90.9% and a specificity of 70.7%.",Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21572388/),[h·μg] / [ml],30,31128,DB00864,Tacrolimus
<,21572388,C0,"Recipients with MPA AUC0-12 levels<30 μg·h/mL on day 28 and 1 year after transplantation had an MPA C0 of <2.0 μg/mL, with a sensitivity of 90.9% and a specificity of 70.7%.",Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21572388/),[μg] / [ml],2.0,31129,DB00864,Tacrolimus
>,21572388,AUC0-12,"To keep the MPA AUC0-12>30 μg·h/mL, the plasma threshold for maintaining the MPA C0 with tacrolimus should be set >2.0 μg/mL as determined by high-performance liquid chromatography.",Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21572388/),[h·μg] / [ml],30,31130,DB00864,Tacrolimus
>,21572388,C0,"To keep the MPA AUC0-12>30 μg·h/mL, the plasma threshold for maintaining the MPA C0 with tacrolimus should be set >2.0 μg/mL as determined by high-performance liquid chromatography.",Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21572388/),[μg] / [ml],2.0,31131,DB00864,Tacrolimus
,29920787,time to therapeutic ta,"Compared with CYP3A poor metabolizers (PM), time to therapeutic tacrolimus trough was increased by 5.1 ± 1.6 days for CYP3A extensive metabolizers (EM, P < 0.001).",Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29920787/),,5,31226,DB00864,Tacrolimus
,20430188,area-under-the-curve from 0 to 2 hours (AUC0-2),"The mean area-under-the-curve from 0 to 2 hours (AUC0-2) was 30.0+/-11.6 microg.h/mL (range, 7.8-60.7).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[h·μg] / [ml],30.0,31279,DB00864,Tacrolimus
,20430188,trough,"Of 114 pharmacokinetic profiles, 40 (35%) AUC and 7 (6.1%) trough values were within the target value (30-60 microg.h/mL and 1.7-4.0 microg/mL, respectively).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],1.7-4.0,31280,DB00864,Tacrolimus
,20430188,C0,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.01-4.46,31281,DB00864,Tacrolimus
,20430188,C1/2,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.14-36.86,31282,DB00864,Tacrolimus
,20430188,C2,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.79-18.19,31283,DB00864,Tacrolimus
,24365986,AUC,"When analyzing visits on Tac, TacMR, and back on Tac combined, the MPA AUC for all 20 patients at baseline was 42.24 (16.98), 37.18 (13.75), and 40.09 (16.69) mg·h·L(-1), respectively, which was not statistically significant using repeated measures (P = 0.1327, R(2) = 0.1109).",Similar MPA exposure on modified release and regular tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365986/),[h·mg] / [l],42.24,32359,DB00864,Tacrolimus
,24365986,AUC,"When analyzing visits on Tac, TacMR, and back on Tac combined, the MPA AUC for all 20 patients at baseline was 42.24 (16.98), 37.18 (13.75), and 40.09 (16.69) mg·h·L(-1), respectively, which was not statistically significant using repeated measures (P = 0.1327, R(2) = 0.1109).",Similar MPA exposure on modified release and regular tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365986/),[h·mg] / [l],37.18,32360,DB00864,Tacrolimus
,24365986,AUC,"When analyzing visits on Tac, TacMR, and back on Tac combined, the MPA AUC for all 20 patients at baseline was 42.24 (16.98), 37.18 (13.75), and 40.09 (16.69) mg·h·L(-1), respectively, which was not statistically significant using repeated measures (P = 0.1327, R(2) = 0.1109).",Similar MPA exposure on modified release and regular tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365986/),[h·mg] / [l],40.09,32361,DB00864,Tacrolimus
,31007740,absorption rate constant (Ka),The absorption rate constant (Ka) was set at 4.48 h-1.,Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31007740/),1/[h],4.48,33018,DB00864,Tacrolimus
,31007740,apparent oral clearance (CL/F),"The typical values of apparent oral clearance (CL/F) and apparent volume of distribution (V/F) in the final model were 5.46 l/h and 57.1 l, respectively.",Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31007740/),[l] / [h],5.46,33019,DB00864,Tacrolimus
,31007740,apparent volume of distribution (V/F),"The typical values of apparent oral clearance (CL/F) and apparent volume of distribution (V/F) in the final model were 5.46 l/h and 57.1 l, respectively.",Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31007740/),l,57.1,33020,DB00864,Tacrolimus
,16100295,area under the concentration-time curve,"Tacrolimus area under the concentration-time curve was 298+/-135 microg*h/L when tacrolimus was administered alone, 305+/-129 microg*h/L (P=.8; confidence interval 89%, 118%) when tacrolimus was given with single-dose micafungin, and 282+/-138 microg*h/L (P=.4; confidence interval 82%, 107%) when tacrolimus was given with steady-state micafungin.",Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100295/),[h·μg] / [l],298,34163,DB00864,Tacrolimus
,16100295,area under the concentration-time curve,"Tacrolimus area under the concentration-time curve was 298+/-135 microg*h/L when tacrolimus was administered alone, 305+/-129 microg*h/L (P=.8; confidence interval 89%, 118%) when tacrolimus was given with single-dose micafungin, and 282+/-138 microg*h/L (P=.4; confidence interval 82%, 107%) when tacrolimus was given with steady-state micafungin.",Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100295/),[h·μg] / [l],305,34164,DB00864,Tacrolimus
,16100295,area under the concentration-time curve,"Tacrolimus area under the concentration-time curve was 298+/-135 microg*h/L when tacrolimus was administered alone, 305+/-129 microg*h/L (P=.8; confidence interval 89%, 118%) when tacrolimus was given with single-dose micafungin, and 282+/-138 microg*h/L (P=.4; confidence interval 82%, 107%) when tacrolimus was given with steady-state micafungin.",Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100295/),[h·μg] / [l],282,34165,DB00864,Tacrolimus
,30498355,CL/F,"The estimated typical values of CL/F and volume of distribution (V/F) were 6.33 L/h and 465 L, respectively.",CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498355/),[l] / [h],6.33,34372,DB00864,Tacrolimus
,30498355,volume of distribution (V/F),"The estimated typical values of CL/F and volume of distribution (V/F) were 6.33 L/h and 465 L, respectively.",CYP3A5 genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30498355/),l,465,34373,DB00864,Tacrolimus
,11605779,g,"Eight children were studied with a median age of 10.6 years, a mean glomerular filtration rate (inulin clearance) of 55 ml/min per 1.73 m2 (range 29-95), and a mean follow-up after transplantation of 5.6 months.",Renal hemodynamic effect of tacrolimus in renal transplanted children. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11605779/),[ml] / [1.73·m2·min],55,34514,DB00864,Tacrolimus
,11605779,ERPF,"Average ERPF at the start of the test was 289 ml/min per 1.73 m2 (range 177-404, SD +/- 106).",Renal hemodynamic effect of tacrolimus in renal transplanted children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11605779/),[ml] / [1.73·m2·min],289,34515,DB00864,Tacrolimus
,10952769,Ki,"When triazolam is the P450 3A4 substrate and ketoconazole the competitive inhibitor, Ki approximately 1.2 microg/mL in humans.",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),[μg] / [ml],1.2,34568,DB00864,Tacrolimus
,10952769,hepatic extraction,"For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state).",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),%,95,34569,DB00864,Tacrolimus
,10952769,hepatic extraction,"For example, human terfenadine hepatic extraction goes from 95% in the absence of a competitive inhibitor to 35% in the presence of one (ketoconazole, 200 mg po Q 12 h dosed to steady-state).",Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10952769/),%,35,34570,DB00864,Tacrolimus
,34290611,C0/D,"In group I (n = 43), the C0/D of CONF was significantly higher than in Controls [225.2 ± 66.3 vs. 155.1 ± 34.6 ng/ml/(mg/kg); p = 0.002].",CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34290611/),[ml·ng] / [kg·mg],225.2,34737,DB00864,Tacrolimus
,34290611,C0/D,"In group I (n = 43), the C0/D of CONF was significantly higher than in Controls [225.2 ± 66.3 vs. 155.1 ± 34.6 ng/ml/(mg/kg); p = 0.002].",CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Nifedipine in Chinese Renal Transplant Patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34290611/),[ml·ng] / [kg·mg],155.1,34738,DB00864,Tacrolimus
,21546866,Acute cellular rejection rate,"Acute cellular rejection rate was lower in the 4-hr CYA-IV group (0%) compared with the CYA-ME group (17%, P=0.038).",Cyclosporine A-based immunotherapy in adult living donor liver transplantation: accurate and improved therapeutic drug monitoring by 4-hr intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21546866/),%,0,34931,DB00864,Tacrolimus
,21546866,Acute cellular rejection rate,"Acute cellular rejection rate was lower in the 4-hr CYA-IV group (0%) compared with the CYA-ME group (17%, P=0.038).",Cyclosporine A-based immunotherapy in adult living donor liver transplantation: accurate and improved therapeutic drug monitoring by 4-hr intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21546866/),,17,34932,DB00864,Tacrolimus
,30719576,apparent clearance (CL/F),"The mean apparent clearance (CL/F) of tacrolimus was 13.4 L/h, with an inter-individual variability of 22.4%.",Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30719576/),[l] / [h],13.4,35338,DB00864,Tacrolimus
,24734081,Absorption rate constant,Absorption rate constant was fixed at two hours(-1).,Clinical pharmacokinetics of tacrolimus in Iranian liver transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24734081/),1/[hours],two,35638,DB00864,Tacrolimus
,24734081,blood trough concentrations,Tacrolimus blood trough concentrations varied widely within the range of 1.8 to 30 ng/mL.,Clinical pharmacokinetics of tacrolimus in Iranian liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24734081/),[ng] / [ml],1.8 to 30,35639,DB00864,Tacrolimus
,24734081,CL/F,"The mean values of CL/F, Vd/F, and t½β were found to be 9.3 ± 0.96 L/h, 101 ± 29 L, and 7.5 hours, respectively.",Clinical pharmacokinetics of tacrolimus in Iranian liver transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24734081/),[l] / [h],9.3,35640,DB00864,Tacrolimus
,24734081,Vd/F,"The mean values of CL/F, Vd/F, and t½β were found to be 9.3 ± 0.96 L/h, 101 ± 29 L, and 7.5 hours, respectively.",Clinical pharmacokinetics of tacrolimus in Iranian liver transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24734081/),l,101,35641,DB00864,Tacrolimus
,24734081,t½β,"The mean values of CL/F, Vd/F, and t½β were found to be 9.3 ± 0.96 L/h, 101 ± 29 L, and 7.5 hours, respectively.",Clinical pharmacokinetics of tacrolimus in Iranian liver transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24734081/),h,7.5,35642,DB00864,Tacrolimus
,19703559,particle size,Mean particle size and drug encapsulation efficiency of PLGA were 218+/-51nm and 60.0+/-1.2% and for PEG-PLGA NP were 220+/-33nm and 60.3+/-2.0%.,Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703559/),nm,218,37436,DB00864,Tacrolimus
,19703559,particle size,Mean particle size and drug encapsulation efficiency of PLGA were 218+/-51nm and 60.0+/-1.2% and for PEG-PLGA NP were 220+/-33nm and 60.3+/-2.0%.,Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703559/),nm,220,37437,DB00864,Tacrolimus
,19703559,drug encapsulation efficiency,Mean particle size and drug encapsulation efficiency of PLGA were 218+/-51nm and 60.0+/-1.2% and for PEG-PLGA NP were 220+/-33nm and 60.3+/-2.0%.,Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703559/),%,60.0,37438,DB00864,Tacrolimus
,19703559,drug encapsulation efficiency,Mean particle size and drug encapsulation efficiency of PLGA were 218+/-51nm and 60.0+/-1.2% and for PEG-PLGA NP were 220+/-33nm and 60.3+/-2.0%.,Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19703559/),%,60.3,37439,DB00864,Tacrolimus
,32803290,AUC0-12h/D,"From 146 SNPs within 39 genes screened, AUC0-12h/D was found higher in recipients with CREB1 rs11904814 TT than with G allele carriers (3.135 ± 0.928 versus 2.084 ± 0.379 μg h ml-1 mg-1, p = 0.007).",Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32803290/),[h·μg] / [mg·ml],3.135,38847,DB00864,Tacrolimus
,32803290,AUC0-12h/D,"From 146 SNPs within 39 genes screened, AUC0-12h/D was found higher in recipients with CREB1 rs11904814 TT than with G allele carriers (3.135 ± 0.928 versus 2.084 ± 0.379 μg h ml-1 mg-1, p = 0.007).",Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32803290/),[h·μg] / [mg·ml],2.084,38848,DB00864,Tacrolimus
,32803290,t1/2,"Recipients with SLC28A3 rs10868138 TT had lower t1/2 as compared to C allele carriers (0.728 ± 0.189 versus 0.951 ± 0.196 h, p = 0.001).",Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32803290/),h,0.728,38849,DB00864,Tacrolimus
,32803290,t1/2,"Recipients with SLC28A3 rs10868138 TT had lower t1/2 as compared to C allele carriers (0.728 ± 0.189 versus 0.951 ± 0.196 h, p = 0.001).",Genetic and clinical determinants of mizoribine pharmacokinetics in renal transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32803290/),h,0.951,38850,DB00864,Tacrolimus
,26518936,concentration-,"(3) However, from the first month after transplantation, patients with grafts from donor carriers of minor allele*1 had lower concentration-dose ratios compared with patients with grafts from donor non-carriers of that allele (71.1 versus 119.3 and 90.5 versus 126.3, for 30 and 90 days after transplantation, respectively; P < .05).",Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26518936/),,119,39213,DB00864,Tacrolimus
,26518936,concentration-,"(3) However, from the first month after transplantation, patients with grafts from donor carriers of minor allele*1 had lower concentration-dose ratios compared with patients with grafts from donor non-carriers of that allele (71.1 versus 119.3 and 90.5 versus 126.3, for 30 and 90 days after transplantation, respectively; P < .05).",Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26518936/),,90,39214,DB00864,Tacrolimus
,26518936,concentration-,"(3) However, from the first month after transplantation, patients with grafts from donor carriers of minor allele*1 had lower concentration-dose ratios compared with patients with grafts from donor non-carriers of that allele (71.1 versus 119.3 and 90.5 versus 126.3, for 30 and 90 days after transplantation, respectively; P < .05).",Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26518936/),,126,39215,DB00864,Tacrolimus
,17437161,distribution volume,"The means of distribution volume and elimination half-life (t (1/2)) during the first 2 weeks were 0.05 l/kg and 9.5 days, respectively.",A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437161/),[l] / [kg],0.05,39821,DB00864,Tacrolimus
,17437161,elimination half-life (t (1/2)),"The means of distribution volume and elimination half-life (t (1/2)) during the first 2 weeks were 0.05 l/kg and 9.5 days, respectively.",A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17437161/),d,9.5,39822,DB00864,Tacrolimus
,12372043,AUC0-12,"Morning and evening doses were independently adjusted to reach an AUC0-12 of 6600-7200 ng h/mL and a C0 of 250-325 ng/mL, respectively.",Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),[h·ng] / [ml],6600-7200,41559,DB00864,Tacrolimus
,12372043,C0,"Morning and evening doses were independently adjusted to reach an AUC0-12 of 6600-7200 ng h/mL and a C0 of 250-325 ng/mL, respectively.",Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),[ng] / [ml],250-325,41560,DB00864,Tacrolimus
,12372043,AUCs,An average of 8 AUCs (range 5-13) were measured in the first 3 months.,Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),,8,41561,DB00864,Tacrolimus
,32924532,clearance,"The typical value of clearance, the distribution volume of the central room, the distribution volume of the peripheral room, and the intercompartmental clearance were 5.05L/h, 4.33L, 155L, and 6.22L/h, respectively.",Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32924532/),[l] / [h],5.05,42814,DB00864,Tacrolimus
,32924532,distribution volume of the central room,"The typical value of clearance, the distribution volume of the central room, the distribution volume of the peripheral room, and the intercompartmental clearance were 5.05L/h, 4.33L, 155L, and 6.22L/h, respectively.",Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32924532/),l,4.33,42815,DB00864,Tacrolimus
,32924532,distribution volume of the central room,"The typical value of clearance, the distribution volume of the central room, the distribution volume of the peripheral room, and the intercompartmental clearance were 5.05L/h, 4.33L, 155L, and 6.22L/h, respectively.",Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32924532/),l,155,42816,DB00864,Tacrolimus
,32924532,distribution volume of,"The typical value of clearance, the distribution volume of the central room, the distribution volume of the peripheral room, and the intercompartmental clearance were 5.05L/h, 4.33L, 155L, and 6.22L/h, respectively.",Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32924532/),l,4.33,42817,DB00864,Tacrolimus
,32924532,distribution volume of,"The typical value of clearance, the distribution volume of the central room, the distribution volume of the peripheral room, and the intercompartmental clearance were 5.05L/h, 4.33L, 155L, and 6.22L/h, respectively.",Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32924532/),l,155,42818,DB00864,Tacrolimus
,32924532,intercompartmental clearance,"The typical value of clearance, the distribution volume of the central room, the distribution volume of the peripheral room, and the intercompartmental clearance were 5.05L/h, 4.33L, 155L, and 6.22L/h, respectively.",Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32924532/),[l] / [h],6.22,42819,DB00864,Tacrolimus
,17253887,maximum plasma concentration (C(max)),"In the total of 72 profiles, the mean maximum plasma concentration (C(max)) and time to reach C(max) (t(max)) were 9.79 +/- 5.26 mg/L and 1.43 +/- 0.78 hours, respectively.",Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253887/),[mg] / [l],9.79,42928,DB00864,Tacrolimus
,17253887,time to reach C(max) (t(max)),"In the total of 72 profiles, the mean maximum plasma concentration (C(max)) and time to reach C(max) (t(max)) were 9.79 +/- 5.26 mg/L and 1.43 +/- 0.78 hours, respectively.",Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253887/),h,1.43,42929,DB00864,Tacrolimus
,17253887,AUC(12),The mean MPA AUC(12) was 46.50 +/- 17.42 mg . h/L (range 17.99-98.73 mg . h/L).,Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253887/),[h·mg] / [l],46.50,42930,DB00864,Tacrolimus
,21157403,predose drug concentration (C0),Sotrastaurin predose drug concentration (C0) was 0.6±0.4 μg/mL and did not differ when combined with standard-exposure versus reduced-exposure tacrolimus (P=0.99) nor when tacrolimus was replaced by MPA (P=0.11).,Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21157403/),[μg] / [ml],0.6,43328,DB00864,Tacrolimus
,21157403,peak concentration,"Sotrastaurin peak concentration was 1.6±0.6 μg/mL, and area under the drug concentration-time curve over a dosing interval (AUC) was 12.2±4.2 μg hr/mL.",Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21157403/),[μg] / [ml],1.6,43329,DB00864,Tacrolimus
,21157403,area under the drug concentration-time curve over a dosing interval (AUC),"Sotrastaurin peak concentration was 1.6±0.6 μg/mL, and area under the drug concentration-time curve over a dosing interval (AUC) was 12.2±4.2 μg hr/mL.",Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21157403/),[h·μg] / [ml],12.2,43330,DB00864,Tacrolimus
,9152601,binding capacity,"The binding capacity of drug with RBCs was independent of hematocrit, with a value of 440 ng/ml of RBCs; the binding affinity was 0.876 ng/ml using plasma or buffer.",Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152601/),[ng] / [ml],440,43495,DB00864,Tacrolimus
,9152601,binding affinity,"The binding capacity of drug with RBCs was independent of hematocrit, with a value of 440 ng/ml of RBCs; the binding affinity was 0.876 ng/ml using plasma or buffer.",Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152601/),[ng] / [ml],0.876,43496,DB00864,Tacrolimus
,9152601,clearance,"Diffusion of tacrolimus from RBCs to buffer was rapid with a clearance of 0.940 ml/min, and equilibration was achieved within 2 min.",Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152601/),[ml] / [min],0.940,43497,DB00864,Tacrolimus
,9152601,clearance,Diffusion in the opposite direction (buffer-RBCs) was slower with a clearance of 0.576 ml/min.,Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152601/),[ml] / [min],0.576,43498,DB00864,Tacrolimus
,9152601,efflux,"In such diffusion studies, plasma produced a greater difference between efflux (1.70 ml/min) and influx (0.276 ml/min) clearances.",Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152601/),[ml] / [min],1.70,43499,DB00864,Tacrolimus
,9152601,influx,"In such diffusion studies, plasma produced a greater difference between efflux (1.70 ml/min) and influx (0.276 ml/min) clearances.",Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152601/),[ml] / [min],0.276,43500,DB00864,Tacrolimus
,9152601,Intrinsic clearances,Intrinsic clearances were 8.43 and 17.44 ml/min for the well-stirred and parallel-tube models.,Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152601/),[ml] / [min],8.43,43501,DB00864,Tacrolimus
,9152601,Intrinsic clearances,Intrinsic clearances were 8.43 and 17.44 ml/min for the well-stirred and parallel-tube models.,Effect of hematocrit and albumin concentration on hepatic clearance of tacrolimus (FK506) during rabbit liver perfusion. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9152601/),[ml] / [min],17.44,43502,DB00864,Tacrolimus
,16049701,apparent clearance (CL/F),The best base model had bi-exponential elimination with a typical population (SE%) apparent clearance (CL/F) of 29 l/h (5%) and apparent volume of the central compartment of 65 l (7%).,Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16049701/),[l] / [h],29,43642,DB00864,Tacrolimus
,16049701,apparent volume of the central compartment,The best base model had bi-exponential elimination with a typical population (SE%) apparent clearance (CL/F) of 29 l/h (5%) and apparent volume of the central compartment of 65 l (7%).,Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16049701/),l,65,43643,DB00864,Tacrolimus
,22232022,AUC,"AUC and C(max) were found to be 45.05 ± 15.64 ng h/ml and 3.91 ± 1.2 ng/ml for TAC-SMEDDS, 12.59 ± 5.54 ng h/ml and 0.48 ± 0.12 ng/ml for plain TAC, and 30.23 ± 10.34 ng h/ml and 2.31 ± 0.68 ng/ml for marketed formulation, respectively.",Rice germ oil as multifunctional excipient in preparation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232022/),[h·ng] / [ml],45.05,43653,DB00864,Tacrolimus
,22232022,AUC,"AUC and C(max) were found to be 45.05 ± 15.64 ng h/ml and 3.91 ± 1.2 ng/ml for TAC-SMEDDS, 12.59 ± 5.54 ng h/ml and 0.48 ± 0.12 ng/ml for plain TAC, and 30.23 ± 10.34 ng h/ml and 2.31 ± 0.68 ng/ml for marketed formulation, respectively.",Rice germ oil as multifunctional excipient in preparation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232022/),[h·ng] / [ml],12.59,43654,DB00864,Tacrolimus
,22232022,AUC,"AUC and C(max) were found to be 45.05 ± 15.64 ng h/ml and 3.91 ± 1.2 ng/ml for TAC-SMEDDS, 12.59 ± 5.54 ng h/ml and 0.48 ± 0.12 ng/ml for plain TAC, and 30.23 ± 10.34 ng h/ml and 2.31 ± 0.68 ng/ml for marketed formulation, respectively.",Rice germ oil as multifunctional excipient in preparation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232022/),[h·ng] / [ml],30.23,43655,DB00864,Tacrolimus
,22232022,C(max),"AUC and C(max) were found to be 45.05 ± 15.64 ng h/ml and 3.91 ± 1.2 ng/ml for TAC-SMEDDS, 12.59 ± 5.54 ng h/ml and 0.48 ± 0.12 ng/ml for plain TAC, and 30.23 ± 10.34 ng h/ml and 2.31 ± 0.68 ng/ml for marketed formulation, respectively.",Rice germ oil as multifunctional excipient in preparation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232022/),[ng] / [ml],3.91,43656,DB00864,Tacrolimus
,22232022,C(max),"AUC and C(max) were found to be 45.05 ± 15.64 ng h/ml and 3.91 ± 1.2 ng/ml for TAC-SMEDDS, 12.59 ± 5.54 ng h/ml and 0.48 ± 0.12 ng/ml for plain TAC, and 30.23 ± 10.34 ng h/ml and 2.31 ± 0.68 ng/ml for marketed formulation, respectively.",Rice germ oil as multifunctional excipient in preparation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232022/),[h·ng] / [ml],30.23,43657,DB00864,Tacrolimus
,22232022,C(max),"AUC and C(max) were found to be 45.05 ± 15.64 ng h/ml and 3.91 ± 1.2 ng/ml for TAC-SMEDDS, 12.59 ± 5.54 ng h/ml and 0.48 ± 0.12 ng/ml for plain TAC, and 30.23 ± 10.34 ng h/ml and 2.31 ± 0.68 ng/ml for marketed formulation, respectively.",Rice germ oil as multifunctional excipient in preparation of self-microemulsifying drug delivery system (SMEDDS) of tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22232022/),[ng] / [ml],2.31,43658,DB00864,Tacrolimus
,23375287,trough levels,"The mean daily tacrolimus dose in the Native Americans was 0.03 ± 0.02 compared with the Caucasians 0.5 ± 0.3 (mg/kg/d; P = .002), with no significant differences in trough levels, (6.7 ± 3.1 vs 7.4 ± 2.1 ng/dL; P = .4).",Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23375287/),[ng] / [dl],6.7,43844,DB00864,Tacrolimus
,23375287,trough levels,"The mean daily tacrolimus dose in the Native Americans was 0.03 ± 0.02 compared with the Caucasians 0.5 ± 0.3 (mg/kg/d; P = .002), with no significant differences in trough levels, (6.7 ± 3.1 vs 7.4 ± 2.1 ng/dL; P = .4).",Genetic differences in Native Americans and tacrolimus dosing after kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23375287/),[ng] / [dl],7.4,43845,DB00864,Tacrolimus
,24071959,Bioavailability,Bioavailability was 49 % lower in expressers of cytochrome P450 3A5 (CYP3A5) than in CYP3A5 nonexpressers.,Importance of hematocrit for a tacrolimus target concentration strategy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071959/),%,49,44207,DB00864,Tacrolimus
,24071959,Bioavailability,Bioavailability increased with age for both males and females towards a common value at age >55 years that was 47 % higher than the male value at age <40 years.,Importance of hematocrit for a tacrolimus target concentration strategy. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071959/),%,47,44208,DB00864,Tacrolimus
,23089531,Trough levels,"Trough levels were fairly consistent at 7.9-18 ng·h/mL in all the patients included in this study, and this did not show variation with age or sex.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[h·ng] / [ml],7.9-18,45100,DB00864,Tacrolimus
,23089531,AUC0-6,"The AUC0-6 was higher [202-290 ng/mL at 3-8 mg bis-daily (b.d.) dosage] in patients who received kidneys from cadavers compared to recipients from live donors (60.5-171 ng/mL at 3-8 mg b.d. dosage), but the clinical significance of this is not known.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],202-290,45101,DB00864,Tacrolimus
,23089531,AUC0-6,"The AUC0-6 was higher [202-290 ng/mL at 3-8 mg bis-daily (b.d.) dosage] in patients who received kidneys from cadavers compared to recipients from live donors (60.5-171 ng/mL at 3-8 mg b.d. dosage), but the clinical significance of this is not known.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],60.5-171,45102,DB00864,Tacrolimus
,23089531,AUC0-6,"The highest AUC0-6 was 246 ng/mL, observed at 4.5 mg b.d. dosage.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],246,45103,DB00864,Tacrolimus
,9664950,Apparent clearance,Apparent clearance of MPA decreased from 5 to 1 ml/min per kg within 2 weeks.,Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9664950/),[ml] / [kg·min],5,45694,DB00864,Tacrolimus
,9664950,Apparent clearance,Apparent clearance of MPA decreased from 5 to 1 ml/min per kg within 2 weeks.,Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9664950/),[ml] / [kg·min],1,45695,DB00864,Tacrolimus
,9664950,area under the curve (AUC),The MPA dose ranged from 178 to 1008 mg/m2 per day to achieve an area under the curve (AUC) of 59.9 micrograms x h/ml +/- 10.5 SD (range 49-65 micrograms).,Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9664950/),[h·μg] / [ml],59.9,45696,DB00864,Tacrolimus
,9664950,AUC,FK506 dose ranged from 1.3 to 8.8 mg/m2 per day to achieve an AUC of 116 ng x h/ml +/- 27 SD (range 83-145).,Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9664950/),[h·ng] / [ml],116,45697,DB00864,Tacrolimus
,16130190,C(max),"The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively.",Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130190/),[μg] / [ml],21.88,48538,DB00864,Tacrolimus
,16130190,t(max),"The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively.",Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130190/),h,1.20,48539,DB00864,Tacrolimus
,16130190,AUC((0-12)),"The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively.",Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130190/),[h·μg] / [ml],52.546,48540,DB00864,Tacrolimus
,32571700,ICU stay,ICU stay was 14 ± 11 vs 15 ± 15 days; P = .76.,Tacrolimus and Mycophenolic Acid Blood Concentration and Cellular Rejection After Heart Transplantation in First Endomyocardial Biopsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32571700/),d,14,49143,DB00864,Tacrolimus
,32571700,ICU stay,ICU stay was 14 ± 11 vs 15 ± 15 days; P = .76.,Tacrolimus and Mycophenolic Acid Blood Concentration and Cellular Rejection After Heart Transplantation in First Endomyocardial Biopsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32571700/),d,15,49144,DB00864,Tacrolimus
,15084173,Half-life,"Half-life (h) did not differ significantly between different transplant groups for SRL and TAC (SRL: LTx: 21.2 h, SBTx: 19.3 h; TAC: LTx: 14.1 h, SBTx: 12.7 h).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,21.2,49545,DB00864,Tacrolimus
,15084173,Half-life,"Half-life (h) did not differ significantly between different transplant groups for SRL and TAC (SRL: LTx: 21.2 h, SBTx: 19.3 h; TAC: LTx: 14.1 h, SBTx: 12.7 h).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,19.3,49546,DB00864,Tacrolimus
,15084173,Half-life,"Half-life (h) did not differ significantly between different transplant groups for SRL and TAC (SRL: LTx: 21.2 h, SBTx: 19.3 h; TAC: LTx: 14.1 h, SBTx: 12.7 h).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,14.1,49547,DB00864,Tacrolimus
,15084173,Half-life,"Half-life (h) did not differ significantly between different transplant groups for SRL and TAC (SRL: LTx: 21.2 h, SBTx: 19.3 h; TAC: LTx: 14.1 h, SBTx: 12.7 h).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,12.7,49548,DB00864,Tacrolimus
,15084173,half-life,"During this period, SRL half-life increased significantly, from 11.2 +/- 1.0-20.1 +/- 3.1 h (n = 4; p = 0.02).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,11.2,49549,DB00864,Tacrolimus
,15084173,half-life,"During this period, SRL half-life increased significantly, from 11.2 +/- 1.0-20.1 +/- 3.1 h (n = 4; p = 0.02).",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),h,20.1,49550,DB00864,Tacrolimus
,15084173,half-life,"After introduction of SRL, TAC half-life did not change (11.6 +/- 3.9-14.0 +/- 10.4, n = 10, P = 0.52) in all the groups analyzed together.",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),,11.6,49551,DB00864,Tacrolimus
,15084173,half-life,"After introduction of SRL, TAC half-life did not change (11.6 +/- 3.9-14.0 +/- 10.4, n = 10, P = 0.52) in all the groups analyzed together.",Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),,14.0,49552,DB00864,Tacrolimus
,15084173,AUC/dose/BSA,TAC AUC/dose/BSA decreased significantly in LTx and SBTx patients (90.9 +/- 55.3 vs. 48.8 +/- 27.3).,Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),,90.9,49553,DB00864,Tacrolimus
,15084173,AUC/dose/BSA,TAC AUC/dose/BSA decreased significantly in LTx and SBTx patients (90.9 +/- 55.3 vs. 48.8 +/- 27.3).,Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15084173/),,48.8,49554,DB00864,Tacrolimus
,33768546,trough concentrations,"For patients carrying the CYP3A5*3/*3 allele and with 30% HCT, the required TAC dose to achieve target trough concentrations of 10-15 ng/ml was 4 mg twice daily (q12h).",Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33768546/),[ng] / [ml],10-15,49698,DB00864,Tacrolimus
,15251324,AUC,We used first-order PK modeling to calculate the doses for a mycophenolic acid (MPA) AUC of 60 ug*h/mL and a Tac AUC of 150 ng*h/mL.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ug] / [ml],60,50026,DB00864,Tacrolimus
,15251324,AUC,We used first-order PK modeling to calculate the doses for a mycophenolic acid (MPA) AUC of 60 ug*h/mL and a Tac AUC of 150 ng*h/mL.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ng] / [ml],150,50027,DB00864,Tacrolimus
,15251324,AUC,"The mean Tac dose was 2.6 +/- 1.2 mg/m2/d or 0.086 +/- 0.038 mg/kg/d, resulting in an average AUC of 120.6 +/- 30.4 ng*h/mL.",Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ng] / [ml],120.6,50028,DB00864,Tacrolimus
,15251324,AUC,"The MMF dose was not normally distributed; the median dose was 549 mg/m2/d (range, 146-1413) and the median MPA AUC was 49.8 ug*h/mL (range, 26.7-156.0).",Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ug] / [ml],49.8,50029,DB00864,Tacrolimus
,15251324,AUC,The mean dose for a Tac AUC of 150 ng*h/mL was 3.50 +/- 1.77 mg/m2/d (0.117 +/- 0.058 mg/kg) and was independent of age or time after transplantation.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[mg] / [d·m2],150,50030,DB00864,Tacrolimus
,15251324,AUC,The mean dose for a Tac AUC of 150 ng*h/mL was 3.50 +/- 1.77 mg/m2/d (0.117 +/- 0.058 mg/kg) and was independent of age or time after transplantation.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[mg] / [d·m2],3.50,50031,DB00864,Tacrolimus
,15251324,AUC,"By contrast, we found a negative relationship between the dose per m2 (r2 = 0.29; P = 0.0038) or per kg (r2 = 0.58; P < .0001) required for an MPA AUC of 60 ug*h/mL and patient age.",Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ug] / [ml],60,50032,DB00864,Tacrolimus
,23921430,Extraction efficiencies,"Extraction efficiencies for TAC and ascomycin were approximately 70%, and matrix effects were minimal.",Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23921430/),%,70,50311,DB00864,Tacrolimus
,23921430,tissue/blood concentrations ratios,"Rat kidney TAC concentrations were higher (range 109-190 pg/mg tissue) than those in the liver (range 22-53 pg/mg of tissue), with median tissue/blood concentrations ratios of 72.0 and 17.6, respectively.",Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23921430/),,72.0,50312,DB00864,Tacrolimus
,23921430,tissue/blood concentrations ratios,"Rat kidney TAC concentrations were higher (range 109-190 pg/mg tissue) than those in the liver (range 22-53 pg/mg of tissue), with median tissue/blood concentrations ratios of 72.0 and 17.6, respectively.",Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23921430/),,17.6,50313,DB00864,Tacrolimus
,24861504,trough levels [C0],"Pharmacokinetic studies have shown that mTOR inhibitors, everolimus (EVR) and sirolimus (SRL), have a large intra- and inter-patient variability in drug exposure, and narrow therapeutic windows (trough levels [C0] 3-8 ng/mL and 5-15 ng/mL, respectively).","Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861504/),[ng] / [ml],3-8,50425,DB00864,Tacrolimus
,24861504,trough levels [C0],"Pharmacokinetic studies have shown that mTOR inhibitors, everolimus (EVR) and sirolimus (SRL), have a large intra- and inter-patient variability in drug exposure, and narrow therapeutic windows (trough levels [C0] 3-8 ng/mL and 5-15 ng/mL, respectively).","Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24861504/),[ng] / [ml],5-15,50426,DB00864,Tacrolimus
,25207550,Apparent clearance (CL/F),"Apparent clearance (CL/F) and apparent volumes of distribution (V/F) in final population model were 5.72 L/h and 131 L, respectively.",Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25207550/),[l] / [h],5.72,50858,DB00864,Tacrolimus
,25207550,apparent volumes of distribution (V/F),"Apparent clearance (CL/F) and apparent volumes of distribution (V/F) in final population model were 5.72 L/h and 131 L, respectively.",Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25207550/),l,131,50859,DB00864,Tacrolimus
,25207550,absorption rate constant (Ka),The absorption rate constant (Ka) was fixed in 4.48 h-1.,Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25207550/),1/[h],4.48,50860,DB00864,Tacrolimus
,16143250,AUC,"AUC was 221 +/- 47.2 ng/ml (range, 156-329.3 ng/ml) at C0 10 to 15 ng/ml and was independent of TAC dose (R2 = 0.002).",Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16143250/),[ng] / [ml],221,50895,DB00864,Tacrolimus
,29374217,AUC0-inf,"AUC0-inf of TAC increased by 22.1% (322.4 ± 174.1 to 393.6 ± 121.7 ng·h/mL; P < 0.05) when co-administered with MMF, whereas the pharmacokinetic parameters of MPA and its metabolites were not changed by TAC.",Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374217/),[h·ng] / [ml],322.4,50918,DB00864,Tacrolimus
,29374217,AUC0-inf,"AUC0-inf of TAC increased by 22.1% (322.4 ± 174.1 to 393.6 ± 121.7 ng·h/mL; P < 0.05) when co-administered with MMF, whereas the pharmacokinetic parameters of MPA and its metabolites were not changed by TAC.",Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374217/),[h·ng] / [ml],393.6,50919,DB00864,Tacrolimus
,29374217,Apparent clearance (CL/F),"Apparent clearance (CL/F) of TAC was 17.8 L/h [relative standard error (RSE) 11%] or 13.8 L/h (RSE 11%) without or with MMF, respectively.",Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374217/),[l] / [h],17.8,50920,DB00864,Tacrolimus
,29374217,Apparent clearance (CL/F),"Apparent clearance (CL/F) of TAC was 17.8 L/h [relative standard error (RSE) 11%] or 13.8 L/h (RSE 11%) without or with MMF, respectively.",Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374217/),[l] / [h],13.8,50921,DB00864,Tacrolimus
,19302272,C0,Therapeutic range (C0: 1.5 +/- 0.5 - C2 : 4.0 +/- 1.0 mg/L) was expressed relative to pivotal pharmacokinetic trial data.,Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302272/),[mg] / [l],1.5,52315,DB00864,Tacrolimus
,19302272,C2,Therapeutic range (C0: 1.5 +/- 0.5 - C2 : 4.0 +/- 1.0 mg/L) was expressed relative to pivotal pharmacokinetic trial data.,Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302272/),[mg] / [l],4.0,52316,DB00864,Tacrolimus
<,19302272,C0,"Despite adaptation, C0 remained <0.5 mg/L (11%), even when the drug was administered intravenously, highlighting the variability of VRZ pharmacokinetics, possibly enhanced by CYP2C19 polymorphism.",Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302272/),[mg] / [l],0.5,52317,DB00864,Tacrolimus
,19302272,C0 to dose ratio,"VRZ acted as a metabolic inhibitor of tacrolimus (C0 to dose ratio 5.8 +/- 2.6, n=31/VRZ versus 1.7 +/- 0.9 alone, P<0.001).",Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302272/),,5.8,52318,DB00864,Tacrolimus
,19302272,C0 to dose ratio,"VRZ acted as a metabolic inhibitor of tacrolimus (C0 to dose ratio 5.8 +/- 2.6, n=31/VRZ versus 1.7 +/- 0.9 alone, P<0.001).",Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302272/),,1.7,52319,DB00864,Tacrolimus
,19302272,C0 at a steady state,"TDM is required because VRZ levels are often undetectable in treated CF lung transplant patients, supporting the use of antifungal drug combinations until achievement of VRZ C0 at a steady state between 1 and 2 mg/L.",Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19302272/),[mg] / [l],1 and 2,52320,DB00864,Tacrolimus
,24081206,area under the concentration-time curve (AUC(0-12 hours)),"The area under the concentration-time curve (AUC(0-12 hours)) for tacrolimus was low early after Tx (eg, median 78.6 around day 4) and variable in all 4 periods ranging from 3.8 to 267 μg h/L, whereas the predose concentrations (C₀) were 0.0-17.9 μg/L.",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[h·μg] / [l],78.6,52621,DB00864,Tacrolimus
,24081206,area under the concentration-time curve (AUC(0-12 hours)),"The area under the concentration-time curve (AUC(0-12 hours)) for tacrolimus was low early after Tx (eg, median 78.6 around day 4) and variable in all 4 periods ranging from 3.8 to 267 μg h/L, whereas the predose concentrations (C₀) were 0.0-17.9 μg/L.",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[h·μg] / [l],3.8 to 267,52622,DB00864,Tacrolimus
,24081206,concentrations (C₀),"The area under the concentration-time curve (AUC(0-12 hours)) for tacrolimus was low early after Tx (eg, median 78.6 around day 4) and variable in all 4 periods ranging from 3.8 to 267 μg h/L, whereas the predose concentrations (C₀) were 0.0-17.9 μg/L.",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[μg] / [l],0.0-17.9,52623,DB00864,Tacrolimus
,24081206,AUC(0-12 hours),"The AUC(0-12 hours) of MPA was in the range 8.6-57.4 mg h/L, with median values from 21.9 to 27.8 mg h/L, whereas C₀ was between 0.0 and 7.3 mg/L in the 4 periods (medians from 1.2 to 1.6 mg/L).",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[h·mg] / [l],8.6-57.4,52624,DB00864,Tacrolimus
,24081206,AUC(0-12 hours),"The AUC(0-12 hours) of MPA was in the range 8.6-57.4 mg h/L, with median values from 21.9 to 27.8 mg h/L, whereas C₀ was between 0.0 and 7.3 mg/L in the 4 periods (medians from 1.2 to 1.6 mg/L).",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[h·mg] / [l],21.9 to 27.8,52625,DB00864,Tacrolimus
,24081206,C₀,"The AUC(0-12 hours) of MPA was in the range 8.6-57.4 mg h/L, with median values from 21.9 to 27.8 mg h/L, whereas C₀ was between 0.0 and 7.3 mg/L in the 4 periods (medians from 1.2 to 1.6 mg/L).",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[mg] / [l],0.0 and 7.3,52626,DB00864,Tacrolimus
,24081206,C₀,"The AUC(0-12 hours) of MPA was in the range 8.6-57.4 mg h/L, with median values from 21.9 to 27.8 mg h/L, whereas C₀ was between 0.0 and 7.3 mg/L in the 4 periods (medians from 1.2 to 1.6 mg/L).",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[mg] / [l],1.2 to 1.6,52627,DB00864,Tacrolimus
,24081206,maximum inhibition,The maximum inhibition of inosine monophosphate dehydrogenase within a dose interval ranged from 9.5% to 100%.,Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),%,9.5,52628,DB00864,Tacrolimus
,24081206,maximum inhibition,The maximum inhibition of inosine monophosphate dehydrogenase within a dose interval ranged from 9.5% to 100%.,Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),%,100,52629,DB00864,Tacrolimus
,7494802,volume of distribution at steady-state (Vss),L-FK 506 exhibited an increased volume of distribution at steady-state (Vss) (from 3.41 to 14.71 L/kg) and increased mean residence time (MRT) (from 2.83 to 16.07 hr).,"Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK 506) in rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494802/),[l] / [kg],3.41 to 14.71,54188,DB00864,Tacrolimus
,7494802,mean residence time (MRT),L-FK 506 exhibited an increased volume of distribution at steady-state (Vss) (from 3.41 to 14.71 L/kg) and increased mean residence time (MRT) (from 2.83 to 16.07 hr).,"Physicochemical, pharmacokinetic and pharmacodynamic evaluation of liposomal tacrolimus (FK 506) in rats. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7494802/),h,2.83 to 16.07,54189,DB00864,Tacrolimus
,24084327,C(0),"On Day 10, 117 patients completed PK profiles (54 GEN tacrolimus and 63 REF tacrolimus) and GEN tacrolimus showed comparable C(0) (9.8 ± 2.5 versus 9.7 ± 3.0 ng/mL, P = 0.80) but significantly higher dose-normalized C(max) (309.1 ± 191.9 versus 192.5 ± 95.2 ng/mL/mg/kg, P < 0.001).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[ng] / [ml],9.8,54684,DB00864,Tacrolimus
,24084327,C(0),"On Day 10, 117 patients completed PK profiles (54 GEN tacrolimus and 63 REF tacrolimus) and GEN tacrolimus showed comparable C(0) (9.8 ± 2.5 versus 9.7 ± 3.0 ng/mL, P = 0.80) but significantly higher dose-normalized C(max) (309.1 ± 191.9 versus 192.5 ± 95.2 ng/mL/mg/kg, P < 0.001).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[ng] / [ml],9.7,54685,DB00864,Tacrolimus
,24084327,dose-normalized C(max),"On Day 10, 117 patients completed PK profiles (54 GEN tacrolimus and 63 REF tacrolimus) and GEN tacrolimus showed comparable C(0) (9.8 ± 2.5 versus 9.7 ± 3.0 ng/mL, P = 0.80) but significantly higher dose-normalized C(max) (309.1 ± 191.9 versus 192.5 ± 95.2 ng/mL/mg/kg, P < 0.001).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[ng] / [kg·mg·ml],309.1,54686,DB00864,Tacrolimus
,24084327,dose-normalized C(max),"On Day 10, 117 patients completed PK profiles (54 GEN tacrolimus and 63 REF tacrolimus) and GEN tacrolimus showed comparable C(0) (9.8 ± 2.5 versus 9.7 ± 3.0 ng/mL, P = 0.80) but significantly higher dose-normalized C(max) (309.1 ± 191.9 versus 192.5 ± 95.2 ng/mL/mg/kg, P < 0.001).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[ng] / [kg·mg·ml],192.5,54687,DB00864,Tacrolimus
,24084327,dose-normalized AUC(0-12),"The dose-normalized AUC(0-12) tended to be higher in the GEN tacrolimus than in the REF tacrolimus group (1513.4 ± 935.4 versus 1262.5 ± 593.5 ng.h/mL/mg/kg, P = 0.084).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[h·ng] / [kg·mg·ml],1513.4,54688,DB00864,Tacrolimus
,24084327,dose-normalized AUC(0-12),"The dose-normalized AUC(0-12) tended to be higher in the GEN tacrolimus than in the REF tacrolimus group (1513.4 ± 935.4 versus 1262.5 ± 593.5 ng.h/mL/mg/kg, P = 0.084).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[h·ng] / [kg·mg·ml],1262.5,54689,DB00864,Tacrolimus
,24084327,dose-normalized AUC(0-12),"At 6 months, GEN tacrolimus showed equivalent dose-normalized AUC(0-12) (1882.2 ± 935.6 versus 1718.1 ± 946.3 ng.h/mL/mg/kg, P = 0.429) but still higher dose-normalized C(max) (346.3 ± 184.4 versus 273.2 ± 148.9 ng/mL/mg/kg, P = 0.056), despite a reduced trough concentration (5.7 ± 1.6 versus 6.9 ± 2.2 ng/mL, P = 0.004).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[h·ng] / [kg·mg·ml],1882.2,54690,DB00864,Tacrolimus
,24084327,dose-normalized AUC(0-12),"At 6 months, GEN tacrolimus showed equivalent dose-normalized AUC(0-12) (1882.2 ± 935.6 versus 1718.1 ± 946.3 ng.h/mL/mg/kg, P = 0.429) but still higher dose-normalized C(max) (346.3 ± 184.4 versus 273.2 ± 148.9 ng/mL/mg/kg, P = 0.056), despite a reduced trough concentration (5.7 ± 1.6 versus 6.9 ± 2.2 ng/mL, P = 0.004).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[h·ng] / [kg·mg·ml],1718.1,54691,DB00864,Tacrolimus
,24084327,dose-normalized C(max),"At 6 months, GEN tacrolimus showed equivalent dose-normalized AUC(0-12) (1882.2 ± 935.6 versus 1718.1 ± 946.3 ng.h/mL/mg/kg, P = 0.429) but still higher dose-normalized C(max) (346.3 ± 184.4 versus 273.2 ± 148.9 ng/mL/mg/kg, P = 0.056), despite a reduced trough concentration (5.7 ± 1.6 versus 6.9 ± 2.2 ng/mL, P = 0.004).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[ng] / [kg·mg·ml],346.3,54692,DB00864,Tacrolimus
,24084327,dose-normalized C(max),"At 6 months, GEN tacrolimus showed equivalent dose-normalized AUC(0-12) (1882.2 ± 935.6 versus 1718.1 ± 946.3 ng.h/mL/mg/kg, P = 0.429) but still higher dose-normalized C(max) (346.3 ± 184.4 versus 273.2 ± 148.9 ng/mL/mg/kg, P = 0.056), despite a reduced trough concentration (5.7 ± 1.6 versus 6.9 ± 2.2 ng/mL, P = 0.004).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[ng] / [kg·mg·ml],273.2,54693,DB00864,Tacrolimus
,24084327,trough concentration,"At 6 months, GEN tacrolimus showed equivalent dose-normalized AUC(0-12) (1882.2 ± 935.6 versus 1718.1 ± 946.3 ng.h/mL/mg/kg, P = 0.429) but still higher dose-normalized C(max) (346.3 ± 184.4 versus 273.2 ± 148.9 ng/mL/mg/kg, P = 0.056), despite a reduced trough concentration (5.7 ± 1.6 versus 6.9 ± 2.2 ng/mL, P = 0.004).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[ng] / [ml],5.7,54694,DB00864,Tacrolimus
,24084327,trough concentration,"At 6 months, GEN tacrolimus showed equivalent dose-normalized AUC(0-12) (1882.2 ± 935.6 versus 1718.1 ± 946.3 ng.h/mL/mg/kg, P = 0.429) but still higher dose-normalized C(max) (346.3 ± 184.4 versus 273.2 ± 148.9 ng/mL/mg/kg, P = 0.056), despite a reduced trough concentration (5.7 ± 1.6 versus 6.9 ± 2.2 ng/mL, P = 0.004).",Therapeutic equivalence and pharmacokinetics of generic tacrolimus formulation in de novo kidney transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24084327/),[ng] / [ml],6.9,54695,DB00864,Tacrolimus
,19885684,0-12 h AUC,We suggest a 0-12 h AUC of around 150 ng x h/ml for stable paediatric renal transplant recipients 1 year after transplantation and around 100 ng x h/ml in the following years.,Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19885684/),[h·ng] / [ml],150,55141,DB00864,Tacrolimus
,19885684,0-12 h AUC,We suggest a 0-12 h AUC of around 150 ng x h/ml for stable paediatric renal transplant recipients 1 year after transplantation and around 100 ng x h/ml in the following years.,Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19885684/),[h·ng] / [ml],100,55142,DB00864,Tacrolimus
,16842519,T1/2,"In the immediate postoperative period, T1/2 of tacrolimus showed great variability between patients, with values ranging from 16.3 to 110.9 h.",A nomogram for predicting the optimal oral dosage of tacrolimus in liver transplant recipients with small-for-size grafts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842519/),h,16.3 to 110.9,55701,DB00864,Tacrolimus
,16842519,T1/2 ratio,"The recovered T1/2 ratio (T1/2 ratio=T1/2 1-10 d/T1/2 30-40 d), this ratio being related to the recovery of hepatic function with ability of the graft to eliminate tacrolimus, showed great variability between patients, with values ranging from 1.08 to 4.21 (mean+/-SD, 1.95+/-0.81).",A nomogram for predicting the optimal oral dosage of tacrolimus in liver transplant recipients with small-for-size grafts. ,t1/2 ratio-Q58,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16842519/),,1.95,55702,DB00864,Tacrolimus
,9246018,clearance,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[ml] / [h·kg],55.6,56123,DB00864,Tacrolimus
,9246018,clearance,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[ml] / [h·kg],42.5,56124,DB00864,Tacrolimus
,9246018,steady-state volume of distribution,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[l] / [kg],0.99,56125,DB00864,Tacrolimus
,9246018,steady-state volume of distribution,"Coadministration of ketoconazole did not consistently affect tacrolimus clearance (55.6 +/- 16.7 ml/hr/kg versus 42.5 +/- 7.6 ml/hr/kg), and steady-state volume of distribution was unchanged (0.99 +/- 0.26 L/kg versus 0.93 +/- 0.25 L/kg).",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),[l] / [kg],0.93,56126,DB00864,Tacrolimus
,9246018,bioavailability,"However, a significant increase in tacrolimus bioavailability (14% +/- 5% versus 30% +/- 8%; p < 0.01) was observed with coadministered ketoconazole.",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,14,56127,DB00864,Tacrolimus
,9246018,bioavailability,"However, a significant increase in tacrolimus bioavailability (14% +/- 5% versus 30% +/- 8%; p < 0.01) was observed with coadministered ketoconazole.",Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,30,56128,DB00864,Tacrolimus
,9246018,Hepatic bioavailability,Hepatic bioavailability was unchanged by the presence of ketoconazole (96% +/- 1% versus 97% +/- 1%).,Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,96,56129,DB00864,Tacrolimus
,9246018,Hepatic bioavailability,Hepatic bioavailability was unchanged by the presence of ketoconazole (96% +/- 1% versus 97% +/- 1%).,Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9246018/),%,97,56130,DB00864,Tacrolimus
,14755312,time to an absolute neutrophil count,"All patients engrafted rapidly; the median time to an absolute neutrophil count >0.5 x 10(9)/l was 14 days (range 11-17 days), and the median time to a platelet count >20 x 10(9)/l was 16 days (range 6-30 days).",Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14755312/),d,14,56589,DB00864,Tacrolimus
>,14755312,time to a platelet count,"All patients engrafted rapidly; the median time to an absolute neutrophil count >0.5 x 10(9)/l was 14 days (range 11-17 days), and the median time to a platelet count >20 x 10(9)/l was 16 days (range 6-30 days).",Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14755312/),,20,56590,DB00864,Tacrolimus
,14755312,time to a platelet count,"All patients engrafted rapidly; the median time to an absolute neutrophil count >0.5 x 10(9)/l was 14 days (range 11-17 days), and the median time to a platelet count >20 x 10(9)/l was 16 days (range 6-30 days).",Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14755312/),d,16,56591,DB00864,Tacrolimus
,15113534,m/z,"The mass transitions m/z 802.5-->560.3 and m/z 407.2-->151.9 were used to measure I and II, respectively.",Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113534/),,802.5,57549,DB00864,Tacrolimus
,15113534,m/z,"The mass transitions m/z 802.5-->560.3 and m/z 407.2-->151.9 were used to measure I and II, respectively.",Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113534/),,560.3,57550,DB00864,Tacrolimus
,15113534,m/z,"The mass transitions m/z 802.5-->560.3 and m/z 407.2-->151.9 were used to measure I and II, respectively.",Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113534/),,407.2,57551,DB00864,Tacrolimus
,15113534,m/z,"The mass transitions m/z 802.5-->560.3 and m/z 407.2-->151.9 were used to measure I and II, respectively.",Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113534/),,151.9,57552,DB00864,Tacrolimus
,15113534,Run time,Run time of 2min for each sample made it possible to analyze a throughput of more than 400 human plasma samples per day.,Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113534/),min,2,57553,DB00864,Tacrolimus
,15113534,observed maximum plasma concentration (C(max)),"The observed maximum plasma concentration (C(max)) of tacrolimus (5mg oral dose) is 440pg/ml, time to observed maximum plasma concentration (T(max)) is 2.5h and elimination half-life (T(1/2)) is 21h.",Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113534/),[pg] / [ml],440,57554,DB00864,Tacrolimus
,15113534,time to observed maximum plasma concentration (T(max)),"The observed maximum plasma concentration (C(max)) of tacrolimus (5mg oral dose) is 440pg/ml, time to observed maximum plasma concentration (T(max)) is 2.5h and elimination half-life (T(1/2)) is 21h.",Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113534/),h,2.5,57555,DB00864,Tacrolimus
,15113534,elimination half-life (T(1/2)),"The observed maximum plasma concentration (C(max)) of tacrolimus (5mg oral dose) is 440pg/ml, time to observed maximum plasma concentration (T(max)) is 2.5h and elimination half-life (T(1/2)) is 21h.",Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15113534/),h,21,57556,DB00864,Tacrolimus
,32170643,apparent clearance (CL/F),"The mean apparent clearance (CL/F) of tacrolimus was 17.1 L/h, with a between-subject variability of 20.1%.",Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32170643/),[l] / [h],17.1,57797,DB00864,Tacrolimus
,32170643,trough concentrations,"For patients with the CYP3A5*3*3 allele, the required tacrolimus dose for 75% of subjects to achieve target trough concentrations of 4.8-15 ng/mL was 2 mg every 12 h (q12h).",Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32170643/),[ng] / [ml],4.8-15,57798,DB00864,Tacrolimus
,23953523,Acute rejection rates,Acute rejection rates were 17.5% with rTAC and 7.7% with sTAC (P = .095).,"A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23953523/),%,17.5,58371,DB00864,Tacrolimus
,23953523,Acute rejection rates,Acute rejection rates were 17.5% with rTAC and 7.7% with sTAC (P = .095).,"A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23953523/),%,7.7,58372,DB00864,Tacrolimus
,30667591,trough concentrations,"Subsequent doses of both drugs were adjusted to maintain tacrolimus trough concentrations of 5 to 20 ng/mL through day 90, and 5-15 ng/mL thereafter.",Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30667591/),[ng] / [ml],5 to 20,59193,DB00864,Tacrolimus
,30667591,trough concentrations,"Subsequent doses of both drugs were adjusted to maintain tacrolimus trough concentrations of 5 to 20 ng/mL through day 90, and 5-15 ng/mL thereafter.",Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30667591/),[ng] / [ml],5-15,59194,DB00864,Tacrolimus
,18819472,CL/F,"Typical value of CL/F and V/F was 21.7 L x h(-1) and 241 L, inter-patient variability (RSD) in CL/F and V/F was 41.6% and 49.7%, respectively.",[Population pharmacokinetics of tacrolimus in Chinese renal transplant patients]. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819472/),[l] / [h],21.7,59408,DB00864,Tacrolimus
,18819472,V/F,"Typical value of CL/F and V/F was 21.7 L x h(-1) and 241 L, inter-patient variability (RSD) in CL/F and V/F was 41.6% and 49.7%, respectively.",[Population pharmacokinetics of tacrolimus in Chinese renal transplant patients]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18819472/),l,241,59409,DB00864,Tacrolimus
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],300.8,59514,DB00864,Tacrolimus
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],287.7,59515,DB00864,Tacrolimus
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],303.05,59516,DB00864,Tacrolimus
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],275.26,59517,DB00864,Tacrolimus
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],8.76,59518,DB00864,Tacrolimus
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],8.8,59519,DB00864,Tacrolimus
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],7.30,59520,DB00864,Tacrolimus
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],8.80,59521,DB00864,Tacrolimus
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],7.19,59522,DB00864,Tacrolimus
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],6.60,59523,DB00864,Tacrolimus
,17667791,Time to maximum concentration (T(max)),"Time to maximum concentration (T(max)) of acetaminophen was significantly longer in diabetics [D: 74.1 minute versus nondiabetics (ND): 29.3 minutes, P = 0.02]; however, tacrolimus T(max) was not significantly different (D: 121 minutes versus ND: 87 minutes, P = 0.15).",Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),min,74.1,59752,DB00864,Tacrolimus
,17667791,Time to maximum concentration (T(max)),"Time to maximum concentration (T(max)) of acetaminophen was significantly longer in diabetics [D: 74.1 minute versus nondiabetics (ND): 29.3 minutes, P = 0.02]; however, tacrolimus T(max) was not significantly different (D: 121 minutes versus ND: 87 minutes, P = 0.15).",Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),min,29.3,59753,DB00864,Tacrolimus
,17667791,T(max),"Time to maximum concentration (T(max)) of acetaminophen was significantly longer in diabetics [D: 74.1 minute versus nondiabetics (ND): 29.3 minutes, P = 0.02]; however, tacrolimus T(max) was not significantly different (D: 121 minutes versus ND: 87 minutes, P = 0.15).",Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),min,121,59754,DB00864,Tacrolimus
,17667791,T(max),"Time to maximum concentration (T(max)) of acetaminophen was significantly longer in diabetics [D: 74.1 minute versus nondiabetics (ND): 29.3 minutes, P = 0.02]; however, tacrolimus T(max) was not significantly different (D: 121 minutes versus ND: 87 minutes, P = 0.15).",Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),min,87,59755,DB00864,Tacrolimus
,17667791,AUC(0-12),Median (interquartile range) of tacrolimus AUC(0-12) was 114 (101-161) microg*hr/L in patients with diabetes and 113 (87-189) microg*hr/L in nondiabetics (P = 0.62).,Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),[h·μg] / [l],114,59756,DB00864,Tacrolimus
,17667791,AUC(0-12),Median (interquartile range) of tacrolimus AUC(0-12) was 114 (101-161) microg*hr/L in patients with diabetes and 113 (87-189) microg*hr/L in nondiabetics (P = 0.62).,Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17667791/),[h·μg] / [l],113,59757,DB00864,Tacrolimus
,19481022,serum concentrations (C(0)),"In the PPI group, the mean daily MMF dose was 1,912 +/- 1,023 mg with mean pre-dose serum concentrations (C(0)) of 1.9 +/- 1.4 mg/liter, without a significant difference from controls.",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],1.9,60240,DB00864,Tacrolimus
,19481022,concentrations at 30 minutes (C(0.5h),"Mean post-dose MPA concentrations at 30 minutes (C(0.5h)) were significantly higher in the control group (control, 17.9 +/- 11.5 mg/liter; PPI, 6.7 +/- 4.6 mg/liter; p < 0.001).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],17.9,60241,DB00864,Tacrolimus
,19481022,concentrations at 30 minutes (C(0.5h),"Mean post-dose MPA concentrations at 30 minutes (C(0.5h)) were significantly higher in the control group (control, 17.9 +/- 11.5 mg/liter; PPI, 6.7 +/- 4.6 mg/liter; p < 0.001).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],6.7,60242,DB00864,Tacrolimus
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],13.8,60243,DB00864,Tacrolimus
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],7.7,60244,DB00864,Tacrolimus
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],7.6,60245,DB00864,Tacrolimus
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],5.0,60246,DB00864,Tacrolimus
,19481022,C(12h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],3.3,60247,DB00864,Tacrolimus
,19481022,C(12h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],1.6,60248,DB00864,Tacrolimus
,19481022,AUC C(0-3h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],59.5,60249,DB00864,Tacrolimus
,19481022,AUC C(0-3h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],41.7,60250,DB00864,Tacrolimus
,19481022,maximum plasma concentration of mycophenolic acid (,"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],10.1,60251,DB00864,Tacrolimus
,19481022,maximum plasma concentration of mycophenolic acid (,"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],45.5,60252,DB00864,Tacrolimus
,19481022,t(max),"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),h,1.1,60253,DB00864,Tacrolimus
,19481022,t(max),"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),h,1.1,60254,DB00864,Tacrolimus
,23715050,trough levels,"In this phase 2 study, adult stable kidney transplant patients on tacrolimus capsules (Prograf) twice-daily were converted to tacrolimus tablets (LCP-Tacro) once-daily; patients continued on LCP-Tacro once-daily for days 8 to 21; trough levels were to be maintained between 5 and 15 ng/mL; 24-hr pharmacokinetic assessments were done on days 7 (baseline pre-switch), 14, and 21.",Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715050/),[ng] / [ml],5 and 15,60290,DB00864,Tacrolimus
,23715050,conversion ratio,The mean conversion ratio was 0.71.,Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase 2 trial of stable renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23715050/),,0.71,60291,DB00864,Tacrolimus
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,0.67,60927,DB00864,Tacrolimus
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,1.36,60928,DB00864,Tacrolimus
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),10,0.42,60929,DB00864,Tacrolimus
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,0.84,60930,DB00864,Tacrolimus
,17192769,area under curve (AUC)(0-12),The unadjusted tacrolimus area under curve (AUC)(0-12) was 106.8+/-17.5 ng/ml x h compared with 133.3+/-42.2 ng/ml x h (P=0.37) without affecting serum creatinine.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),[ng] / [h·ml],106.8,60931,DB00864,Tacrolimus
,17192769,area under curve (AUC)(0-12),The unadjusted tacrolimus area under curve (AUC)(0-12) was 106.8+/-17.5 ng/ml x h compared with 133.3+/-42.2 ng/ml x h (P=0.37) without affecting serum creatinine.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),[ng] / [h·ml],133.3,60932,DB00864,Tacrolimus
,23528073,venous plasma,The mean umbilical cord venous plasma (0.09 ± 0.04 ng ml(-1)) and unbound drug concentrations (0.003 ± 0.001 ng ml(-1)) were approximately one fifth of the respective maternal concentrations.,Tacrolimus placental transfer at delivery and neonatal exposure through breast milk. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23528073/),[ng] / [ml],0.09,61469,DB00864,Tacrolimus
,23528073,unbound drug concentrations,The mean umbilical cord venous plasma (0.09 ± 0.04 ng ml(-1)) and unbound drug concentrations (0.003 ± 0.001 ng ml(-1)) were approximately one fifth of the respective maternal concentrations.,Tacrolimus placental transfer at delivery and neonatal exposure through breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23528073/),[ng] / [ml],0.003,61470,DB00864,Tacrolimus
,24526611,C0,Values for initial dosing regimen of tacrolimus in order to reach a C0 of 10 ng/ml at day 5 (assuming a constant dosing schedule) as a function of CYP3A5 donor genotype and patient's hematocrit and body weight are proposed.,Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24526611/),[ng] / [ml],10,63172,DB00864,Tacrolimus
,24673714,AUC levels,"The mean AUC levels at day 3 and day 5 in the SD group were significantly higher than in the LD group (57.4 mg·h/l vs. 38.2 mg·h/l and 59.3 mg·h/l vs. 44.8 mg·h/l, respectively, p < 0.01).",Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],57.4,64141,DB00864,Tacrolimus
,24673714,AUC levels,"The mean AUC levels at day 3 and day 5 in the SD group were significantly higher than in the LD group (57.4 mg·h/l vs. 38.2 mg·h/l and 59.3 mg·h/l vs. 44.8 mg·h/l, respectively, p < 0.01).",Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],38.2,64142,DB00864,Tacrolimus
,24673714,AUC levels,"The mean AUC levels at day 3 and day 5 in the SD group were significantly higher than in the LD group (57.4 mg·h/l vs. 38.2 mg·h/l and 59.3 mg·h/l vs. 44.8 mg·h/l, respectively, p < 0.01).",Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],59.3,64143,DB00864,Tacrolimus
,24673714,AUC levels,"The mean AUC levels at day 3 and day 5 in the SD group were significantly higher than in the LD group (57.4 mg·h/l vs. 38.2 mg·h/l and 59.3 mg·h/l vs. 44.8 mg·h/l, respectively, p < 0.01).",Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],44.8,64144,DB00864,Tacrolimus
<,24673714,AUC,There were significantly more acute rejections (all definitions) in patients with MPA AUC levels < 30 mg·h/l compared with those with MPA AUC levels ≥ 30 mg·h/l within 6 months (p < 0.05).,Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],30,64145,DB00864,Tacrolimus
≥,24673714,AUC,There were significantly more acute rejections (all definitions) in patients with MPA AUC levels < 30 mg·h/l compared with those with MPA AUC levels ≥ 30 mg·h/l within 6 months (p < 0.05).,Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],30,64146,DB00864,Tacrolimus
greater,25511793,AUC12,MPA AUC12 was greater than 60 mg·h/L in 57 % of renal transplant recipients (RTR) with 71 % of patients demonstrating gastrointestinal AEs and a higher score noted in females.,Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25511793/),[h·mg] / [l],60,65086,DB00864,Tacrolimus
,23689735,AUC(0-12h),"The mean values of AUC(0-12h), pre-dose MPA trough concentration (C0), maximum concentrations (C(max)), and time to reach C(max) (T(max)) were 61.17 ± 26.39 mg·h/l (range 22.9-123.0 mg·h/l), 4.98 ± 4.65 mg/l (range 0.13-20.04 mg/l), 17.54 ± 10.67 mg/l (range 4.08-42.36 mg/l), and 5.0 ± 2.6 h (range 1.0-10.5 h), respectively.",Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23689735/),[h·mg] / [l],61.17,65299,DB00864,Tacrolimus
,23689735,time to reach C(max) (T(max)),"The mean values of AUC(0-12h), pre-dose MPA trough concentration (C0), maximum concentrations (C(max)), and time to reach C(max) (T(max)) were 61.17 ± 26.39 mg·h/l (range 22.9-123.0 mg·h/l), 4.98 ± 4.65 mg/l (range 0.13-20.04 mg/l), 17.54 ± 10.67 mg/l (range 4.08-42.36 mg/l), and 5.0 ± 2.6 h (range 1.0-10.5 h), respectively.",Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23689735/),h,5.0,65300,DB00864,Tacrolimus
,29965950,area under the concentration-time curve from 0 to 24 hours,Mean (SD) area under the concentration-time curve from 0 to 24 hours was 253.97 (61.90) ng/mL per hour for ODT and 282.44 (68.2) ng/mL per hour for LCPT.,Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965950/),[ng] / [h·ml],253.97,65881,DB00864,Tacrolimus
,29965950,area under the concentration-time curve from 0 to 24 hours,Mean (SD) area under the concentration-time curve from 0 to 24 hours was 253.97 (61.90) ng/mL per hour for ODT and 282.44 (68.2) ng/mL per hour for LCPT.,Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965950/),[ng] / [h·ml],282.44,65882,DB00864,Tacrolimus
,29965950,Time to maximum concentration,Time to maximum concentration was 125 minutes for ODT and 325 minutes for LCPT (P < 0.001).,Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965950/),min,125,65883,DB00864,Tacrolimus
,29965950,Time to maximum concentration,Time to maximum concentration was 125 minutes for ODT and 325 minutes for LCPT (P < 0.001).,Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29965950/),min,325,65884,DB00864,Tacrolimus
,9730427,first-dose time at which maximal concentration is reached (t(max)),"The interpatient variance in pharmacokinetic parameters in a subset of 10 patients was much higher after the first oral dose of tacrolimus than at steady-state (eg, first-dose time at which maximal concentration is reached (t(max)): 3.5+/-2.5h, steady-state t(max): 2.0+/-0.7h), and patients treated with intravenous tacrolimus (n=13) rather than oral tacrolimus (n=30) reached target concentrations faster and with less interpatient variability (eg, at day 0: 9.72+/-10.9 ng/mL intravenously vs 3.31+/-8.1 orally).",Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9730427/),h,3.5,65957,DB00864,Tacrolimus
,9730427,steady-state t(max),"The interpatient variance in pharmacokinetic parameters in a subset of 10 patients was much higher after the first oral dose of tacrolimus than at steady-state (eg, first-dose time at which maximal concentration is reached (t(max)): 3.5+/-2.5h, steady-state t(max): 2.0+/-0.7h), and patients treated with intravenous tacrolimus (n=13) rather than oral tacrolimus (n=30) reached target concentrations faster and with less interpatient variability (eg, at day 0: 9.72+/-10.9 ng/mL intravenously vs 3.31+/-8.1 orally).",Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9730427/),h,2.0,65958,DB00864,Tacrolimus
,9730427,steady-state t(max),"The interpatient variance in pharmacokinetic parameters in a subset of 10 patients was much higher after the first oral dose of tacrolimus than at steady-state (eg, first-dose time at which maximal concentration is reached (t(max)): 3.5+/-2.5h, steady-state t(max): 2.0+/-0.7h), and patients treated with intravenous tacrolimus (n=13) rather than oral tacrolimus (n=30) reached target concentrations faster and with less interpatient variability (eg, at day 0: 9.72+/-10.9 ng/mL intravenously vs 3.31+/-8.1 orally).",Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9730427/),,3.31,65959,DB00864,Tacrolimus
,33398393,Co/D ratio,"Additionally, PPARA variant homozygotes had a lower Co/D ratio than wild allele carriers in the 12-month post-transplant period, with a median value of 0.65 ng/mL/mg.",CYP3A5 and PPARA genetic variants are associated with low trough concentration to dose ratio of tacrolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33398393/),[ng] / [mg·ml],0.65,66642,DB00864,Tacrolimus
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],954,66805,DB00864,Tacrolimus
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66806,DB00864,Tacrolimus
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66807,DB00864,Tacrolimus
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],4787,66808,DB00864,Tacrolimus
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],451,66809,DB00864,Tacrolimus
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.3,66810,DB00864,Tacrolimus
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.2,66811,DB00864,Tacrolimus
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.1,66812,DB00864,Tacrolimus
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.3,66813,DB00864,Tacrolimus
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],186,66814,DB00864,Tacrolimus
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],200,66815,DB00864,Tacrolimus
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.20,67246,DB00864,Tacrolimus
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.25,67247,DB00864,Tacrolimus
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.44,67248,DB00864,Tacrolimus
,32452705,clearance rates,"With same weight and post-transplant days, tacrolimus clearance rates from patients carrying CYP3A5*3/*3 and without WZ, carrying CYP3A5*1 allele and without WZ, carrying CYP3A5*3/*3 and with WZ, carrying CYP3A5*1 allele and with WZ were 1, 1.6, 0.72, and 1.152, respectively.",Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32452705/),,1,67683,DB00864,Tacrolimus
,32452705,clearance rates,"With same weight and post-transplant days, tacrolimus clearance rates from patients carrying CYP3A5*3/*3 and without WZ, carrying CYP3A5*1 allele and without WZ, carrying CYP3A5*3/*3 and with WZ, carrying CYP3A5*1 allele and with WZ were 1, 1.6, 0.72, and 1.152, respectively.",Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32452705/),,1.6,67684,DB00864,Tacrolimus
,32452705,clearance rates,"With same weight and post-transplant days, tacrolimus clearance rates from patients carrying CYP3A5*3/*3 and without WZ, carrying CYP3A5*1 allele and without WZ, carrying CYP3A5*3/*3 and with WZ, carrying CYP3A5*1 allele and with WZ were 1, 1.6, 0.72, and 1.152, respectively.",Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32452705/),,0.72,67685,DB00864,Tacrolimus
,32452705,clearance rates,"With same weight and post-transplant days, tacrolimus clearance rates from patients carrying CYP3A5*3/*3 and without WZ, carrying CYP3A5*1 allele and without WZ, carrying CYP3A5*3/*3 and with WZ, carrying CYP3A5*1 allele and with WZ were 1, 1.6, 0.72, and 1.152, respectively.",Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32452705/),,1.152,67686,DB00864,Tacrolimus
,29159710,K B,"The protein-binding rate constant (KB [relative standard error, RSE%]) increased nonlinearly with renal function according to K B = 43.1 (3.13)·(CLCR/59.51)0.394(10.66) h-1.",Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159710/),1/[h],43.1,67746,DB00864,Tacrolimus
,29159710,K B,"The protein-binding rate constant (KB [relative standard error, RSE%]) increased nonlinearly with renal function according to K B = 43.1 (3.13)·(CLCR/59.51)0.394(10.66) h-1.",Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159710/),1/[h],0.394,67747,DB00864,Tacrolimus
,22310595,C(min),Mean C(min) decreased from 4.55 ± 1.79 to 3.20 ± 1.22 ng/dL.,Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22310595/),[ng] / [dl],4.55,67831,DB00864,Tacrolimus
,22310595,C(min),Mean C(min) decreased from 4.55 ± 1.79 to 3.20 ± 1.22 ng/dL.,Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22310595/),[ng] / [dl],3.20,67832,DB00864,Tacrolimus
,22310595,CDW,"The mean CDW also decreased, from 99.8 ± 69.5 to 75.0 ± 55.1 mg/dL/kg over the 2 months.",Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22310595/),[mg] / [dl·kg],99.8,67833,DB00864,Tacrolimus
,22310595,CDW,"The mean CDW also decreased, from 99.8 ± 69.5 to 75.0 ± 55.1 mg/dL/kg over the 2 months.",Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22310595/),[mg] / [dl·kg],75.0,67834,DB00864,Tacrolimus
,22310595,TC,"Mean TC increased from 187.5 ± 51.4 to 194.3 ± 43.4 mg/dL, and mean HDL-C changed from 53.7 ± 12.0 to 56.1 ± 11 mg/dL.",Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22310595/),[mg] / [dl],187.5,67835,DB00864,Tacrolimus
,22310595,TC,"Mean TC increased from 187.5 ± 51.4 to 194.3 ± 43.4 mg/dL, and mean HDL-C changed from 53.7 ± 12.0 to 56.1 ± 11 mg/dL.",Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22310595/),[mg] / [dl],194.3,67836,DB00864,Tacrolimus
,22310595,C(min),"With Graceptor, the ratio of area under trough level to area under the curve (AUC) is low compared with Prograf, resulting in low C(min) values of 1-2 ng/mL, and the AUC for Graceptor is very similar to that for Prograf.",Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22310595/),[ng] / [ml],1-2,67837,DB00864,Tacrolimus
,11210398,terminal exponential half-life,"Food had a clinically significant effect in reducing relative bioavailability, as well as slowing absorption, but did not affect terminal exponential half-life (approximately 34 hours).",Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210398/),h,34,68889,DB00864,Tacrolimus
,11210398,maximum tacrolimus blood concentration (Cmax),"Mean maximum tacrolimus blood concentration (Cmax) values were 25.6, 5.88, and 9.03 ng/mL for the fasting, high-fat, and low-fat treatments, respectively; mean area under the blood concentration-time curve (AUC(0-infinity) values were 272, 181, and 201 (ng/mL)-h, respectively; and mean time of Cmax (tmax) values were 1.37, 6.47, and 3.20 hours, respectively.",Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210398/),[ng] / [ml],25.6,68890,DB00864,Tacrolimus
,11210398,maximum tacrolimus blood concentration (Cmax),"Mean maximum tacrolimus blood concentration (Cmax) values were 25.6, 5.88, and 9.03 ng/mL for the fasting, high-fat, and low-fat treatments, respectively; mean area under the blood concentration-time curve (AUC(0-infinity) values were 272, 181, and 201 (ng/mL)-h, respectively; and mean time of Cmax (tmax) values were 1.37, 6.47, and 3.20 hours, respectively.",Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210398/),[ng] / [ml],5.88,68891,DB00864,Tacrolimus
,11210398,maximum tacrolimus blood concentration (Cmax),"Mean maximum tacrolimus blood concentration (Cmax) values were 25.6, 5.88, and 9.03 ng/mL for the fasting, high-fat, and low-fat treatments, respectively; mean area under the blood concentration-time curve (AUC(0-infinity) values were 272, 181, and 201 (ng/mL)-h, respectively; and mean time of Cmax (tmax) values were 1.37, 6.47, and 3.20 hours, respectively.",Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210398/),[ng] / [ml],9.03,68892,DB00864,Tacrolimus
,11210398,area under the blood concentration-time curve (AUC(0-infinity),"Mean maximum tacrolimus blood concentration (Cmax) values were 25.6, 5.88, and 9.03 ng/mL for the fasting, high-fat, and low-fat treatments, respectively; mean area under the blood concentration-time curve (AUC(0-infinity) values were 272, 181, and 201 (ng/mL)-h, respectively; and mean time of Cmax (tmax) values were 1.37, 6.47, and 3.20 hours, respectively.",Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210398/),[ng] / [ml)-h],272,68893,DB00864,Tacrolimus
,11210398,area under the blood concentration-time curve (AUC(0-infinity),"Mean maximum tacrolimus blood concentration (Cmax) values were 25.6, 5.88, and 9.03 ng/mL for the fasting, high-fat, and low-fat treatments, respectively; mean area under the blood concentration-time curve (AUC(0-infinity) values were 272, 181, and 201 (ng/mL)-h, respectively; and mean time of Cmax (tmax) values were 1.37, 6.47, and 3.20 hours, respectively.",Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210398/),[ng] / [ml)-h],181,68894,DB00864,Tacrolimus
,11210398,area under the blood concentration-time curve (AUC(0-infinity),"Mean maximum tacrolimus blood concentration (Cmax) values were 25.6, 5.88, and 9.03 ng/mL for the fasting, high-fat, and low-fat treatments, respectively; mean area under the blood concentration-time curve (AUC(0-infinity) values were 272, 181, and 201 (ng/mL)-h, respectively; and mean time of Cmax (tmax) values were 1.37, 6.47, and 3.20 hours, respectively.",Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210398/),[ng] / [ml)-h],201,68895,DB00864,Tacrolimus
,11210398,time of Cmax (tmax),"Mean maximum tacrolimus blood concentration (Cmax) values were 25.6, 5.88, and 9.03 ng/mL for the fasting, high-fat, and low-fat treatments, respectively; mean area under the blood concentration-time curve (AUC(0-infinity) values were 272, 181, and 201 (ng/mL)-h, respectively; and mean time of Cmax (tmax) values were 1.37, 6.47, and 3.20 hours, respectively.",Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210398/),h,1.37,68896,DB00864,Tacrolimus
,11210398,time of Cmax (tmax),"Mean maximum tacrolimus blood concentration (Cmax) values were 25.6, 5.88, and 9.03 ng/mL for the fasting, high-fat, and low-fat treatments, respectively; mean area under the blood concentration-time curve (AUC(0-infinity) values were 272, 181, and 201 (ng/mL)-h, respectively; and mean time of Cmax (tmax) values were 1.37, 6.47, and 3.20 hours, respectively.",Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210398/),h,6.47,68897,DB00864,Tacrolimus
,11210398,time of Cmax (tmax),"Mean maximum tacrolimus blood concentration (Cmax) values were 25.6, 5.88, and 9.03 ng/mL for the fasting, high-fat, and low-fat treatments, respectively; mean area under the blood concentration-time curve (AUC(0-infinity) values were 272, 181, and 201 (ng/mL)-h, respectively; and mean time of Cmax (tmax) values were 1.37, 6.47, and 3.20 hours, respectively.",Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11210398/),h,3.20,68898,DB00864,Tacrolimus
,12966368,trough levels,"Tacrolimus dose-adjusted trough levels were higher in CYP3A5*3/*3 patients (n = 45) than in *1/*3 plus *1/*1 patients (n = 17), as follows: median and range, 94 (34-398) ng/mL per mg/kg versus 61 (37-163) ng/mL per mg/kg (P <.0001, Mann-Whitney test).","Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966368/),[ng] / [kg·mg·ml],94,69586,DB00864,Tacrolimus
,12966368,trough levels,"Tacrolimus dose-adjusted trough levels were higher in CYP3A5*3/*3 patients (n = 45) than in *1/*3 plus *1/*1 patients (n = 17), as follows: median and range, 94 (34-398) ng/mL per mg/kg versus 61 (37-163) ng/mL per mg/kg (P <.0001, Mann-Whitney test).","Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966368/),[ng] / [kg·mg·ml],61,69587,DB00864,Tacrolimus
,12966368,trough levels,"CYP3A4*1B allele carriers (n = 10) had lower tacrolimus dose-adjusted trough levels compared with those in patients with the wild-type (*1/*1) genotype (n = 54): median and range, 57 (40-163) ng/mL per mg/kg versus 89 (34-398) ng/mL per mg/kg) (P =.003, Mann-Whitney test).","Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966368/),[ng] / [kg·mg·ml],57,69588,DB00864,Tacrolimus
,12966368,trough levels,"CYP3A4*1B allele carriers (n = 10) had lower tacrolimus dose-adjusted trough levels compared with those in patients with the wild-type (*1/*1) genotype (n = 54): median and range, 57 (40-163) ng/mL per mg/kg versus 89 (34-398) ng/mL per mg/kg) (P =.003, Mann-Whitney test).","Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12966368/),[ng] / [kg·mg·ml],89,69589,DB00864,Tacrolimus
,7690698,apparent plasma clearance,The apparent plasma clearance 1.67 liters/hr/kg is more than 5-fold higher than blood clearance 0.31 liters/hr/kg.,Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),[l] / [h·kg],1.67,69796,DB00864,Tacrolimus
,7690698,blood clearance,The apparent plasma clearance 1.67 liters/hr/kg is more than 5-fold higher than blood clearance 0.31 liters/hr/kg.,Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),[l] / [h·kg],0.31,69797,DB00864,Tacrolimus
,7690698,steady-state volume of distribution,The steady-state volume of distribution is 30.7 liters/kg for plasma and 6.3 liters/kg for whole blood.,Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),[l] / [kg],30.7,69798,DB00864,Tacrolimus
,7690698,steady-state volume of distribution,The steady-state volume of distribution is 30.7 liters/kg for plasma and 6.3 liters/kg for whole blood.,Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),[l] / [kg],6.3,69799,DB00864,Tacrolimus
,7690698,bioavailability,The bioavailability after oral administration calculated from plasma and whole blood is low with a mean value of 9.7%.,Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),%,9.7,69800,DB00864,Tacrolimus
,7690698,t1/2,"The in vitro studies and fitting using a nonlinear red blood cell (RBC)-plasma binding/diffusion model showed slow diffusion of drug from RBC to plasma (t1/2 = 7 min, CLD = 0.085 ml/min).",Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),min,7,69801,DB00864,Tacrolimus
,7690698,extraction ratio,"In perfused liver studies, the extraction ratio of tacrolimus from blood with hematocrit of 0.1 is low (0.20).",Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),,0.20,69802,DB00864,Tacrolimus
,7690698,extraction of,"However, extraction of drug from plasma is moderate (0.42), and plasma concentrations are elevated by an average of 28% because of redistribution of tacrolimus from RBC.",Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),,0.42,69803,DB00864,Tacrolimus
,7690698,apparent plasma clearance (DO/AUC),This creates a lower apparent plasma clearance (DO/AUC) for equilibrated (30 min at 37 degrees C) samples (15.4 ml/min) compared with samples centrifuged within 5 min (22.1 ml/min).,Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),[ml] / [min],15.4,69804,DB00864,Tacrolimus
,7690698,apparent plasma clearance (DO/AUC),This creates a lower apparent plasma clearance (DO/AUC) for equilibrated (30 min at 37 degrees C) samples (15.4 ml/min) compared with samples centrifuged within 5 min (22.1 ml/min).,Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),[ml] / [min],22.1,69805,DB00864,Tacrolimus
,7690698,intrinsic metabolic clearance,The intrinsic metabolic clearance averaged 29.2 ml/min.,Disposition of tacrolimus (FK 506) in rabbits. Role of red blood cell binding in hepatic clearance. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690698/),[ml] / [min],29.2,69806,DB00864,Tacrolimus
,25474192,concentrations,"The mean concentrations at 24 and 32 h postdose were 8.3 μg/l (7.5-9.1) and 6.7 μg/l (6.1-7.4), respectively (P < 0.0001).",Delayed trough level measurement with the use of prolonged-release tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25474192/),[μg] / [l],8.3,69954,DB00864,Tacrolimus
,25474192,concentrations,"The mean concentrations at 24 and 32 h postdose were 8.3 μg/l (7.5-9.1) and 6.7 μg/l (6.1-7.4), respectively (P < 0.0001).",Delayed trough level measurement with the use of prolonged-release tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25474192/),[μg] / [l],6.7,69955,DB00864,Tacrolimus
,29277422,elimination half-life,"In an in vivo pharmacokinetic study in fasted Cynomolgus monkeys, the drug level in blood was gradually increased over 4.7 h and high drug concentration was maintained until 24 h, with an elimination half-life of 16.6 h.",Formulation and in vivo pharmacokinetic evaluation of ethyl cellulose-coated sustained release multiple-unit system of tacrolimus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29277422/),h,16.6,70489,DB00864,Tacrolimus
,19038099,AUC,"Regarding mycophenolate mofetil, the targeted AUC has been defined between 30 and 60 mg/h/l.",[Recents advances in the pharmacology of immunosuppressive drugs used in organ transplantation]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19038099/),[mg] / [h·l],30 and 60,72503,DB00864,Tacrolimus
,31654150,clearance/bioavailability,"Furthermore, the median clearance/bioavailability of tacrolimus after discontinuation of clotrimazole was 2.2-fold greater than that before its discontinuation (0.27 vs. 0.59 L/h/kg, P < 0.05).",Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31654150/),[l] / [h·kg],0.27,72751,DB00864,Tacrolimus
,31654150,clearance/bioavailability,"Furthermore, the median clearance/bioavailability of tacrolimus after discontinuation of clotrimazole was 2.2-fold greater than that before its discontinuation (0.27 vs. 0.59 L/h/kg, P < 0.05).",Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31654150/),[l] / [h·kg],0.59,72752,DB00864,Tacrolimus
,31654150,C0,The median C0 decreased from 10.7 ng/mL on the day after discontinuation of clotrimazole to 6.5 ng/mL at 1 day and 5.3 ng/mL at 2 days after its discontinuation.,Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31654150/),[ng] / [ml],10.7,72753,DB00864,Tacrolimus
,31654150,C0,The median C0 decreased from 10.7 ng/mL on the day after discontinuation of clotrimazole to 6.5 ng/mL at 1 day and 5.3 ng/mL at 2 days after its discontinuation.,Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31654150/),[ng] / [ml],6.5,72754,DB00864,Tacrolimus
,31654150,C0,The median C0 decreased from 10.7 ng/mL on the day after discontinuation of clotrimazole to 6.5 ng/mL at 1 day and 5.3 ng/mL at 2 days after its discontinuation.,Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31654150/),[ng] / [ml],5.3,72755,DB00864,Tacrolimus
,34133842,CL/F,"The estimates of CL/F and V/F were 8.88 L/h and 495.82 L, respectively.",Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34133842/),[l] / [h],8.88,72972,DB00864,Tacrolimus
,34133842,V/F,"The estimates of CL/F and V/F were 8.88 L/h and 495.82 L, respectively.",Effects of Postoperative Day and NR1I2 on Tacrolimus Clearance in Chinese Liver Transplant Recipients-A Population Model Approach. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34133842/),l,495.82,72973,DB00864,Tacrolimus
,30251062,apparent oral clearance,"After clotrimazole was discontinued, the CYP3A5 expresser (CYP3A5*1/*1 or *1/*3) group had a 3.3-fold median increase in apparent oral clearance of tacrolimus (0.27 vs. 0.89 L/h/kg, P = 0.002) compared with the CYP3A5 non-expresser (CYP3A5*3/*3) group with a 2.2-fold median increase (0.18 vs. 0.39 L/h/kg, P < 0.0001).",Effects of clotrimazole on tacrolimus pharmacokinetics in patients with heart transplants with different CYP3A5 genotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30251062/),[l] / [h·kg],0.27,74170,DB00864,Tacrolimus
,30251062,apparent oral clearance,"After clotrimazole was discontinued, the CYP3A5 expresser (CYP3A5*1/*1 or *1/*3) group had a 3.3-fold median increase in apparent oral clearance of tacrolimus (0.27 vs. 0.89 L/h/kg, P = 0.002) compared with the CYP3A5 non-expresser (CYP3A5*3/*3) group with a 2.2-fold median increase (0.18 vs. 0.39 L/h/kg, P < 0.0001).",Effects of clotrimazole on tacrolimus pharmacokinetics in patients with heart transplants with different CYP3A5 genotypes. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30251062/),[l] / [h·kg],0.89,74171,DB00864,Tacrolimus
greater,27898598,area under the plasma concentration-time curve from 0 to 12 hours (AUC0-12),The aim of this study was to determine the MMF/MPS dosage required to achieve an area under the plasma concentration-time curve from 0 to 12 hours (AUC0-12) for mycophenolic acid (MPA) greater than 30 mg·h·L in children after intestinal transplantation.,Pharmacokinetics of Mycophenolic Acid and Dose Optimization in Children After Intestinal Transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27898598/),h·l·mg,30,75092,DB00864,Tacrolimus
below,27898598,AUC0-12,One of the 3 patients who received MPS and 2 of the 6 patients who received MMF had an MPA AUC0-12 value below 30 mg.h.L.,Pharmacokinetics of Mycophenolic Acid and Dose Optimization in Children After Intestinal Transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27898598/),h·l·mg,30,75093,DB00864,Tacrolimus
above,27898598,AUC0-12,The median MMF dosage had to be increased by 91% (1319 mg·m·d versus 687 mg·m·d) to reach AUC0-12 values above the defined target level of 30 mg·h·L.,Pharmacokinetics of Mycophenolic Acid and Dose Optimization in Children After Intestinal Transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27898598/),h·l·mg,30,75094,DB00864,Tacrolimus
,10051048,oral clearance (CL/F),The mean oral clearance (CL/F) and apparent volume of distribution (Vd/F) averaged 0.21+/-0.08 L/hour/kg and 2.4+/-0.8 L/kg while the half-life averaged 8.7+/-3.5 hours.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[l] / [h·kg],0.21,76612,DB00864,Tacrolimus
,10051048,apparent volume of distribution (Vd/F),The mean oral clearance (CL/F) and apparent volume of distribution (Vd/F) averaged 0.21+/-0.08 L/hour/kg and 2.4+/-0.8 L/kg while the half-life averaged 8.7+/-3.5 hours.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[l] / [kg],2.4,76613,DB00864,Tacrolimus
,10051048,half-life,The mean oral clearance (CL/F) and apparent volume of distribution (Vd/F) averaged 0.21+/-0.08 L/hour/kg and 2.4+/-0.8 L/kg while the half-life averaged 8.7+/-3.5 hours.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),h,8.7,76614,DB00864,Tacrolimus
,10051048,accumulation,Tacrolimus accumulation index during chronic therapy (Rac = Cmin(steady state)/Cmin(first dose) normalized to the same dose) averaged 1.3.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),,1.3,76615,DB00864,Tacrolimus
,10051048,trough blood levels,Eighty-eight percent of the trough blood levels measured in our patients were within 5 and 20 ng/ml.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[ng] / [ml],5,76616,DB00864,Tacrolimus
,10051048,trough blood levels,Eighty-eight percent of the trough blood levels measured in our patients were within 5 and 20 ng/ml.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[ng] / [ml],20,76617,DB00864,Tacrolimus
,10051048,trough blood concentrations,Pharmacokinetic data suggest that maintenance tacrolimus daily dose should be equal to 0.1 mg/kg/day to obtain trough blood concentrations of approximately 10 ng/ml.,Clinical pharmacokinetics of tacrolimus in heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10051048/),[ng] / [ml],10,76618,DB00864,Tacrolimus
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"2,260",77923,DB00864,Tacrolimus
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"1,730",77924,DB00864,Tacrolimus
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"5,200",77925,DB00864,Tacrolimus
,14570757,AUC,"For the dual CYP3A and P-gp substrate, tacrolimus, AUC +/- S.D. was decreased from control (2,260 +/- 430 ng. min/ml) by GG918 (1,730 +/- 270 ng. min/ml, P < 0.05) and was increased by troleandomycin (5,200 +/- 2,470 ng. min/ml, P < 0.05) and cyclosporine (4,390 +/- 2,080 ng. min/ml, P < 0.05).","Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14570757/),[min·ng] / [ml],"4,390",77926,DB00864,Tacrolimus
,10746167,kE0,"The pharmacodynamic parameters thus obtained were as follows: kE0 2.72 x 10(-4) (min-1), Emax 27.1 (ms), EC50 0.376 (ng/ml) for FK506; and kE0 0.148 (min-1), K 8.41 (ms.ml/microgram) for QND.",Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10746167/),1/[min],2.72 x 10(-4),78123,DB00864,Tacrolimus
,10746167,Emax,"The pharmacodynamic parameters thus obtained were as follows: kE0 2.72 x 10(-4) (min-1), Emax 27.1 (ms), EC50 0.376 (ng/ml) for FK506; and kE0 0.148 (min-1), K 8.41 (ms.ml/microgram) for QND.",Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10746167/),ms,27.1,78124,DB00864,Tacrolimus
,10746167,EC50,"The pharmacodynamic parameters thus obtained were as follows: kE0 2.72 x 10(-4) (min-1), Emax 27.1 (ms), EC50 0.376 (ng/ml) for FK506; and kE0 0.148 (min-1), K 8.41 (ms.ml/microgram) for QND.",Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10746167/),[ng] / [ml],0.376,78125,DB00864,Tacrolimus
,10746167,kE0,"The pharmacodynamic parameters thus obtained were as follows: kE0 2.72 x 10(-4) (min-1), Emax 27.1 (ms), EC50 0.376 (ng/ml) for FK506; and kE0 0.148 (min-1), K 8.41 (ms.ml/microgram) for QND.",Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10746167/),1/[min],0.148,78126,DB00864,Tacrolimus
,10746167,K,"The pharmacodynamic parameters thus obtained were as follows: kE0 2.72 x 10(-4) (min-1), Emax 27.1 (ms), EC50 0.376 (ng/ml) for FK506; and kE0 0.148 (min-1), K 8.41 (ms.ml/microgram) for QND.",Pharmacokinetic/pharmacodynamic analysis of tacrolimus-induced QT prolongation in guinea pigs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10746167/),[ml·ms] / [μg],8.41,78127,DB00864,Tacrolimus
,31376625,trough EVR level,The trough EVR level in both groups was maintained within 3-8 ng/mL during the perioperative period.,Optimal dose of everolimus administered with tacrolimus in living donor kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31376625/),[ng] / [ml],3-8,78330,DB00864,Tacrolimus
,21168674,time after transplantation,"Mean patient age was 58.2 ± 8.8 years, and mean time after transplantation was 2.3 ± 4.0 years (range, 0.2-13.0 years).",Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),years,2.3,78356,DB00864,Tacrolimus
,21168674,serum concentrations,Mean predose (C0) MPA serum concentrations were insignificantly lower with PPI comedication (2.5 ± 2.2 mg/L vs 2.8 ± 1.7 mg/L; P = .15).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[mg] / [l],2.5,78357,DB00864,Tacrolimus
,21168674,serum concentrations,Mean predose (C0) MPA serum concentrations were insignificantly lower with PPI comedication (2.5 ± 2.2 mg/L vs 2.8 ± 1.7 mg/L; P = .15).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[mg] / [l],2.8,78358,DB00864,Tacrolimus
,21168674,AUCs,Dose-adjusted abbreviated MPA AUCs (adjusted to morning dose) were significantly lower during PPI therapy (45.2 ± 20.3 vs 65.2 ± 38.8 mg·h/L·g [MMF]; P = .02).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[h·mg] / [g·l],45.2,78359,DB00864,Tacrolimus
,21168674,AUCs,Dose-adjusted abbreviated MPA AUCs (adjusted to morning dose) were significantly lower during PPI therapy (45.2 ± 20.3 vs 65.2 ± 38.8 mg·h/L·g [MMF]; P = .02).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[h·mg] / [g·l],65.2,78360,DB00864,Tacrolimus
,19177449,time to the maximum plasma concentration,"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),h,1.25,78917,DB00864,Tacrolimus
,19177449,time to the maximum plasma concentration,"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),h,1.28,78918,DB00864,Tacrolimus
,19177449,maximum plasma concentration,"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),[μg] / [ml],15.5,78919,DB00864,Tacrolimus
,19177449,maximum plasma concentration,"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),[μg] / [ml],13.6,78920,DB00864,Tacrolimus
,19177449,area under the concentration-time curve from 0 to 12 hours (AUC(0-12),"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),[h·μg] / [ml],53.0,78921,DB00864,Tacrolimus
,19177449,area under the concentration-time curve from 0 to 12 hours (AUC(0-12),"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),[h·μg] / [ml],43.8,78922,DB00864,Tacrolimus
above,25663618,area under the time-concentration curve (AUC0-12),All patients reached MPA area under the time-concentration curve (AUC0-12) above 30 µg h/mL.,Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663618/),[h·μg] / [ml],30,79134,DB00864,Tacrolimus
,22105586,Cl,"Of 19 volunteers, 12 were men, with age (mean ± SD) 46 ± 11 years, weight 83 ± 19 kg, and calculated Cl(creatinine) 64 ± 27 mL/min.","Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105586/),,64,79249,DB00864,Tacrolimus
,16507509,hepatic clearance,"GF120918 significantly decreased mean intrinsic metabolic clearance (by 86 and 41% based on the well-stirred and tube models, respectively) as well as hepatic clearance (from 47.3 to 44.2 ml min(-1)).",Role of P-glycoprotein in the hepatic metabolism of tacrolimus. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507509/),[ml] / [min],47.3,80024,DB00864,Tacrolimus
,16507509,hepatic clearance,"GF120918 significantly decreased mean intrinsic metabolic clearance (by 86 and 41% based on the well-stirred and tube models, respectively) as well as hepatic clearance (from 47.3 to 44.2 ml min(-1)).",Role of P-glycoprotein in the hepatic metabolism of tacrolimus. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16507509/),[ml] / [min],44.2,80025,DB00864,Tacrolimus
,16318929,retention times,"The retention times were approximately 4.1 min for M1, 6.8 min for M2, 6.0 min for M3, and 3.9 min for IS1 and 6.4 min for IS2, respectively.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),min,4.1,80653,DB00864,Tacrolimus
,16318929,retention times,"The retention times were approximately 4.1 min for M1, 6.8 min for M2, 6.0 min for M3, and 3.9 min for IS1 and 6.4 min for IS2, respectively.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),min,6.8,80654,DB00864,Tacrolimus
,16318929,retention times,"The retention times were approximately 4.1 min for M1, 6.8 min for M2, 6.0 min for M3, and 3.9 min for IS1 and 6.4 min for IS2, respectively.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),min,6.0,80655,DB00864,Tacrolimus
,16318929,retention times,"The retention times were approximately 4.1 min for M1, 6.8 min for M2, 6.0 min for M3, and 3.9 min for IS1 and 6.4 min for IS2, respectively.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),min,3.9,80656,DB00864,Tacrolimus
,16318929,retention times,"The retention times were approximately 4.1 min for M1, 6.8 min for M2, 6.0 min for M3, and 3.9 min for IS1 and 6.4 min for IS2, respectively.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),min,6.4,80657,DB00864,Tacrolimus
,16318929,Extraction recoveries,"Extraction recoveries were 72% for M1, 87% for M2, 69% for M3, 79% for IS1, and 74% for IS2 from blood; and 94% for M1, 96% for M2, 98% for M3, 92% for IS1, and 93% for IS2 from plasma.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),%,72,80658,DB00864,Tacrolimus
,16318929,Extraction recoveries,"Extraction recoveries were 72% for M1, 87% for M2, 69% for M3, 79% for IS1, and 74% for IS2 from blood; and 94% for M1, 96% for M2, 98% for M3, 92% for IS1, and 93% for IS2 from plasma.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),%,87,80659,DB00864,Tacrolimus
,16318929,Extraction recoveries,"Extraction recoveries were 72% for M1, 87% for M2, 69% for M3, 79% for IS1, and 74% for IS2 from blood; and 94% for M1, 96% for M2, 98% for M3, 92% for IS1, and 93% for IS2 from plasma.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),%,69,80660,DB00864,Tacrolimus
,16318929,Extraction recoveries,"Extraction recoveries were 72% for M1, 87% for M2, 69% for M3, 79% for IS1, and 74% for IS2 from blood; and 94% for M1, 96% for M2, 98% for M3, 92% for IS1, and 93% for IS2 from plasma.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),%,79,80661,DB00864,Tacrolimus
,16318929,Extraction recoveries,"Extraction recoveries were 72% for M1, 87% for M2, 69% for M3, 79% for IS1, and 74% for IS2 from blood; and 94% for M1, 96% for M2, 98% for M3, 92% for IS1, and 93% for IS2 from plasma.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),%,74,80662,DB00864,Tacrolimus
,16318929,Extraction recoveries,"Extraction recoveries were 72% for M1, 87% for M2, 69% for M3, 79% for IS1, and 74% for IS2 from blood; and 94% for M1, 96% for M2, 98% for M3, 92% for IS1, and 93% for IS2 from plasma.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),%,94,80663,DB00864,Tacrolimus
,16318929,Extraction recoveries,"Extraction recoveries were 72% for M1, 87% for M2, 69% for M3, 79% for IS1, and 74% for IS2 from blood; and 94% for M1, 96% for M2, 98% for M3, 92% for IS1, and 93% for IS2 from plasma.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),%,96,80664,DB00864,Tacrolimus
,16318929,Extraction recoveries,"Extraction recoveries were 72% for M1, 87% for M2, 69% for M3, 79% for IS1, and 74% for IS2 from blood; and 94% for M1, 96% for M2, 98% for M3, 92% for IS1, and 93% for IS2 from plasma.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),%,98,80665,DB00864,Tacrolimus
,16318929,Extraction recoveries,"Extraction recoveries were 72% for M1, 87% for M2, 69% for M3, 79% for IS1, and 74% for IS2 from blood; and 94% for M1, 96% for M2, 98% for M3, 92% for IS1, and 93% for IS2 from plasma.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),%,92,80666,DB00864,Tacrolimus
,16318929,Extraction recoveries,"Extraction recoveries were 72% for M1, 87% for M2, 69% for M3, 79% for IS1, and 74% for IS2 from blood; and 94% for M1, 96% for M2, 98% for M3, 92% for IS1, and 93% for IS2 from plasma.",Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16318929/),%,93,80667,DB00864,Tacrolimus
,34318518,Tmax times,"FN patients also had significant shorter Tmax times (1.6±0.2 hours versus 2.8±0.3 hours, p<0.05).",Pharmacokinetics of a Once Daily Tacrolimus Formulation in First Nations and Caucasian Liver Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34318518/),h,1.6,81374,DB00864,Tacrolimus
,34318518,Tmax times,"FN patients also had significant shorter Tmax times (1.6±0.2 hours versus 2.8±0.3 hours, p<0.05).",Pharmacokinetics of a Once Daily Tacrolimus Formulation in First Nations and Caucasian Liver Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34318518/),h,2.8,81375,DB00864,Tacrolimus
,24199740,AUC,"When compared to the suspension, the microemulsion containing tacrolimus presented higher values of AUC (2,912.5±245.4 min.ng/mL vs. 1,669.8±93 min.ng/mL) and Cmax (26.8±2.3 ng/mL vs. 20.7±2.8 ng/mL).",Evaluation of the pharmacokinetics and ocular tolerance of a microemulsion containing tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24199740/),[min·ng] / [ml],"2,912.5",81426,DB00864,Tacrolimus
,24199740,AUC,"When compared to the suspension, the microemulsion containing tacrolimus presented higher values of AUC (2,912.5±245.4 min.ng/mL vs. 1,669.8±93 min.ng/mL) and Cmax (26.8±2.3 ng/mL vs. 20.7±2.8 ng/mL).",Evaluation of the pharmacokinetics and ocular tolerance of a microemulsion containing tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24199740/),[min·ng] / [ml],"1,669.8",81427,DB00864,Tacrolimus
,24199740,Cmax,"When compared to the suspension, the microemulsion containing tacrolimus presented higher values of AUC (2,912.5±245.4 min.ng/mL vs. 1,669.8±93 min.ng/mL) and Cmax (26.8±2.3 ng/mL vs. 20.7±2.8 ng/mL).",Evaluation of the pharmacokinetics and ocular tolerance of a microemulsion containing tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24199740/),[ng] / [ml],26.8,81428,DB00864,Tacrolimus
,24199740,Cmax,"When compared to the suspension, the microemulsion containing tacrolimus presented higher values of AUC (2,912.5±245.4 min.ng/mL vs. 1,669.8±93 min.ng/mL) and Cmax (26.8±2.3 ng/mL vs. 20.7±2.8 ng/mL).",Evaluation of the pharmacokinetics and ocular tolerance of a microemulsion containing tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24199740/),[ng] / [ml],20.7,81429,DB00864,Tacrolimus
,17096757,trough levels,SRL was dosed to achieve target trough levels between 10 and 20 ng/mL.,Sirolimus pharmacokinetics in pediatric renal transplant recipients receiving calcineurin inhibitor co-therapy. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17096757/),[ng] / [ml],10 and 20,81471,DB00864,Tacrolimus
<,17996430,total systemic absorption,The total systemic absorption was <or=0.8% of dose.,Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17996430/),%,0.8,81501,DB00864,Tacrolimus
,17996430,blood concentrations,Highest pimecrolimus blood concentrations (0.44 ng/mL) were reached between 2 and 6h post-end of topical application.,Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17996430/),[ng] / [ml],0.44,81502,DB00864,Tacrolimus
,17391292,AUC,"Higher AUC (231.4 vs. 220 ng.h/mL, P = 0.06) and C(max) (34.1 +/- 12.6 vs. 24.4 +/- 9.8 ng/mL, P < 0.001), and lower T(max) (1.6 +/- 0.8 vs. 2.7 +/- 2.0 h, P = 0.05) values were observed comparing a.m. and p.m. administrations.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),[h·ng] / [ml],231.4,82043,DB00864,Tacrolimus
,17391292,AUC,"Higher AUC (231.4 vs. 220 ng.h/mL, P = 0.06) and C(max) (34.1 +/- 12.6 vs. 24.4 +/- 9.8 ng/mL, P < 0.001), and lower T(max) (1.6 +/- 0.8 vs. 2.7 +/- 2.0 h, P = 0.05) values were observed comparing a.m. and p.m. administrations.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),[h·ng] / [ml],220,82044,DB00864,Tacrolimus
,17391292,C(max),"Higher AUC (231.4 vs. 220 ng.h/mL, P = 0.06) and C(max) (34.1 +/- 12.6 vs. 24.4 +/- 9.8 ng/mL, P < 0.001), and lower T(max) (1.6 +/- 0.8 vs. 2.7 +/- 2.0 h, P = 0.05) values were observed comparing a.m. and p.m. administrations.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),[ng] / [ml],34.1,82045,DB00864,Tacrolimus
,17391292,C(max),"Higher AUC (231.4 vs. 220 ng.h/mL, P = 0.06) and C(max) (34.1 +/- 12.6 vs. 24.4 +/- 9.8 ng/mL, P < 0.001), and lower T(max) (1.6 +/- 0.8 vs. 2.7 +/- 2.0 h, P = 0.05) values were observed comparing a.m. and p.m. administrations.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),[ng] / [ml],24.4,82046,DB00864,Tacrolimus
,17391292,T(max),"Higher AUC (231.4 vs. 220 ng.h/mL, P = 0.06) and C(max) (34.1 +/- 12.6 vs. 24.4 +/- 9.8 ng/mL, P < 0.001), and lower T(max) (1.6 +/- 0.8 vs. 2.7 +/- 2.0 h, P = 0.05) values were observed comparing a.m. and p.m. administrations.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),h,1.6,82047,DB00864,Tacrolimus
,17391292,T(max),"Higher AUC (231.4 vs. 220 ng.h/mL, P = 0.06) and C(max) (34.1 +/- 12.6 vs. 24.4 +/- 9.8 ng/mL, P < 0.001), and lower T(max) (1.6 +/- 0.8 vs. 2.7 +/- 2.0 h, P = 0.05) values were observed comparing a.m. and p.m. administrations.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),h,2.7,82048,DB00864,Tacrolimus
,17391292,dose-normalized AUC,"Comparing D7, M6 and M12, there was a significant increase in dose-normalized AUC (31.4 +/- 22.2 vs. 50.1 +/- 33 vs. 39.2 +/- 24.4 ng.h/mL/mg, P = 0.005), C(max) (4.4 +/- 2.4 vs. 7.8 +/- 3.5 vs. 6.0 +/- 3.3 ng/mL/mg, P < 0.001) and T(max) (1.6 +/- 1.1 vs. 1.7 +/- 0.4 vs. 1.8 +/- 0.8 h, P = 0.006), respectively.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),[h·ng] / [mg·ml],31.4,82049,DB00864,Tacrolimus
,17391292,dose-normalized AUC,"Comparing D7, M6 and M12, there was a significant increase in dose-normalized AUC (31.4 +/- 22.2 vs. 50.1 +/- 33 vs. 39.2 +/- 24.4 ng.h/mL/mg, P = 0.005), C(max) (4.4 +/- 2.4 vs. 7.8 +/- 3.5 vs. 6.0 +/- 3.3 ng/mL/mg, P < 0.001) and T(max) (1.6 +/- 1.1 vs. 1.7 +/- 0.4 vs. 1.8 +/- 0.8 h, P = 0.006), respectively.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),[h·ng] / [mg·ml],50.1,82050,DB00864,Tacrolimus
,17391292,dose-normalized AUC,"Comparing D7, M6 and M12, there was a significant increase in dose-normalized AUC (31.4 +/- 22.2 vs. 50.1 +/- 33 vs. 39.2 +/- 24.4 ng.h/mL/mg, P = 0.005), C(max) (4.4 +/- 2.4 vs. 7.8 +/- 3.5 vs. 6.0 +/- 3.3 ng/mL/mg, P < 0.001) and T(max) (1.6 +/- 1.1 vs. 1.7 +/- 0.4 vs. 1.8 +/- 0.8 h, P = 0.006), respectively.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),[h·ng] / [mg·ml],39.2,82051,DB00864,Tacrolimus
,17391292,C(max),"Comparing D7, M6 and M12, there was a significant increase in dose-normalized AUC (31.4 +/- 22.2 vs. 50.1 +/- 33 vs. 39.2 +/- 24.4 ng.h/mL/mg, P = 0.005), C(max) (4.4 +/- 2.4 vs. 7.8 +/- 3.5 vs. 6.0 +/- 3.3 ng/mL/mg, P < 0.001) and T(max) (1.6 +/- 1.1 vs. 1.7 +/- 0.4 vs. 1.8 +/- 0.8 h, P = 0.006), respectively.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),[ng] / [mg·ml],4.4,82052,DB00864,Tacrolimus
,17391292,C(max),"Comparing D7, M6 and M12, there was a significant increase in dose-normalized AUC (31.4 +/- 22.2 vs. 50.1 +/- 33 vs. 39.2 +/- 24.4 ng.h/mL/mg, P = 0.005), C(max) (4.4 +/- 2.4 vs. 7.8 +/- 3.5 vs. 6.0 +/- 3.3 ng/mL/mg, P < 0.001) and T(max) (1.6 +/- 1.1 vs. 1.7 +/- 0.4 vs. 1.8 +/- 0.8 h, P = 0.006), respectively.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),[ng] / [mg·ml],7.8,82053,DB00864,Tacrolimus
,17391292,C(max),"Comparing D7, M6 and M12, there was a significant increase in dose-normalized AUC (31.4 +/- 22.2 vs. 50.1 +/- 33 vs. 39.2 +/- 24.4 ng.h/mL/mg, P = 0.005), C(max) (4.4 +/- 2.4 vs. 7.8 +/- 3.5 vs. 6.0 +/- 3.3 ng/mL/mg, P < 0.001) and T(max) (1.6 +/- 1.1 vs. 1.7 +/- 0.4 vs. 1.8 +/- 0.8 h, P = 0.006), respectively.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),[ng] / [mg·ml],6.0,82054,DB00864,Tacrolimus
,17391292,T(max),"Comparing D7, M6 and M12, there was a significant increase in dose-normalized AUC (31.4 +/- 22.2 vs. 50.1 +/- 33 vs. 39.2 +/- 24.4 ng.h/mL/mg, P = 0.005), C(max) (4.4 +/- 2.4 vs. 7.8 +/- 3.5 vs. 6.0 +/- 3.3 ng/mL/mg, P < 0.001) and T(max) (1.6 +/- 1.1 vs. 1.7 +/- 0.4 vs. 1.8 +/- 0.8 h, P = 0.006), respectively.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),h,1.6,82055,DB00864,Tacrolimus
,17391292,T(max),"Comparing D7, M6 and M12, there was a significant increase in dose-normalized AUC (31.4 +/- 22.2 vs. 50.1 +/- 33 vs. 39.2 +/- 24.4 ng.h/mL/mg, P = 0.005), C(max) (4.4 +/- 2.4 vs. 7.8 +/- 3.5 vs. 6.0 +/- 3.3 ng/mL/mg, P < 0.001) and T(max) (1.6 +/- 1.1 vs. 1.7 +/- 0.4 vs. 1.8 +/- 0.8 h, P = 0.006), respectively.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),h,1.7,82056,DB00864,Tacrolimus
,17391292,T(max),"Comparing D7, M6 and M12, there was a significant increase in dose-normalized AUC (31.4 +/- 22.2 vs. 50.1 +/- 33 vs. 39.2 +/- 24.4 ng.h/mL/mg, P = 0.005), C(max) (4.4 +/- 2.4 vs. 7.8 +/- 3.5 vs. 6.0 +/- 3.3 ng/mL/mg, P < 0.001) and T(max) (1.6 +/- 1.1 vs. 1.7 +/- 0.4 vs. 1.8 +/- 0.8 h, P = 0.006), respectively.",Circadian and time-dependent variability in tacrolimus pharmacokinetics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391292/),h,1.8,82057,DB00864,Tacrolimus
,20357699,area under the curve,Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[h·μg] / [ml],42.9,83387,DB00864,Tacrolimus
,20357699,dose-normalized AUC,Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[h·μg] / [g·ml],52.9,83388,DB00864,Tacrolimus
,20357699,maximal concentration (Cmax),Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[μg] / [ml],13.0,83389,DB00864,Tacrolimus
,20357699,time to Cmax (tmax),Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),h,1.2,83390,DB00864,Tacrolimus
,20357699,minimum concentration (Cmin),Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[μg] / [ml],1.4,83391,DB00864,Tacrolimus
,20357699,Area under the curve ratios,"Area under the curve ratios of MPAG/MPA and AcMPAG/MPA were 17.8 +/- 12.4 and 0.1 +/- 0.1, respectively.",Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),,17.8,83392,DB00864,Tacrolimus
,20357699,Area under the curve ratios,"Area under the curve ratios of MPAG/MPA and AcMPAG/MPA were 17.8 +/- 12.4 and 0.1 +/- 0.1, respectively.",Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),,0.1,83393,DB00864,Tacrolimus
,15787787,trough level,Mean trough level was 11.9 +/- 5.0 ng/mL.,"Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787787/),[ng] / [ml],11.9,83635,DB00864,Tacrolimus
,15787787,area under the curve (AUC),Mean area under the curve (AUC) was 192 +/- 84 with a range of 78-360 h x (ng/mL).,"Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15787787/),[h·ng] / [ml],192,83636,DB00864,Tacrolimus
,14748618,trough concentration,The target trough concentration of everolimus should range between 3 and 15 microg/L in combination therapy with ciclosporin (trough concentration 100-300 microg/L) and prednisone.,Clinical pharmacokinetics of everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748618/),[μg] / [l],3 and 15,83849,DB00864,Tacrolimus
,14748618,trough concentration,The target trough concentration of everolimus should range between 3 and 15 microg/L in combination therapy with ciclosporin (trough concentration 100-300 microg/L) and prednisone.,Clinical pharmacokinetics of everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748618/),[μg] / [l],100-300,83850,DB00864,Tacrolimus
,8536129,tmax,tmax ranged from one to four hours (mean + SD; 2.8 + 1.3) and fluctuated in both intra- and interindividual measurements.,Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients--importance of trough level as a practical indicator. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8536129/),h,2.8,84329,DB00864,Tacrolimus
,22326299,zeta potentials,Stable colloidal dispersions of the nanoparticles were formed with zeta potentials of the range of -24.9 to -38.4 mV.,"Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β-cyclodextrin inclusion complex-loaded albumin nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326299/),mv,24.9,85214,DB00864,Tacrolimus
,22326299,zeta potentials,Stable colloidal dispersions of the nanoparticles were formed with zeta potentials of the range of -24.9 to -38.4 mV.,"Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β-cyclodextrin inclusion complex-loaded albumin nanoparticles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22326299/),mv,38.4,85215,DB00864,Tacrolimus
,22996305,AUC0-36 h,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],1103.2,85610,DB00864,Tacrolimus
,22996305,AUC0-36 h,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],4336.5,85611,DB00864,Tacrolimus
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[h·ng] / [ml],4336.5,85612,DB00864,Tacrolimus
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[ng] / [ml],208.5,85613,DB00864,Tacrolimus
,22996305,Cmax,"Interestingly, after a single oral co-administration of WZ and low dose of CsA (1.89 mg/kg), the AUC0-36 h and Cmax of CsA were dramatically increased by 293.1% (from 1103.2 ± 293.0 to 4336.5 ± 1728.3 ng.h/mL; p < 0.05) and 84.1% (from 208.5 ± 67.9 to 383.1 ± 92.5 ng/mL; p < 0.05), respectively.",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[ng] / [ml],383.1,85614,DB00864,Tacrolimus
,22996305,CL/F,The CL/F was decreased from 1.7 L/h/kg to 0.5 L/h/kg.,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[l] / [h·kg],1.7,85615,DB00864,Tacrolimus
,22996305,CL/F,The CL/F was decreased from 1.7 L/h/kg to 0.5 L/h/kg.,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of cyclosporin A in rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22996305/),[l] / [h·kg],0.5,85616,DB00864,Tacrolimus
,24435759,AUC0-24,"Both AUC0-24 and Cmin decreased after conversion (223.3 to 197.5 ng.h/ml and 6.5 to 5.6 ng/ml; p = 0.03 and 0.01, respectively).",Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435759/),[h·ng] / [ml],223.3 to 197.5,86149,DB00864,Tacrolimus
,24435759,Cmin,"Both AUC0-24 and Cmin decreased after conversion (223.3 to 197.5 ng.h/ml and 6.5 to 5.6 ng/ml; p = 0.03 and 0.01, respectively).",Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24435759/),[ng] / [ml],6.5 to 5.6,86150,DB00864,Tacrolimus
,19076975,concentrations,"Mean +/- SD tacrolimus concentrations in the skin at 24 h after first and last ointment applications were 94 +/- 20 and 595 +/- 98 ng cm(-3), respectively.",Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076975/),[ng] / [(cm)^3],94,87035,DB00864,Tacrolimus
,19076975,concentrations,"Mean +/- SD tacrolimus concentrations in the skin at 24 h after first and last ointment applications were 94 +/- 20 and 595 +/- 98 ng cm(-3), respectively.",Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19076975/),[ng] / [(cm)^3],595,87036,DB00864,Tacrolimus
,9269646,trough levels,Pharmacokinetic investigations were performed after establishing a stable maintenance dose with trough levels in the desired window of 5-12 ng/ml.,Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),[ng] / [ml],5-12,87786,DB00864,Tacrolimus
,9269646,trough level,Mean trough level was 7.1 +/- 2.6 ng/ml in the morning and 6.5 +/- 2.0 ng/ml in the evening.,Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),[ng] / [ml],7.1,87787,DB00864,Tacrolimus
,9269646,trough level,Mean trough level was 7.1 +/- 2.6 ng/ml in the morning and 6.5 +/- 2.0 ng/ml in the evening.,Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),[ng] / [ml],6.5,87788,DB00864,Tacrolimus
,9269646,time of maximum concentration (tmax),"Median time of maximum concentration (tmax) was 120 min after application, and the mean maximum concentration (Cmax) was 15.2 +/- 6.7 ng/ml.",Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),min,120,87789,DB00864,Tacrolimus
,9269646,maximum concentration (Cmax),"Median time of maximum concentration (tmax) was 120 min after application, and the mean maximum concentration (Cmax) was 15.2 +/- 6.7 ng/ml.",Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),[ng] / [ml],15.2,87790,DB00864,Tacrolimus
,9269646,area under the curve (AUC),"Mean area under the curve (AUC) was 104 +/- 33 ng* h/ml, with a range from 65 yo 169 ng* h/ml.",Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9269646/),[h·ng] / [ml],104,87791,DB00864,Tacrolimus
greater,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,500,87809,DB00864,Tacrolimus
,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,15,87810,DB00864,Tacrolimus
,7540071,time to an absolute neutrophil count of,The median time to an absolute neutrophil count of greater than 500/microL was 15 days for patients receiving FK506 alone or FK506 plus methylprednisolone and 23 days for FK506 plus short MTX.,Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),d,23,87811,DB00864,Tacrolimus
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.49,87812,DB00864,Tacrolimus
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.27,87813,DB00864,Tacrolimus
,7540071,bioavailability,"The mean bioavailability after oral administration in these same three groups was 0.49 +/- 0.1, 0.27 +/- 0.12, and 0.16 +/- 0.08, respectively (P = .003).",Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7540071/),,0.16,87814,DB00864,Tacrolimus
,28401703,Ka,The Ka was fixed to 4.5 h-1 .,Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28401703/),1/[h],4.5,87844,DB00864,Tacrolimus
,30260084,clearances,"Tacrolimus clearances were 26, 18.8 and 12.3 L/h, for patients with genetic polymorphisms CYP3A5*1*1, *1*3 and *3*3, respectively.",Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260084/),[l] / [h],26,89681,DB00864,Tacrolimus
,30260084,clearances,"Tacrolimus clearances were 26, 18.8 and 12.3 L/h, for patients with genetic polymorphisms CYP3A5*1*1, *1*3 and *3*3, respectively.",Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260084/),[l] / [h],18.8,89682,DB00864,Tacrolimus
,30260084,clearances,"Tacrolimus clearances were 26, 18.8 and 12.3 L/h, for patients with genetic polymorphisms CYP3A5*1*1, *1*3 and *3*3, respectively.",Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260084/),[l] / [h],12.3,89683,DB00864,Tacrolimus
,30260084,Total volume of distribution,Total volume of distribution was 604 L.,Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260084/),l,604,89684,DB00864,Tacrolimus
,30260084,Relative bioavailability,Relative bioavailability was calculated between generic formulations A (0.53) and B (1) of tacrolimus.,Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260084/),,0.53,89685,DB00864,Tacrolimus
,30260084,Relative bioavailability,Relative bioavailability was calculated between generic formulations A (0.53) and B (1) of tacrolimus.,Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30260084/),,1,89686,DB00864,Tacrolimus
,19889885,maximum inactivation rate constant (k(inact)),"The in vitro maximum inactivation rate constant (k(inact)) and concentration of inhibitor that gave half-maximal k(inact) (K(I)) were estimated to be 10.1 h(-1) and 2050 ng/ml, respectively.","Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889885/),1/[h],10.1,90345,DB00864,Tacrolimus
,19889885,half-maximal k(inact) (K(I)),"The in vitro maximum inactivation rate constant (k(inact)) and concentration of inhibitor that gave half-maximal k(inact) (K(I)) were estimated to be 10.1 h(-1) and 2050 ng/ml, respectively.","Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889885/),[ng] / [ml],2050,90346,DB00864,Tacrolimus
,19889885,inactivation rate,"A pharmacokinetic model developed for this study, which described the time course of concentrations of both FK1706 and midazolam and incorporated CYP3A4/5 inactivation in the liver and intestine, successfully predicted the change in the pharmacokinetics of midazolam using in vitro k(inact) and K(I) values (1.66- to 2.81-fold increases in AUC predicted) and estimated the in vivo inactivation rate to be 0.00404 to 0.0318 h(-1) x ml/ng.","Time-dependent inhibitory effects of (1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl-23,25-dimethoxy-13,19,21,27-tetramethyl-17-(2-oxopropyl)-11,28-dioxa-4-azatricyclo[22.3.1.0(4.9)]octacos-18-ene-2,3,10,16-tetrone (FK1706), a novel nonimmunosuppressive immunophilin ligand, on CYP3A4/5 activity in humans in vivo and in vitro. ",KI-Q13,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19889885/),[ml] / [h·ng],0.00404 to 0.0318,90347,DB00864,Tacrolimus
,22263871,heart rate,He was found to be bradycardic with a heart rate of 42/min.,"Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),1/[min],42,90698,DB00864,Tacrolimus
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],14,90699,DB00864,Tacrolimus
,22263871,trough,"The tacrolimus trough was elevated at 14 ng/mL, which decreased after stopping ranolazine, reaching 7 ng/mL after 3 days, while continuing the same dose of tacrolimus.","Ranolazine, tacrolimus, and diltiazem might be a hazardous combination in a transplant patient. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22263871/),[ng] / [ml],7,90700,DB00864,Tacrolimus
,27721963,whole blood concentration,The mean±SD administered daily dose of tacrolimus during the first three weeks after transplantation was 0.085±0.024 mg/kg of IBW that resulted in a mean±SD whole blood concentration of 10.34±5.44 ng/mL.,Tacrolimus Dose Requirement in Iranian Kidney Transplant Recipients within the First Three Weeks after Transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27721963/),ng,10,90701,DB00864,Tacrolimus
,15383495,tmax,"Comparison between patients with and without delayed gastric emptying confirmed that maximum blood tacrolimus concentration was reached significantly more slowly in the former group (tmax, 2 +/- 1 h versus 1.48 +/- 0.68 h; p = 0.04), whereas the extent of tacrolimus absorption was not different.",The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15383495/),h,2,91646,DB00864,Tacrolimus
,15383495,tmax,"Comparison between patients with and without delayed gastric emptying confirmed that maximum blood tacrolimus concentration was reached significantly more slowly in the former group (tmax, 2 +/- 1 h versus 1.48 +/- 0.68 h; p = 0.04), whereas the extent of tacrolimus absorption was not different.",The rate of gastric emptying determines the timing but not the extent of oral tacrolimus absorption: simultaneous measurement of drug exposure and gastric emptying by carbon-14-octanoic acid breath test in stable renal allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15383495/),h,1.48,91647,DB00864,Tacrolimus
,11781626,Population clearance (CL),Population clearance (CL) was 5.22 l/h and bioavailability (F) was 0.28.,Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11781626/),[l] / [h],5.22,92011,DB00864,Tacrolimus
,11781626,bioavailability (F),Population clearance (CL) was 5.22 l/h and bioavailability (F) was 0.28.,Factors affecting the pharmacokinetics of tacrolimus (FK506) in hematopoietic cell transplant (HCT) patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11781626/),,0.28,92012,DB00864,Tacrolimus
,15183289,trough concentrations,"In maintenance adult patients after conversion to a calcineurin inhibitor-free regimen, sirolimus trough concentrations of 5-10 microg/l are proposed in combination with mycophenolate mofetil.",Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15183289/),[μg] / [l],5-10,93468,DB00864,Tacrolimus
above,25325985,trough,"Area under the curve (AUC) and the trough of Tac QD showed a correlation, and the trough should be maintained above 7.5 ng/ml to provide an adequate AUC.",Pharmacokinetics for once-daily modified release formulation of tacrolimus hydrate in unrelated hematopoietic stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25325985/),[ng] / [ml],7.5,93506,DB00864,Tacrolimus
above,25325985,whole-blood,The modification of Tac QD to maintain a whole-blood trough concentration above 7.5 ng/ml may be as effective as Tac BID.,Pharmacokinetics for once-daily modified release formulation of tacrolimus hydrate in unrelated hematopoietic stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25325985/),[ng] / [ml],7.5,93507,DB00864,Tacrolimus
above,25325985,trough concentration,The modification of Tac QD to maintain a whole-blood trough concentration above 7.5 ng/ml may be as effective as Tac BID.,Pharmacokinetics for once-daily modified release formulation of tacrolimus hydrate in unrelated hematopoietic stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25325985/),[ng] / [ml],7.5,93508,DB00864,Tacrolimus
,19531983,AUC0-12h,"From April 2007 to December 2007, MMF was given to 14 patients at a dose of 1 g twice a day until day 7 and was then adapted to reach an MPA AUC0-12h target of 30-60 mg x h/L.",Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531983/),[h·mg] / [l],30-60,93870,DB00864,Tacrolimus
below,19531983,AUC0-12h,The proportion of patients with MPA AUC0-12h below 30 mg x h/L tended to be higher in the fixed dose group within the first month posttransplant.,Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531983/),[h·mg] / [l],30,93871,DB00864,Tacrolimus
below,19531983,AUC0-12h,There was a trend toward a lower proportion of patients with MPA AUC0-12h below 30 mg x h/L in the concentration-controlled group.,Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531983/),[h·mg] / [l],30,93872,DB00864,Tacrolimus
,15752372,free fraction,"Mycophenolic acid free fraction was on average 70% higher in patients with albumin concentrations below a specified albumin cut-off concentration of 31 g l(-1)[free fraction = 7 +/- 4% for lower albumin and 4 +/- 3% for higher albumin, respectively; P = 0.001; 95% confidence interval (CI) for the difference 1.9, 4.2].",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),%,7,94667,DB00864,Tacrolimus
,15752372,free fraction,"Mycophenolic acid free fraction was on average 70% higher in patients with albumin concentrations below a specified albumin cut-off concentration of 31 g l(-1)[free fraction = 7 +/- 4% for lower albumin and 4 +/- 3% for higher albumin, respectively; P = 0.001; 95% confidence interval (CI) for the difference 1.9, 4.2].",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),%,4,94668,DB00864,Tacrolimus
,15752372,Free AUC0-6,"Free AUC0-6 was significantly higher in those patients with thrombocytopenic, leukopenic and/or infectious outcomes than in those without (mean +/- SD 1.9 +/- 0.3 mg h(-1) l(-1) and 1.1 +/- 0.1 mg h(-1) l(-1), P = 0.0043; 95% CI for the difference 0.3, 1.4).",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),[mg] / [h·l],1.9,94669,DB00864,Tacrolimus
,15752372,Free AUC0-6,"Free AUC0-6 was significantly higher in those patients with thrombocytopenic, leukopenic and/or infectious outcomes than in those without (mean +/- SD 1.9 +/- 0.3 mg h(-1) l(-1) and 1.1 +/- 0.1 mg h(-1) l(-1), P = 0.0043; 95% CI for the difference 0.3, 1.4).",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),[mg] / [h·l],1.1,94670,DB00864,Tacrolimus
<,16198779,area under the curve(0-10h),"In patients with measurable blood drug concentrations, systemic exposure to tacrolimus (mean area under the curve(0-10h) < 9.7 ng.h/mL; n = 7) was higher than to pimecrolimus (mean area under the curve(0-10h) < 2.5 ng.h/mL; n = 2).","Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198779/),[h·ng] / [ml],9.7,96305,DB00864,Tacrolimus
<,16198779,area under the curve(0-10h),"In patients with measurable blood drug concentrations, systemic exposure to tacrolimus (mean area under the curve(0-10h) < 9.7 ng.h/mL; n = 7) was higher than to pimecrolimus (mean area under the curve(0-10h) < 2.5 ng.h/mL; n = 2).","Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198779/),[h·ng] / [ml],2.5,96306,DB00864,Tacrolimus
,28646274,absorption rate constant (K a),"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),1/[h],1.96,96725,DB00864,Tacrolimus
,28646274,V/F,"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),l,3550,96726,DB00864,Tacrolimus
,28646274,apparent oral clearance (CL/F),"The absorption rate constant (K a), V/F, and apparent oral clearance (CL/F) of the final population pharmacokinetic (PopPK) model of diltiazem were 1.96/h, 3550 L, and 92.4 L/h, respectively.",Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28646274/),[l] / [h],92.4,96727,DB00864,Tacrolimus
,12953343,area under the concentration-time curve (AUC0-12),There were no circadian changes in the area under the concentration-time curve (AUC0-12) (214 ng.h/mL during daytime vs. 223 ng.h/mL during nighttime) resulting from morning and night doses.,Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953343/),[h·ng] / [ml],214,96794,DB00864,Tacrolimus
,12953343,area under the concentration-time curve (AUC0-12),There were no circadian changes in the area under the concentration-time curve (AUC0-12) (214 ng.h/mL during daytime vs. 223 ng.h/mL during nighttime) resulting from morning and night doses.,Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12953343/),[h·ng] / [ml],223,96795,DB00864,Tacrolimus
,21168693,dose,"Mean dose, C(0), and AUC of SL tacrolimus were 0.116 ± 0.096 mg/kg, 12.9 ± 5 ng/mL, and 230 ± 74 ng·h/mL, respectively, with an average 1 hour time to peak concentration.",Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168693/),[mg] / [kg],0.116,97129,DB00864,Tacrolimus
,21168693,C(0),"Mean dose, C(0), and AUC of SL tacrolimus were 0.116 ± 0.096 mg/kg, 12.9 ± 5 ng/mL, and 230 ± 74 ng·h/mL, respectively, with an average 1 hour time to peak concentration.",Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168693/),[ng] / [ml],12.9,97130,DB00864,Tacrolimus
,21168693,AUC,"Mean dose, C(0), and AUC of SL tacrolimus were 0.116 ± 0.096 mg/kg, 12.9 ± 5 ng/mL, and 230 ± 74 ng·h/mL, respectively, with an average 1 hour time to peak concentration.",Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168693/),[h·ng] / [ml],230,97131,DB00864,Tacrolimus
,21168693,time to peak concentration,"Mean dose, C(0), and AUC of SL tacrolimus were 0.116 ± 0.096 mg/kg, 12.9 ± 5 ng/mL, and 230 ± 74 ng·h/mL, respectively, with an average 1 hour time to peak concentration.",Sublingual tacrolimus as an alternative to intravenous route in patients with thoracic transplant: a retrospective study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168693/),h,1,97132,DB00864,Tacrolimus
,24567233,trough,"The mean trough and peak levels were 3.04 ± 1.21 μg/mL (569 samples) and 9.63 ± 3.62 μg/mL (44 samples), respectively.","Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24567233/),[μg] / [ml],3.04,97325,DB00864,Tacrolimus
,24567233,peak levels,"The mean trough and peak levels were 3.04 ± 1.21 μg/mL (569 samples) and 9.63 ± 3.62 μg/mL (44 samples), respectively.","Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24567233/),[μg] / [ml],9.63,97326,DB00864,Tacrolimus
up to,24567233,trough level,"In a patient, the trough level of MCFG transiently increased up to 10.21 μg/mL during hepatic dysfunction due to acute graft-versus-host disease.","Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24567233/),[μg] / [ml],10.21,97327,DB00864,Tacrolimus
,18589558,AUC(0-t),"Under fasting conditions, mean AUC(0-t), AUC(0-inf) and C(max) were comparable between the test (296 ng x h/mL, 318 ng x h/mL and 32 ng/ mL, respectively) and the reference formulations (289 ng x h/mL, 309 ng x h/mL and 33 ng/mL, respectively).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],296,97630,DB00864,Tacrolimus
,18589558,AUC(0-t),"Under fasting conditions, mean AUC(0-t), AUC(0-inf) and C(max) were comparable between the test (296 ng x h/mL, 318 ng x h/mL and 32 ng/ mL, respectively) and the reference formulations (289 ng x h/mL, 309 ng x h/mL and 33 ng/mL, respectively).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],289,97631,DB00864,Tacrolimus
,18589558,AUC(0-t),"Under fasting conditions, mean AUC(0-t), AUC(0-inf) and C(max) were comparable between the test (296 ng x h/mL, 318 ng x h/mL and 32 ng/ mL, respectively) and the reference formulations (289 ng x h/mL, 309 ng x h/mL and 33 ng/mL, respectively).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],309,97632,DB00864,Tacrolimus
,18589558,AUC(0-inf),"Under fasting conditions, mean AUC(0-t), AUC(0-inf) and C(max) were comparable between the test (296 ng x h/mL, 318 ng x h/mL and 32 ng/ mL, respectively) and the reference formulations (289 ng x h/mL, 309 ng x h/mL and 33 ng/mL, respectively).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],318,97633,DB00864,Tacrolimus
,18589558,AUC(0-inf),"Under fasting conditions, mean AUC(0-t), AUC(0-inf) and C(max) were comparable between the test (296 ng x h/mL, 318 ng x h/mL and 32 ng/ mL, respectively) and the reference formulations (289 ng x h/mL, 309 ng x h/mL and 33 ng/mL, respectively).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],289,97634,DB00864,Tacrolimus
,18589558,AUC(0-inf),"Under fasting conditions, mean AUC(0-t), AUC(0-inf) and C(max) were comparable between the test (296 ng x h/mL, 318 ng x h/mL and 32 ng/ mL, respectively) and the reference formulations (289 ng x h/mL, 309 ng x h/mL and 33 ng/mL, respectively).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],309,97635,DB00864,Tacrolimus
,18589558,C(max),"Under fasting conditions, mean AUC(0-t), AUC(0-inf) and C(max) were comparable between the test (296 ng x h/mL, 318 ng x h/mL and 32 ng/ mL, respectively) and the reference formulations (289 ng x h/mL, 309 ng x h/mL and 33 ng/mL, respectively).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[ng] / [ml],32,97636,DB00864,Tacrolimus
,18589558,C(max),"Under fasting conditions, mean AUC(0-t), AUC(0-inf) and C(max) were comparable between the test (296 ng x h/mL, 318 ng x h/mL and 32 ng/ mL, respectively) and the reference formulations (289 ng x h/mL, 309 ng x h/mL and 33 ng/mL, respectively).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[ng] / [ml],33,97637,DB00864,Tacrolimus
,18589558,T(max),T(max) was reached between 1.5 and 2 h post-dose.,Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),h,1.5 and 2,97638,DB00864,Tacrolimus
,18589558,AUC(0-t),"Mean AUC(0-t), AUC(0-inf) and C(max) were also comparable under fed conditions (154 ng x h/mL, 169 ng x h/mL and 7.6 ng/mL, respectively, for the test and 161 ng x h/mL, 176 ng x h/mL and 7.5 ng/mL, respectively, for the reference formulation).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],154,97639,DB00864,Tacrolimus
,18589558,AUC(0-t),"Mean AUC(0-t), AUC(0-inf) and C(max) were also comparable under fed conditions (154 ng x h/mL, 169 ng x h/mL and 7.6 ng/mL, respectively, for the test and 161 ng x h/mL, 176 ng x h/mL and 7.5 ng/mL, respectively, for the reference formulation).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],161,97640,DB00864,Tacrolimus
,18589558,AUC(0-t),"Mean AUC(0-t), AUC(0-inf) and C(max) were also comparable under fed conditions (154 ng x h/mL, 169 ng x h/mL and 7.6 ng/mL, respectively, for the test and 161 ng x h/mL, 176 ng x h/mL and 7.5 ng/mL, respectively, for the reference formulation).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],176,97641,DB00864,Tacrolimus
,18589558,AUC(0-inf),"Mean AUC(0-t), AUC(0-inf) and C(max) were also comparable under fed conditions (154 ng x h/mL, 169 ng x h/mL and 7.6 ng/mL, respectively, for the test and 161 ng x h/mL, 176 ng x h/mL and 7.5 ng/mL, respectively, for the reference formulation).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],169,97642,DB00864,Tacrolimus
,18589558,AUC(0-inf),"Mean AUC(0-t), AUC(0-inf) and C(max) were also comparable under fed conditions (154 ng x h/mL, 169 ng x h/mL and 7.6 ng/mL, respectively, for the test and 161 ng x h/mL, 176 ng x h/mL and 7.5 ng/mL, respectively, for the reference formulation).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],161,97643,DB00864,Tacrolimus
,18589558,AUC(0-inf),"Mean AUC(0-t), AUC(0-inf) and C(max) were also comparable under fed conditions (154 ng x h/mL, 169 ng x h/mL and 7.6 ng/mL, respectively, for the test and 161 ng x h/mL, 176 ng x h/mL and 7.5 ng/mL, respectively, for the reference formulation).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[h·ng] / [ml],176,97644,DB00864,Tacrolimus
,18589558,AUC(0-inf),"Mean AUC(0-t), AUC(0-inf) and C(max) were also comparable under fed conditions (154 ng x h/mL, 169 ng x h/mL and 7.6 ng/mL, respectively, for the test and 161 ng x h/mL, 176 ng x h/mL and 7.5 ng/mL, respectively, for the reference formulation).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[ng] / [ml],7.5,97645,DB00864,Tacrolimus
,18589558,C(max),"Mean AUC(0-t), AUC(0-inf) and C(max) were also comparable under fed conditions (154 ng x h/mL, 169 ng x h/mL and 7.6 ng/mL, respectively, for the test and 161 ng x h/mL, 176 ng x h/mL and 7.5 ng/mL, respectively, for the reference formulation).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[ng] / [ml],7.6,97646,DB00864,Tacrolimus
,18589558,C(max),"Mean AUC(0-t), AUC(0-inf) and C(max) were also comparable under fed conditions (154 ng x h/mL, 169 ng x h/mL and 7.6 ng/mL, respectively, for the test and 161 ng x h/mL, 176 ng x h/mL and 7.5 ng/mL, respectively, for the reference formulation).",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),[ng] / [ml],7.5,97647,DB00864,Tacrolimus
,18589558,T(max),"Under fed conditions, T(max) was reached between 5 and 6 h post-dose.",Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589558/),h,5 and 6,97648,DB00864,Tacrolimus
,25156476,Dose-normalized AUC,"Dose-normalized AUC values in expressers were 12.7 ± 11.9 and 48.7 ± 20.4 ng·h/mL/mg for Limustin(®) and Prograf(®), whereas in non-expressers, dose-normalized AUC was 54.4 ± 49.1 and 110.4 ± 42.9 ng·h/mL/mg for Limustin(®) and Prograf(®), respectively (p < 0.05).","Limustin®, a non-innovator tacrolimus formulation, yields reduced drug exposure in pediatric renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25156476/),[h·ng] / [mg·ml],12.7,98621,DB00864,Tacrolimus
,25156476,Dose-normalized AUC,"Dose-normalized AUC values in expressers were 12.7 ± 11.9 and 48.7 ± 20.4 ng·h/mL/mg for Limustin(®) and Prograf(®), whereas in non-expressers, dose-normalized AUC was 54.4 ± 49.1 and 110.4 ± 42.9 ng·h/mL/mg for Limustin(®) and Prograf(®), respectively (p < 0.05).","Limustin®, a non-innovator tacrolimus formulation, yields reduced drug exposure in pediatric renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25156476/),[h·ng] / [mg·ml],48.7,98622,DB00864,Tacrolimus
,25156476,dose-normalized AUC,"Dose-normalized AUC values in expressers were 12.7 ± 11.9 and 48.7 ± 20.4 ng·h/mL/mg for Limustin(®) and Prograf(®), whereas in non-expressers, dose-normalized AUC was 54.4 ± 49.1 and 110.4 ± 42.9 ng·h/mL/mg for Limustin(®) and Prograf(®), respectively (p < 0.05).","Limustin®, a non-innovator tacrolimus formulation, yields reduced drug exposure in pediatric renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25156476/),[h·ng] / [mg·ml],54.4,98623,DB00864,Tacrolimus
,25156476,dose-normalized AUC,"Dose-normalized AUC values in expressers were 12.7 ± 11.9 and 48.7 ± 20.4 ng·h/mL/mg for Limustin(®) and Prograf(®), whereas in non-expressers, dose-normalized AUC was 54.4 ± 49.1 and 110.4 ± 42.9 ng·h/mL/mg for Limustin(®) and Prograf(®), respectively (p < 0.05).","Limustin®, a non-innovator tacrolimus formulation, yields reduced drug exposure in pediatric renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25156476/),[h·ng] / [mg·ml],110.4,98624,DB00864,Tacrolimus
,12682891,plasma trough concentration (C(0)),"MPA plasma trough concentration (C(0)), maximal concentration, and AUC(0-7) values ranged 9- to 14-fold at a median of 1.81 mg/L (range, 0.4 to 3.7 mg/L), 10.5 mg/L (range, 2.8 to 40.0 mg/L), and 30.2 mg/L.hr (range, 9.3 to 80.3 mg/L.hr), respectively.",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [l],1.81,99872,DB00864,Tacrolimus
,12682891,maximal concentration,"MPA plasma trough concentration (C(0)), maximal concentration, and AUC(0-7) values ranged 9- to 14-fold at a median of 1.81 mg/L (range, 0.4 to 3.7 mg/L), 10.5 mg/L (range, 2.8 to 40.0 mg/L), and 30.2 mg/L.hr (range, 9.3 to 80.3 mg/L.hr), respectively.",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [l],10.5,99873,DB00864,Tacrolimus
,12682891,AUC(0-7),"MPA plasma trough concentration (C(0)), maximal concentration, and AUC(0-7) values ranged 9- to 14-fold at a median of 1.81 mg/L (range, 0.4 to 3.7 mg/L), 10.5 mg/L (range, 2.8 to 40.0 mg/L), and 30.2 mg/L.hr (range, 9.3 to 80.3 mg/L.hr), respectively.",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [h·l],30.2,99874,DB00864,Tacrolimus
,12682891,AUC(0-7),Median AUC(0-7) (29.6 v 31.4 mg/L.hr; P =.918) was similar in children comedicated with CsA or Tac.,Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [h·l],29.6,99875,DB00864,Tacrolimus
,12682891,AUC(0-7),Median AUC(0-7) (29.6 v 31.4 mg/L.hr; P =.918) was similar in children comedicated with CsA or Tac.,Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [h·l],31.4,99876,DB00864,Tacrolimus
,12682891,AUC(0-7),"Consequently, median AUC(0-7) was significantly lower in the CsA group when equalized for dose and body weight (2.02 v 3.85 microg/L.hr per mg of MMF dose per kg of weight; P =.002).",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[μg] / [h·l·mg],2.02,99877,DB00864,Tacrolimus
,12682891,AUC(0-7),"Consequently, median AUC(0-7) was significantly lower in the CsA group when equalized for dose and body weight (2.02 v 3.85 microg/L.hr per mg of MMF dose per kg of weight; P =.002).",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[μg] / [h·l·mg],3.85,99878,DB00864,Tacrolimus
,23734831,C0 concentrations,"Although the mean C0 concentrations (4.10 ± 1.16-3.53 ± 1.10 ng/mL, p = 0.004), and AUC0-24 (151.8 ± 41.6-129.8 ± 39.3 ng h/mL, p < 0.001) were decreased significantly after a 1:1 based conversion, there was high interindividual variability.",Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23734831/),[ng] / [ml],4.10,100552,DB00864,Tacrolimus
,23734831,C0 concentrations,"Although the mean C0 concentrations (4.10 ± 1.16-3.53 ± 1.10 ng/mL, p = 0.004), and AUC0-24 (151.8 ± 41.6-129.8 ± 39.3 ng h/mL, p < 0.001) were decreased significantly after a 1:1 based conversion, there was high interindividual variability.",Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23734831/),[ng] / [ml],3.53,100553,DB00864,Tacrolimus
,23734831,AUC0-24,"Although the mean C0 concentrations (4.10 ± 1.16-3.53 ± 1.10 ng/mL, p = 0.004), and AUC0-24 (151.8 ± 41.6-129.8 ± 39.3 ng h/mL, p < 0.001) were decreased significantly after a 1:1 based conversion, there was high interindividual variability.",Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23734831/),[h·ng] / [ml],151.8,100554,DB00864,Tacrolimus
,23734831,AUC0-24,"Although the mean C0 concentrations (4.10 ± 1.16-3.53 ± 1.10 ng/mL, p = 0.004), and AUC0-24 (151.8 ± 41.6-129.8 ± 39.3 ng h/mL, p < 0.001) were decreased significantly after a 1:1 based conversion, there was high interindividual variability.",Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23734831/),[h·ng] / [ml],129.8,100555,DB00864,Tacrolimus
,29731062,concentration/dose ratio,The tacrolimus concentration/dose ratio in the CYP3A5 expressor group was lower than in the CYP3A5 nonexpressor group (1.49 ± 0.69 vs 3.49 ± 3.08 [P = .003] at 1 month; and 1.54 ± 0.9 vs 7.88 ± 8.25 [P = .0001] at 3 months).,CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29731062/),,1.49,101112,DB00864,Tacrolimus
,29731062,concentration/dose ratio,The tacrolimus concentration/dose ratio in the CYP3A5 expressor group was lower than in the CYP3A5 nonexpressor group (1.49 ± 0.69 vs 3.49 ± 3.08 [P = .003] at 1 month; and 1.54 ± 0.9 vs 7.88 ± 8.25 [P = .0001] at 3 months).,CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29731062/),,3.49,101113,DB00864,Tacrolimus
,29731062,concentration/dose ratio,The tacrolimus concentration/dose ratio in the CYP3A5 expressor group was lower than in the CYP3A5 nonexpressor group (1.49 ± 0.69 vs 3.49 ± 3.08 [P = .003] at 1 month; and 1.54 ± 0.9 vs 7.88 ± 8.25 [P = .0001] at 3 months).,CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29731062/),,1.54,101114,DB00864,Tacrolimus
,29731062,concentration/dose ratio,The tacrolimus concentration/dose ratio in the CYP3A5 expressor group was lower than in the CYP3A5 nonexpressor group (1.49 ± 0.69 vs 3.49 ± 3.08 [P = .003] at 1 month; and 1.54 ± 0.9 vs 7.88 ± 8.25 [P = .0001] at 3 months).,CYP3A5*3 Genetic Polymorphism and Tacrolimus Concentration in Myanmar Renal Transplant Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29731062/),,7.88,101115,DB00864,Tacrolimus
,10627642,clearance,"The mean clearance, based on first steady-state tacrolimus concentrations necessary for achieving a therapeutic level (10-20 microg/ml), was 108.1 ml/h/kg (range 79.7-142.0 ml/h/kg), greater than that reported in adult BMT patients (71 +/- 34 ml/h/kg).",Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10627642/),[ml] / [h·kg],108.1,101200,DB00864,Tacrolimus
,10627642,clearance,"The mean clearance, based on first steady-state tacrolimus concentrations necessary for achieving a therapeutic level (10-20 microg/ml), was 108.1 ml/h/kg (range 79.7-142.0 ml/h/kg), greater than that reported in adult BMT patients (71 +/- 34 ml/h/kg).",Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10627642/),[ml] / [h·kg],71,101201,DB00864,Tacrolimus
,10627642,clearance,"Over the entire course of intravenous tacrolimus, mean clearance was 97.0 ml/h/kg (range 33.4-153.3 ml/h/kg).",Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10627642/),[ml] / [h·kg],97.0,101202,DB00864,Tacrolimus
,10627642,clearance,"In six of the seven patients, clearance values dropped after 2-4 weeks of therapy by an average of 32.5 ml/h/kg.",Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10627642/),[ml] / [h·kg],32.5,101203,DB00864,Tacrolimus
over,10627642,initial clearance levels,"Three of the seven patients died of severe acute GVHD; all these had undergone matched unrelated donor transplantation, and two of these three had initial clearance levels over 120 ml/h/kg.",Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10627642/),[ml] / [h·kg],120,101204,DB00864,Tacrolimus
,21802143,Drug Interaction Probability Score,"The calculated Drug Interaction Probability Score between TAC and LAN was 6, indicating a probable interaction.",Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21802143/),,6,101788,DB00864,Tacrolimus
,11427455,c(min),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],2.63,101864,DB00864,Tacrolimus
,11427455,c(min),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],1.75,101865,DB00864,Tacrolimus
,11427455,c(30),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],10.47,101866,DB00864,Tacrolimus
,11427455,c(30),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],7.66,101867,DB00864,Tacrolimus
,11427455,c(60),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],9.67,101868,DB00864,Tacrolimus
,11427455,c(60),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],5.83,101869,DB00864,Tacrolimus
,11427455,-AUC((0-12))],"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,48.38,101870,DB00864,Tacrolimus
,11427455,-AUC((0-12))],"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,36.04,101871,DB00864,Tacrolimus
,11427455,dose-normalized MP,"h/L (P = 0.0006); mean dose-normalized MPA-AUC, 0.16 +/- 0.05 vs 0.12 +/- 0.04 (mg. h/L)/(mg/m(2)) (P = 0.0015).",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[h·l·mg·mg] / [m(2],0.16,101872,DB00864,Tacrolimus
,11427455,-AUC,"h/L (P = 0.0006); mean dose-normalized MPA-AUC, 0.16 +/- 0.05 vs 0.12 +/- 0.04 (mg. h/L)/(mg/m(2)) (P = 0.0015).",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[h·l·mg·mg] / [m(2],0.16,101873,DB00864,Tacrolimus
,11427455,-AUC,"h/L (P = 0.0006); mean dose-normalized MPA-AUC, 0.16 +/- 0.05 vs 0.12 +/- 0.04 (mg. h/L)/(mg/m(2)) (P = 0.0015).",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[h·l·mg·mg] / [m(2],0.12,101874,DB00864,Tacrolimus
,11427455,c(min),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],1.86,101875,DB00864,Tacrolimus
,11427455,c(min),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],1.76,101876,DB00864,Tacrolimus
,11427455,c(min),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],3.83,101877,DB00864,Tacrolimus
,11427455,AUC((0-12)),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,37.7,101878,DB00864,Tacrolimus
,11427455,AUC((0-12)),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,24.9,101879,DB00864,Tacrolimus
,11427455,AUC((0-12)),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,104.9,101880,DB00864,Tacrolimus
,11427455,maximum,"h/L. The threshold of toxicity was 3 mg/L (sensitivity, 38.7%; specificity, 91.5%) for c(min), 8.09 mg/L for maximum MPA concentration during the first hour (sensitivity, 77.8%; specificity, 67.4%), and 37.6 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],8.,101881,DB00864,Tacrolimus
,26976646,area under the curve from 0 to 24 hours,"When the actual dose was examined, area under the curve from 0 to 24 hours on day 14 was 1.8-fold higher than that on day 6 (423.9 vs 235.7 ng × h/mL).",A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26976646/),[h·ng] / [ml],423.9,102674,DB00864,Tacrolimus
,26976646,area under the curve from 0 to 24 hours,"When the actual dose was examined, area under the curve from 0 to 24 hours on day 14 was 1.8-fold higher than that on day 6 (423.9 vs 235.7 ng × h/mL).",A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26976646/),[h·ng] / [ml],235.7,102675,DB00864,Tacrolimus
,26976646,area under the curve from 0 to 24 hours,"When tacrolimus was normalized to 0.1 mg/kg, area under the curve from 0 to 24 hours on day 14 was 1.5-fold higher than on day 6 (279.3 vs 183.4 ng × h/mL).",A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26976646/),[h·ng] / [ml],279.3,102676,DB00864,Tacrolimus
,26976646,area under the curve from 0 to 24 hours,"When tacrolimus was normalized to 0.1 mg/kg, area under the curve from 0 to 24 hours on day 14 was 1.5-fold higher than on day 6 (279.3 vs 183.4 ng × h/mL).",A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26976646/),[h·ng] / [ml],183.4,102677,DB00864,Tacrolimus
,12856780,elimination half-life,"Mean (+/- SD) values of elimination half-life, time to maximum concentration, maximum blood concentration, and area under the concentration versus time curve from the last dose of tacrolimus to 12 hours later were 20.5 +/- 9.8 hours, 0.77 +/- 0.37 hours, 27.5 +/- 31.8 ng/mL, and 161 +/- 168 hours x ng/mL, respectively.",Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856780/),h,20.5,102727,DB00864,Tacrolimus
,12856780,time to maximum concentration,"Mean (+/- SD) values of elimination half-life, time to maximum concentration, maximum blood concentration, and area under the concentration versus time curve from the last dose of tacrolimus to 12 hours later were 20.5 +/- 9.8 hours, 0.77 +/- 0.37 hours, 27.5 +/- 31.8 ng/mL, and 161 +/- 168 hours x ng/mL, respectively.",Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856780/),h,0.77,102728,DB00864,Tacrolimus
,12856780,time to maximum concentration,"Mean (+/- SD) values of elimination half-life, time to maximum concentration, maximum blood concentration, and area under the concentration versus time curve from the last dose of tacrolimus to 12 hours later were 20.5 +/- 9.8 hours, 0.77 +/- 0.37 hours, 27.5 +/- 31.8 ng/mL, and 161 +/- 168 hours x ng/mL, respectively.",Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856780/),[ng] / [ml],27.5,102729,DB00864,Tacrolimus
,12856780,maximum blood concentration,"Mean (+/- SD) values of elimination half-life, time to maximum concentration, maximum blood concentration, and area under the concentration versus time curve from the last dose of tacrolimus to 12 hours later were 20.5 +/- 9.8 hours, 0.77 +/- 0.37 hours, 27.5 +/- 31.8 ng/mL, and 161 +/- 168 hours x ng/mL, respectively.",Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856780/),h,0.77,102730,DB00864,Tacrolimus
,12856780,maximum blood concentration,"Mean (+/- SD) values of elimination half-life, time to maximum concentration, maximum blood concentration, and area under the concentration versus time curve from the last dose of tacrolimus to 12 hours later were 20.5 +/- 9.8 hours, 0.77 +/- 0.37 hours, 27.5 +/- 31.8 ng/mL, and 161 +/- 168 hours x ng/mL, respectively.",Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856780/),[ng] / [ml],27.5,102731,DB00864,Tacrolimus
,12856780,area under the concentration versus time curve,"Mean (+/- SD) values of elimination half-life, time to maximum concentration, maximum blood concentration, and area under the concentration versus time curve from the last dose of tacrolimus to 12 hours later were 20.5 +/- 9.8 hours, 0.77 +/- 0.37 hours, 27.5 +/- 31.8 ng/mL, and 161 +/- 168 hours x ng/mL, respectively.",Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12856780/),[h·ng] / [ml],161,102732,DB00864,Tacrolimus
,16863483,V/F,"A final analysis in all 51 patients, which consisted of 1775 blood samples for concentration measurements, identified the following regression model: Cl/F (L/hr) = (0.36 + 2.01/POD * L) * TBIL(-0.23 (TBIL = 1 if TBIL level < or = 1.2 mg/dl, otherwise TBIL = TBIL level)) *49((if POD < or = 3 days)) * 0.75((if INR > 1.4)) * 0.86((if GRWR < or = 1.25%)) * WT, where L was 1 if postoperative day (POD) was greater than 35 days, otherwise L was 0; V/F was 568 L, TBIL was total bilirubin, and WT was body weight.",Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16863483/),l,568,103142,DB00864,Tacrolimus
,17175302,trough level (C0),At study entry tacrolimus trough level (C0) was 7.9 +/- 3.9 ng/mL and area under the curve over a dosing interval (AUC) was 132 +/- 56 ng x h/mL.,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],7.9,103909,DB00864,Tacrolimus
,17175302,area under the curve over a dosing interval (AUC),At study entry tacrolimus trough level (C0) was 7.9 +/- 3.9 ng/mL and area under the curve over a dosing interval (AUC) was 132 +/- 56 ng x h/mL.,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],132,103910,DB00864,Tacrolimus
,17175302,C0,"The addition of everolimus in period 1 did not change tacrolimus exposure: C0 8.4 +/- 4.0 ng/mL, AUC 134 +/- 70 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],8.4,103911,DB00864,Tacrolimus
,17175302,AUC,"The addition of everolimus in period 1 did not change tacrolimus exposure: C0 8.4 +/- 4.0 ng/mL, AUC 134 +/- 70 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],134,103912,DB00864,Tacrolimus
,17175302,C0,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],3.3,103913,DB00864,Tacrolimus
,17175302,Cmax,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],10.4,103914,DB00864,Tacrolimus
,17175302,AUC,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],58,103915,DB00864,Tacrolimus
,17175302,C0,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],3.0,103916,DB00864,Tacrolimus
,17175302,Cmax,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],8.2,103917,DB00864,Tacrolimus
,17175302,AUC,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],49,103918,DB00864,Tacrolimus
,22706623,weight normalized oral clearance CL/F [CL/F/ (weight/70),"The weight normalized oral clearance CL/F [CL/F/ (weight/70)(0.75)] was lower in patients with CYP3A5 3/3 as compared to patients with the CYP3A5 1/3 (32.2 ± 10.1 vs. 53.5 ± 20.2 L/h, p = 0.01).",Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706623/),[l] / [h],0.,104212,DB00864,Tacrolimus
,22706623,weight normalized oral clearance CL/F [CL/F/ (weight/70),"The weight normalized oral clearance CL/F [CL/F/ (weight/70)(0.75)] was lower in patients with CYP3A5 3/3 as compared to patients with the CYP3A5 1/3 (32.2 ± 10.1 vs. 53.5 ± 20.2 L/h, p = 0.01).",Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706623/),[l] / [h],32.2,104213,DB00864,Tacrolimus
,22706623,weight normalized oral clearance CL/F [CL/F/ (weight/70),"The weight normalized oral clearance CL/F [CL/F/ (weight/70)(0.75)] was lower in patients with CYP3A5 3/3 as compared to patients with the CYP3A5 1/3 (32.2 ± 10.1 vs. 53.5 ± 20.2 L/h, p = 0.01).",Population pharmacokinetics and pharmacogenetics of once daily prolonged-release formulation of tacrolimus in pediatric and adolescent kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22706623/),[l] / [h],53.5,104214,DB00864,Tacrolimus
,19531982,clearance,"Typical clearance was 106 mL x h(-1) x kg(-0.75), typical distribution volume was 3.71 L/kg, and typical bioavailability was 15.7%.",Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531982/),[ml] / [(kg)^0·h],106,104254,DB00864,Tacrolimus
,19531982,distribution volume,"Typical clearance was 106 mL x h(-1) x kg(-0.75), typical distribution volume was 3.71 L/kg, and typical bioavailability was 15.7%.",Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531982/),[l] / [kg],3.71,104255,DB00864,Tacrolimus
,19531982,bioavailability,"Typical clearance was 106 mL x h(-1) x kg(-0.75), typical distribution volume was 3.71 L/kg, and typical bioavailability was 15.7%.",Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531982/),%,15.7,104256,DB00864,Tacrolimus
,19531982,steady state concentration,A more suitable infusion rate to obtain a steady state concentration of 12 ng/mL was predicted to be 0.035 mg x kg(-0.75) x (-1)d.,Population pharmacokinetics of tacrolimus in pediatric hematopoietic stem cell transplant recipients: new initial dosage suggestions and a model-based dosage adjustment tool. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531982/),[ng] / [ml],12,104257,DB00864,Tacrolimus
,21347736,ME,"After 21 days of treatment, there was an insignificant bias ME (0.22 ± 2.59 ng/ml), a reasonable precision MAE (1.97 ± 1.69 ng/ml) and RMSE (1.28 ± 0.58 ng/ml).",Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347736/),[ng] / [ml],0.22,104966,DB00864,Tacrolimus
,21347736,MAE,"After 21 days of treatment, there was an insignificant bias ME (0.22 ± 2.59 ng/ml), a reasonable precision MAE (1.97 ± 1.69 ng/ml) and RMSE (1.28 ± 0.58 ng/ml).",Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347736/),[ng] / [ml],1.97,104967,DB00864,Tacrolimus
,9402690,Cmin,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],50.2,105168,DB00864,Tacrolimus
,9402690,area under the curve,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],32.1,105169,DB00864,Tacrolimus
,9402690,AUC,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],50.2,105170,DB00864,Tacrolimus
,9402690,AUC,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],32.1,105171,DB00864,Tacrolimus
,9402690,AUC,"There were also significantly lower levels of the glucuronide metabolite of MPA (MPAG) (755 +/- 280 vs 1230 +/- 250 micrograms h/ml AUC, p = 0.02), suggesting a specific inhibition (either direct or indirect) of the conversion of MPA to MPAG in tacrolimus patients, as opposed to those receiving CsA.","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],755,105172,DB00864,Tacrolimus
,9402690,AUC,"There were also significantly lower levels of the glucuronide metabolite of MPA (MPAG) (755 +/- 280 vs 1230 +/- 250 micrograms h/ml AUC, p = 0.02), suggesting a specific inhibition (either direct or indirect) of the conversion of MPA to MPAG in tacrolimus patients, as opposed to those receiving CsA.","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],1230,105173,DB00864,Tacrolimus
,9402690,AUC,"There were also significantly lower levels of the glucuronide metabolite of MPA (MPAG) (755 +/- 280 vs 1230 +/- 250 micrograms h/ml AUC, p = 0.02), suggesting a specific inhibition (either direct or indirect) of the conversion of MPA to MPAG in tacrolimus patients, as opposed to those receiving CsA.","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],250,105174,DB00864,Tacrolimus
,9402690,trough concentrations,Culture media containing MPA and tacrolimus equal to clinical therapeutic trough concentrations (10 ng/ml) were significantly more MLC inhibitory than CsA at equivalent clinical therapeutic trough concentrations (200 ng/ml) with equivalent MPA levels.,"Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[ng] / [ml],10,105175,DB00864,Tacrolimus
,9402690,trough concentrations,Culture media containing MPA and tacrolimus equal to clinical therapeutic trough concentrations (10 ng/ml) were significantly more MLC inhibitory than CsA at equivalent clinical therapeutic trough concentrations (200 ng/ml) with equivalent MPA levels.,"Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[ng] / [ml],200,105176,DB00864,Tacrolimus
,25869250,Apparent clearance (CL/F),"Apparent clearance (CL/F) and apparent volumes of distribution (V/F) in final population model were 17.6 L/h and 225 L, respectively.","Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25869250/),[l] / [h],17.6,106064,DB00864,Tacrolimus
,25869250,apparent volumes of distribution (V/F),"Apparent clearance (CL/F) and apparent volumes of distribution (V/F) in final population model were 17.6 L/h and 225 L, respectively.","Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25869250/),l,225,106065,DB00864,Tacrolimus
,25869250,absorption rate constant (Ka),The absorption rate constant (Ka) was fixed at 4.48 h(-1).,"Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25869250/),1/[h],4.48,106066,DB00864,Tacrolimus
,25708713,half-lives,"Cyclosporine and tacrolimus half-lives increased from 7 to 25 h and 32 to 232 h, respectively.","Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25708713/),h,7 to 25,106418,DB00864,Tacrolimus
,25708713,half-lives,"Cyclosporine and tacrolimus half-lives increased from 7 to 25 h and 32 to 232 h, respectively.","Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25708713/),h,32 to 232,106419,DB00864,Tacrolimus
,22595383,AUC,Median MPA AUC was constantly within the therapeutic window of 30 - 60 mg/l × h throughout the three months of evaluation.,Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595383/),[mg] / [h·l],30 - 60,107762,DB00864,Tacrolimus
above,22595383,AUC,More than 75% of patients had a MPA AUC above 30 mg/l × h at Day 2 and Day 7 post-transplant.,Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595383/),[mg] / [h·l],30,107763,DB00864,Tacrolimus
,30229398,clearance,The mean estimated total body MPA clearance of the elderly recipients was not significantly different from that of the controls at any analyzed time point (the mean clearance across all time points was 0.31 ± 0.17 vs 0.30 ± 0.25 L/h/kg).,Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[l] / [h·kg],0.31,107867,DB00864,Tacrolimus
,30229398,clearance,The mean estimated total body MPA clearance of the elderly recipients was not significantly different from that of the controls at any analyzed time point (the mean clearance across all time points was 0.31 ± 0.17 vs 0.30 ± 0.25 L/h/kg).,Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[l] / [h·kg],0.30,107868,DB00864,Tacrolimus
,30229398,exposure,"MPA exposure, as evaluated from the area under the 12-h time versus measured MPA concentration (adjusted for dose/body weight) curve, did not differ between the groups at any time point (mean exposure across all time points was 4.68 ± 3.61 vs 5.95 ± 4.29 µg·h/mL per mg/kg for the elderly recipients and the controls).",Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[h·μg] / [kg·mg·ml],4.68,107869,DB00864,Tacrolimus
,30229398,exposure,"MPA exposure, as evaluated from the area under the 12-h time versus measured MPA concentration (adjusted for dose/body weight) curve, did not differ between the groups at any time point (mean exposure across all time points was 4.68 ± 3.61 vs 5.95 ± 4.29 µg·h/mL per mg/kg for the elderly recipients and the controls).",Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[h·μg] / [kg·mg·ml],5.95,107870,DB00864,Tacrolimus
,32387086,CL/F,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),[l] / [h],12.4,108066,DB00864,Tacrolimus
,32387086,Q/F,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),l,45.6,108067,DB00864,Tacrolimus
,32387086,V2/F,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),l,45.6,108068,DB00864,Tacrolimus
,32387086,Ka,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),1/[h],1.67,108069,DB00864,Tacrolimus
,1713626,"total plasma clearance, CLtot","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [min],7.028,108215,DB00864,Tacrolimus
,1713626,"total plasma clearance, CLtot","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [min],7.651,108216,DB00864,Tacrolimus
,1713626,"steady-state distribution volume, Vd.ss","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [kg],4623,108217,DB00864,Tacrolimus
,1713626,"steady-state distribution volume, Vd.ss","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [kg],4201,108218,DB00864,Tacrolimus
,1713626,"elimination half-life at the terminal elimination phase, t1/2 beta","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),h,2.36,108219,DB00864,Tacrolimus
,1713626,"elimination half-life at the terminal elimination phase, t1/2 beta","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),h,2.54,108220,DB00864,Tacrolimus
,1713626,"volume of the initial distribution space, V1","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [kg],1336,108221,DB00864,Tacrolimus
,1713626,"volume of the initial distribution space, V1","After the i.v. injection of FK at 1.0 and 5.0 mg/kg, the total plasma clearance, CLtot, was 7.028 +/- 0.076 (mean +/- S.E.) and 7.651 +/- 0.755 ml/min, steady-state distribution volume, Vd.ss, was 4623 +/- 28 and 4201 +/- 529 ml/kg, elimination half-life at the terminal elimination phase, t1/2 beta, was 2.36 +/- 0.25 and 2.54 +/- 0.29 h, and the volume of the initial distribution space, V1, was 1336 +/- 150 and 1065 +/- 115 ml/kg, respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),[ml] / [kg],1065,108222,DB00864,Tacrolimus
,1713626,percentage,"The mean percentage of FK transferred into the thoracic lymphatics over 6 h were 0.09 +/- 0.02% (1.0 mg/kg) and 0.16 +/- 0.02% (5.0 mg/kg), respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),%,0.09,108223,DB00864,Tacrolimus
,1713626,percentage,"The mean percentage of FK transferred into the thoracic lymphatics over 6 h were 0.09 +/- 0.02% (1.0 mg/kg) and 0.16 +/- 0.02% (5.0 mg/kg), respectively.","Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1713626/),%,0.16,108224,DB00864,Tacrolimus
,10075604,bioavailabilities,"Pharmacokinetic studies revealed bioavailabilities of 2% and 6% respectively, while D-xylose and B12 absorption were found to be within normal limits and fecal fat was only slightly increased, suggesting that there was a selective absorptive defect for these drugs.",Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10075604/),%,2,108902,DB00864,Tacrolimus
,10075604,bioavailabilities,"Pharmacokinetic studies revealed bioavailabilities of 2% and 6% respectively, while D-xylose and B12 absorption were found to be within normal limits and fecal fat was only slightly increased, suggesting that there was a selective absorptive defect for these drugs.",Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10075604/),%,6,108903,DB00864,Tacrolimus
,15639695,T(max),"However, recipients with acute rejection reached mean (SD) tacrolimus T(max) significantly faster than those who were free from rejection (0.96 [0.56] hour vs 1.77 [1.06] hours; P < 0.001).","Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15639695/),h,0.96,109041,DB00864,Tacrolimus
,15639695,T(max),"However, recipients with acute rejection reached mean (SD) tacrolimus T(max) significantly faster than those who were free from rejection (0.96 [0.56] hour vs 1.77 [1.06] hours; P < 0.001).","Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15639695/),h,1.77,109042,DB00864,Tacrolimus
,15639695,MRT,"As part of the previous study, 100 patients (59 male, 41 female; mean [SD] age, 51.4 [13.8] years;age range, 20-75 years) were enrolled in the study The calculated MRT was significantly shorter in recipients with acute allograft rejection (11.32 [031] hours vs 11.52 [028] hours; P = 0.02), just like T(max) was an independent risk factor for acute rejection in a multivariate logistic regression model (odds ratio, 0.092 [95% CI, 0.014-0.629]; P = 0.01).","Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15639695/),h,11.32,109043,DB00864,Tacrolimus
,15639695,MRT,"As part of the previous study, 100 patients (59 male, 41 female; mean [SD] age, 51.4 [13.8] years;age range, 20-75 years) were enrolled in the study The calculated MRT was significantly shorter in recipients with acute allograft rejection (11.32 [031] hours vs 11.52 [028] hours; P = 0.02), just like T(max) was an independent risk factor for acute rejection in a multivariate logistic regression model (odds ratio, 0.092 [95% CI, 0.014-0.629]; P = 0.01).","Time to reach tacrolimus maximum blood concentration,mean residence time, and acute renal allograft rejection: an open-label, prospective, pharmacokinetic study in adult recipients. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15639695/),h,11.52,109044,DB00864,Tacrolimus
,9165550,area under the curve (AUC),"The area under the curve (AUC) of tacrolimus in the morning dose was significantly larger than that in the evening dose (219 +/- 54 ng.hr/ml and 188 +/- 57 ng.hr/ml, respectively, p = 0.004).",Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165550/),[h·ng] / [ml],219,109382,DB00864,Tacrolimus
,9165550,area under the curve (AUC),"The area under the curve (AUC) of tacrolimus in the morning dose was significantly larger than that in the evening dose (219 +/- 54 ng.hr/ml and 188 +/- 57 ng.hr/ml, respectively, p = 0.004).",Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165550/),[h·ng] / [ml],188,109383,DB00864,Tacrolimus
,9165550,time to peak concentration (Tmax),"The mean time to peak concentration (Tmax) was significantly shorter for the morning dose than for the evening dose (1.6 +/- 0.7 hrs and 3.5 +/- 2.9 hrs, respectively, p = 0.01).",Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165550/),h,1.6,109384,DB00864,Tacrolimus
,9165550,time to peak concentration (Tmax),"The mean time to peak concentration (Tmax) was significantly shorter for the morning dose than for the evening dose (1.6 +/- 0.7 hrs and 3.5 +/- 2.9 hrs, respectively, p = 0.01).",Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165550/),h,3.5,109385,DB00864,Tacrolimus
,9165550,peak concentration (Cmax),"The mean peak concentration (Cmax) was significantly higher in the morning dose than in the evening dose (32.2 +/- 9.1 ng/ml and 21.6 +/- 8.3 ng/ml, respectively, p = 0.008).",Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165550/),[ng] / [ml],32.2,109386,DB00864,Tacrolimus
,9165550,peak concentration (Cmax),"The mean peak concentration (Cmax) was significantly higher in the morning dose than in the evening dose (32.2 +/- 9.1 ng/ml and 21.6 +/- 8.3 ng/ml, respectively, p = 0.008).",Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165550/),[ng] / [ml],21.6,109387,DB00864,Tacrolimus
,9165550,AUC,"Endothelin-1 concentrations followed the same pattern as tacrolimus, with AUC and Cmax for the morning significantly higher than those for the evening dose of tacrolimus (AUC 13.8 +/- 3.7 pg.hr/ml, morning, and 11.0 +/- 3.5 pg.hr/ml, evening, p = 0.005; Cmax 2.4 +/- 1.1 pg/ml morning, and 1.5 +/- 0.6 pg/ml evening, p = 0.02).",Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165550/),[h·pg] / [ml],13.8,109388,DB00864,Tacrolimus
,9165550,AUC,"Endothelin-1 concentrations followed the same pattern as tacrolimus, with AUC and Cmax for the morning significantly higher than those for the evening dose of tacrolimus (AUC 13.8 +/- 3.7 pg.hr/ml, morning, and 11.0 +/- 3.5 pg.hr/ml, evening, p = 0.005; Cmax 2.4 +/- 1.1 pg/ml morning, and 1.5 +/- 0.6 pg/ml evening, p = 0.02).",Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165550/),[h·pg] / [ml],11.0,109389,DB00864,Tacrolimus
,9165550,Cmax,"Endothelin-1 concentrations followed the same pattern as tacrolimus, with AUC and Cmax for the morning significantly higher than those for the evening dose of tacrolimus (AUC 13.8 +/- 3.7 pg.hr/ml, morning, and 11.0 +/- 3.5 pg.hr/ml, evening, p = 0.005; Cmax 2.4 +/- 1.1 pg/ml morning, and 1.5 +/- 0.6 pg/ml evening, p = 0.02).",Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165550/),[pg] / [ml],2.4,109390,DB00864,Tacrolimus
,9165550,Cmax,"Endothelin-1 concentrations followed the same pattern as tacrolimus, with AUC and Cmax for the morning significantly higher than those for the evening dose of tacrolimus (AUC 13.8 +/- 3.7 pg.hr/ml, morning, and 11.0 +/- 3.5 pg.hr/ml, evening, p = 0.005; Cmax 2.4 +/- 1.1 pg/ml morning, and 1.5 +/- 0.6 pg/ml evening, p = 0.02).",Time-dependent disposition of tacrolimus and its effect on endothelin-1 in liver allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165550/),[pg] / [ml],1.5,109391,DB00864,Tacrolimus
,25279405,whole blood clearance/bioavailability,"Tacrolimus whole blood clearance/bioavailability standardized to haematocrit of 45% and fat free mass of 60 kg was estimated to be 16.1 l h−1 [95% CI 12.6, 18.0 l h−1].",Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25279405/),[l] / [h],16.1,109434,DB00864,Tacrolimus
,9794505,bioavailability,"The bioavailability of tacrolimus was about 40% and 25% after intraportal and intraintestinal administration, respectively.",Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9794505/),%,40,109936,DB00864,Tacrolimus
,9794505,bioavailability,"The bioavailability of tacrolimus was about 40% and 25% after intraportal and intraintestinal administration, respectively.",Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9794505/),%,25,109937,DB00864,Tacrolimus
,15050160,time to peak concentration,In Group 4 animals showed a 60-minute time to peak concentration.,The colon displays an absorptive capacity of tacrolimus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15050160/),min,60,111123,DB00864,Tacrolimus
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,15,111482,DB00864,Tacrolimus
,26242764,time to neutrophil engraftment,"Median (range) time to neutrophil engraftment (>500 cells/µL) and platelet engraftment (>20,000/mm(3) ) were 15 (12-28) and 25 (17-30) days, respectively.",Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26242764/),d,25,111483,DB00864,Tacrolimus
,29356211,sustained virologic response rate,The sustained virologic response rate at 12 weeks was 95.8%.,Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29356211/),%,95.8,111647,DB00864,Tacrolimus
,32296499,absorption rate constant Ka,One compartment model with first-order absorption (absorption rate constant Ka was fixed as 4.48/hour) was employed to establish the population pharmacokinetic model using a non-linear mixed-effects modelling approach.,Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32296499/),1/[h],4.48,111859,DB00864,Tacrolimus
,32296499,clearance (CL/F),"Pharmacokinetic parameter population typical estimates for clearance (CL/F) and apparent distribution volume (V/F) were 14.23 L/hour and 760.80 L, respectively.",Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32296499/),[l] / [h],14.23,111860,DB00864,Tacrolimus
,32296499,apparent distribution volume (V/F),"Pharmacokinetic parameter population typical estimates for clearance (CL/F) and apparent distribution volume (V/F) were 14.23 L/hour and 760.80 L, respectively.",Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32296499/),l,760.80,111861,DB00864,Tacrolimus
,27771258,run time,Chromatographic separation were achieved on an Acquity UPLC BEH C18 column by a gradient elution using 2mM ammonium acetate/0.1% (v/v) formic acid in water (mobile phase A) and in methanol (mobile phase B) with a 2.2min chromatographic run time.,Development and validation of a sensitive and selective LC-MS/MS method for determination of tacrolimus in oral fluids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27771258/),min,2.2,112091,DB00864,Tacrolimus
,11368293,time to reach maximum concentration,"In adult patients, tacrolimus is generally rapidly absorbed following oral administration (the time to reach maximum concentration is 1 to 2 hours), but in some patients absorption is slow or even delayed.",Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),h,1 to 2,112807,DB00864,Tacrolimus
,11368293,oral bioavailability,"Because of presystemic elimination, the oral bioavailability is low (around 20%) but may vary between 4 and 89%.",Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),%,20,112808,DB00864,Tacrolimus
,11368293,oral bioavailability,"Because of presystemic elimination, the oral bioavailability is low (around 20%) but may vary between 4 and 89%.",Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),%,4 and 89,112809,DB00864,Tacrolimus
,11368293,binding,Its binding to plasma proteins varies between 72 and 98% depending on the methodology used.,Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),%,72,112810,DB00864,Tacrolimus
,11368293,apparent volume of distribution (Vd),"Because of the extensive partitioning of tacrolimus into erythrocytes, its apparent volume of distribution (Vd) based on blood concentrations is much lower (1.0 to 1.5 L/kg) compared with values based on plasma concentrations (about 30 L/kg).",Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),[l] / [kg],1.0 to 1.5,112811,DB00864,Tacrolimus
,11368293,Systemic plasma clearance,"Systemic plasma clearance of tacrolimus is very high (0.6 to 5.4 L/h/kg), whereas blood clearance is much lower (0.03 to 0.09 L/h/kg).",Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),[l] / [h·kg],0.6 to 5.4,112812,DB00864,Tacrolimus
,11368293,blood clearance,"Systemic plasma clearance of tacrolimus is very high (0.6 to 5.4 L/h/kg), whereas blood clearance is much lower (0.03 to 0.09 L/h/kg).",Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),[l] / [h·kg],0.03 to 0.09,112813,DB00864,Tacrolimus
,11368293,terminal elimination half-life (t1/2beta),The terminal elimination half-life (t1/2beta) of tacrolimus is approximately 12 hours (with a range of 3.5 to 40.5 hours).,Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),h,12,112814,DB00864,Tacrolimus
,11368293,Vd,The Vd of tacrolimus based on blood concentrations in paediatric patients (2.6 L/kg) is approximately twice the adult value.,Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),[l] / [kg],2.6,112815,DB00864,Tacrolimus
,11368293,Blood clearance,Blood clearance of tacrolimus is also approximately twice as high in paediatric (0.14 L/h/kg) compared with adult (0.06 L/h/kg) patients.,Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),[l] / [h·kg],0.14,112816,DB00864,Tacrolimus
,11368293,Blood clearance,Blood clearance of tacrolimus is also approximately twice as high in paediatric (0.14 L/h/kg) compared with adult (0.06 L/h/kg) patients.,Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11368293/),[l] / [h·kg],0.06,112817,DB00864,Tacrolimus
,26915847,Co,There was a significant difference in the whole-blood tacrolimus Co between the 2 groups (6.16 ± 1.74 ng/mL vs 4.90 ± 1.06 ng/mL; P = .0001).,Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26915847/),[ng] / [ml],6.16,113420,DB00864,Tacrolimus
,26915847,Co,There was a significant difference in the whole-blood tacrolimus Co between the 2 groups (6.16 ± 1.74 ng/mL vs 4.90 ± 1.06 ng/mL; P = .0001).,Effects of CYP3A5 Genetic Polymorphism on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26915847/),[ng] / [ml],4.90,113421,DB00864,Tacrolimus
,24809233,relative bioavailability,"Sublingual administration showed no clinically significant exposure, contrary to rectal administration, where all subjects had clinically relevant exposure, with a lower relative bioavailability (78%), a lower maximal blood concentration and a later time of maximal blood concentration compared with oral administration.",Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24809233/),%,78,116395,DB00864,Tacrolimus
,16044098,AUC,"No significant differences were found between calculated and estimated AUC (165.6 +/- 41.1 and 166.7 +/- 43.2 ng.h/mL, respectively).",Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044098/),[h·ng] / [ml],165.6,116457,DB00864,Tacrolimus
,16044098,AUC,"No significant differences were found between calculated and estimated AUC (165.6 +/- 41.1 and 166.7 +/- 43.2 ng.h/mL, respectively).",Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044098/),[h·ng] / [ml],166.7,116458,DB00864,Tacrolimus
,11034268,analytical recovery,"At the limit of quantification (0.25 microg/L), for both sirolimus and tacrolimus, the interday imprecision was < 3% and the analytical recovery was between 97.0% and 102%, respectively.","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,97.0,116587,DB00864,Tacrolimus
,11034268,analytical recovery,"At the limit of quantification (0.25 microg/L), for both sirolimus and tacrolimus, the interday imprecision was < 3% and the analytical recovery was between 97.0% and 102%, respectively.","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,102,116588,DB00864,Tacrolimus
,11034268,analytical recovery,"The analytical recovery, at the three control concentrations, ranged from 99.2% to 104% of the nominal concentration.","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,99.2,116589,DB00864,Tacrolimus
,11034268,analytical recovery,"The analytical recovery, at the three control concentrations, ranged from 99.2% to 104% of the nominal concentration.","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,104,116590,DB00864,Tacrolimus
,11034268,absolute recovery,"The mean absolute recovery (+/- standard deviation) of tacrolimus, sirolimus, and internal standard was 82 +/- 7%, 89 +/- 12%, and 77 +/- 8%, respectively (n = 12).","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,82,116591,DB00864,Tacrolimus
,11034268,absolute recovery,"The mean absolute recovery (+/- standard deviation) of tacrolimus, sirolimus, and internal standard was 82 +/- 7%, 89 +/- 12%, and 77 +/- 8%, respectively (n = 12).","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,89,116592,DB00864,Tacrolimus
,11034268,absolute recovery,"The mean absolute recovery (+/- standard deviation) of tacrolimus, sirolimus, and internal standard was 82 +/- 7%, 89 +/- 12%, and 77 +/- 8%, respectively (n = 12).","Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11034268/),%,77,116593,DB00864,Tacrolimus
,17529886,area under the plasma concentration-time curve from zero to 12 hours (AUC0-12),"The mean dose-adjusted area under the plasma concentration-time curve from zero to 12 hours (AUC0-12) of MPA in UGT1A7*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 were 95, 98, 99, 88, and 86 ng.h/mL/mg, respectively (P = 0.9475).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],95,117546,DB00864,Tacrolimus
,17529886,area under the plasma concentration-time curve from zero to 12 hours (AUC0-12),"The mean dose-adjusted area under the plasma concentration-time curve from zero to 12 hours (AUC0-12) of MPA in UGT1A7*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 were 95, 98, 99, 88, and 86 ng.h/mL/mg, respectively (P = 0.9475).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],98,117547,DB00864,Tacrolimus
,17529886,area under the plasma concentration-time curve from zero to 12 hours (AUC0-12),"The mean dose-adjusted area under the plasma concentration-time curve from zero to 12 hours (AUC0-12) of MPA in UGT1A7*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 were 95, 98, 99, 88, and 86 ng.h/mL/mg, respectively (P = 0.9475).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],99,117548,DB00864,Tacrolimus
,17529886,area under the plasma concentration-time curve from zero to 12 hours (AUC0-12),"The mean dose-adjusted area under the plasma concentration-time curve from zero to 12 hours (AUC0-12) of MPA in UGT1A7*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 were 95, 98, 99, 88, and 86 ng.h/mL/mg, respectively (P = 0.9475).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],88,117549,DB00864,Tacrolimus
,17529886,area under the plasma concentration-time curve from zero to 12 hours (AUC0-12),"The mean dose-adjusted area under the plasma concentration-time curve from zero to 12 hours (AUC0-12) of MPA in UGT1A7*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 were 95, 98, 99, 88, and 86 ng.h/mL/mg, respectively (P = 0.9475).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],86,117550,DB00864,Tacrolimus
,17529886,AUC0-12,"The mean dose-adjusted AUC0-12 of MPA in UGT1A9 I399C/C, C/T, and T/T were 87, 99, and 95 ng.h/mL/mg, respectively (P = 0.6937).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],87,117551,DB00864,Tacrolimus
,17529886,AUC0-12,"The mean dose-adjusted AUC0-12 of MPA in UGT1A9 I399C/C, C/T, and T/T were 87, 99, and 95 ng.h/mL/mg, respectively (P = 0.6937).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],99,117552,DB00864,Tacrolimus
,17529886,AUC0-12,"The mean dose-adjusted AUC0-12 of MPA in UGT1A9 I399C/C, C/T, and T/T were 87, 99, and 95 ng.h/mL/mg, respectively (P = 0.6937).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],95,117553,DB00864,Tacrolimus
,17529886,trough levels,"The dose-adjusted trough levels of MPA in UGT1A9 I399C/C, C/T, and T/T were 5.4, 5.5, and 4.7 ng/mL/mg (P = 0.5845).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[ng] / [mg·ml],5.4,117554,DB00864,Tacrolimus
,17529886,trough levels,"The dose-adjusted trough levels of MPA in UGT1A9 I399C/C, C/T, and T/T were 5.4, 5.5, and 4.7 ng/mL/mg (P = 0.5845).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[ng] / [mg·ml],5.5,117555,DB00864,Tacrolimus
,17529886,trough levels,"The dose-adjusted trough levels of MPA in UGT1A9 I399C/C, C/T, and T/T were 5.4, 5.5, and 4.7 ng/mL/mg (P = 0.5845).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[ng] / [mg·ml],4.7,117556,DB00864,Tacrolimus
,12962871,Cmax,A Cmax (30.5+/-13.8 ng/mL) was reached at 2.3+/-1.5 h.,Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[ng] / [ml],30.5,118331,DB00864,Tacrolimus
,12962871,trough levels,"When target trough levels were achieved (10-20 ng/mL), the mean tacrolimus exposure was 230.6+/-59.2 ng h/mL (120.14-327.7) (n=19).",Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[ng] / [ml],10-20,118332,DB00864,Tacrolimus
,12962871,exposure,"When target trough levels were achieved (10-20 ng/mL), the mean tacrolimus exposure was 230.6+/-59.2 ng h/mL (120.14-327.7) (n=19).",Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[h·ng] / [ml],230.6,118333,DB00864,Tacrolimus
,17438408,terminal elimination half-lives,"Rat pharmacokinetic studies with intravenous dosing demonstrated terminal elimination half-lives of 9.4 hours and 14.0 hours for zotarolimus and sirolimus, respectively.","Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17438408/),h,9.4,120010,DB00864,Tacrolimus
,17438408,terminal elimination half-lives,"Rat pharmacokinetic studies with intravenous dosing demonstrated terminal elimination half-lives of 9.4 hours and 14.0 hours for zotarolimus and sirolimus, respectively.","Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17438408/),h,14.0,120011,DB00864,Tacrolimus
,17438408,T1/2,"Given orally, T1/2 values were 7.9 hours and 33.4 hours, respectively.","Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17438408/),h,7.9,120012,DB00864,Tacrolimus
,17438408,T1/2,"Given orally, T1/2 values were 7.9 hours and 33.4 hours, respectively.","Zotarolimus, a novel sirolimus analogue with potent anti-proliferative activity on coronary smooth muscle cells and reduced potential for systemic immunosuppression. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17438408/),h,33.4,120013,DB00864,Tacrolimus
,12021639,area under the concentration-time curve (AUC),"The 12-hour area under the concentration-time curve (AUC) values for MPA and its major metabolite the phenolic glucuronide MPAG were 55.1 mg.h/L and 800 mg.h/L, respectively.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],55.1,120123,DB00864,Tacrolimus
,12021639,area under the concentration-time curve (AUC),"The 12-hour area under the concentration-time curve (AUC) values for MPA and its major metabolite the phenolic glucuronide MPAG were 55.1 mg.h/L and 800 mg.h/L, respectively.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],800,120124,DB00864,Tacrolimus
,12021639,12-h,"An unusually high concentration (12-h AUC, 165 mg.h/L) of the phenolic glucose conjugate of MPA was found.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],165,120125,DB00864,Tacrolimus
,12021639,AUC,"An unusually high concentration (12-h AUC, 165 mg.h/L) of the phenolic glucose conjugate of MPA was found.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],165,120126,DB00864,Tacrolimus
,12021639,apparent renal clearance,The apparent renal clearance of MPAG was only 2.2 mL/min.,Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[ml] / [min],2.2,120127,DB00864,Tacrolimus
,15502717,trough level,"The pharmacokinetics of tacrolimus was analyzed on day 28 after transplant, when the daily dose was adjusted to the target trough level of 10-15 ng/mL.",Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502717/),[ng] / [ml],10-15,120223,DB00864,Tacrolimus
,15502717,trough level,"The dose-adjusted trough level and the area under the concentration-time curve (AUC0-12) were significantly lower in CYP3A5 *1 carriers than CYP3A5 *3/*3 carriers (0.040+/-0.014 vs. 0.057+/-0.024 ng/mL/mg/kg, P=0.015 and 0.583+/-0.162 vs. 0.899+/-0.319 ng.hr/mL/mg/kg, P=0.004), respectively.",Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502717/),[ng] / [kg·mg·ml],0.040,120224,DB00864,Tacrolimus
,15502717,area under the concentration-time curve (AUC0-12),"The dose-adjusted trough level and the area under the concentration-time curve (AUC0-12) were significantly lower in CYP3A5 *1 carriers than CYP3A5 *3/*3 carriers (0.040+/-0.014 vs. 0.057+/-0.024 ng/mL/mg/kg, P=0.015 and 0.583+/-0.162 vs. 0.899+/-0.319 ng.hr/mL/mg/kg, P=0.004), respectively.",Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502717/),[h·ng] / [kg·mg·ml],0.583,120225,DB00864,Tacrolimus
,15502717,area under the concentration-time curve (AUC0-12),"The dose-adjusted trough level and the area under the concentration-time curve (AUC0-12) were significantly lower in CYP3A5 *1 carriers than CYP3A5 *3/*3 carriers (0.040+/-0.014 vs. 0.057+/-0.024 ng/mL/mg/kg, P=0.015 and 0.583+/-0.162 vs. 0.899+/-0.319 ng.hr/mL/mg/kg, P=0.004), respectively.",Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502717/),[h·ng] / [kg·mg·ml],0.899,120226,DB00864,Tacrolimus
,26919549,concentrations,"In TAC (STN → MPS) group, dose-adjusted TAC concentrations decreased from baseline to first week (2.3 ± 1.1 versus 1.5 ± 1.0 ng·mL·mg, P < 0.05).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),,1.5,121430,DB00864,Tacrolimus
,26919549,concentrations,"In EVR (STN → TAC) group, dose-adjusted EVR concentrations decreased from baseline to first week (3.6 ± 2.3 ng·mL·mg versus 1.9 ± 0.8 ng·mL·mg, P < 0.01).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),mg·ml·ng,3.,121431,DB00864,Tacrolimus
,26919549,concentrations,"In EVR (STN → TAC) group, dose-adjusted EVR concentrations decreased from baseline to first week (3.6 ± 2.3 ng·mL·mg versus 1.9 ± 0.8 ng·mL·mg, P < 0.01).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),mg·ml·ng,1.9,121432,DB00864,Tacrolimus
,19274604,V(max),"V(max) and K(m) values of MMF hydrolysis in pooled human liver microsomes were 1368 +/- 44 nmol min(-1) mg(-1) protein and 1030 +/- 65 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),[nM] / [mg·min],1368,121494,DB00864,Tacrolimus
,19274604,K(m),"V(max) and K(m) values of MMF hydrolysis in pooled human liver microsomes were 1368 +/- 44 nmol min(-1) mg(-1) protein and 1030 +/- 65 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,1030,121495,DB00864,Tacrolimus
,19274604,IC(50),"Hydrolytic activity was inhibited by the CES inhibitors phenylmethylsulfonylfluoride, bis-p-nitorophenylphosphate and diisopropylfluorophosphate, with IC(50) values of 77.1, 3.59 and 0.0312 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,77.1,121496,DB00864,Tacrolimus
,19274604,IC(50),"Hydrolytic activity was inhibited by the CES inhibitors phenylmethylsulfonylfluoride, bis-p-nitorophenylphosphate and diisopropylfluorophosphate, with IC(50) values of 77.1, 3.59 and 0.0312 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,3.59,121497,DB00864,Tacrolimus
,19274604,IC(50),"Hydrolytic activity was inhibited by the CES inhibitors phenylmethylsulfonylfluoride, bis-p-nitorophenylphosphate and diisopropylfluorophosphate, with IC(50) values of 77.1, 3.59 and 0.0312 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,0.0312,121498,DB00864,Tacrolimus
,26829596,Tac,"The mean Tac C0 at day 10 in the POR*1/*1 group was 15.3 ± 9.7 ng/mL compared with 15.7 ± 7.8 ng/mL in the POR*1/*28 group and 14.2 ± 6.8 ng/mL, in the POR*28/*28 group, P = 0.8.",A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829596/),[ng] / [ml],15.3,121544,DB00864,Tacrolimus
,26829596,C0,"The mean Tac C0 at day 10 in the POR*1/*1 group was 15.3 ± 9.7 ng/mL compared with 15.7 ± 7.8 ng/mL in the POR*1/*28 group and 14.2 ± 6.8 ng/mL, in the POR*28/*28 group, P = 0.8.",A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829596/),[ng] / [ml],15.3,121545,DB00864,Tacrolimus
,26829596,C0,"The mean Tac C0 at day 10 in the POR*1/*1 group was 15.3 ± 9.7 ng/mL compared with 15.7 ± 7.8 ng/mL in the POR*1/*28 group and 14.2 ± 6.8 ng/mL, in the POR*28/*28 group, P = 0.8.",A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829596/),[ng] / [ml],15.7,121546,DB00864,Tacrolimus
,26829596,C0,"The mean Tac C0 at day 10 in the POR*1/*1 group was 15.3 ± 9.7 ng/mL compared with 15.7 ± 7.8 ng/mL in the POR*1/*28 group and 14.2 ± 6.8 ng/mL, in the POR*28/*28 group, P = 0.8.",A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829596/),[ng] / [ml],14.2,121547,DB00864,Tacrolimus
,32317615,MST,PRCL-02 monotherapy only marginally prolonged graft survival (MST = 13.16 d; group 2) compared with untreated controls.,Targeting Calcium Release-activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32317615/),d,13.16,121684,DB00864,Tacrolimus
,24238261,clearance (CL/F),"The estimated population mean of clearance (CL/F), volume of distribution (V/F) and absorption rate (Ka ) were 21.9 L/hr, 205 L, and 3.43/hr, respectively, and the lag time was fixed at 0.25 hr.",Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24238261/),[l] / [h],21.9,122580,DB00864,Tacrolimus
,24238261,volume of distribution (V/F),"The estimated population mean of clearance (CL/F), volume of distribution (V/F) and absorption rate (Ka ) were 21.9 L/hr, 205 L, and 3.43/hr, respectively, and the lag time was fixed at 0.25 hr.",Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24238261/),l,205,122581,DB00864,Tacrolimus
,24238261,absorption rate (Ka ),"The estimated population mean of clearance (CL/F), volume of distribution (V/F) and absorption rate (Ka ) were 21.9 L/hr, 205 L, and 3.43/hr, respectively, and the lag time was fixed at 0.25 hr.",Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24238261/),1/[h],3.43,122582,DB00864,Tacrolimus
,24238261,lag time,"The estimated population mean of clearance (CL/F), volume of distribution (V/F) and absorption rate (Ka ) were 21.9 L/hr, 205 L, and 3.43/hr, respectively, and the lag time was fixed at 0.25 hr.",Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24238261/),h,0.25,122583,DB00864,Tacrolimus
,30713247,milk/plasma concentration ratio,"5) In breastfeeding women, the median milk/plasma concentration ratio of amlodipine was 0.85.",Optimization of Individual Pharmacotherapy Based on Multiple Evaluations of Patient Data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30713247/),,0.85,123684,DB00864,Tacrolimus
,22105583,apparent clearance,"Typical apparent clearance of tacrolimus was 0.148 L·h(-1)·kg(-0.75) immediately after transplantation, increasing to a maximum of 1.37 L·h(-1)·kg(-0.75).",Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105583/),[l] / [(kg)^0·h],0.148,124433,DB00864,Tacrolimus
,22105583,apparent clearance,"Typical apparent clearance of tacrolimus was 0.148 L·h(-1)·kg(-0.75) immediately after transplantation, increasing to a maximum of 1.37 L·h(-1)·kg(-0.75).",Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105583/),[l] / [(kg)^0·h],1.37,124434,DB00864,Tacrolimus
,22105583,apparent distribution volume,Typical apparent distribution volume was 27.2 L/kg.,Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105583/),[l] / [kg],27.2,124435,DB00864,Tacrolimus
,22105583,trough concentration,Simulation studies reveal that in 60% of subjects the current initial standard dose without subsequent dosage adjustments overshoot the desired trough concentration range of 10-20 ng/mL.,Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105583/),[ng] / [ml],10-20,124436,DB00864,Tacrolimus
,11442656,absolute bioavailability,"The mean absolute bioavailability was 17.7% in preoperative and 11.1% in postoperative state, respectively and a large interindividual variation was confirmed in this parameter, which was 7.0-27.2% for preoperative and 6.4-22.0% for postoperative area under the curve, respectively.",Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442656/),%,17.7,124574,DB00864,Tacrolimus
,11442656,absolute bioavailability,"The mean absolute bioavailability was 17.7% in preoperative and 11.1% in postoperative state, respectively and a large interindividual variation was confirmed in this parameter, which was 7.0-27.2% for preoperative and 6.4-22.0% for postoperative area under the curve, respectively.",Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442656/),%,11.1,124575,DB00864,Tacrolimus
,11442656,absolute bioavailability,"The mean absolute bioavailability was 17.7% in preoperative and 11.1% in postoperative state, respectively and a large interindividual variation was confirmed in this parameter, which was 7.0-27.2% for preoperative and 6.4-22.0% for postoperative area under the curve, respectively.",Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442656/),%,7.0-27.2,124576,DB00864,Tacrolimus
,11442656,absolute bioavailability,"The mean absolute bioavailability was 17.7% in preoperative and 11.1% in postoperative state, respectively and a large interindividual variation was confirmed in this parameter, which was 7.0-27.2% for preoperative and 6.4-22.0% for postoperative area under the curve, respectively.",Chrono and clinical pharmacokinetic study of tacrolimus in continuous intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11442656/),%,6.4-22.0,124577,DB00864,Tacrolimus
,34145119,apparent clearance (CL/F),"The average parameter estimates for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 9.1 L/h and 912 L, respectively.",Estimation of Tacrolimus Clearance in Saudi Adult Kidney Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34145119/),[l] / [h],9.1,125423,DB00864,Tacrolimus
,34145119,apparent volume of distribution (V/F),"The average parameter estimates for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 9.1 L/h and 912 L, respectively.",Estimation of Tacrolimus Clearance in Saudi Adult Kidney Transplant Recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34145119/),l,912,125424,DB00864,Tacrolimus
,23007747,oral clearance (CL/F),"The mean oral clearance (CL/F) based on whole-blood tacrolimus concentration was 39% higher during mid-pregnancy and late pregnancy compared with postpartum (47.4 ± 12.6 vs. 34.2 ± 14.8 L/h, P < 0.03).",Pharmacokinetics of tacrolimus during pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23007747/),[l] / [h],47.4,125428,DB00864,Tacrolimus
,23007747,oral clearance (CL/F),"The mean oral clearance (CL/F) based on whole-blood tacrolimus concentration was 39% higher during mid-pregnancy and late pregnancy compared with postpartum (47.4 ± 12.6 vs. 34.2 ± 14.8 L/h, P < 0.03).",Pharmacokinetics of tacrolimus during pregnancy. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23007747/),[l] / [h],34.2,125429,DB00864,Tacrolimus
,10084872,coupling molar ratio,The conjugate was estimated to contain 0.45% of FK506 and the coupling molar ratio was approximately 1:1 (dextran-FK-506).,"Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084872/),,1:1,125435,DB00864,Tacrolimus
,10084872,half-life,"Low molecular weight radioactive compound(s), which was eluted in the same fractions as [(3)H]FK506, was released from [(3)H]FK506-dextran conjugate by chemical hydrolysis with a half-life of 150 h in phosphate buffer.","Synthesis and pharmacokinetics of a novel macromolecular prodrug of Tacrolimus (FK506), FK506-dextran conjugate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10084872/),h,150,125436,DB00864,Tacrolimus
,25500866,V2/F,"The estimates of V2/F, Q/F and V3/F were 22.7 L, 76.3 L/h and 916 L, respectively.",A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500866/),l,22.7,125516,DB00864,Tacrolimus
,25500866,Q/F,"The estimates of V2/F, Q/F and V3/F were 22.7 L, 76.3 L/h and 916 L, respectively.",A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500866/),[l] / [h],76.3,125517,DB00864,Tacrolimus
,25500866,V3/F,"The estimates of V2/F, Q/F and V3/F were 22.7 L, 76.3 L/h and 916 L, respectively.",A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500866/),l,916,125518,DB00864,Tacrolimus
,25500866,CL/F,"The estimated CL/F in the volunteers and liver transplant recipients was 32.8 and 18.4 L/h, respectively.",A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500866/),[l] / [h],32.8,125519,DB00864,Tacrolimus
,25500866,CL/F,"The estimated CL/F in the volunteers and liver transplant recipients was 32.8 and 18.4 L/h, respectively.",A population pharmacokinetic study of tacrolimus in healthy Chinese volunteers and liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500866/),[l] / [h],18.4,125520,DB00864,Tacrolimus
,24673713,maximum plasma concentrations (Cmax ),"The mean maximum plasma concentrations (Cmax ) of MPA in the CsA and Tac groups were 11.365 ± 9.522 and 9.748 ± 7.523 μg/ml, respectively (p = 0.137).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[μg] / [ml],11.365,125813,DB00864,Tacrolimus
,24673713,maximum plasma concentrations (Cmax ),"The mean maximum plasma concentrations (Cmax ) of MPA in the CsA and Tac groups were 11.365 ± 9.522 and 9.748 ± 7.523 μg/ml, respectively (p = 0.137).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[μg] / [ml],9.748,125814,DB00864,Tacrolimus
,24673713,maximum times to Cmax (Tmax ),"The maximum times to Cmax (Tmax ) were 2.54 ± 1.53 and 2.67 ± 1.08 h, respectively (p = 0.341).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,2.54,125815,DB00864,Tacrolimus
,24673713,maximum times to Cmax (Tmax ),"The maximum times to Cmax (Tmax ) were 2.54 ± 1.53 and 2.67 ± 1.08 h, respectively (p = 0.341).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,2.67,125816,DB00864,Tacrolimus
,24673713,areas under the curve (MPA-AUC0-12 h ),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[h·μg] / [ml],59.463,125817,DB00864,Tacrolimus
,24673713,areas under the curve (MPA-AUC0-12 h ),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[h·μg] / [ml],77.535,125818,DB00864,Tacrolimus
,24673713,mean residence times (MRT),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,3.71,125819,DB00864,Tacrolimus
,24673713,mean residence times (MRT),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,3.928,125820,DB00864,Tacrolimus
,11402631,clearance,"Mean blood pharmacokinetic parameters with mild hepatic dysfunction were as follows: clearance = 0.035 L/h/kg, terminal exponential volume of distribution = 2.59 L/kg, terminal exponential half-life = 60.6 hours (i.v.), p.o. maximum blood concentration = 48.2 ng/mL, time of p.o. maximum blood concentration = 1.5 hours, and absolute bioavailability = 22.3%.",Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402631/),[l] / [h·kg],0.035,125889,DB00864,Tacrolimus
,11402631,terminal exponential volume of distribution,"Mean blood pharmacokinetic parameters with mild hepatic dysfunction were as follows: clearance = 0.035 L/h/kg, terminal exponential volume of distribution = 2.59 L/kg, terminal exponential half-life = 60.6 hours (i.v.), p.o. maximum blood concentration = 48.2 ng/mL, time of p.o. maximum blood concentration = 1.5 hours, and absolute bioavailability = 22.3%.",Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402631/),[l] / [kg],2.59,125890,DB00864,Tacrolimus
,11402631,terminal exponential half-life,"Mean blood pharmacokinetic parameters with mild hepatic dysfunction were as follows: clearance = 0.035 L/h/kg, terminal exponential volume of distribution = 2.59 L/kg, terminal exponential half-life = 60.6 hours (i.v.), p.o. maximum blood concentration = 48.2 ng/mL, time of p.o. maximum blood concentration = 1.5 hours, and absolute bioavailability = 22.3%.",Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402631/),h,60.6,125891,DB00864,Tacrolimus
,11402631,maximum blood concentration,"Mean blood pharmacokinetic parameters with mild hepatic dysfunction were as follows: clearance = 0.035 L/h/kg, terminal exponential volume of distribution = 2.59 L/kg, terminal exponential half-life = 60.6 hours (i.v.), p.o. maximum blood concentration = 48.2 ng/mL, time of p.o. maximum blood concentration = 1.5 hours, and absolute bioavailability = 22.3%.",Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402631/),[ng] / [ml],48.2,125892,DB00864,Tacrolimus
,11402631,time of p.o. maximum blood concentration,"Mean blood pharmacokinetic parameters with mild hepatic dysfunction were as follows: clearance = 0.035 L/h/kg, terminal exponential volume of distribution = 2.59 L/kg, terminal exponential half-life = 60.6 hours (i.v.), p.o. maximum blood concentration = 48.2 ng/mL, time of p.o. maximum blood concentration = 1.5 hours, and absolute bioavailability = 22.3%.",Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402631/),h,1.5,125893,DB00864,Tacrolimus
,11402631,absolute bioavailability,"Mean blood pharmacokinetic parameters with mild hepatic dysfunction were as follows: clearance = 0.035 L/h/kg, terminal exponential volume of distribution = 2.59 L/kg, terminal exponential half-life = 60.6 hours (i.v.), p.o. maximum blood concentration = 48.2 ng/mL, time of p.o. maximum blood concentration = 1.5 hours, and absolute bioavailability = 22.3%.",Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402631/),%,22.3,125894,DB00864,Tacrolimus
,11271216,trough level,"The mean trough level of FK 506 in whole blood and the mean serum creatinine level in year 2 were 7.9 ng/ml and 1.9 mg/dl, respectively.",Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11271216/),[ng] / [ml],7.9,126169,DB00864,Tacrolimus
,11271216,trough level,"The mean trough level of FK 506 in whole blood and the mean serum creatinine level in year 2 were 7.9 ng/ml and 1.9 mg/dl, respectively.",Two-year follow-up study of the efficacy and safety of FK 506 in kidney transplant patients. Japanese FK 506 Study Group. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11271216/),mg,1.9,126170,DB00864,Tacrolimus
,23676788,trough concentration,"The target trough concentration of sirolimus and cyclosporine was set to around 15 ng/mL and 180 ng/mL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[ng] / [ml],15,126304,DB00864,Tacrolimus
,23676788,trough concentration,"The target trough concentration of sirolimus and cyclosporine was set to around 15 ng/mL and 180 ng/mL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[ng] / [ml],180,126305,DB00864,Tacrolimus
,23676788,T-bil,"Thereafter, the levels of AST and ALT as well as the T-bil were successfully decreased to 73 U/L, 83 U/L, and 3.0 mg/dL, respectively.",Effectiveness of sirolimus in combination with cyclosporine against chronic rejection in a pediatric liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23676788/),[mg] / [dl],3.0,126306,DB00864,Tacrolimus
,25151742,trough concentrations,Seven sampling designs were investigated using various number of trough concentrations per individual ranging from 1-4.,[Effects of multiple-trough sampling design and algorithm on the estimation of population and individual pharmacokinetic parameters]. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25151742/),,1-4,126413,DB00864,Tacrolimus
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,821.49,127188,DB00864,Tacrolimus
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,4768.35,127189,DB00864,Tacrolimus
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,931.69,127190,DB00864,Tacrolimus
,18074760,m/z(+1),Multiple reaction monitoring was used for the measurement of tacrolimus (m/z(+1) 821.49-->4768.35 Th) and sirolimus as internal standard (m/z(+1) 931.69-->864.39 Th).,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),th,864.39,127191,DB00864,Tacrolimus
,18074760,absolute recovery,"Method showed to be accurate, precise and linear over the range from 1 to 80 ng/ml, having an absolute recovery of 94%.","Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),%,94,127192,DB00864,Tacrolimus
,18074760,Total run-time,Total run-time is around 1.5 min.,"Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),min,1.5,127193,DB00864,Tacrolimus
,18074760,maximum blood concentration,"Mean maximum blood concentration was 32.63 +/- 1.74 ng/ml, and was reached at 1 h post-dose; elimination half-life was 14.18 +/- 5.71 h.","Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),[ng] / [ml],32.63,127194,DB00864,Tacrolimus
,18074760,elimination half-life,"Mean maximum blood concentration was 32.63 +/- 1.74 ng/ml, and was reached at 1 h post-dose; elimination half-life was 14.18 +/- 5.71 h.","Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18074760/),h,14.18,127195,DB00864,Tacrolimus
,19335418,apparent half-life,Mean apparent half-life of tacrolimus was 80 +/- 35 h (range: 25-175 h).,The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19335418/),h,80,127368,DB00864,Tacrolimus
≥,29110351,PTLs,Target PTLs were ≥700 ng/mL (prophylaxis) and ≥1250 ng/mL (therapy).,Posaconazole liquid vs tablet formulation in lung transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29110351/),[ng] / [ml],700,127530,DB00864,Tacrolimus
≥,29110351,PTLs,Target PTLs were ≥700 ng/mL (prophylaxis) and ≥1250 ng/mL (therapy).,Posaconazole liquid vs tablet formulation in lung transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29110351/),[ng] / [ml],1250,127531,DB00864,Tacrolimus
,29110351,overall,"The overall prophylactic and therapeutic response rates were 78% and 67%, respectively.",Posaconazole liquid vs tablet formulation in lung transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29110351/),,78,127532,DB00864,Tacrolimus
,16476117,area under the curve (AUC),"Despite a comparable MMF dose, a large inter-patient variability in both MPA area under the curve (AUC) from 0 to 12 h (range 10.03-135.4 microg h/mL) and in predose concentrations (0.31-6.09 microg/mL) was observed.",Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[h·μg] / [ml],10.03-135.4,127533,DB00864,Tacrolimus
>,16476117,AUC,Patients with AUC > 35 microg h/mL showed better (P < 0.1) renal function than patients with AUC < 20 microg h/mL (mean creatinine concentration 1.48 +/- 0.12 vs. 3.35 +/- 0.4 mg/dL respectively).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[h·μg] / [ml],35,127534,DB00864,Tacrolimus
<,16476117,AUC,Patients with AUC > 35 microg h/mL showed better (P < 0.1) renal function than patients with AUC < 20 microg h/mL (mean creatinine concentration 1.48 +/- 0.12 vs. 3.35 +/- 0.4 mg/dL respectively).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[h·μg] / [ml],20,127535,DB00864,Tacrolimus
,16476117,trough level,A higher trough level of the metabolite MPA glucuronide (MPAG) in the 1 week after transplantation was found when compared with the 3-month level (mean 150.1 +/- 146.7; range 17.1 to 560 vs. 75.8 +/- 40.0; range 27.3 to 174.2 microg/mL).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[μg] / [ml],150.1,127536,DB00864,Tacrolimus
,16476117,trough level,A higher trough level of the metabolite MPA glucuronide (MPAG) in the 1 week after transplantation was found when compared with the 3-month level (mean 150.1 +/- 146.7; range 17.1 to 560 vs. 75.8 +/- 40.0; range 27.3 to 174.2 microg/mL).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[μg] / [ml],75.8,127537,DB00864,Tacrolimus
,21206424,troughs,"During the 6-month study, AAs had consistently lower median (interquartile range) troughs than non-AAs, 6.2 (4.4-8.4) ng/mL vs. 8.3 (6.4-10.4) ng/mL (P<0.0001), despite 60% higher daily doses, 8 (5-10) mg vs. 5 (4-7) mg (P<0.0001).",Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21206424/),[ng] / [ml],6.2,128089,DB00864,Tacrolimus
,21206424,troughs,"During the 6-month study, AAs had consistently lower median (interquartile range) troughs than non-AAs, 6.2 (4.4-8.4) ng/mL vs. 8.3 (6.4-10.4) ng/mL (P<0.0001), despite 60% higher daily doses, 8 (5-10) mg vs. 5 (4-7) mg (P<0.0001).",Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21206424/),[ng] / [ml],8.3,128090,DB00864,Tacrolimus
,21206424,trough concentration,"The median tacrolimus trough concentration in week 1 posttransplant was particularly low in AAs (2.1 [1.2-3.5] ng/mL) compared with non-AAs (5.0 [3.1-8.2] ng/mL) (P<0.0001), despite similar initial doses.",Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21206424/),[ng] / [ml],2.1,128091,DB00864,Tacrolimus
,21206424,trough concentration,"The median tacrolimus trough concentration in week 1 posttransplant was particularly low in AAs (2.1 [1.2-3.5] ng/mL) compared with non-AAs (5.0 [3.1-8.2] ng/mL) (P<0.0001), despite similar initial doses.",Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21206424/),[ng] / [ml],5.0,128092,DB00864,Tacrolimus
,20720518,clearance,"Median clearance was 30.2, 45.6, and 10.7 L/h in RTx, HSCTx, and AID patients, respectively.","Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20720518/),[l] / [h],30.2,128319,DB00864,Tacrolimus
,20720518,clearance,"Median clearance was 30.2, 45.6, and 10.7 L/h in RTx, HSCTx, and AID patients, respectively.","Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20720518/),[l] / [h],45.6,128320,DB00864,Tacrolimus
,20720518,clearance,"Median clearance was 30.2, 45.6, and 10.7 L/h in RTx, HSCTx, and AID patients, respectively.","Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20720518/),[l] / [h],10.7,128321,DB00864,Tacrolimus
,25017487,trough concentration,Everolimus exposure is unaffected when tacrolimus exposure is down-titrated within the trough concentration range of 1.5-7 ng/mL.,The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: an analysis from the randomized ASSET study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25017487/),[ng] / [ml],1.5-7,130074,DB00864,Tacrolimus
,27340950,total daily dose,The median (interquartile range) total daily dose was 6.0 (4.0-8.0) mg for IR-Tac and ER-Tac and 4.8 (3.3-6.3) for LCPT.,"A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27340950/),mg,6.0,130466,DB00864,Tacrolimus
,27340950,total daily dose,The median (interquartile range) total daily dose was 6.0 (4.0-8.0) mg for IR-Tac and ER-Tac and 4.8 (3.3-6.3) for LCPT.,"A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27340950/),,4.8,130467,DB00864,Tacrolimus
,9657047,hepatic extraction ratio,"In the normal rats, the hepatic extraction ratio of tacrolimus (EH) was dose-independent, ranging from 0.556-0.598 at 0.3 and 1.0 mg/kg doses.",Hepatic extraction of tacrolimus in rats with experimental liver diseases. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9657047/),,0.556-0.598,130889,DB00864,Tacrolimus
,19258929,clearance,"TRL clearance was 1.5-fold higher for patients with the CYP3A5*1/*3 genotype compared with the CYP3A5*3/*3 genotype (5.5 +/- 0.5 L/h versus 3.7 +/- 0.3 L/h, respectively).",Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258929/),[l] / [h],5.5,131131,DB00864,Tacrolimus
,19258929,clearance,"TRL clearance was 1.5-fold higher for patients with the CYP3A5*1/*3 genotype compared with the CYP3A5*3/*3 genotype (5.5 +/- 0.5 L/h versus 3.7 +/- 0.3 L/h, respectively).",Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258929/),[l] / [h],3.7,131132,DB00864,Tacrolimus
,19258929,clearance,"Also, a relationship between the pregnane X receptor A+7635G genotype and TRL clearance was identified with a clearance of 3.9 +/- 0.3 L/h in the A allele carriers versus 5.4 +/- 0.6 L/h in the GG genotype.",Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258929/),[l] / [h],3.9,131133,DB00864,Tacrolimus
,19258929,clearance,"Also, a relationship between the pregnane X receptor A+7635G genotype and TRL clearance was identified with a clearance of 3.9 +/- 0.3 L/h in the A allele carriers versus 5.4 +/- 0.6 L/h in the GG genotype.",Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258929/),[l] / [h],5.4,131134,DB00864,Tacrolimus
,23735178,CL/F,"In 4 - 15 days PT for E-2007, low levels of HCT and ALB as CL/F predictors confirmed a subgroup with higher CL/F (23.8 l/h vs. 19.3 l/h).","Tacrolimus dose individualization in ""de novo"" patients after 10 years of experience in liver transplantation: pharmacokinetic considerations and patient pathophysiology. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735178/),[l] / [h],23.8,131276,DB00864,Tacrolimus
,23735178,CL/F,"In 4 - 15 days PT for E-2007, low levels of HCT and ALB as CL/F predictors confirmed a subgroup with higher CL/F (23.8 l/h vs. 19.3 l/h).","Tacrolimus dose individualization in ""de novo"" patients after 10 years of experience in liver transplantation: pharmacokinetic considerations and patient pathophysiology. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735178/),[l] / [h],19.3,131277,DB00864,Tacrolimus
,22136074,peak serum concentration (C(max)) of systemic absorption,The peak serum concentration (C(max)) of systemic absorption ranged from 4.31±0.79 ng/mL to 14.89±6.85 ng/mL.,Ocular safety and pharmacokinetics study of FK506 suspension eye drops after corneal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136074/),[ng] / [ml],4.31,131321,DB00864,Tacrolimus
,22136074,peak serum concentration (C(max)) of systemic absorption,The peak serum concentration (C(max)) of systemic absorption ranged from 4.31±0.79 ng/mL to 14.89±6.85 ng/mL.,Ocular safety and pharmacokinetics study of FK506 suspension eye drops after corneal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22136074/),[ng] / [ml],14.89,131322,DB00864,Tacrolimus
,27885697,C0,Less of the recipients achieving target C0 (4-8 ng/mL) were found in CYP3A5 expressers than in non-expressers after initial dose (35·7% vs. 50%).,Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885697/),[ng] / [ml],4-8,131527,DB00864,Tacrolimus
>,27885697,C0,"Meanwhile, CYP3A5 non-expressers were detected having higher C0 (>8 ng/mL) during 3 months post-transplantation.",Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27885697/),[ng] / [ml],8,131528,DB00864,Tacrolimus
,18367972,Sir AUC,The average Sir AUC was 64.9 +/- 29.7 ng*h/mL.,Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],64.9,133309,DB00864,Tacrolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],7.6,133310,DB00864,Tacrolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.1,133311,DB00864,Tacrolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],4.3,133312,DB00864,Tacrolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.5,133313,DB00864,Tacrolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.6,133314,DB00864,Tacrolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],5.0,133315,DB00864,Tacrolimus
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],4.3,133316,DB00864,Tacrolimus
,30195818,survival times (MSTs),"In MMF monotherapy, oral administration of 20 or 40 mg/kg/day prolonged graft survival with median survival times (MSTs) of 16.5 days and 33 days, respectively, whereas untreated animals showed MST of 6 days.","Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30195818/),d,16.5,133331,DB00864,Tacrolimus
,30195818,survival times (MSTs),"In MMF monotherapy, oral administration of 20 or 40 mg/kg/day prolonged graft survival with median survival times (MSTs) of 16.5 days and 33 days, respectively, whereas untreated animals showed MST of 6 days.","Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30195818/),d,33,133332,DB00864,Tacrolimus
,30195818,MST,"In MMF monotherapy, oral administration of 20 or 40 mg/kg/day prolonged graft survival with median survival times (MSTs) of 16.5 days and 33 days, respectively, whereas untreated animals showed MST of 6 days.","Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30195818/),d,6,133333,DB00864,Tacrolimus
,34155947,trough,"The median doseadjusted tacrolimus trough and tacrolimus total daily dose prior to rivaroxaban/apixaban initiation was 2.15 ng/mL/mg (IQR 1.17, 3.37) and 4 mg (IQR 1.88, 6.25), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),[ng] / [mg·ml],2.15,133517,DB00864,Tacrolimus
,34155947,total daily dose,"The median doseadjusted tacrolimus trough and tacrolimus total daily dose prior to rivaroxaban/apixaban initiation was 2.15 ng/mL/mg (IQR 1.17, 3.37) and 4 mg (IQR 1.88, 6.25), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),mg,4,133518,DB00864,Tacrolimus
,34155947,trough,"The median dose-adjusted tacrolimus trough and tacrolimus total daily dose after rivaroxaban/apixaban initiation was 2.16 ng/mL/mg (IQR 1.24, 4.10) and 3.55 mg (IQR 1.5, 6.35), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),[ng] / [mg·ml],2.16,133519,DB00864,Tacrolimus
,34155947,total daily dose,"The median dose-adjusted tacrolimus trough and tacrolimus total daily dose after rivaroxaban/apixaban initiation was 2.16 ng/mL/mg (IQR 1.24, 4.10) and 3.55 mg (IQR 1.5, 6.35), respectively.",The Impact of Rivaroxaban and Apixaban on Tacrolimus Trough Levels. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155947/),mg,3.55,133520,DB00864,Tacrolimus
,22075549,apparent clearance (CL/F),"The typical population values of tacrolimus for the pharmacokinetic parameters of apparent clearance (CL/F), apparent distribution volume of the central compartment (V(2)/F), intercompartmental clearance (Q/F), apparent distribution volume of the peripheral compartment (V(3)/F), absorption rate (ka) and lag time (ALAG) were 27.7 l/h, 37.5 liters, 34.4 l/h, 357 liters, 0.795 h(-1) and 0.226 h, respectively.",Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075549/),[l] / [h],27.7,133605,DB00864,Tacrolimus
,22075549,lag time (ALAG),"The typical population values of tacrolimus for the pharmacokinetic parameters of apparent clearance (CL/F), apparent distribution volume of the central compartment (V(2)/F), intercompartmental clearance (Q/F), apparent distribution volume of the peripheral compartment (V(3)/F), absorption rate (ka) and lag time (ALAG) were 27.7 l/h, 37.5 liters, 34.4 l/h, 357 liters, 0.795 h(-1) and 0.226 h, respectively.",Population pharmacokinetics and pharmacogenetics of tacrolimus in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22075549/),h,0.226,133606,DB00864,Tacrolimus
,15919452,IC50 ratio,The mean IC50 ratio of CyA and Tac (CyA/Tac of IC50) was 25.1.,Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919452/),,25.1,134145,DB00864,Tacrolimus
,15919452,area under the concentration-time curve (AUC) ratio (CyA/Tac of AUC,"The mean area under the concentration-time curve (AUC) ratio (CyA/Tac of AUC) was 25.5, the mean trough level (C(min)) ratio (CyA/Tac of C(min)) was 13.2, and the mean dose per body weight ratio was 25.2.",Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919452/),,25.5,134146,DB00864,Tacrolimus
,15919452,trough level (C(min)) ratio (CyA/Tac of C(min),"The mean area under the concentration-time curve (AUC) ratio (CyA/Tac of AUC) was 25.5, the mean trough level (C(min)) ratio (CyA/Tac of C(min)) was 13.2, and the mean dose per body weight ratio was 25.2.",Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919452/),,13.2,134147,DB00864,Tacrolimus
,28833329,CL/F,"The CL/F, V2 /F, Q/F, V3 /F, Ka and lag time were 17.4±0.81 L/h, 165±44.1 L, 54.9±25.8L/h, 594±87.5 L, 0.51±0.095 L/h and 1.57±0.34 h.",Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833329/),[l] / [h],17.4,135164,DB00864,Tacrolimus
,28833329,lag time,"The CL/F, V2 /F, Q/F, V3 /F, Ka and lag time were 17.4±0.81 L/h, 165±44.1 L, 54.9±25.8L/h, 594±87.5 L, 0.51±0.095 L/h and 1.57±0.34 h.",Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28833329/),h,1.57,135165,DB00864,Tacrolimus
,22664010,AUC,"AUC was 4.3, 5.9, and 8.3 in the 200-mg/d dose group on days 3, 7, and 21, respectively.",Pharmacokinetics of mizoribine in adult living donor liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664010/),,4.3,135308,DB00864,Tacrolimus
,22664010,AUC,"AUC was 4.3, 5.9, and 8.3 in the 200-mg/d dose group on days 3, 7, and 21, respectively.",Pharmacokinetics of mizoribine in adult living donor liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664010/),,5.9,135309,DB00864,Tacrolimus
,22664010,AUC,"AUC was 4.3, 5.9, and 8.3 in the 200-mg/d dose group on days 3, 7, and 21, respectively.",Pharmacokinetics of mizoribine in adult living donor liver transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22664010/),,8.3,135310,DB00864,Tacrolimus
,30665258,AUCtau,"Mean AUCtau after first dose of tacrolimus was 211, 97, and 224 hour*ng/mL in liver, kidney, and heart transplant recipients, respectively; corresponding mean AUCtau at steady state was 195, 208, and 165 hour*ng/mL.","Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30665258/),[h·ng] / [ml],211,135351,DB00864,Tacrolimus
,30665258,AUCtau,"Mean AUCtau after first dose of tacrolimus was 211, 97, and 224 hour*ng/mL in liver, kidney, and heart transplant recipients, respectively; corresponding mean AUCtau at steady state was 195, 208, and 165 hour*ng/mL.","Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30665258/),[h·ng] / [ml],97,135352,DB00864,Tacrolimus
,30665258,AUCtau,"Mean AUCtau after first dose of tacrolimus was 211, 97, and 224 hour*ng/mL in liver, kidney, and heart transplant recipients, respectively; corresponding mean AUCtau at steady state was 195, 208, and 165 hour*ng/mL.","Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30665258/),[h·ng] / [ml],224,135353,DB00864,Tacrolimus
,30665258,AUCtau at steady state,"Mean AUCtau after first dose of tacrolimus was 211, 97, and 224 hour*ng/mL in liver, kidney, and heart transplant recipients, respectively; corresponding mean AUCtau at steady state was 195, 208, and 165 hour*ng/mL.","Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30665258/),[h·ng] / [ml],195,135354,DB00864,Tacrolimus
,30665258,AUCtau at steady state,"Mean AUCtau after first dose of tacrolimus was 211, 97, and 224 hour*ng/mL in liver, kidney, and heart transplant recipients, respectively; corresponding mean AUCtau at steady state was 195, 208, and 165 hour*ng/mL.","Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30665258/),[h·ng] / [ml],208,135355,DB00864,Tacrolimus
,30665258,AUCtau at steady state,"Mean AUCtau after first dose of tacrolimus was 211, 97, and 224 hour*ng/mL in liver, kidney, and heart transplant recipients, respectively; corresponding mean AUCtau at steady state was 195, 208, and 165 hour*ng/mL.","Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30665258/),[h·ng] / [ml],165,135356,DB00864,Tacrolimus
,30995884,apparent volume of distribution (V/F),"The apparent volume of distribution (V/F) and clearance (CL/F) of tacrolimus were 179 L and 15.4 L/h, respectively.",Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30995884/),l,179,136871,DB00864,Tacrolimus
,30995884,clearance (CL/F),"The apparent volume of distribution (V/F) and clearance (CL/F) of tacrolimus were 179 L and 15.4 L/h, respectively.",Impact of body composition on pharmacokinetics of tacrolimus in liver transplantation recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30995884/),[l] / [h],15.4,136872,DB00864,Tacrolimus
,18362900,trough blood levels,Tacrolimus was given orally from day -1 to achieve trough blood levels of 5-10 ng/ml.,Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362900/),[ng] / [ml],5-10,137652,DB00864,Tacrolimus
,18362900,AUC,The MMF dose was modified to achieve an MPA AUC of 35-60 microg/ml/h.,Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362900/),[μg] / [h·ml],35-60,137653,DB00864,Tacrolimus
,23061766,trough level,"The average tacrolimus trough level at the time of discontinuation and one wk after stopping fluconazole was unchanged (11.69 ± 3.18 and 11.15 ± 3.69 ng/mL, p = 0.145, n = 103).",Low-dose fluconazole prophylaxis in kidney transplant recipients receiving tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061766/),[ng] / [ml],11.69,137674,DB00864,Tacrolimus
,23061766,trough level,"The average tacrolimus trough level at the time of discontinuation and one wk after stopping fluconazole was unchanged (11.69 ± 3.18 and 11.15 ± 3.69 ng/mL, p = 0.145, n = 103).",Low-dose fluconazole prophylaxis in kidney transplant recipients receiving tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061766/),[ng] / [ml],11.15,137675,DB00864,Tacrolimus
,8937932,trough levels,Tacrolimus trough levels were adjusted to a therapeutic window of 5-8 ng/ml.,Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937932/),[ng] / [ml],5-8,137955,DB00864,Tacrolimus
>,8937932,trough levels,"Overall, 82 adverse events were noted, of which 29 (35%) were associated with high trough levels (> 10 ng/ml).",Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937932/),[ng] / [ml],10,137956,DB00864,Tacrolimus
<,8937932,trough levels,"In contrast, 3 patients with trough levels < 4 ng/ml had ongoing rejection.",Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937932/),[ng] / [ml],4,137957,DB00864,Tacrolimus
,8937932,trough levels,We conclude: Tacrolimus conversion for rescue therapy after renal transplantation is efficient and safe with target trough levels between 5 -8 ng/ml.,Clinical pharmacokinetics of tacrolimus in rescue therapy after renal transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8937932/),[ng] / [ml],5 -8,137958,DB00864,Tacrolimus
,20970601,concentration/dose ratios,Tacrolimus concentration/dose ratios in heterozygote patients for CYP3A5*3 genotypes was >120% lower than for the homozygote CYP3A5*3 genotype (0.65±0.04 vs 1.45±0.05; P<.0001).,Genetic polymorphisms and individualized tacrolimus dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970601/),,1,139189,DB00864,Tacrolimus
,8776613,trough concentration,The smaller dosage of tacrolimus led to a higher trough concentration of 14.1 +/- 1.6 ng/mL in the three-times-a-day regimen compared with 12.7 +/- 1.9 ng/ml in twice-a-day therapy (P < 0.01).,Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8776613/),[ng] / [ml],14.1,139202,DB00864,Tacrolimus
,8776613,trough concentration,The smaller dosage of tacrolimus led to a higher trough concentration of 14.1 +/- 1.6 ng/mL in the three-times-a-day regimen compared with 12.7 +/- 1.9 ng/ml in twice-a-day therapy (P < 0.01).,Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8776613/),[ng] / [ml],12.7,139203,DB00864,Tacrolimus
<,8776613,trough concentration,Our target trough concentration was decreased finally to < 5 ng/mL.,Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8776613/),[ng] / [ml],5,139204,DB00864,Tacrolimus
,21099740,time to peak concentration,"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),h,2.5,139588,DB00864,Tacrolimus
,21099740,time to peak concentration,"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),h,4.6,139589,DB00864,Tacrolimus
,21099740,peak concentration (Cmax),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[mg] / [l],19.3,139590,DB00864,Tacrolimus
,21099740,peak concentration (Cmax),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[mg] / [l],109.4,139591,DB00864,Tacrolimus
,21099740,area under the curve from 6 to 12 hours (AUC6-12),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],32.2,139592,DB00864,Tacrolimus
,21099740,area under the curve from 6 to 12 hours (AUC6-12),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],373.7,139593,DB00864,Tacrolimus
,21099740,AUC0-12,The AUC0-12 for MPA measured 77.8 ± 53.1 mg·hr/L and for MPAG 869.2 ± 388.8 mg·hr/L.,The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],77.8,139594,DB00864,Tacrolimus
,21099740,AUC0-12,The AUC0-12 for MPA measured 77.8 ± 53.1 mg·hr/L and for MPAG 869.2 ± 388.8 mg·hr/L.,The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],869.2,139595,DB00864,Tacrolimus
,18043470,area under the curve(0-12),"Median (range) of MPA area under the curve(0-12) was 36.7 (range, 16.4-116.4) mg*h/L in diabetic and 48.2 (range, 34.9-80.1) mg*h/L in nondiabetic patients (P=0.49).",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[h·mg] / [l],36.7,140632,DB00864,Tacrolimus
,18043470,area under the curve(0-12),"Median (range) of MPA area under the curve(0-12) was 36.7 (range, 16.4-116.4) mg*h/L in diabetic and 48.2 (range, 34.9-80.1) mg*h/L in nondiabetic patients (P=0.49).",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[h·mg] / [l],48.2,140633,DB00864,Tacrolimus
,18043470,activity,"In contrast, IMPDH activity was 17.5+/-2.8 versus 46.6+/-2.5 nmol XMP/h/microg protein in diabetics and nondiabetics, respectively (P<0.0001) and was significantly lower in the diabetics irrespective of concomitant therapy with cyclosporine or tacrolimus.",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[Mp·nM] / [h·μg],17.5,140634,DB00864,Tacrolimus
,18043470,activity,"In contrast, IMPDH activity was 17.5+/-2.8 versus 46.6+/-2.5 nmol XMP/h/microg protein in diabetics and nondiabetics, respectively (P<0.0001) and was significantly lower in the diabetics irrespective of concomitant therapy with cyclosporine or tacrolimus.",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[Mp·nM] / [h·μg],46.6,140635,DB00864,Tacrolimus
,11699612,CL,"Interindividual variabilities in CL, volume of distribution (V), and bioavailability (F) were 57.4%. 39.7%, and 63.0%, respectively, and the correlation between individual CL and F was 0.776.",Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699612/),%,57.4,140914,DB00864,Tacrolimus
,11699612,volume of distribution (V),"Interindividual variabilities in CL, volume of distribution (V), and bioavailability (F) were 57.4%. 39.7%, and 63.0%, respectively, and the correlation between individual CL and F was 0.776.",Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699612/),%,39.7,140915,DB00864,Tacrolimus
,11699612,bioavailability (F),"Interindividual variabilities in CL, volume of distribution (V), and bioavailability (F) were 57.4%. 39.7%, and 63.0%, respectively, and the correlation between individual CL and F was 0.776.",Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699612/),%,63.0,140916,DB00864,Tacrolimus
,11699612,Residual,Residual intraindividual variability was 2.9 ng ml(-1).,Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699612/),[ng] / [ml],2.9,140917,DB00864,Tacrolimus
,11699612,CL,"Based on the estimated final parameters, a typical recipient of LDLT with grafted hepatic weight of 600 g and normal hepatic and renal function would have a CL of 0.737 l h(-1) on POD 0 and 1.14 l h(-1) on POD 30, V of 1.52 l kg(-1) and F of 6.8%.",Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699612/),[l] / [h],0.737,140918,DB00864,Tacrolimus
,11699612,CL,"Based on the estimated final parameters, a typical recipient of LDLT with grafted hepatic weight of 600 g and normal hepatic and renal function would have a CL of 0.737 l h(-1) on POD 0 and 1.14 l h(-1) on POD 30, V of 1.52 l kg(-1) and F of 6.8%.",Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699612/),[l] / [h],1.14,140919,DB00864,Tacrolimus
,11699612,V,"Based on the estimated final parameters, a typical recipient of LDLT with grafted hepatic weight of 600 g and normal hepatic and renal function would have a CL of 0.737 l h(-1) on POD 0 and 1.14 l h(-1) on POD 30, V of 1.52 l kg(-1) and F of 6.8%.",Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699612/),[l] / [kg],1.52,140920,DB00864,Tacrolimus
,11699612,F,"Based on the estimated final parameters, a typical recipient of LDLT with grafted hepatic weight of 600 g and normal hepatic and renal function would have a CL of 0.737 l h(-1) on POD 0 and 1.14 l h(-1) on POD 30, V of 1.52 l kg(-1) and F of 6.8%.",Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11699612/),%,6.8,140921,DB00864,Tacrolimus
,28947731,clearance (CL),The clearance (CL) of tacrolimus decreased significantly from 1.28 to 0.68 mL/min/kg with concomitant use of fentanyl.,Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947731/),[ml] / [kg·min],1.28,141253,DB00864,Tacrolimus
,28947731,clearance (CL),The clearance (CL) of tacrolimus decreased significantly from 1.28 to 0.68 mL/min/kg with concomitant use of fentanyl.,Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28947731/),[ml] / [kg·min],0.68,141254,DB00864,Tacrolimus
,22660442,CL/F₀₋₃,"Three groups were identified with the following clearances: CL/F₀₋₃ = 8.93 L/h for AST ≥ 500 U/L and CL/F₀₋₃ = 11.0 L/h for AST <500 U/L. During 4-15 Day PLT, low values of ALB (<2.5 g/dL) and HCT (<28 %) combined were determinant of a patient subgroup with a tendency to underexposure and complexity in empirical dose adjustment.",Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660442/),[l] / [h],8.93,141323,DB00864,Tacrolimus
,22660442,CL/F₀₋₃,"Three groups were identified with the following clearances: CL/F₀₋₃ = 8.93 L/h for AST ≥ 500 U/L and CL/F₀₋₃ = 11.0 L/h for AST <500 U/L. During 4-15 Day PLT, low values of ALB (<2.5 g/dL) and HCT (<28 %) combined were determinant of a patient subgroup with a tendency to underexposure and complexity in empirical dose adjustment.",Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660442/),[l] / [h],11.0,141324,DB00864,Tacrolimus
,22660442,CL/F₄₋₁₅,The CL/F₄₋₁₅ = 25.1 L/h for this subgroup compared to CL/F₄₋₁₅ = 17.1 L/h for the others in that period.,Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660442/),[l] / [h],25.1,141325,DB00864,Tacrolimus
,22660442,CL/F₄₋₁₅,The CL/F₄₋₁₅ = 25.1 L/h for this subgroup compared to CL/F₄₋₁₅ = 17.1 L/h for the others in that period.,Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660442/),[l] / [h],17.1,141326,DB00864,Tacrolimus
,17377957,area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)),"The mean daily dose and the dose-adjusted area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)) of tacrolimus coadministered with rabeprazole or lansoprazole were the lowest and highest, respectively, in CYP2C19 poor metabolizers (PMs) having the CYP3A5*3/*3 genotype (0.084 and 0.112 mg/kg/day and 1.269 and 1.033 ng.h/ml/mg/kg, respectively).","Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17377957/),[h·ng] / [kg·mg·ml],1.269,141953,DB00864,Tacrolimus
,17377957,area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)),"The mean daily dose and the dose-adjusted area under the plasma concentration-time curves from 0 to 12 h (AUC(0-12)) of tacrolimus coadministered with rabeprazole or lansoprazole were the lowest and highest, respectively, in CYP2C19 poor metabolizers (PMs) having the CYP3A5*3/*3 genotype (0.084 and 0.112 mg/kg/day and 1.269 and 1.033 ng.h/ml/mg/kg, respectively).","Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17377957/),[h·ng] / [kg·mg·ml],1.033,141954,DB00864,Tacrolimus
,30895841,encap,"The prepared TAC-NPs were 82.9 ± 1.3 nm in size, and the drug loading and encapsulation efficiency were 8.01 ± 0.23% and 80.10 ± 2.33%.",Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30895841/),%,8.01,142163,DB00864,Tacrolimus
,30895841,encap,"The prepared TAC-NPs were 82.9 ± 1.3 nm in size, and the drug loading and encapsulation efficiency were 8.01 ± 0.23% and 80.10 ± 2.33%.",Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30895841/),%,80.10,142164,DB00864,Tacrolimus
,14681346,AUC,Coadministration of St. John's wort significantly decreased tacrolimus AUC (306.9 microg.h/L +/- 175.8 microg.h/L vs. 198.7 microg.h/L +/- 139.6 microg.h/L; p=0.004) and increased apparent oral clearance (349.0 mL/h/kg +/- 126.0 mL/h/kg vs. 586.4 mL/h/kg +/- 274.9 mL/h/kg; p=0.01) and apparent oral volume of distribution at steady state (11.5 L/kg +/- 4.3 L/kg vs. 17.6 L/kg +/- 9.6 L/kg; p=0.04).,Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681346/),[h·μg] / [l],306.9,142235,DB00864,Tacrolimus
,14681346,AUC,Coadministration of St. John's wort significantly decreased tacrolimus AUC (306.9 microg.h/L +/- 175.8 microg.h/L vs. 198.7 microg.h/L +/- 139.6 microg.h/L; p=0.004) and increased apparent oral clearance (349.0 mL/h/kg +/- 126.0 mL/h/kg vs. 586.4 mL/h/kg +/- 274.9 mL/h/kg; p=0.01) and apparent oral volume of distribution at steady state (11.5 L/kg +/- 4.3 L/kg vs. 17.6 L/kg +/- 9.6 L/kg; p=0.04).,Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681346/),[h·μg] / [l],198.7,142236,DB00864,Tacrolimus
,14681346,apparent oral clearance,Coadministration of St. John's wort significantly decreased tacrolimus AUC (306.9 microg.h/L +/- 175.8 microg.h/L vs. 198.7 microg.h/L +/- 139.6 microg.h/L; p=0.004) and increased apparent oral clearance (349.0 mL/h/kg +/- 126.0 mL/h/kg vs. 586.4 mL/h/kg +/- 274.9 mL/h/kg; p=0.01) and apparent oral volume of distribution at steady state (11.5 L/kg +/- 4.3 L/kg vs. 17.6 L/kg +/- 9.6 L/kg; p=0.04).,Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681346/),[ml] / [h·kg],349.0,142237,DB00864,Tacrolimus
,14681346,apparent oral clearance,Coadministration of St. John's wort significantly decreased tacrolimus AUC (306.9 microg.h/L +/- 175.8 microg.h/L vs. 198.7 microg.h/L +/- 139.6 microg.h/L; p=0.004) and increased apparent oral clearance (349.0 mL/h/kg +/- 126.0 mL/h/kg vs. 586.4 mL/h/kg +/- 274.9 mL/h/kg; p=0.01) and apparent oral volume of distribution at steady state (11.5 L/kg +/- 4.3 L/kg vs. 17.6 L/kg +/- 9.6 L/kg; p=0.04).,Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681346/),[ml] / [h·kg],586.4,142238,DB00864,Tacrolimus
,14681346,apparent oral volume of distribution at steady state,Coadministration of St. John's wort significantly decreased tacrolimus AUC (306.9 microg.h/L +/- 175.8 microg.h/L vs. 198.7 microg.h/L +/- 139.6 microg.h/L; p=0.004) and increased apparent oral clearance (349.0 mL/h/kg +/- 126.0 mL/h/kg vs. 586.4 mL/h/kg +/- 274.9 mL/h/kg; p=0.01) and apparent oral volume of distribution at steady state (11.5 L/kg +/- 4.3 L/kg vs. 17.6 L/kg +/- 9.6 L/kg; p=0.04).,Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681346/),[l] / [kg],11.5,142239,DB00864,Tacrolimus
,14681346,apparent oral volume of distribution at steady state,Coadministration of St. John's wort significantly decreased tacrolimus AUC (306.9 microg.h/L +/- 175.8 microg.h/L vs. 198.7 microg.h/L +/- 139.6 microg.h/L; p=0.004) and increased apparent oral clearance (349.0 mL/h/kg +/- 126.0 mL/h/kg vs. 586.4 mL/h/kg +/- 274.9 mL/h/kg; p=0.01) and apparent oral volume of distribution at steady state (11.5 L/kg +/- 4.3 L/kg vs. 17.6 L/kg +/- 9.6 L/kg; p=0.04).,Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14681346/),[l] / [kg],17.6,142240,DB00864,Tacrolimus
,17425625,minimal clearance,The typical value of minimal clearance was 1.8 +/- 0.2 l h(-1).,Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),[l] / [h],1.8,143249,DB00864,Tacrolimus
,17425625,maximal,"Clearance increased with time post transplantation to reach 50% of maximal value after 3.8 +/- 0.5 days, with a maximal value of 5.6 l h(-1).",Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),[l] / [h],5.6,143250,DB00864,Tacrolimus
,17425625,"volume of distribution, V","The typical value for volume of distribution, V, (98 +/- 13 l kg(-1)) was similar to reported values in kidney transplant patients.",Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),[l] / [kg],98,143251,DB00864,Tacrolimus
,17425625,oral bioavailability,The oral bioavailability of tacrolimus was poor and ranged from 11.2 to 19.1%.,Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),%,11.2 to 19.1,143252,DB00864,Tacrolimus
<,9249946,bioavailability,"After excluding poor compliance, drug interactions and analytical problems and identifying poor bioavailability (< 2.6%) and rapid clearance (4.2 l/h), fluconazole (100 mg/day) was initiated to inhibit tacrolimus metabolism and consistent therapeutic blood levels of tacrolimus were achieved.",Tacrolimus (FK506) malabsorption: management with fluconazole coadministration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249946/),%,2.6,143611,DB00864,Tacrolimus
,9249946,clearance,"After excluding poor compliance, drug interactions and analytical problems and identifying poor bioavailability (< 2.6%) and rapid clearance (4.2 l/h), fluconazole (100 mg/day) was initiated to inhibit tacrolimus metabolism and consistent therapeutic blood levels of tacrolimus were achieved.",Tacrolimus (FK506) malabsorption: management with fluconazole coadministration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9249946/),[l] / [h],4.2,143612,DB00864,Tacrolimus
,12919182,dose-adjusted,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],83,143834,DB00864,Tacrolimus
,12919182,dose-adjusted,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],119,143835,DB00864,Tacrolimus
,12919182,C0,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],83,143836,DB00864,Tacrolimus
,12919182,C0,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],119,143837,DB00864,Tacrolimus
,10336506,concentration ratios,"In marked contrast to previous results with i.a. cyclosporin A infusion, only a minimal regional advantage of local FK506 delivery (mean right/left concentration ratios 1.0-1.4) was obtained in all forearm tissues over the dose range studied.",Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10336506/),,1.0-1.4,144610,DB00864,Tacrolimus
,10230718,diameter,The mean diameter of the o/w emulsion droplets was 0.47 microm immediately after preparation.,Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10230718/),μm,0.47,144889,DB00864,Tacrolimus
,10230718,entrapping efficiency,The tacrolimus entrapping efficiency of o/w emulsion was 71.3+/-5.0% in 12 h and did not change for 2 d.,Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10230718/),%,71.3,144890,DB00864,Tacrolimus
,10230718,bioavailability,"In contrast, the values of constant elimination rate and total clearance in the O/W group were significantly lower (P<0.01) than those in the T group, with a comparative bioavailability of 115.9%.",Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10230718/),%,115.9,144891,DB00864,Tacrolimus
,26729532,relative bioavailability,"Following a single oral administration, a relative bioavailability of 193.33% was achieved compared to pure tacrolimus suspension.","Design, Characterization, and In Vivo Pharmacokinetics of Tacrolimus Proliposomes. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26729532/),%,193.33,145361,DB00864,Tacrolimus
,16467136,t(max),"After t(max) (1-3 h), its blood concentrations fell quickly to 3% of C(max) at 24 h, followed by a slow terminal elimination phase (average t(1/2) 62 h).","Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16467136/),h,1-3,146044,DB00864,Tacrolimus
,16467136,t(1/2),"After t(max) (1-3 h), its blood concentrations fell quickly to 3% of C(max) at 24 h, followed by a slow terminal elimination phase (average t(1/2) 62 h).","Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16467136/),h,62,146045,DB00864,Tacrolimus
,16467136,fecal excretion,The average fecal excretion of radioactivity between 0 and 240 h amounted to 78% of dose and represented predominantly a complex mixture of metabolites.,"Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16467136/),%,78,146046,DB00864,Tacrolimus
,9834211,t1/2,"Pharmacokinetic sampling was performed in 10 patients; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L, and the Vd/kg was 0. 05 +/- 0.01 L/kg.","A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834211/),h,9.1,146337,DB00864,Tacrolimus
,9834211,Cmax,"Pharmacokinetic sampling was performed in 10 patients; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L, and the Vd/kg was 0. 05 +/- 0.01 L/kg.","A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834211/),[ng] / [ml],"2,549",146338,DB00864,Tacrolimus
,9834211,Vd,"Pharmacokinetic sampling was performed in 10 patients; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L, and the Vd/kg was 0. 05 +/- 0.01 L/kg.","A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834211/),l,3.97,146339,DB00864,Tacrolimus
,9834211,Vd/kg,"Pharmacokinetic sampling was performed in 10 patients; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L, and the Vd/kg was 0. 05 +/- 0.01 L/kg.","A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834211/),[l] / [kg],0. 05,146340,DB00864,Tacrolimus
,9834211,total response rate,"At the end of treatment (day 11), there were six patients with complete responses and five with a reduction in grade of GVHD for a total response rate of 55% (95% confidence interval [CI], 32% to 77%).","A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9834211/),%,55,146341,DB00864,Tacrolimus
,22339449,relative bioavailability,"The relative bioavailability in patients with CF was approximately 60% of the relative bioavailability observed in patients without CF, and the transfer rate constant between the transit compartments was 2-fold smaller in patients with CF than in those without CF (3.32 vs 7.06 h-1).",Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339449/),%,60,147268,DB00864,Tacrolimus
,22339449,transfer rate constant,"The relative bioavailability in patients with CF was approximately 60% of the relative bioavailability observed in patients without CF, and the transfer rate constant between the transit compartments was 2-fold smaller in patients with CF than in those without CF (3.32 vs 7.06 h-1).",Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339449/),1/[h],3.32,147269,DB00864,Tacrolimus
,22339449,transfer rate constant,"The relative bioavailability in patients with CF was approximately 60% of the relative bioavailability observed in patients without CF, and the transfer rate constant between the transit compartments was 2-fold smaller in patients with CF than in those without CF (3.32 vs 7.06 h-1).",Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339449/),1/[h],7.06,147270,DB00864,Tacrolimus
,22339449,apparent clearance,The apparent clearance was 40% faster in CYP3A5 expressers than in non-expressers (24.5 vs 17.5 L/h).,Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339449/),[l] / [h],24.5,147271,DB00864,Tacrolimus
,22339449,apparent clearance,The apparent clearance was 40% faster in CYP3A5 expressers than in non-expressers (24.5 vs 17.5 L/h).,Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339449/),[l] / [h],17.5,147272,DB00864,Tacrolimus
,26135137,C0,"Median C0 in remission was higher than in relapse group (2.95 ng/ml, versus 1.20 ng/ml, p = 0.005).",Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135137/),[ng] / [ml],2.95,147807,DB00864,Tacrolimus
,26135137,C0,"Median C0 in remission was higher than in relapse group (2.95 ng/ml, versus 1.20 ng/ml, p = 0.005).",Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135137/),[ng] / [ml],1.20,147808,DB00864,Tacrolimus
,26135137,AUC0-12 h,Median AUC0-12 h in remission was higher compared to those in relapse group (79.75 versus 35.15 μg × h/l; p = 0.025).,Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135137/),[h·μg] / [l],79.75,147809,DB00864,Tacrolimus
,26135137,AUC0-12 h,Median AUC0-12 h in remission was higher compared to those in relapse group (79.75 versus 35.15 μg × h/l; p = 0.025).,Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26135137/),[h·μg] / [l],35.15,147810,DB00864,Tacrolimus
,23733010,relative bioavailability,"The median (quartile 1-quartile 3) tacrolimus relative bioavailability for recipients with the CYP3A5*1 or CYP3A5*3/*3 alleles was significantly lower for the tacrolimus QD group [9.1 % (6.3-10.7 %) and 15.4 % (11.5-18.7 %), respectively] than for the tacrolimus BID group [12.6 % (9.9-14.2 %) and 19.3 % (16.5-24.8 %), respectively] (P = 0.004 and 0.028, respectively).",Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23733010/),%,9.1,147893,DB00864,Tacrolimus
,23733010,relative bioavailability,"The median (quartile 1-quartile 3) tacrolimus relative bioavailability for recipients with the CYP3A5*1 or CYP3A5*3/*3 alleles was significantly lower for the tacrolimus QD group [9.1 % (6.3-10.7 %) and 15.4 % (11.5-18.7 %), respectively] than for the tacrolimus BID group [12.6 % (9.9-14.2 %) and 19.3 % (16.5-24.8 %), respectively] (P = 0.004 and 0.028, respectively).",Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23733010/),%,15.4,147894,DB00864,Tacrolimus
,23733010,relative bioavailability,"The median (quartile 1-quartile 3) tacrolimus relative bioavailability for recipients with the CYP3A5*1 or CYP3A5*3/*3 alleles was significantly lower for the tacrolimus QD group [9.1 % (6.3-10.7 %) and 15.4 % (11.5-18.7 %), respectively] than for the tacrolimus BID group [12.6 % (9.9-14.2 %) and 19.3 % (16.5-24.8 %), respectively] (P = 0.004 and 0.028, respectively).",Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23733010/),%,12.6,147895,DB00864,Tacrolimus
,23733010,relative bioavailability,"The median (quartile 1-quartile 3) tacrolimus relative bioavailability for recipients with the CYP3A5*1 or CYP3A5*3/*3 alleles was significantly lower for the tacrolimus QD group [9.1 % (6.3-10.7 %) and 15.4 % (11.5-18.7 %), respectively] than for the tacrolimus BID group [12.6 % (9.9-14.2 %) and 19.3 % (16.5-24.8 %), respectively] (P = 0.004 and 0.028, respectively).",Pharmaceutical and genetic determinants for interindividual differences of tacrolimus bioavailability in renal transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23733010/),%,19.3,147896,DB00864,Tacrolimus
,23267661,AUC(0-24h),"After 14 days of co-administration of WZ and PRED, the AUC(0-24h) of oral TAC was increased (from 59.6±37.3 to 95.3±39.4 ng h/ml, p=0.18) and the clearance was decreased (from 38.4±28.4 to 17.7±6.4 l/h/kg, p=0.15).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[h·ng] / [ml],59.6,148133,DB00864,Tacrolimus
,23267661,AUC(0-24h),"After 14 days of co-administration of WZ and PRED, the AUC(0-24h) of oral TAC was increased (from 59.6±37.3 to 95.3±39.4 ng h/ml, p=0.18) and the clearance was decreased (from 38.4±28.4 to 17.7±6.4 l/h/kg, p=0.15).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[h·ng] / [ml],95.3,148134,DB00864,Tacrolimus
,23267661,clearance,"After 14 days of co-administration of WZ and PRED, the AUC(0-24h) of oral TAC was increased (from 59.6±37.3 to 95.3±39.4 ng h/ml, p=0.18) and the clearance was decreased (from 38.4±28.4 to 17.7±6.4 l/h/kg, p=0.15).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[l] / [h·kg],38.4,148135,DB00864,Tacrolimus
,23267661,clearance,"After 14 days of co-administration of WZ and PRED, the AUC(0-24h) of oral TAC was increased (from 59.6±37.3 to 95.3±39.4 ng h/ml, p=0.18) and the clearance was decreased (from 38.4±28.4 to 17.7±6.4 l/h/kg, p=0.15).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[l] / [h·kg],17.7,148136,DB00864,Tacrolimus
,23267661,AUC(0-24h),"When only co-administered with WZ, AUC(0-24h) of TAC was demonstrated a significantly increase (from 59.6±37.3 to 135.9±34.8 ng h/ml, p<0.05).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[h·ng] / [ml],59.6,148137,DB00864,Tacrolimus
,23267661,AUC(0-24h),"When only co-administered with WZ, AUC(0-24h) of TAC was demonstrated a significantly increase (from 59.6±37.3 to 135.9±34.8 ng h/ml, p<0.05).",Effect of long-term co-administration of Wuzhi tablet (Schisandra sphenanthera extract) and prednisone on the pharmacokinetics of tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23267661/),[h·ng] / [ml],135.9,148138,DB00864,Tacrolimus
,18429967,AUC(0-12),"Tacrolimus pharmacokinetics did not show circadian variation in either the early or maintenance stage [AUC(0-12) 197.1 (95% confidence interval 182.9, 212.3) in daytime vs. 203.6 ng h ml(-1) (189.8, 217.4) in the night-time at day 28, 102.0 (92.1, 111.9) vs. 107.7 (97.9, 117.5) at 1 year, respectively].",Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18429967/),[h·ng] / [ml],197.1,148769,DB00864,Tacrolimus
,18429967,AUC(0-12),"Tacrolimus pharmacokinetics did not show circadian variation in either the early or maintenance stage [AUC(0-12) 197.1 (95% confidence interval 182.9, 212.3) in daytime vs. 203.6 ng h ml(-1) (189.8, 217.4) in the night-time at day 28, 102.0 (92.1, 111.9) vs. 107.7 (97.9, 117.5) at 1 year, respectively].",Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18429967/),[h·ng] / [ml],203.6,148770,DB00864,Tacrolimus
,18429967,AUC(0-12),"Tacrolimus pharmacokinetics did not show circadian variation in either the early or maintenance stage [AUC(0-12) 197.1 (95% confidence interval 182.9, 212.3) in daytime vs. 203.6 ng h ml(-1) (189.8, 217.4) in the night-time at day 28, 102.0 (92.1, 111.9) vs. 107.7 (97.9, 117.5) at 1 year, respectively].",Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18429967/),,102.0,148771,DB00864,Tacrolimus
,18429967,AUC(0-12),"Tacrolimus pharmacokinetics did not show circadian variation in either the early or maintenance stage [AUC(0-12) 197.1 (95% confidence interval 182.9, 212.3) in daytime vs. 203.6 ng h ml(-1) (189.8, 217.4) in the night-time at day 28, 102.0 (92.1, 111.9) vs. 107.7 (97.9, 117.5) at 1 year, respectively].",Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18429967/),,107.7,148772,DB00864,Tacrolimus
,18771060,trough blood concentrations,"After the switch, tacrolimus trough blood concentrations significantly dropped in all patients (mean +/- SD 6.9 +/- 2.6 versus 3.2 +/- 2.0 ng/ml before and after the switch, respectively; P=0.01), so that a marked dosage increase was needed (0.29 +/- 0.14 versus 0.88 +/- 0.48 mg/day, 1-3 days before and 3 weeks after the switch, respectively; P=0.046) to attain the desired target (8.7 +/- 2.3 ng/ml).",Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771060/),[ng] / [ml],6.9,149900,DB00864,Tacrolimus
,18771060,trough blood concentrations,"After the switch, tacrolimus trough blood concentrations significantly dropped in all patients (mean +/- SD 6.9 +/- 2.6 versus 3.2 +/- 2.0 ng/ml before and after the switch, respectively; P=0.01), so that a marked dosage increase was needed (0.29 +/- 0.14 versus 0.88 +/- 0.48 mg/day, 1-3 days before and 3 weeks after the switch, respectively; P=0.046) to attain the desired target (8.7 +/- 2.3 ng/ml).",Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771060/),[ng] / [ml],3.2,149901,DB00864,Tacrolimus
,18771060,trough blood concentrations,"After the switch, tacrolimus trough blood concentrations significantly dropped in all patients (mean +/- SD 6.9 +/- 2.6 versus 3.2 +/- 2.0 ng/ml before and after the switch, respectively; P=0.01), so that a marked dosage increase was needed (0.29 +/- 0.14 versus 0.88 +/- 0.48 mg/day, 1-3 days before and 3 weeks after the switch, respectively; P=0.046) to attain the desired target (8.7 +/- 2.3 ng/ml).",Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771060/),,0,149902,DB00864,Tacrolimus
,18771060,trough blood concentrations,"After the switch, tacrolimus trough blood concentrations significantly dropped in all patients (mean +/- SD 6.9 +/- 2.6 versus 3.2 +/- 2.0 ng/ml before and after the switch, respectively; P=0.01), so that a marked dosage increase was needed (0.29 +/- 0.14 versus 0.88 +/- 0.48 mg/day, 1-3 days before and 3 weeks after the switch, respectively; P=0.046) to attain the desired target (8.7 +/- 2.3 ng/ml).",Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771060/),,8.,149903,DB00864,Tacrolimus
,18771060,concentration/dose ratio,"Consistently, marked changes of the concentration/dose ratio of tacrolimus were observed in all cases (27.2 +/- 9.7 ng/ml per mg/kg/day versus 9.7 +/- 4.0 ng/ml per mg/kg/day before and after the switch, respectively; P<0.001).",Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771060/),[ng] / [d·kg·mg·ml],27.2,149904,DB00864,Tacrolimus
,18771060,concentration/dose ratio,"Consistently, marked changes of the concentration/dose ratio of tacrolimus were observed in all cases (27.2 +/- 9.7 ng/ml per mg/kg/day versus 9.7 +/- 4.0 ng/ml per mg/kg/day before and after the switch, respectively; P<0.001).",Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18771060/),[ng] / [d·kg·mg·ml],9.7,149905,DB00864,Tacrolimus
,8787947,blood to plasma ratio,"Tacrolimus is extensively bound to red blood cells, with a mean blood to plasma ratio of about 15; albumin and alpha 1-acid glycoprotein appear to primarily bind tacrolimus in plasma.",Clinical pharmacokinetics of tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787947/),,15,150667,DB00864,Tacrolimus
,8787947,disposition half-life,The mean disposition half-life is 12 hours and the total body clearance based on blood concentration is approximately 0.06 L/h/kg.,Clinical pharmacokinetics of tacrolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787947/),h,12,150668,DB00864,Tacrolimus
,8787947,total body clearance,The mean disposition half-life is 12 hours and the total body clearance based on blood concentration is approximately 0.06 L/h/kg.,Clinical pharmacokinetics of tacrolimus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8787947/),[l] / [h·kg],0.06,150669,DB00864,Tacrolimus
,18203434,zeta potential,"NLs were found to have average size of 140 nm, 96% +/- 1.5% drug entrapment, and zeta potential of 1.107 mV.","Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18203434/),mv,1.107,151222,DB00864,Tacrolimus
,18203434,maximum fine particle fraction (FPF),"Trehalose based formulation was found to have low density, good flowability, particle size of 9.46 +/- 0.8 microm, maximum fine particle fraction (FPF) of 71.1 +/- 2.5%, mean mass aerodynamic diameter (MMAD) 2.2 +/- 0.1 microm, and geometric standard deviation (GSD) 1.7 +/- 0.2.","Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18203434/),%,71.1,151223,DB00864,Tacrolimus
,18203434,mass aerodynamic diameter,"Trehalose based formulation was found to have low density, good flowability, particle size of 9.46 +/- 0.8 microm, maximum fine particle fraction (FPF) of 71.1 +/- 2.5%, mean mass aerodynamic diameter (MMAD) 2.2 +/- 0.1 microm, and geometric standard deviation (GSD) 1.7 +/- 0.2.","Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18203434/),μ,2.2,151224,DB00864,Tacrolimus
,18203434,maximal residence,"In vivo studies revealed maximal residence of tacrolimus within lungs of 24 hours, suggesting slow clearance from the lungs.","Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18203434/),h,24,151225,DB00864,Tacrolimus
,30415142,m/z,The highest response ion pairs m/z at 931.5→864.5 were chosen for sirolimus.,Pharmacokinetic study of sirolimus ophthalmic formulations by consecutive sampling and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30415142/),,931.5,151249,DB00864,Tacrolimus
,30415142,m/z,The highest response ion pairs m/z at 931.5→864.5 were chosen for sirolimus.,Pharmacokinetic study of sirolimus ophthalmic formulations by consecutive sampling and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30415142/),,864.5,151250,DB00864,Tacrolimus
,20046074,C(max),"The mean C(max) and area under the tacrolimus concentrationti-me curve (AUC(0-24 h)) were 12.7 ng/ml and 163.1 ng x h/ml, respectively.",Pharmacokinetics of orally administered tacrolimus in lupus nephritis patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20046074/),[ng] / [ml],12.7,151533,DB00864,Tacrolimus
,20046074,area under the tacrolimus concentrationti-me curve (AUC(0-24 h)),"The mean C(max) and area under the tacrolimus concentrationti-me curve (AUC(0-24 h)) were 12.7 ng/ml and 163.1 ng x h/ml, respectively.",Pharmacokinetics of orally administered tacrolimus in lupus nephritis patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20046074/),[h·ng] / [ml],163.1,151534,DB00864,Tacrolimus
,16027400,AUC(0-12),"Total mycophenolic acid AUC(0-12) mcg x h/mL before day 60 was 62.1-67.8, declining to 33.6-64.7 thereafter (P = .61).",Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·mcg] / [ml],62.1-67.8,151954,DB00864,Tacrolimus
,16027400,AUC(0-12),"Total mycophenolic acid AUC(0-12) mcg x h/mL before day 60 was 62.1-67.8, declining to 33.6-64.7 thereafter (P = .61).",Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·mcg] / [ml],33.6-64.7,151955,DB00864,Tacrolimus
,16027400,total trough concentrations,Median total trough concentrations were 1.16-2.90 mcg/mL.,Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[mcg] / [ml],1.16-2.90,151956,DB00864,Tacrolimus
,16027400,Unbound AUC(0-12),Unbound AUC(0-12) was 412-673 ng x h/mL and did not change over time (P = .30).,Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·ng] / [ml],412-673,151957,DB00864,Tacrolimus
,21753749,Systemic,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],269,152160,DB00864,Tacrolimus
,21753749,Systemic,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],354,152161,DB00864,Tacrolimus
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],354,152162,DB00864,Tacrolimus
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],31,152163,DB00864,Tacrolimus
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],479,152164,DB00864,Tacrolimus
,21753749,apparent oral midazolam clearance,"Systemic and apparent oral midazolam clearance were 24% (269 ± 73 vs. 354 ± 102 ml/min, P = 0.022) and 31% (479 ± 190 vs. 688 ± 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).",In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21753749/),[ml] / [min],688,152165,DB00864,Tacrolimus
,27310199,Ctrough,"Estimated tacrolimus Ctrough values (median; interquartile range) before and during 3D treatment were comparable (5.7 ng/mL; 4.9-6.5 ng/mL versus 5.2 ng/mL; 4.2-6.3 ng/mL, respectively).",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],5.7,152910,DB00864,Tacrolimus
,27310199,Ctrough,"Estimated tacrolimus Ctrough values (median; interquartile range) before and during 3D treatment were comparable (5.7 ng/mL; 4.9-6.5 ng/mL versus 5.2 ng/mL; 4.2-6.3 ng/mL, respectively).",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],5.2,152911,DB00864,Tacrolimus
,27310199,Ctrough,"Based on simulations, in a patient with a starting Ctrough of 6 ng/mL, 0.5 mg tacrolimus every 7 or 14 days or 0.2 mg tacrolimus every 3 days will result in Ctrough levels of 6-9 ng/mL, 4-6 ng/mL, and 6-10 ng/mL, respectively, during 3D treatment.",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],6,152912,DB00864,Tacrolimus
,27310199,Ctrough,"Based on simulations, in a patient with a starting Ctrough of 6 ng/mL, 0.5 mg tacrolimus every 7 or 14 days or 0.2 mg tacrolimus every 3 days will result in Ctrough levels of 6-9 ng/mL, 4-6 ng/mL, and 6-10 ng/mL, respectively, during 3D treatment.",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],6-9,152913,DB00864,Tacrolimus
,27310199,Ctrough,"Based on simulations, in a patient with a starting Ctrough of 6 ng/mL, 0.5 mg tacrolimus every 7 or 14 days or 0.2 mg tacrolimus every 3 days will result in Ctrough levels of 6-9 ng/mL, 4-6 ng/mL, and 6-10 ng/mL, respectively, during 3D treatment.",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],4-6,152914,DB00864,Tacrolimus
,27310199,Ctrough,"Based on simulations, in a patient with a starting Ctrough of 6 ng/mL, 0.5 mg tacrolimus every 7 or 14 days or 0.2 mg tacrolimus every 3 days will result in Ctrough levels of 6-9 ng/mL, 4-6 ng/mL, and 6-10 ng/mL, respectively, during 3D treatment.",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],6-10,152915,DB00864,Tacrolimus
,27310199,Ctrough,"For CSA, Ctrough values (median; interquartile range) before and during 3D treatment were comparable (126 ng/mL; 94-140 ng/mL versus 104 ng/mL; 82-140 ng/mL).",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],126,152916,DB00864,Tacrolimus
,27310199,Ctrough,"For CSA, Ctrough values (median; interquartile range) before and during 3D treatment were comparable (126 ng/mL; 94-140 ng/mL versus 104 ng/mL; 82-140 ng/mL).",Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310199/),[ng] / [ml],104,152917,DB00864,Tacrolimus
,31471014,AUC0-12,Mean MPA AUC0-12 of Immucept® was higher than CellCept® without statistical significance (48.27 ± 2.31 μg⋅hr/mL vs 42.19±15.20 μg⋅hr/mL; P value = .59).,A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471014/),[h·μg] / [ml],48.27,153177,DB00864,Tacrolimus
,31471014,AUC0-12,Mean MPA AUC0-12 of Immucept® was higher than CellCept® without statistical significance (48.27 ± 2.31 μg⋅hr/mL vs 42.19±15.20 μg⋅hr/mL; P value = .59).,A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471014/),[h·μg] / [ml],42.19,153178,DB00864,Tacrolimus
<,31471014,AUC0-12,"While on CellCept®, 5 patients (25%) had an MPA AUC0-12 < 30.0 μg⋅hr/mL, but 3 patients (15%) had MPA AUC0-12 < 30.0 μg⋅hr/mL when receiving Immucept®.",A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471014/),[h·μg] / [ml],30.0,153179,DB00864,Tacrolimus
>,31471014,AUC0-12,"However, 3 (15%) and 6 (30%) patients had MPA AUC0-12 > 60.0 μg⋅hr./mL when treated with CellCept® and Immucept®, respectively.",A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471014/),[h·μg] / [ml],60.0,153180,DB00864,Tacrolimus
more,31471014,AUC0-12,MPA AUC0-12 was more than 30.0 μg⋅hr/mL among most patients receiving MMF 1000 mg/day.,A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471014/),[h·μg] / [ml],30.0,153181,DB00864,Tacrolimus
,17373177,maximum concentrations,"In the pharmacokinetic studies, 89% to 95% of tacrolimus whole blood concentration samples were less than 1 ng/mL; mean maximum concentrations ranged from 0.2 to 1.6 ng/mL and mean area under the blood concentration-time curves (0-12 hours) ranged from 1.4 to 13.1 ng x hr/mL.",Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17373177/),[ng] / [ml],0.2 to 1.6,153592,DB00864,Tacrolimus
,17373177,area under the blood concentration-time curves (0-12 hours),"In the pharmacokinetic studies, 89% to 95% of tacrolimus whole blood concentration samples were less than 1 ng/mL; mean maximum concentrations ranged from 0.2 to 1.6 ng/mL and mean area under the blood concentration-time curves (0-12 hours) ranged from 1.4 to 13.1 ng x hr/mL.",Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17373177/),[h·ng] / [ml],1.4 to 13.1,153593,DB00864,Tacrolimus
,8595724,turnaround time,The turnaround time for a batch of 20 samples was 2.5 h.,"Sensitive, specific quantitative analysis of tacrolimus (FK506) in blood by liquid chromatography-electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8595724/),h,2.5,153686,DB00864,Tacrolimus
,11597545,elimination half-life,The elimination half-life was prolonged (4.7 hours compared with 3 hours in healthy volunteers).,Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,4.7,153703,DB00864,Tacrolimus
,11597545,elimination half-life,The elimination half-life was prolonged (4.7 hours compared with 3 hours in healthy volunteers).,Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,3,153704,DB00864,Tacrolimus
,11597545,half-life,"The area under the concentration-time data for UK was about threefold larger than in healthy volunteers, and the half-life was prolonged from 3.8 hours to 11.4 hours.",Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,3.8,153705,DB00864,Tacrolimus
,11597545,half-life,"The area under the concentration-time data for UK was about threefold larger than in healthy volunteers, and the half-life was prolonged from 3.8 hours to 11.4 hours.",Interactions of sildenafil and tacrolimus in men with erectile dysfunction after kidney transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11597545/),h,11.4,153706,DB00864,Tacrolimus
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],47.7,154308,DB00864,Tacrolimus
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],83.1,154309,DB00864,Tacrolimus
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],569,154310,DB00864,Tacrolimus
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],911,154311,DB00864,Tacrolimus
,24232127,C(0),"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],2.6,154312,DB00864,Tacrolimus
,24232127,C(0),"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],4.6,154313,DB00864,Tacrolimus
,24232127,maximum serum concentration,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],9.2,154314,DB00864,Tacrolimus
,24232127,maximum serum concentration,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],20.3,154315,DB00864,Tacrolimus
,24232127,apparent oral clearance,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·l] / [kg],0.26,154316,DB00864,Tacrolimus
,24232127,apparent oral clearance,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·l] / [kg],0.13,154317,DB00864,Tacrolimus
,17097975,AUC,"The maximum mean values of MPA AUC and predose concentration (C0h) (20.8 +/- 11.8 and 2.3 +/- 1.8, respectively) were reached on the third day.",Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),,20.8,155609,DB00864,Tacrolimus
,17097975,predose,"The maximum mean values of MPA AUC and predose concentration (C0h) (20.8 +/- 11.8 and 2.3 +/- 1.8, respectively) were reached on the third day.",Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),,20.8,155610,DB00864,Tacrolimus
,17097975,concentration (C0h),"The maximum mean values of MPA AUC and predose concentration (C0h) (20.8 +/- 11.8 and 2.3 +/- 1.8, respectively) were reached on the third day.",Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),,2.3,155611,DB00864,Tacrolimus
>/=,17097975,tmax,The single sample showing the greatest correlation with the MPA AUC was the one collected after 3 hours (r(2) = 0.575); 59.1% of profiles displayed a single peak with more than half showing a tmax >/= 3 hours.,Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),h,3,155612,DB00864,Tacrolimus
,20497746,clearance,"Typical mean value of tacrolimus clearance, estimated by the base model (without covariates), in our population was 1.03 l h-1.",Population pharmacokinetics of tacrolimus in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20497746/),[l] / [h],1.03,155926,DB00864,Tacrolimus
,30950096,apparent oral clearance,Tacrolimus apparent oral clearance was 44.3 L/h in Whites and 59% higher in Asians.,"Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30950096/),[l] / [h],44.3,156411,DB00864,Tacrolimus
,30950096,central volume of distribution,Tacrolimus central volume of distribution was 108 L in males and 55% lower in females; trough concentrations were similar between formulations.,"Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30950096/),l,108,156412,DB00864,Tacrolimus
,30950096,relative bioavailability,"Asians had 83% and 51% higher relative bioavailability than Whites and Blacks, respectively, for IR-T and PR-T.","Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30950096/),%,83,156413,DB00864,Tacrolimus
,30950096,relative bioavailability,"Asians had 83% and 51% higher relative bioavailability than Whites and Blacks, respectively, for IR-T and PR-T.","Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30950096/),%,51,156414,DB00864,Tacrolimus
,30950096,relative bioavailability,"Whites had 49% and 77% higher relative bioavailability than Blacks for PR-T and IR-T, respectively.","Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30950096/),%,49,156415,DB00864,Tacrolimus
,30950096,relative bioavailability,"Whites had 49% and 77% higher relative bioavailability than Blacks for PR-T and IR-T, respectively.","Population pharmacokinetics of immediate- and prolonged-release tacrolimus formulations in liver, kidney and heart transplant recipients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30950096/),%,77,156416,DB00864,Tacrolimus
,9842978,clearance,"Mean estimates for clearance and terminal half-life were 2.3+/-1.2 ml/min/kg and 11.5+/-3.8 h, respectively, following intravenous tacrolimus.",Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842978/),[ml] / [kg·min],2.3,156453,DB00864,Tacrolimus
,9842978,terminal half-life,"Mean estimates for clearance and terminal half-life were 2.3+/-1.2 ml/min/kg and 11.5+/-3.8 h, respectively, following intravenous tacrolimus.",Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842978/),h,11.5,156454,DB00864,Tacrolimus
,9842978,bioavailability,The mean bioavailability of oral tacrolimus was 25+/-20%.,Pharmacokinetics of tacrolimus (FK506) in paediatric liver transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9842978/),%,25,156455,DB00864,Tacrolimus
<,20498245,AUC,"Significantly more acute rejections (treated, biopsy-proven including and excluding borderline) occurred in patients with MPA AUC levels<30 mg.h/L compared with those >or=30 mg.h/L at day 5.","The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498245/),[h·mg] / [l],30,156812,DB00864,Tacrolimus
>,20498245,AUC,"Significantly more acute rejections (treated, biopsy-proven including and excluding borderline) occurred in patients with MPA AUC levels<30 mg.h/L compared with those >or=30 mg.h/L at day 5.","The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498245/),[h·mg] / [l],30,156813,DB00864,Tacrolimus
,22770208,Trough whole blood levels,"Trough whole blood levels, area under the concentration-time curve, T(max), and C(max) after oral and sublingual administration of tacrolimus were not significantly different (10.4 ± 7.4 vs 11.2 ± 11.3 ng/mL for trough blood concentration, 181.5 ± 114.1 vs 160.8 ± 115.9 ng.h/mL for AUC, 1.9 ± 1.2 vs 1.4 ± 0.7 h for T(max), and 19.9 ± 10.8 vs 17.2 ± 11.7 ng/mL for C(max)).",Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770208/),[ng] / [ml],10.4,157262,DB00864,Tacrolimus
,22770208,trough blood concentration,"Trough whole blood levels, area under the concentration-time curve, T(max), and C(max) after oral and sublingual administration of tacrolimus were not significantly different (10.4 ± 7.4 vs 11.2 ± 11.3 ng/mL for trough blood concentration, 181.5 ± 114.1 vs 160.8 ± 115.9 ng.h/mL for AUC, 1.9 ± 1.2 vs 1.4 ± 0.7 h for T(max), and 19.9 ± 10.8 vs 17.2 ± 11.7 ng/mL for C(max)).",Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770208/),[ng] / [ml],11.2,157263,DB00864,Tacrolimus
,22770208,AUC,"Trough whole blood levels, area under the concentration-time curve, T(max), and C(max) after oral and sublingual administration of tacrolimus were not significantly different (10.4 ± 7.4 vs 11.2 ± 11.3 ng/mL for trough blood concentration, 181.5 ± 114.1 vs 160.8 ± 115.9 ng.h/mL for AUC, 1.9 ± 1.2 vs 1.4 ± 0.7 h for T(max), and 19.9 ± 10.8 vs 17.2 ± 11.7 ng/mL for C(max)).",Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770208/),[h·ng] / [ml],181.5,157264,DB00864,Tacrolimus
,22770208,AUC,"Trough whole blood levels, area under the concentration-time curve, T(max), and C(max) after oral and sublingual administration of tacrolimus were not significantly different (10.4 ± 7.4 vs 11.2 ± 11.3 ng/mL for trough blood concentration, 181.5 ± 114.1 vs 160.8 ± 115.9 ng.h/mL for AUC, 1.9 ± 1.2 vs 1.4 ± 0.7 h for T(max), and 19.9 ± 10.8 vs 17.2 ± 11.7 ng/mL for C(max)).",Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770208/),[h·ng] / [ml],160.8,157265,DB00864,Tacrolimus
,22770208,T(max),"Trough whole blood levels, area under the concentration-time curve, T(max), and C(max) after oral and sublingual administration of tacrolimus were not significantly different (10.4 ± 7.4 vs 11.2 ± 11.3 ng/mL for trough blood concentration, 181.5 ± 114.1 vs 160.8 ± 115.9 ng.h/mL for AUC, 1.9 ± 1.2 vs 1.4 ± 0.7 h for T(max), and 19.9 ± 10.8 vs 17.2 ± 11.7 ng/mL for C(max)).",Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770208/),h,1.9,157266,DB00864,Tacrolimus
,22770208,T(max),"Trough whole blood levels, area under the concentration-time curve, T(max), and C(max) after oral and sublingual administration of tacrolimus were not significantly different (10.4 ± 7.4 vs 11.2 ± 11.3 ng/mL for trough blood concentration, 181.5 ± 114.1 vs 160.8 ± 115.9 ng.h/mL for AUC, 1.9 ± 1.2 vs 1.4 ± 0.7 h for T(max), and 19.9 ± 10.8 vs 17.2 ± 11.7 ng/mL for C(max)).",Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770208/),h,1.4,157267,DB00864,Tacrolimus
,22770208,C(max),"Trough whole blood levels, area under the concentration-time curve, T(max), and C(max) after oral and sublingual administration of tacrolimus were not significantly different (10.4 ± 7.4 vs 11.2 ± 11.3 ng/mL for trough blood concentration, 181.5 ± 114.1 vs 160.8 ± 115.9 ng.h/mL for AUC, 1.9 ± 1.2 vs 1.4 ± 0.7 h for T(max), and 19.9 ± 10.8 vs 17.2 ± 11.7 ng/mL for C(max)).",Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770208/),[ng] / [ml],19.9,157268,DB00864,Tacrolimus
,22770208,C(max),"Trough whole blood levels, area under the concentration-time curve, T(max), and C(max) after oral and sublingual administration of tacrolimus were not significantly different (10.4 ± 7.4 vs 11.2 ± 11.3 ng/mL for trough blood concentration, 181.5 ± 114.1 vs 160.8 ± 115.9 ng.h/mL for AUC, 1.9 ± 1.2 vs 1.4 ± 0.7 h for T(max), and 19.9 ± 10.8 vs 17.2 ± 11.7 ng/mL for C(max)).",Clinical pharmacokinetics of oral versus sublingual administration of tacrolimus in adult liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22770208/),[ng] / [ml],17.2,157269,DB00864,Tacrolimus
,15502939,arterial oxygen tension (PaO2),We encountered a patient (2.3-year-old girl) with hypoxemia [arterial oxygen tension (PaO2) 40.9 mmHg in room air] due to hepatopulmonary syndrome who had undergone living related liver transplantation.,Case report of unchanged tacrolimus clearance in a hypoxemic pediatric liver transplant recipient with hepatopulmonary syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502939/),mmhg,40.9,157822,DB00864,Tacrolimus
more,15502939,PaO2,"After transplantation, tacrolimus was initially administered by continuous intravenous infusion, and her PaO2 was maintained at more than 50 mmHg [72.8+/-10.4 (SD) mmHg] by oxygen supplementation.",Case report of unchanged tacrolimus clearance in a hypoxemic pediatric liver transplant recipient with hepatopulmonary syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502939/),mmhg,50,157823,DB00864,Tacrolimus
,15502939,PaO2,"After transplantation, tacrolimus was initially administered by continuous intravenous infusion, and her PaO2 was maintained at more than 50 mmHg [72.8+/-10.4 (SD) mmHg] by oxygen supplementation.",Case report of unchanged tacrolimus clearance in a hypoxemic pediatric liver transplant recipient with hepatopulmonary syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502939/),mmhg,72.8,157824,DB00864,Tacrolimus
,15502939,Apparent clearance,"Apparent clearance of tacrolimus (calculated as: the infusion rate of tacrolimus/blood concentration) in the patient (0.075 l/h per kg) was comparable to those of non-hypoxemic control pediatric cases (0.092+/-0.014 l/h per kg, n=7, mean age 2.2 years, PaO2 149.2+/-41.5 mmHg), except for the acute decline in the early period after transplantation.",Case report of unchanged tacrolimus clearance in a hypoxemic pediatric liver transplant recipient with hepatopulmonary syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502939/),[l] / [h·kg],0.075,157825,DB00864,Tacrolimus
,15502939,Apparent clearance,"Apparent clearance of tacrolimus (calculated as: the infusion rate of tacrolimus/blood concentration) in the patient (0.075 l/h per kg) was comparable to those of non-hypoxemic control pediatric cases (0.092+/-0.014 l/h per kg, n=7, mean age 2.2 years, PaO2 149.2+/-41.5 mmHg), except for the acute decline in the early period after transplantation.",Case report of unchanged tacrolimus clearance in a hypoxemic pediatric liver transplant recipient with hepatopulmonary syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15502939/),[l] / [h·kg],0.092,157826,DB00864,Tacrolimus
,16120063,clearance,"Using this model, no statistically significant difference was observed in clearance of MPA between TACR and CsA co-administration (11.9 and 14.1 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],11.9,157933,DB00864,Tacrolimus
,16120063,clearance,"Using this model, no statistically significant difference was observed in clearance of MPA between TACR and CsA co-administration (11.9 and 14.1 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],14.1,157934,DB00864,Tacrolimus
,16120063,Total clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],1.45,157935,DB00864,Tacrolimus
,16120063,Total clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],0.92,157936,DB00864,Tacrolimus
,16120063,renal clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],1.09,157937,DB00864,Tacrolimus
,16120063,renal clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],0.92,157938,DB00864,Tacrolimus
,11571449,half-life,"Pharmacokinetic analysis in the first week of SRL administration suggested a short half-life (11.8+/-5.5 hr, n=21).",Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11571449/),h,11.8,158457,DB00864,Tacrolimus
,27138785,concentration (C 0),Dose simulations show that a daily tacrolimus dose of 0.2 mg/kg generates a pre-dose concentration (C 0) ranging from 5 to 10 µg/L depending on the weight and CYP3A5 polymorphism.,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[μg] / [l],5 to 10,160046,DB00864,Tacrolimus
,27138785,area under the plasma concentration-time curve (AUC),The median area under the plasma concentration-time curve (AUC) corresponding with a tacrolimus C 0 of 4-8 µg/L was 97 h·µg/L (interquartile range 80-120).,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[h·μg] / [l],97,160047,DB00864,Tacrolimus
,27138785,C 0,The median area under the plasma concentration-time curve (AUC) corresponding with a tacrolimus C 0 of 4-8 µg/L was 97 h·µg/L (interquartile range 80-120).,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[μg] / [l],4-8,160048,DB00864,Tacrolimus
,27138785,C 0,The median area under the plasma concentration-time curve (AUC) corresponding with a tacrolimus C 0 of 4-8 µg/L was 97 h·µg/L (interquartile range 80-120).,The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27138785/),[h·μg] / [l],97,160049,DB00864,Tacrolimus
,27128604,Tmax,"AUC0-24, C24, and Cmax, were lower in the fed state and Tmax was 1 hour postponed.",Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27128604/),h·postponed,1,160866,DB00864,Tacrolimus
,21528942,Delay since g,Delay since grafting was similar for both groups of patients (expressors: 49 ± 24 months; non-expressors: 45 ± 22 months).,"Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21528942/),month,49,160938,DB00864,Tacrolimus
,21528942,Delay since g,Delay since grafting was similar for both groups of patients (expressors: 49 ± 24 months; non-expressors: 45 ± 22 months).,"Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21528942/),month,45,160939,DB00864,Tacrolimus
,21528942,AUC(24),"Following the switch to Advagraf®, there was a significant decrease in the dose-adjusted AUC(24) for both non-expressor (5910 ± 3019 vs 5334 ± 2668 ng·h/mL per mg/kg/day; p = 0.041) and expressor patients (3701 ± 1409 vs 3273 ± 1372 ng·h/mL per mg/kg/day; p = 0.03).","Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21528942/),[h·ng] / [d·kg·mg·ml],5910,160940,DB00864,Tacrolimus
,21528942,AUC(24),"Following the switch to Advagraf®, there was a significant decrease in the dose-adjusted AUC(24) for both non-expressor (5910 ± 3019 vs 5334 ± 2668 ng·h/mL per mg/kg/day; p = 0.041) and expressor patients (3701 ± 1409 vs 3273 ± 1372 ng·h/mL per mg/kg/day; p = 0.03).","Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21528942/),[h·ng] / [d·kg·mg·ml],5334,160941,DB00864,Tacrolimus
,21528942,AUC(24),"Following the switch to Advagraf®, there was a significant decrease in the dose-adjusted AUC(24) for both non-expressor (5910 ± 3019 vs 5334 ± 2668 ng·h/mL per mg/kg/day; p = 0.041) and expressor patients (3701 ± 1409 vs 3273 ± 1372 ng·h/mL per mg/kg/day; p = 0.03).","Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21528942/),[h·ng] / [d·kg·mg·ml],3701,160942,DB00864,Tacrolimus
,21528942,AUC(24),"Following the switch to Advagraf®, there was a significant decrease in the dose-adjusted AUC(24) for both non-expressor (5910 ± 3019 vs 5334 ± 2668 ng·h/mL per mg/kg/day; p = 0.041) and expressor patients (3701 ± 1409 vs 3273 ± 1372 ng·h/mL per mg/kg/day; p = 0.03).","Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21528942/),[h·ng] / [d·kg·mg·ml],3273,160943,DB00864,Tacrolimus
,21528942,blood trough concentration (C(0)),"In the non-expressor group, mean blood trough concentration (C(0)) was comparable for both formulations while it decreased significantly in the expressor group after the switch (8.2 ± 2.2 vs 6.3 ± 2.5 ng/mL; p = 0.02).","Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21528942/),[ng] / [ml],8.2,160944,DB00864,Tacrolimus
,21528942,blood trough concentration (C(0)),"In the non-expressor group, mean blood trough concentration (C(0)) was comparable for both formulations while it decreased significantly in the expressor group after the switch (8.2 ± 2.2 vs 6.3 ± 2.5 ng/mL; p = 0.02).","Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21528942/),[ng] / [ml],6.3,160945,DB00864,Tacrolimus
,14606933,time to maximum blood concentration,Pimecrolimus was rapidly absorbed (time to maximum blood concentration 0.7-2 hours).,"Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606933/),h,0.7-2,161191,DB00864,Tacrolimus
,14606933,terminal half-life,"Blood concentrations appear to have a long-terminal half-life (30-40 hours after a single dose in fasted subjects, 50-100 hours after the final dose on day 28 in psoriasis patients).","Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606933/),h,30-40,161192,DB00864,Tacrolimus
,14606933,terminal half-life,"Blood concentrations appear to have a long-terminal half-life (30-40 hours after a single dose in fasted subjects, 50-100 hours after the final dose on day 28 in psoriasis patients).","Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606933/),h,50-100,161193,DB00864,Tacrolimus
,14606933,C(max ),"At the highest dose administered in the multiple-dose study (30mg twice daily), a C(max ) of 54.7 microg/L was measured and an AUC(24) of 589.8 microg.h/L was calculated at steady state (day 13).","Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606933/),[μg] / [l],54.7,161194,DB00864,Tacrolimus
,14606933,AUC(24),"At the highest dose administered in the multiple-dose study (30mg twice daily), a C(max ) of 54.7 microg/L was measured and an AUC(24) of 589.8 microg.h/L was calculated at steady state (day 13).","Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606933/),[h·μg] / [l],589.8,161195,DB00864,Tacrolimus
,32078103,fraction absorbed,The in vivo contribution of P-gp is minimal for high permeable compounds owing to their fraction absorbed of nearly 1.0.,"Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078103/),,1.0,161619,DB00864,Tacrolimus
,7534100,tmax,"2. Blood drug concentrations were described by an open two compartment model with first-order absorption giving the following mean data: tmax: 1.9 (h), Cmax: 17.4 (microgram l-1), AUC: 328.1 (microgram l-1 h), t1/2,1: 0.74 (h).",Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534100/),h,1.9,161724,DB00864,Tacrolimus
,7534100,Cmax,"2. Blood drug concentrations were described by an open two compartment model with first-order absorption giving the following mean data: tmax: 1.9 (h), Cmax: 17.4 (microgram l-1), AUC: 328.1 (microgram l-1 h), t1/2,1: 0.74 (h).",Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534100/),[μg] / [l],17.4,161725,DB00864,Tacrolimus
,7534100,AUC,"2. Blood drug concentrations were described by an open two compartment model with first-order absorption giving the following mean data: tmax: 1.9 (h), Cmax: 17.4 (microgram l-1), AUC: 328.1 (microgram l-1 h), t1/2,1: 0.74 (h).",Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534100/),[h·μg] / [l],328.1,161726,DB00864,Tacrolimus
,7534100,t1/2,"2. Blood drug concentrations were described by an open two compartment model with first-order absorption giving the following mean data: tmax: 1.9 (h), Cmax: 17.4 (microgram l-1), AUC: 328.1 (microgram l-1 h), t1/2,1: 0.74 (h).",Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534100/),h,0.74,161727,DB00864,Tacrolimus
,7534100,terminal elimination half-life,The terminal elimination half-life was estimated at about 26 h using the h.p.l.c.-MS assay.,Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7534100/),h,26,161728,DB00864,Tacrolimus
,16678035,AUC,Only 9 of 52 LTx patients had a prednisolone AUC within the previously reported reference range for healthy adult control subjects (170 to 260 nmol x hr/liter/milligram prednisolone).,Therapeutic drug monitoring of prednisolone after lung transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678035/),[h·nM] / [l·milligram],170 to 260,162032,DB00864,Tacrolimus
,16678035,AUC,"Prednisolone AUC was higher in patients with CF compared with non-CF patients (511 +/- 82 vs 349 +/- 27 nmol x hr/liter/milligram, p < 0.02) and 70% of LTx recipients had measurable prednisolone levels at baseline (26.5 +/- 4.5 nmol/liter), unlike normal controls.",Therapeutic drug monitoring of prednisolone after lung transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678035/),[h·nM] / [l·milligram],511,162033,DB00864,Tacrolimus
,16678035,AUC,"Prednisolone AUC was higher in patients with CF compared with non-CF patients (511 +/- 82 vs 349 +/- 27 nmol x hr/liter/milligram, p < 0.02) and 70% of LTx recipients had measurable prednisolone levels at baseline (26.5 +/- 4.5 nmol/liter), unlike normal controls.",Therapeutic drug monitoring of prednisolone after lung transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16678035/),[h·nM] / [l·milligram],349,162034,DB00864,Tacrolimus
,18822327,relative oral bioavailability,The relative oral bioavailability of tacrolimus was 4.9 and 2.45 fold compared to the commercial product in rats and pigs respectively.,"Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18822327/),,4,163347,DB00864,Tacrolimus
,18822327,relative oral bioavailability,The relative oral bioavailability of tacrolimus was 4.9 and 2.45 fold compared to the commercial product in rats and pigs respectively.,"Novel double coated nanocapsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18822327/),,2,163348,DB00864,Tacrolimus
,24033383,trough level,"The trough level and the dose-adjusted trough level on days 2-5 were significantly higher in the Non-Exp group than in the Exp group (10.16 ± 5.84 vs 4.47 ± 2.50 ng/mL, P < 0.0001, 139.36 ± 77.43 vs 61.37 ± 41.55 ng/mL per mg/kg/day, P < 0.0001).",Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24033383/),[ng] / [ml],10.16,163480,DB00864,Tacrolimus
,24033383,trough level,"The trough level and the dose-adjusted trough level on days 2-5 were significantly higher in the Non-Exp group than in the Exp group (10.16 ± 5.84 vs 4.47 ± 2.50 ng/mL, P < 0.0001, 139.36 ± 77.43 vs 61.37 ± 41.55 ng/mL per mg/kg/day, P < 0.0001).",Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24033383/),[ng] / [ml],4.47,163481,DB00864,Tacrolimus
,24033383,dose-adjusted trough level,"The trough level and the dose-adjusted trough level on days 2-5 were significantly higher in the Non-Exp group than in the Exp group (10.16 ± 5.84 vs 4.47 ± 2.50 ng/mL, P < 0.0001, 139.36 ± 77.43 vs 61.37 ± 41.55 ng/mL per mg/kg/day, P < 0.0001).",Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24033383/),[ng] / [ml],4.47,163482,DB00864,Tacrolimus
,24033383,dose-adjusted trough level,"The trough level and the dose-adjusted trough level on days 2-5 were significantly higher in the Non-Exp group than in the Exp group (10.16 ± 5.84 vs 4.47 ± 2.50 ng/mL, P < 0.0001, 139.36 ± 77.43 vs 61.37 ± 41.55 ng/mL per mg/kg/day, P < 0.0001).",Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24033383/),[ng] / [d·kg·mg·ml],139.36,163483,DB00864,Tacrolimus
,24033383,dose-adjusted trough level,"The trough level and the dose-adjusted trough level on days 2-5 were significantly higher in the Non-Exp group than in the Exp group (10.16 ± 5.84 vs 4.47 ± 2.50 ng/mL, P < 0.0001, 139.36 ± 77.43 vs 61.37 ± 41.55 ng/mL per mg/kg/day, P < 0.0001).",Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24033383/),[ng] / [d·kg·mg·ml],61.37,163484,DB00864,Tacrolimus
,24033383,remission rate,"The remission rate was significantly higher in the Non-Exp group than in the Exp group (47.6% vs 16.7%, P = 0.046).",Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24033383/),%,47.6,163485,DB00864,Tacrolimus
,24033383,remission rate,"The remission rate was significantly higher in the Non-Exp group than in the Exp group (47.6% vs 16.7%, P = 0.046).",Impact of CYP3A5 genetic polymorphisms on the pharmacokinetics and short-term remission in patients with ulcerative colitis treated with tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24033383/),%,16.7,163486,DB00864,Tacrolimus
,18978521,area under the concentration-time curve (AUC0-12),"The area under the concentration-time curve (AUC0-12) of MPA normalized to mycophenolate mofetil (MMF) dose (mg/kg) was significantly lower in LN patients and CyA-treated KT recipients than in Tac-treated KT recipients [median (range), 2.19 (0.87-4.23), 2.36 (1.13-5.74), and 4.86 (3.25-6.75) microg x h/mL per mg/kg, P < 0.05 and P < 0.01, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],2.19,163570,DB00864,Tacrolimus
,18978521,area under the concentration-time curve (AUC0-12),"The area under the concentration-time curve (AUC0-12) of MPA normalized to mycophenolate mofetil (MMF) dose (mg/kg) was significantly lower in LN patients and CyA-treated KT recipients than in Tac-treated KT recipients [median (range), 2.19 (0.87-4.23), 2.36 (1.13-5.74), and 4.86 (3.25-6.75) microg x h/mL per mg/kg, P < 0.05 and P < 0.01, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],2.36,163571,DB00864,Tacrolimus
,18978521,area under the concentration-time curve (AUC0-12),"The area under the concentration-time curve (AUC0-12) of MPA normalized to mycophenolate mofetil (MMF) dose (mg/kg) was significantly lower in LN patients and CyA-treated KT recipients than in Tac-treated KT recipients [median (range), 2.19 (0.87-4.23), 2.36 (1.13-5.74), and 4.86 (3.25-6.75) microg x h/mL per mg/kg, P < 0.05 and P < 0.01, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],4.86,163572,DB00864,Tacrolimus
,18978521,AUC0-12,"Dose-normalized MPAG AUC0-12 was significantly lower in LN patients and slightly lower in Tac-treated KT recipients than in CyA-treated KT recipients [median (range), 35.0 (8.34-69.8), 51.6 (34.4-94.8), and 84.1 (34.7-152) microg x h/mL per mg/kg, P < 0.05 and P = 0.13, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],35.0,163573,DB00864,Tacrolimus
,18978521,AUC0-12,"Dose-normalized MPAG AUC0-12 was significantly lower in LN patients and slightly lower in Tac-treated KT recipients than in CyA-treated KT recipients [median (range), 35.0 (8.34-69.8), 51.6 (34.4-94.8), and 84.1 (34.7-152) microg x h/mL per mg/kg, P < 0.05 and P = 0.13, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],51.6,163574,DB00864,Tacrolimus
,18978521,AUC0-12,"Dose-normalized MPAG AUC0-12 was significantly lower in LN patients and slightly lower in Tac-treated KT recipients than in CyA-treated KT recipients [median (range), 35.0 (8.34-69.8), 51.6 (34.4-94.8), and 84.1 (34.7-152) microg x h/mL per mg/kg, P < 0.05 and P = 0.13, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],84.1,163575,DB00864,Tacrolimus
,19835971,time to myeloid,"Median time to myeloid and platelet engraftment was 18 and 31 days, respectively.",An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19835971/),d,18,164616,DB00864,Tacrolimus
,19835971,time to myeloid,"Median time to myeloid and platelet engraftment was 18 and 31 days, respectively.",An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19835971/),d,31,164617,DB00864,Tacrolimus
,9638846,area under the blood concentration-time curve (AUC),"The area under the blood concentration-time curve (AUC), the maximum blood level (Cmax), and the time to reach Cmax (Tmax) after FK506 capsules and FK506 granules were, respectively, 93.1 +/- 66.4 and 97.0 +/- 89.1 ng.h/ml (P = 0.81), 12.7 +/- 7.1 and 15.2 +/- 11.7 ng/ml (P = 0.39), and 2.0 +/- 1.7 and 1.3 +/- 0.6 h (P = 0.29).",A comparative study of FK506 granules and capsules in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638846/),[h·ng] / [ml],93.1,164827,DB00864,Tacrolimus
,9638846,maximum blood level (Cmax),"The area under the blood concentration-time curve (AUC), the maximum blood level (Cmax), and the time to reach Cmax (Tmax) after FK506 capsules and FK506 granules were, respectively, 93.1 +/- 66.4 and 97.0 +/- 89.1 ng.h/ml (P = 0.81), 12.7 +/- 7.1 and 15.2 +/- 11.7 ng/ml (P = 0.39), and 2.0 +/- 1.7 and 1.3 +/- 0.6 h (P = 0.29).",A comparative study of FK506 granules and capsules in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638846/),[h·ng] / [ml],97.0,164828,DB00864,Tacrolimus
,9638846,maximum blood level (Cmax),"The area under the blood concentration-time curve (AUC), the maximum blood level (Cmax), and the time to reach Cmax (Tmax) after FK506 capsules and FK506 granules were, respectively, 93.1 +/- 66.4 and 97.0 +/- 89.1 ng.h/ml (P = 0.81), 12.7 +/- 7.1 and 15.2 +/- 11.7 ng/ml (P = 0.39), and 2.0 +/- 1.7 and 1.3 +/- 0.6 h (P = 0.29).",A comparative study of FK506 granules and capsules in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638846/),[ng] / [ml],12.7,164829,DB00864,Tacrolimus
,9638846,maximum blood level (Cmax),"The area under the blood concentration-time curve (AUC), the maximum blood level (Cmax), and the time to reach Cmax (Tmax) after FK506 capsules and FK506 granules were, respectively, 93.1 +/- 66.4 and 97.0 +/- 89.1 ng.h/ml (P = 0.81), 12.7 +/- 7.1 and 15.2 +/- 11.7 ng/ml (P = 0.39), and 2.0 +/- 1.7 and 1.3 +/- 0.6 h (P = 0.29).",A comparative study of FK506 granules and capsules in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638846/),[ng] / [ml],15.2,164830,DB00864,Tacrolimus
,9638846,maximum blood level (Cmax),"The area under the blood concentration-time curve (AUC), the maximum blood level (Cmax), and the time to reach Cmax (Tmax) after FK506 capsules and FK506 granules were, respectively, 93.1 +/- 66.4 and 97.0 +/- 89.1 ng.h/ml (P = 0.81), 12.7 +/- 7.1 and 15.2 +/- 11.7 ng/ml (P = 0.39), and 2.0 +/- 1.7 and 1.3 +/- 0.6 h (P = 0.29).",A comparative study of FK506 granules and capsules in renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638846/),h,2.0,164831,DB00864,Tacrolimus
,9638846,time to reach Cmax (Tmax),"The area under the blood concentration-time curve (AUC), the maximum blood level (Cmax), and the time to reach Cmax (Tmax) after FK506 capsules and FK506 granules were, respectively, 93.1 +/- 66.4 and 97.0 +/- 89.1 ng.h/ml (P = 0.81), 12.7 +/- 7.1 and 15.2 +/- 11.7 ng/ml (P = 0.39), and 2.0 +/- 1.7 and 1.3 +/- 0.6 h (P = 0.29).",A comparative study of FK506 granules and capsules in renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638846/),[ng] / [ml],15.2,164832,DB00864,Tacrolimus
,9638846,time to reach Cmax (Tmax),"The area under the blood concentration-time curve (AUC), the maximum blood level (Cmax), and the time to reach Cmax (Tmax) after FK506 capsules and FK506 granules were, respectively, 93.1 +/- 66.4 and 97.0 +/- 89.1 ng.h/ml (P = 0.81), 12.7 +/- 7.1 and 15.2 +/- 11.7 ng/ml (P = 0.39), and 2.0 +/- 1.7 and 1.3 +/- 0.6 h (P = 0.29).",A comparative study of FK506 granules and capsules in renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638846/),h,2.0,164833,DB00864,Tacrolimus
,9638846,trough blood level,"The mean trough blood level during FK506 medication was 4.25 +/- 3.42 and 4.02 +/- 3.83 ng/ml, respectively, for the capsules and the granules.",A comparative study of FK506 granules and capsules in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638846/),[ng] / [ml],4.25,164834,DB00864,Tacrolimus
,9638846,trough blood level,"The mean trough blood level during FK506 medication was 4.25 +/- 3.42 and 4.02 +/- 3.83 ng/ml, respectively, for the capsules and the granules.",A comparative study of FK506 granules and capsules in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638846/),[ng] / [ml],4.02,164835,DB00864,Tacrolimus
,17391324,AUC(0-infinity),"AUC(0-infinity) for the CYP3A5*1/*1 or *1/*3 genotype was 131.5 +/- 44.8 ng h ml(-1) (CI 109.6, 153.5), which was much lower compared with the CYP3A5*3/*3 genotype of 323.8 +/- 129.3 ng h ml(-1) (CI 253.5, 394.1) (P = 2.063E-07).",Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391324/),[h·ng] / [ml],131.5,165026,DB00864,Tacrolimus
,17391324,AUC(0-infinity),"AUC(0-infinity) for the CYP3A5*1/*1 or *1/*3 genotype was 131.5 +/- 44.8 ng h ml(-1) (CI 109.6, 153.5), which was much lower compared with the CYP3A5*3/*3 genotype of 323.8 +/- 129.3 ng h ml(-1) (CI 253.5, 394.1) (P = 2.063E-07).",Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391324/),[h·ng] / [ml],323.8,165027,DB00864,Tacrolimus
,17391324,C(max),"Similarly, C(max) for the CYP3A5*1/*1 or *1/*3 genotype was 11.8 +/- 3.4 ng ml(-1) (CI 10.1, 13.5), which was also much lower compared with the CYP3A5*3/*3 genotype of 24.4 +/- 12.3 ng ml(-1) (CI 17.8, 31.1) (P = 0.0001).",Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391324/),[ng] / [ml],11.8,165028,DB00864,Tacrolimus
,17391324,C(max),"Similarly, C(max) for the CYP3A5*1/*1 or *1/*3 genotype was 11.8 +/- 3.4 ng ml(-1) (CI 10.1, 13.5), which was also much lower compared with the CYP3A5*3/*3 genotype of 24.4 +/- 12.3 ng ml(-1) (CI 17.8, 31.1) (P = 0.0001).",Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391324/),[ng] / [ml],24.4,165029,DB00864,Tacrolimus
,15116056,AUC(0-12),"Finally, for recipients who did not simultaneously have a target tacrolimus AUC(0-12) of 150 ng x h/mL and a mycophenolic acid AUC(0-12) of 45 mg x h/L by day 7, the incidence of acute rejection tended to be higher (26.3%) compared with patients who reached both target values (7.7%) (P =.07).",Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116056/),[h·ng] / [ml],150,165572,DB00864,Tacrolimus
,15116056,AUC(0-12),"Finally, for recipients who did not simultaneously have a target tacrolimus AUC(0-12) of 150 ng x h/mL and a mycophenolic acid AUC(0-12) of 45 mg x h/L by day 7, the incidence of acute rejection tended to be higher (26.3%) compared with patients who reached both target values (7.7%) (P =.07).",Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116056/),[h·mg] / [l],45,165573,DB00864,Tacrolimus
,31095909,bioavailability,"A complete pharmacokinetic (PK) analysis of FAF revealed that the bioavailability of SC FAF was 60%, with significantly higher blood concentration during the elimination phase compared to IV FAF.",Berunda Polypeptides: Biheaded Rapamycin Carriers for Subcutaneous Treatment of Autoimmune Dry Eye Disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31095909/),%,60,166573,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,0,168060,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,20,168061,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,40,168062,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,60,168063,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,90,168064,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,120,168065,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,180,168066,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,240,168067,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,360,168068,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,480,168069,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,600,168070,DB00864,Tacrolimus
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,720,168071,DB00864,Tacrolimus
,8610430,steady state c,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],320.3,168869,DB00864,Tacrolimus
,8610430,steady state c,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],18.2,168870,DB00864,Tacrolimus
,8610430,steady state c,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],389.2,168871,DB00864,Tacrolimus
,8610430,steady state c,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],21.2,168872,DB00864,Tacrolimus
,8610430,concentrations,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],320.3,168873,DB00864,Tacrolimus
,8610430,concentrations,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],18.2,168874,DB00864,Tacrolimus
,8610430,concentrations,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],389.2,168875,DB00864,Tacrolimus
,8610430,concentrations,"The mean steady state cyclosporine and tacrolimus concentrations without fluconazole were 320.3 and 18.2 ng/ml and increased to 389.2 and 21.2 ng/ml, respectively, after the addition of fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) increase.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ng] / [ml],21.2,168876,DB00864,Tacrolimus
,8610430,steady state clearance,"The mean steady state clearance of cyclosporine and tacrolimus without fluconazole was 6.82 and 1.28 ml/min/kg, which decreased to 5.57 and 1.10 ml/min/kg with fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) decrease, respectively.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ml] / [kg·min],6.82,168877,DB00864,Tacrolimus
,8610430,steady state clearance,"The mean steady state clearance of cyclosporine and tacrolimus without fluconazole was 6.82 and 1.28 ml/min/kg, which decreased to 5.57 and 1.10 ml/min/kg with fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) decrease, respectively.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ml] / [kg·min],1.28,168878,DB00864,Tacrolimus
,8610430,steady state clearance,"The mean steady state clearance of cyclosporine and tacrolimus without fluconazole was 6.82 and 1.28 ml/min/kg, which decreased to 5.57 and 1.10 ml/min/kg with fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) decrease, respectively.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ml] / [kg·min],5.57,168879,DB00864,Tacrolimus
,8610430,steady state clearance,"The mean steady state clearance of cyclosporine and tacrolimus without fluconazole was 6.82 and 1.28 ml/min/kg, which decreased to 5.57 and 1.10 ml/min/kg with fluconazole, corresponding to a 21% (P=0.031) and 16% (P=0.125) decrease, respectively.",Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610430/),[ml] / [kg·min],1.10,168880,DB00864,Tacrolimus
,29847459,AUC0-12h,"Normalized to 720 mg twice daily, the AUC0-12h of total MPA and MPAG was 43.0 ± 17.4 and 653 ± 329 mg·h/L, respectively, whereas the free MPA AUC0-12h was 1.368 ± 0.988 mg·h/L. The free fraction of MPA was 3.01% ± 3.15%.",Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29847459/),[h·mg] / [l],43.0,169838,DB00864,Tacrolimus
,29847459,AUC0-12h,"Normalized to 720 mg twice daily, the AUC0-12h of total MPA and MPAG was 43.0 ± 17.4 and 653 ± 329 mg·h/L, respectively, whereas the free MPA AUC0-12h was 1.368 ± 0.988 mg·h/L. The free fraction of MPA was 3.01% ± 3.15%.",Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29847459/),[h·mg] / [l],653,169839,DB00864,Tacrolimus
,29847459,AUC0-12h,"Normalized to 720 mg twice daily, the AUC0-12h of total MPA and MPAG was 43.0 ± 17.4 and 653 ± 329 mg·h/L, respectively, whereas the free MPA AUC0-12h was 1.368 ± 0.988 mg·h/L. The free fraction of MPA was 3.01% ± 3.15%.",Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29847459/),[h·mg] / [l],1.368,169840,DB00864,Tacrolimus
,29847459,free fraction,"Normalized to 720 mg twice daily, the AUC0-12h of total MPA and MPAG was 43.0 ± 17.4 and 653 ± 329 mg·h/L, respectively, whereas the free MPA AUC0-12h was 1.368 ± 0.988 mg·h/L. The free fraction of MPA was 3.01% ± 3.15%.",Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29847459/),%,3.01,169841,DB00864,Tacrolimus
,23792649,Twenty-four hours,"Twenty-four hours area under the curve (AUC0-24) was not different in both groups (285 ± 78.7 and 281 ± 62.4 ng hr/mL in Tacrolimus QD and Tacrolimus BID, respectively).",Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792649/),[h·ng] / [ml],285,171220,DB00864,Tacrolimus
,23792649,area under the curve (AUC0-24),"Twenty-four hours area under the curve (AUC0-24) was not different in both groups (285 ± 78.7 and 281 ± 62.4 ng hr/mL in Tacrolimus QD and Tacrolimus BID, respectively).",Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792649/),[h·ng] / [ml],285,171221,DB00864,Tacrolimus
,23792649,area under the curve (AUC0-24),"Twenty-four hours area under the curve (AUC0-24) was not different in both groups (285 ± 78.7 and 281 ± 62.4 ng hr/mL in Tacrolimus QD and Tacrolimus BID, respectively).",Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792649/),[h·ng] / [ml],281,171222,DB00864,Tacrolimus
,23792649,AUC0-24,C0 was well correlated with AUC0-24 in both groups and AUC0-24 between 260 and 280 in the Tacrolimus QD group was achieved by 6 to 8 ng/mL of C0.,Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792649/),,260 and 280,171223,DB00864,Tacrolimus
,23792649,C0,C0 was well correlated with AUC0-24 in both groups and AUC0-24 between 260 and 280 in the Tacrolimus QD group was achieved by 6 to 8 ng/mL of C0.,Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792649/),[ng] / [ml],6 to 8,171224,DB00864,Tacrolimus
,30704156,first blood trough level,"The first blood trough level of CYP3A5 expressors, CYP3A5*1/*3 or CYP3A5*1/*1, and the overall rate in achieving the target blood trough level within a week in the individualized-dose group were significantly higher than those in the fixed-dose group (5.15±2.33 ng/mL vs. 9.63±0.79 ng/mL, P=0.035 and 12.5% vs. 66.7%, P=0.01).",Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30704156/),[ng] / [ml],5.15,171469,DB00864,Tacrolimus
,30704156,first blood trough level,"The first blood trough level of CYP3A5 expressors, CYP3A5*1/*3 or CYP3A5*1/*1, and the overall rate in achieving the target blood trough level within a week in the individualized-dose group were significantly higher than those in the fixed-dose group (5.15±2.33 ng/mL vs. 9.63±0.79 ng/mL, P=0.035 and 12.5% vs. 66.7%, P=0.01).",Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30704156/),[ng] / [ml],9.63,171470,DB00864,Tacrolimus
,15534067,concentrations,"Fifteen minutes after FK506 (0.1 mg/kg) administration, the concentrations in the cortex and striatum were 20.0 +/- 1.7 ng/g and 14.1 +/- 1.7 ng/g, respectively.",Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15534067/),[ng] / [g],20.0,171491,DB00864,Tacrolimus
,15534067,concentrations,"Fifteen minutes after FK506 (0.1 mg/kg) administration, the concentrations in the cortex and striatum were 20.0 +/- 1.7 ng/g and 14.1 +/- 1.7 ng/g, respectively.",Pharmacokinetic animal PET study of FK506 as a potent neuroprotective agent. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15534067/),[ng] / [g],14.1,171492,DB00864,Tacrolimus
<,22549498,AUC,"Similarly, the number of patients underexposed to MPA (AUC < 30 ng·h/mL) was higher at most periods in the PPI group but again not statistically significant.",Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22549498/),[h·ng] / [ml],30,171979,DB00864,Tacrolimus
,23738951,apparent clearance,"The population estimate and inter-individual variability (%CV) of tacrolimus apparent clearance were found to be 0.977 l h(-1) kg(-1) (95% CI 0.958, 0.996) and 40.0%, respectively, while the residual variability between the observed and predicted concentrations was 35.4%.",Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23738951/),[l] / [h·kg],0.977,172347,DB00864,Tacrolimus
,32514937,CL,The median tacrolimus CL decreased from POD1 to POD4 (from 2.73 to 1.40 L/h) and was then stable until POD7.,Relationship Between Change Rate of Tacrolimus Clearance During Continuous Intravenous Infusion and Recipient Recovery at an Early Stage After Living Donor Liver Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32514937/),[l] / [h],2.73,172671,DB00864,Tacrolimus
,32514937,CL,The median tacrolimus CL decreased from POD1 to POD4 (from 2.73 to 1.40 L/h) and was then stable until POD7.,Relationship Between Change Rate of Tacrolimus Clearance During Continuous Intravenous Infusion and Recipient Recovery at an Early Stage After Living Donor Liver Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32514937/),[l] / [h],1.40,172672,DB00864,Tacrolimus
,10684356,trough concentration,"We recently published pharmacokinetic (PK) profiles of MMF in combination with tacrolimus (FK506): in order to keep the mycophenolic acid (MPA) pre-dose trough concentration between 2 and 5 microg/ml and to avoid side effects, mean MMF doses were reduced to 300 mg/m(2) b.i.d.",Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684356/),[μg] / [ml],2 and 5,173014,DB00864,Tacrolimus
,10684356,area under the curve (AUC),Mean area under the curve (AUC) in all PK profiles was 61.9+/-23.8 microgxh/ml.,Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684356/),[h·μg] / [ml],61.9,173015,DB00864,Tacrolimus
,25540593,AUC,"The mean AUC was 39.49 mg-h/L (28.39-89.58 mg-h/L), which was in the therapeutic range.",Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540593/),[mg-h] / [l],39.49,173022,DB00864,Tacrolimus
,24492423,AUC0-24 hr,Mean AUC0-24 hr was 279.8 ng mL/hr for TAC BID and 278.7 ng mL/hr for TAC QD (P=0.92).,Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492423/),[ml·ng] / [h],279.8,173211,DB00864,Tacrolimus
,24492423,AUC0-24 hr,Mean AUC0-24 hr was 279.8 ng mL/hr for TAC BID and 278.7 ng mL/hr for TAC QD (P=0.92).,Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24492423/),[ml·ng] / [h],278.7,173212,DB00864,Tacrolimus
,31192749,V/F,"Finally, a new model applicable to our real-world dataset was established as follows: CL/F = 22.9 × (WT/70)0.75 × (1 - WZ × 0.264) × (1 - FCZ × 0.338) × (1 + ASPI × 0.281) × (POD/41)0.0486 L/h; V/F = 906 × (WT/70) L. Where WT, WZ, FCZ, ASPI and POD were weight, Wuzhi capsule, fluconazole, aspirin and post-transplantation day, respectively.",Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31192749/),,90,174531,DB00864,Tacrolimus
,26114223,clearance,Tacrolimus clearance decreased gradually throughout the entire first year but only in CYP3A5*3/*3 homozygous recipients (25.6 ± 11.1 l h(-1) at day 7; 17 ± 9.1 l h(-1) at month 12; P < 0.001).,Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[l] / [h],25.6,174693,DB00864,Tacrolimus
,26114223,clearance,Tacrolimus clearance decreased gradually throughout the entire first year but only in CYP3A5*3/*3 homozygous recipients (25.6 ± 11.1 l h(-1) at day 7; 17 ± 9.1 l h(-1) at month 12; P < 0.001).,Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[l] / [h],17,174694,DB00864,Tacrolimus
,26114223,apparent oral MDZ clearance,"In mixed model analysis, decreasing CYP3A4 activity, measured by apparent oral MDZ clearance (924 ± 443 ml min(-1) at day 7 vs.",Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26114223/),[ml] / [min],924,174695,DB00864,Tacrolimus
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),[ng] / [ml],3970,175021,DB00864,Tacrolimus
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),[ng] / [ml],2520,175022,DB00864,Tacrolimus
,24649882,plasma concentrations,"Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980-4430) ng/ml and 2520 (1870-8730) ng/ml in patients after OLT and ciclosporin- or tacrolimus-based IS, respectively, as compared to 2790 (1870-3140) in non-OLT patients (P = 0.3).",Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24649882/),,2790,175023,DB00864,Tacrolimus
,23307542,area under the concentration-time curve from 0-6 hours,"The area under the concentration-time curve from 0-6 hours for sublingual and oral tacrolimus ranged from 27.2-66 and 32.4-76 mg·hour/L, respectively, in the tacrolimus plus clotrimazole group and from 9.3-63 and 4.9-23.2 mg·hour/L, respectively, in the tacrolimus plus nystatin group.",Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307542/),[h·mg] / [l],27.2-66,175850,DB00864,Tacrolimus
,23307542,area under the concentration-time curve from 0-6 hours,"The area under the concentration-time curve from 0-6 hours for sublingual and oral tacrolimus ranged from 27.2-66 and 32.4-76 mg·hour/L, respectively, in the tacrolimus plus clotrimazole group and from 9.3-63 and 4.9-23.2 mg·hour/L, respectively, in the tacrolimus plus nystatin group.",Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307542/),[h·mg] / [l],32.4-76,175851,DB00864,Tacrolimus
,23307542,area under the concentration-time curve from 0-6 hours,"The area under the concentration-time curve from 0-6 hours for sublingual and oral tacrolimus ranged from 27.2-66 and 32.4-76 mg·hour/L, respectively, in the tacrolimus plus clotrimazole group and from 9.3-63 and 4.9-23.2 mg·hour/L, respectively, in the tacrolimus plus nystatin group.",Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307542/),[h·mg] / [l],9.3-63,175852,DB00864,Tacrolimus
,23307542,area under the concentration-time curve from 0-6 hours,"The area under the concentration-time curve from 0-6 hours for sublingual and oral tacrolimus ranged from 27.2-66 and 32.4-76 mg·hour/L, respectively, in the tacrolimus plus clotrimazole group and from 9.3-63 and 4.9-23.2 mg·hour/L, respectively, in the tacrolimus plus nystatin group.",Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307542/),[h·mg] / [l],4.9-23.2,175853,DB00864,Tacrolimus
,23307542,maximum concentration,The average maximum concentration was higher during sublingual administration than during oral administration: 16.7 versus 12.9 ng/ml in the tacrolimus plus clotrimazole group and 9.5 versus 6 ng/ml in the tacrolimus plus nystatin group.,Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307542/),[ng] / [ml],16.7,175854,DB00864,Tacrolimus
,23307542,maximum concentration,The average maximum concentration was higher during sublingual administration than during oral administration: 16.7 versus 12.9 ng/ml in the tacrolimus plus clotrimazole group and 9.5 versus 6 ng/ml in the tacrolimus plus nystatin group.,Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307542/),[ng] / [ml],12.9,175855,DB00864,Tacrolimus
,23307542,maximum concentration,The average maximum concentration was higher during sublingual administration than during oral administration: 16.7 versus 12.9 ng/ml in the tacrolimus plus clotrimazole group and 9.5 versus 6 ng/ml in the tacrolimus plus nystatin group.,Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307542/),[ng] / [ml],9.5,175856,DB00864,Tacrolimus
,23307542,maximum concentration,The average maximum concentration was higher during sublingual administration than during oral administration: 16.7 versus 12.9 ng/ml in the tacrolimus plus clotrimazole group and 9.5 versus 6 ng/ml in the tacrolimus plus nystatin group.,Sublingual tacrolimus: a pharmacokinetic evaluation pilot study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23307542/),[ng] / [ml],6,175857,DB00864,Tacrolimus
,26990259,trough concentration,To examine whether a trough concentration of everolimus in the therapeutic range of 3-5 ng/mL affects the pharmacokinetics of tacrolimus in renal transplant patients.,Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26990259/),[ng] / [ml],3-5,175895,DB00864,Tacrolimus
,12637655,Dose-corrected AUC((0-12)),Dose-corrected AUC((0-12)) of TAC decreased significantly from 180 ng/ml/h at baseline to 75.9 ng/ml/h after 2 weeks of SJW treatment.,Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637655/),[ng] / [h·ml],180,175941,DB00864,Tacrolimus
,12637655,Dose-corrected AUC((0-12)),Dose-corrected AUC((0-12)) of TAC decreased significantly from 180 ng/ml/h at baseline to 75.9 ng/ml/h after 2 weeks of SJW treatment.,Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637655/),[ng] / [h·ml],75.9,175942,DB00864,Tacrolimus
,12496747,CL/F,"Average parameter estimates were as follows: CL/F = 31.8 L/h (hematocrit <0.33), CL/F = 24.2 L/h (hematocrit >0.33), and V/F = 2080 L.",Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496747/),[l] / [h],31.8,176060,DB00864,Tacrolimus
,12496747,CL/F,"Average parameter estimates were as follows: CL/F = 31.8 L/h (hematocrit <0.33), CL/F = 24.2 L/h (hematocrit >0.33), and V/F = 2080 L.",Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496747/),[l] / [h],24.2,176061,DB00864,Tacrolimus
,12496747,V/F,"Average parameter estimates were as follows: CL/F = 31.8 L/h (hematocrit <0.33), CL/F = 24.2 L/h (hematocrit >0.33), and V/F = 2080 L.",Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496747/),l,2080,176062,DB00864,Tacrolimus
,12496747,steady-state trough concentration,"On the basis of the derived model, a patient with normal AST (20 U/L) or high AST (200 U/L) concentrations 7 days after commencement of therapy would require a tacrolimus dose of 4.6 mg or 4.0 mg, respectively, to achieve a steady-state trough concentration of 10 ng/mL.",Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496747/),[ng] / [ml],10,176063,DB00864,Tacrolimus
,15848561,saturation concentration,"Serum basiliximab concentrations declined to 0.16 microg/mL on day 33, which is below the IL-2R saturation concentration (0.2 microg/mL).",Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848561/),[μg] / [ml],0.2,177134,DB00864,Tacrolimus
,15848561,elimination rate,Multiple sessions of plasmapheresis using DFPP enhanced the elimination of serum basiliximab at an average elimination rate of 19.1%.,Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848561/),%,19.1,177135,DB00864,Tacrolimus
,15848561,saturation level,"In the patient reported on here, the serum basiliximab concentration fell to below the IL-2R saturation level (0.2 microg/mL) within 1 month of living-related kidney transplantation.",Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848561/),[μg] / [ml],0.2,177136,DB00864,Tacrolimus
,27498124,area under the concentration-time curve from 0 to 12 hours,Mean (± SD) area under the concentration-time curve from 0 to 12 hours was 4805 ± 3265 hour * ng/mL on day 0 and 5917 ± 4048 hour * ng/mL on day +10.,A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27498124/),[h·ng] / [ml],4805,177950,DB00864,Tacrolimus
,27498124,area under the concentration-time curve from 0 to 12 hours,Mean (± SD) area under the concentration-time curve from 0 to 12 hours was 4805 ± 3265 hour * ng/mL on day 0 and 5917 ± 4048 hour * ng/mL on day +10.,A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27498124/),[h·ng] / [ml],5917,177951,DB00864,Tacrolimus
,25359003,T1/2,"Pharmacokinetic analysis revealed that Tregs have two phases of elimination: an α phase, with a T1/2 in the peripheral blood of 32.4 ± 11.3 h and a β phase with a T1/2 of 120.4 ± 19.7 h.",Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359003/),h,32.4,178109,DB00864,Tacrolimus
,25359003,T1/2,"Pharmacokinetic analysis revealed that Tregs have two phases of elimination: an α phase, with a T1/2 in the peripheral blood of 32.4 ± 11.3 h and a β phase with a T1/2 of 120.4 ± 19.7 h.",Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359003/),h,120.4,178110,DB00864,Tacrolimus
,25359003,α phase,"In contrast, rapamycin significantly stabilized both CD25 and FoxP3, and supported an increased half-life, with an α phase of 67.7 ± 6.9 h and a β phase of 252.1 ± 54.9 h.",Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359003/),h,67.7,178111,DB00864,Tacrolimus
,25359003,β phase,"In contrast, rapamycin significantly stabilized both CD25 and FoxP3, and supported an increased half-life, with an α phase of 67.7 ± 6.9 h and a β phase of 252.1 ± 54.9 h.",Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25359003/),h,252.1,178112,DB00864,Tacrolimus
,31841106,Cmax,"The arithmetic mean (SD) Cmax for the reference and test formulations was 40.62 (11.30) and 46.20 (10.73) ng/mL, and AUC0-72 was 348.34 (156.41) and 361.04 (158.71) ng×h/mL, respectively.","Bioequivalence of two tacrolimus 1-mg formulations under fasting conditions in healthy subjects: A randomized, two-period crossover trial . ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31841106/),[ng] / [ml],40.62,178242,DB00864,Tacrolimus
,31841106,Cmax,"The arithmetic mean (SD) Cmax for the reference and test formulations was 40.62 (11.30) and 46.20 (10.73) ng/mL, and AUC0-72 was 348.34 (156.41) and 361.04 (158.71) ng×h/mL, respectively.","Bioequivalence of two tacrolimus 1-mg formulations under fasting conditions in healthy subjects: A randomized, two-period crossover trial . ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31841106/),[ng] / [ml],46.20,178243,DB00864,Tacrolimus
,31841106,AUC0-72,"The arithmetic mean (SD) Cmax for the reference and test formulations was 40.62 (11.30) and 46.20 (10.73) ng/mL, and AUC0-72 was 348.34 (156.41) and 361.04 (158.71) ng×h/mL, respectively.","Bioequivalence of two tacrolimus 1-mg formulations under fasting conditions in healthy subjects: A randomized, two-period crossover trial . ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31841106/),[h·ng] / [ml],348.34,178244,DB00864,Tacrolimus
,31841106,AUC0-72,"The arithmetic mean (SD) Cmax for the reference and test formulations was 40.62 (11.30) and 46.20 (10.73) ng/mL, and AUC0-72 was 348.34 (156.41) and 361.04 (158.71) ng×h/mL, respectively.","Bioequivalence of two tacrolimus 1-mg formulations under fasting conditions in healthy subjects: A randomized, two-period crossover trial . ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31841106/),[h·ng] / [ml],361.04,178245,DB00864,Tacrolimus
,18406587,surface area,The surface area of URF processed TAC was higher (25-29 m2/g) than that of the unprocessed TAC (0.53 m2/g) and subsequently enhanced dissolution rates.,Nebulization of nanoparticulate amorphous or crystalline tacrolimus--single-dose pharmacokinetics study in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18406587/),[m2] / [g],25-29,178425,DB00864,Tacrolimus
,18406587,surface area,The surface area of URF processed TAC was higher (25-29 m2/g) than that of the unprocessed TAC (0.53 m2/g) and subsequently enhanced dissolution rates.,Nebulization of nanoparticulate amorphous or crystalline tacrolimus--single-dose pharmacokinetics study in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18406587/),[m2] / [g],0.53,178426,DB00864,Tacrolimus
,10751036,F,The mean F of tacrolimus (an apparently highly permeable compound) was increased from 0.22 in normal mice to 0.72 in knockout mice.,"Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10751036/),,0.22,178883,DB00864,Tacrolimus
,10751036,F,The mean F of tacrolimus (an apparently highly permeable compound) was increased from 0.22 in normal mice to 0.72 in knockout mice.,"Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10751036/),,0.72,178884,DB00864,Tacrolimus
,10751036,Eh,"These values were consistent with mean predicted Eh (based on intravenous data) of 0.77 and 0.27 in normal and knockout mice, respectively.","Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10751036/),,0.77,178885,DB00864,Tacrolimus
,10751036,Eh,"These values were consistent with mean predicted Eh (based on intravenous data) of 0.77 and 0.27 in normal and knockout mice, respectively.","Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10751036/),,0.27,178886,DB00864,Tacrolimus
,25141896,apparent volume of the central compartment,"Estimates of apparent volume of the central compartment, intestinal clearance, hepatic clearance and intercompartmental clearance were 79 l, 0.01 l/h, 10.9 l/h and 105 l/h, respectively.","Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25141896/),l,79,179258,DB00864,Tacrolimus
,25141896,hepatic clearance,"Estimates of apparent volume of the central compartment, intestinal clearance, hepatic clearance and intercompartmental clearance were 79 l, 0.01 l/h, 10.9 l/h and 105 l/h, respectively.","Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25141896/),[l] / [h],0.01,179259,DB00864,Tacrolimus
,25141896,hepatic clearance,"Estimates of apparent volume of the central compartment, intestinal clearance, hepatic clearance and intercompartmental clearance were 79 l, 0.01 l/h, 10.9 l/h and 105 l/h, respectively.","Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25141896/),[l] / [h],10.9,179260,DB00864,Tacrolimus
,25141896,intercompartmental clearance,"Estimates of apparent volume of the central compartment, intestinal clearance, hepatic clearance and intercompartmental clearance were 79 l, 0.01 l/h, 10.9 l/h and 105 l/h, respectively.","Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25141896/),[l] / [h],105,179261,DB00864,Tacrolimus
,19858252,apparent clearance,"A one-compartment model with first-order absorption and elimination as the basic structural model appropriately described the data, with the apparent clearance being 75.8 liters/h (95% confidence interval [CI], 65.2 to 86.4 liters/h) and the apparent volume being distribution of 835 liters (95% CI, 559 to 1,111 liters).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),[l] / [h],75.8,179515,DB00864,Tacrolimus
,19858252,apparent volume being distribution,"A one-compartment model with first-order absorption and elimination as the basic structural model appropriately described the data, with the apparent clearance being 75.8 liters/h (95% confidence interval [CI], 65.2 to 86.4 liters/h) and the apparent volume being distribution of 835 liters (95% CI, 559 to 1,111 liters).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),l,835,179516,DB00864,Tacrolimus
,19858252,volume of distribution,"Among the covariates tested, significant effects were found for age (decrease in the volume of distribution of 123 liters per year of age) and the presence of diarrhea (59% loss of bioavailability).",Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19858252/),l,123,179517,DB00864,Tacrolimus
,20055140,CL,"The population typical values of tacrolimus CL, V, F were 12.1 L x h(-1), 686 L, 42.2%; and the inter-individual variability of these parameters were 23.5%, 96.4%, 43.8%, respectively.",[Population pharmacokinetic study of tacrolimus in patients with hematopoietic stem cell transplant]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20055140/),[l] / [h],12.1,179875,DB00864,Tacrolimus
,20055140,V,"The population typical values of tacrolimus CL, V, F were 12.1 L x h(-1), 686 L, 42.2%; and the inter-individual variability of these parameters were 23.5%, 96.4%, 43.8%, respectively.",[Population pharmacokinetic study of tacrolimus in patients with hematopoietic stem cell transplant]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20055140/),l,686,179876,DB00864,Tacrolimus
,20055140,absorption rate constant,The absorption rate constant was fixed 4.3 h(-1).,[Population pharmacokinetic study of tacrolimus in patients with hematopoietic stem cell transplant]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20055140/),1/[h],4.3,179877,DB00864,Tacrolimus
,33588739,trough level,The mean tacrolimus trough level was 4.91 ng/mL standard deviation (SD) (SD ±1.7) before and 5.06 ng/mL (SD ±1.97) after conversion.,"STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33588739/),[ng] / [ml],4.91,180822,DB00864,Tacrolimus
,33588739,trough level,The mean tacrolimus trough level was 4.91 ng/mL standard deviation (SD) (SD ±1.7) before and 5.06 ng/mL (SD ±1.97) after conversion.,"STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33588739/),[ng] / [ml],5.06,180823,DB00864,Tacrolimus
,33588739,trough concentration-dose-ratio,"Mean tacrolimus trough concentration-dose-ratio (+/- SD) was 187.1 ng/mL/mg/kg/day (SD 99.2) for the reference and 205.1 ng/mL/mg/kg/day (SD 133) for the generic product, resulting in a non-significant difference of 18.0 ng/mL/mg/kg/day (SD 71.8) (p=0.84, Wilcoxon V=180).","STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33588739/),[ng] / [d·kg·mg·ml],187.1,180824,DB00864,Tacrolimus
,33588739,trough concentration-dose-ratio,"Mean tacrolimus trough concentration-dose-ratio (+/- SD) was 187.1 ng/mL/mg/kg/day (SD 99.2) for the reference and 205.1 ng/mL/mg/kg/day (SD 133) for the generic product, resulting in a non-significant difference of 18.0 ng/mL/mg/kg/day (SD 71.8) (p=0.84, Wilcoxon V=180).","STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients - an Observational Study in Germany. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33588739/),[ng] / [d·kg·mg·ml],205.1,180825,DB00864,Tacrolimus
> or =,20517177,target trough levels,"Data were from a prospective, multicenter, open-label, randomized, exploratory 6-month study of 92 renal transplant patients treated de novo with concentration-controlled Evl (target trough levels > or =3 ng/mL) plus low-dose Tac or Evl plus standard-dose Tac; both groups received basiliximab and corticosteroids.",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180909,DB00864,Tacrolimus
less,20517177,Evl,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180910,DB00864,Tacrolimus
less,20517177,trough levels,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180911,DB00864,Tacrolimus
less,20517177,trough levels,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3 to 8,180912,DB00864,Tacrolimus
more,20517177,trough levels,"Data were pooled across study arms to examine BPAR rates in patients with Evl trough levels less than 3 (n=26), 3 to 8 (n=62), or more than 8 ng/mL (n=4).",Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],8,180913,DB00864,Tacrolimus
more,20517177,Evl trough level,Evl trough level of more than or equal to 3 ng/mL was associated with significantly lower rates of BPAR as compared with a trough level of less than 3 ng/mL.,Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180914,DB00864,Tacrolimus
less,20517177,trough level,Evl trough level of more than or equal to 3 ng/mL was associated with significantly lower rates of BPAR as compared with a trough level of less than 3 ng/mL.,Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180915,DB00864,Tacrolimus
> or =,20517177,trough levels,Evl trough levels > or =3 ng/mL plus Tac are associated with low rates of BPAR without adversely affecting renal function.,Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20517177/),[ng] / [ml],3,180916,DB00864,Tacrolimus
,15369399,oral,"Pharmacokinetic evaluation in rat and rhesus monkey showed that 1 had both a low oral (2-4%) and a low pulmonary (7%, monkey) bioavailability.",A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15369399/),%,2-4,182238,DB00864,Tacrolimus
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],39.95,182275,DB00864,Tacrolimus
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],25.24,182276,DB00864,Tacrolimus
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],43.96,182277,DB00864,Tacrolimus
,29766530,apparent oral clearance (CL/F),"The typical values of apparent oral clearance (CL/F) and the apparent volume of distribution (V/F) in the final model were 2.05 L/h and 309 L, respectively.",Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29766530/),[l] / [h],2.05,183022,DB00864,Tacrolimus
,29766530,apparent volume of distribution (V/F),"The typical values of apparent oral clearance (CL/F) and the apparent volume of distribution (V/F) in the final model were 2.05 L/h and 309 L, respectively.",Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29766530/),l,309,183023,DB00864,Tacrolimus
,16995869,AUC(0-9 h),"The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L(-1) (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L(-1) (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05).",A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995869/),[mg] / [h·l],44.9,185175,DB00864,Tacrolimus
,16995869,AUC(0-9 h),"The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L(-1) (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L(-1) (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05).",A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995869/),[mg] / [h·l],30.5,185176,DB00864,Tacrolimus
,17211619,dose-adjusted AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.47,185275,DB00864,Tacrolimus
,17211619,dose-adjusted AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.33,185276,DB00864,Tacrolimus
,17211619,dose-adjusted AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.57,185277,DB00864,Tacrolimus
,17211619,AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.15,185278,DB00864,Tacrolimus
,17211619,AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.00,185279,DB00864,Tacrolimus
,17211619,AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.08,185280,DB00864,Tacrolimus
,17211619,daytime,"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.61,185281,DB00864,Tacrolimus
,17211619,daytime,"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.24,185282,DB00864,Tacrolimus
,17211619,daytime,"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.03,185283,DB00864,Tacrolimus
,17211619,daytime,"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.18,185284,DB00864,Tacrolimus
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.61,185285,DB00864,Tacrolimus
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.24,185286,DB00864,Tacrolimus
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.03,185287,DB00864,Tacrolimus
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.18,185288,DB00864,Tacrolimus
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],1.94,185289,DB00864,Tacrolimus
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],1.45,185290,DB00864,Tacrolimus
,9486490,terminal elimination half-life,"The mean terminal elimination half-life of tacrolimus was 18.2 h following i.v. administration; the total body clearance was 71 ml/h/kg, the volume of distribution was 1.67 1/kg.",Tacrolimus pharmacokinetics in BMT patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),h,18.2,185873,DB00864,Tacrolimus
,9486490,total body clearance,"The mean terminal elimination half-life of tacrolimus was 18.2 h following i.v. administration; the total body clearance was 71 ml/h/kg, the volume of distribution was 1.67 1/kg.",Tacrolimus pharmacokinetics in BMT patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),[ml] / [h·kg],71,185874,DB00864,Tacrolimus
,9486490,volume of distribution,"The mean terminal elimination half-life of tacrolimus was 18.2 h following i.v. administration; the total body clearance was 71 ml/h/kg, the volume of distribution was 1.67 1/kg.",Tacrolimus pharmacokinetics in BMT patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),[1] / [kg],1.67,185875,DB00864,Tacrolimus
,9486490,bioavailability,The p.o. bioavailability was 31-49%.,Tacrolimus pharmacokinetics in BMT patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9486490/),%,31-49,185876,DB00864,Tacrolimus
,29511796,AUC0 - tau,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[h·μg] / [ml],31.9,186291,DB00864,Tacrolimus
,29511796,AUC0 - tau,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[h·μg] / [ml],26.2,186292,DB00864,Tacrolimus
,29511796,AUC0 - tau,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[h·μg] / [ml],21.0,186293,DB00864,Tacrolimus
,29511796,Ctrough,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],0.25,186294,DB00864,Tacrolimus
,29511796,Ctrough,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],0.35,186295,DB00864,Tacrolimus
,29511796,Ctrough,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],0.37,186296,DB00864,Tacrolimus
,29511796,Cmax,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],10.8,186297,DB00864,Tacrolimus
,29511796,Cmax,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],9.2,186298,DB00864,Tacrolimus
,29511796,Cmax,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],5.5,186299,DB00864,Tacrolimus
,27191538,apparent clearance (CL/F),"The population estimate of tacrolimus apparent clearance (CL/F) and apparent volume of distribution (V/F) in the final population model was 21·5 L/h (95% CI; 18·38, 24·34) and 333 L (95% CI; 222·66, 484·35), respectively.",Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191538/),[l] / [h],21·5,187218,DB00864,Tacrolimus
,27191538,apparent volume of distribution (V/F),"The population estimate of tacrolimus apparent clearance (CL/F) and apparent volume of distribution (V/F) in the final population model was 21·5 L/h (95% CI; 18·38, 24·34) and 333 L (95% CI; 222·66, 484·35), respectively.",Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27191538/),l,333,187219,DB00864,Tacrolimus
,20202988,blood levels,"Median tacrolimus blood levels were 6.6, 3.0 and 7.9 ng/mL over a follow-up period of 8, 22 and 33 months, respectively.",Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20202988/),,3.0,187620,DB00864,Tacrolimus
,20202988,blood levels,"Median tacrolimus blood levels were 6.6, 3.0 and 7.9 ng/mL over a follow-up period of 8, 22 and 33 months, respectively.",Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20202988/),,7.9,187621,DB00864,Tacrolimus
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,4.3,188010,DB00864,Tacrolimus
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,3.6,188011,DB00864,Tacrolimus
,16404634,EC(50),"The EC(50) values of cyclosporin A, tacrolimus and sirolimus for inhibition of BCRP-mediated pheophorbide A efflux were 4.3 +/- 1.9 microM, 3.6 +/- 1.8 microM and 1.9 +/- 0.4 microM, respectively.","Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16404634/),μM,1.9,188012,DB00864,Tacrolimus
,15518745,dose-normalized C(0),The mean dose-normalized C(0) was 2.13 +/- 0.91 ng/mL/mg.,Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518745/),[ng] / [mg·ml],2.13,188527,DB00864,Tacrolimus
,19492954,maximum concentrations,"The maximum concentrations of aqueous humor after single dose and multiple dose administrations were 31.40 +/- 9.32 ng/mL and 37.73 +/- 11.25 ng/mL, respectively.",Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19492954/),[ng] / [ml],31.40,189717,DB00864,Tacrolimus
,19492954,maximum concentrations,"The maximum concentrations of aqueous humor after single dose and multiple dose administrations were 31.40 +/- 9.32 ng/mL and 37.73 +/- 11.25 ng/mL, respectively.",Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19492954/),[ng] / [ml],37.73,189718,DB00864,Tacrolimus
,25059890,concentration to reach 50% of kinact (KI ),"Telaprevir inhibited M-I formation in a time-dependent fashion with rate of enzyme inactivation (kinact ) and concentration to reach 50% of kinact (KI ) values of 0.113 min(-1) and 0.511 µm, respectively.",Effect of telaprevir on the metabolism and hepatic uptake of tacrolimus (FK506). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25059890/),µm,0.511,191091,DB00864,Tacrolimus
,32469966,L/D ratio,The median TAC dose was 0.1 mg/kg/day and L/D ratio was 100.01.,"Gut microbial diversity, inflammation, and oxidative stress are associated with tacrolimus dosing requirements early after heart transplantation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32469966/),,100.01,191185,DB00864,Tacrolimus
,11510015,trough levels,"A series of 56 liver transplant recipients were administered a combination of SRL and TAC (target trough levels, 7 and 5 ng/mL, respectively).",Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510015/),[ng] / [ml],7,191276,DB00864,Tacrolimus
,11510015,trough levels,"A series of 56 liver transplant recipients were administered a combination of SRL and TAC (target trough levels, 7 and 5 ng/mL, respectively).",Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510015/),[ng] / [ml],5,191277,DB00864,Tacrolimus
,11510015,rate of acute cellular rejection,The rate of acute cellular rejection was 14%.,Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510015/),%,14,191278,DB00864,Tacrolimus
,23792500,C0,Significantly higher levels of dose-normalized MPA C0 and AUC0-12h were associated with the events than with the absence of the events (C0: 1.04±0.42 vs. 0.84±0.85 µg/mL/g [p=0.047]; AUC0-12h: 20.37±3.21 vs. 14.97±1.13 µg × h/mL/g; [p=0.038]).,Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792500/),[μg] / [g·ml],1.04,191907,DB00864,Tacrolimus
,23792500,C0,Significantly higher levels of dose-normalized MPA C0 and AUC0-12h were associated with the events than with the absence of the events (C0: 1.04±0.42 vs. 0.84±0.85 µg/mL/g [p=0.047]; AUC0-12h: 20.37±3.21 vs. 14.97±1.13 µg × h/mL/g; [p=0.038]).,Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792500/),[μg] / [g·ml],0.84,191908,DB00864,Tacrolimus
,23792500,AUC0-12h,Significantly higher levels of dose-normalized MPA C0 and AUC0-12h were associated with the events than with the absence of the events (C0: 1.04±0.42 vs. 0.84±0.85 µg/mL/g [p=0.047]; AUC0-12h: 20.37±3.21 vs. 14.97±1.13 µg × h/mL/g; [p=0.038]).,Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792500/),[h·μg] / [g·ml],20.37,191909,DB00864,Tacrolimus
,23792500,AUC0-12h,Significantly higher levels of dose-normalized MPA C0 and AUC0-12h were associated with the events than with the absence of the events (C0: 1.04±0.42 vs. 0.84±0.85 µg/mL/g [p=0.047]; AUC0-12h: 20.37±3.21 vs. 14.97±1.13 µg × h/mL/g; [p=0.038]).,Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792500/),[h·μg] / [g·ml],14.97,191910,DB00864,Tacrolimus
,11271189,Blood concentrations,"Blood concentrations ranged from 0.5 to 391 ng/ml and from 0.5 to 616 ng/ml after intravenous and oral doses, respectively.",Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11271189/),[ng] / [ml],0.5 to 391,191983,DB00864,Tacrolimus
,11271189,Blood concentrations,"Blood concentrations ranged from 0.5 to 391 ng/ml and from 0.5 to 616 ng/ml after intravenous and oral doses, respectively.",Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11271189/),[ng] / [ml],0.5 to 616,191984,DB00864,Tacrolimus
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,6.1,192732,DB00864,Tacrolimus
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,7.1,192733,DB00864,Tacrolimus
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,26.5,192734,DB00864,Tacrolimus
,34287102,Elimination half-lives,Elimination half-lives of tramadol (6.1 h) and M1 (7.1 h) were normal while those of M2 (26.5 h) and M5 (16.7 h) prolonged.,Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),h,16.7,192735,DB00864,Tacrolimus
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,0.12,192736,DB00864,Tacrolimus
,34287102,metabolic ratio,"M1 metabolic ratio (0.12) was 2-fold reduced, M2 metabolic ratio (197) 1000-fold increased and M5 metabolic ratio (0.12) normal.",Marked and prolonged serotonin toxicity in a tramadol-poisoned patient with a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34287102/),,197,192737,DB00864,Tacrolimus
,21927013,bioadhesive strength,The bioadhesive strength was as high as 0.98±0.06 N/cm(2).,Novel gastroretentive sustained-release tablet of tacrolimus based on self-microemulsifying mixture: in vitro evaluation and in vivo bioavailability test. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21927013/),[n] / [cm(2],0.98,193825,DB00864,Tacrolimus
,21927013,relative bioavailability,"Compared with the commercially available capsules of tacrolimus, the relative bioavailability of the SME gastroretentive sustained-release tablets was 553.4%±353.8%.",Novel gastroretentive sustained-release tablet of tacrolimus based on self-microemulsifying mixture: in vitro evaluation and in vivo bioavailability test. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21927013/),%,553.4,193826,DB00864,Tacrolimus
greater,21695772,area under the plasma concentration-time curve from 0 to 12 hours (AUC(0-12) ),The aim of this study was to determine the MMF dosage required for pediatric liver transplant recipients to achieve an area under the plasma concentration-time curve from 0 to 12 hours (AUC(0-12) ) for mycophenolic acid (MPA) greater than 30 mg hour/L.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194863,DB00864,Tacrolimus
less,21695772,AUC(0-12),Thirteen of the 15 patients had an MPA AUC(0-12) value less than 30 mg hour/L.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194864,DB00864,Tacrolimus
greater,21695772,AUC(0-12),The MMF dosage required to reach an MPA AUC(0-12) value greater than the defined target of 30 mg hour/L ranged from 371 to 1014 mg/m(2) /day.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194865,DB00864,Tacrolimus
,21695772,AUC(0-12),The MMF dosage required to reach an MPA AUC(0-12) value greater than the defined target of 30 mg hour/L ranged from 371 to 1014 mg/m(2) /day.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[mg] / [·d·m(2)],371 to 1014,194866,DB00864,Tacrolimus
greater,21695772,AUC(0-12),"In conclusion, an initial MMF dose of 600 mg/m(2) twice a day led to MPA AUC(0-12) values greater than the 30 mg hour/L threshold except when rifampin was coadministered.",Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194867,DB00864,Tacrolimus
,27798513,trough level (Ctrough,"Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2-5 ng/mL).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],3-8,195366,DB00864,Tacrolimus
,27798513,Ctrough,"Patients received EVL (target trough level (Ctrough, 3-8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2-5 ng/mL).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],2-5,195367,DB00864,Tacrolimus
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],7.2,195368,DB00864,Tacrolimus
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.9,195369,DB00864,Tacrolimus
,27798513,TCL-Ctrough,"Mean TCL-Ctrough was 7.2 ± 3.8, 4.9 ± 2.2, 4.9 ± 2.2, and 4.5 ± 1.2 ng/mL at PK1, PK2, PK3, and PK4, respectively.",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.5,195370,DB00864,Tacrolimus
,27798513,Ctrough,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],4.7,195371,DB00864,Tacrolimus
,27798513,AUC0-12h,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [h·ml],106,195372,DB00864,Tacrolimus
,27798513,Caverage,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],8.8,195373,DB00864,Tacrolimus
,27798513,Cmax,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[ng] / [ml],19.2,195374,DB00864,Tacrolimus
,27798513,apparent Half-life,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),h,11.7,195375,DB00864,Tacrolimus
,27798513,total body clearance,"There were no differences among timepoints for mean EVL daily dose (data shown as PK3) (3.5 ± 1.3 mg/d), Ctrough (4.7 ± 2.5 ng/mL), AUC0-12h (106 ± 51 ng/h per mL), Caverage (8.8 ± 4.2 ng/mL), Cmax (19.2 ± 9.7 ng/mL), apparent Half-life (11.7 ± 4.2 hours), estimated total body clearance (0.39 ± 0.27 L/h), or fluctuation (166 ± 65%).",Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27798513/),[l] / [h],0.39,195376,DB00864,Tacrolimus
,15032307,zeta potential,"Following 1:10 aqueous dilution of optimal paclitaxel SMEDDS, the droplet size of resulting microemulsions was 2.0 +/- 0.4 nm, and the zeta potential was -45.5 +/- 0.5 mV.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),m,-,195658,DB00864,Tacrolimus
,15032307,zeta potential,"Following 1:10 aqueous dilution of optimal paclitaxel SMEDDS, the droplet size of resulting microemulsions was 2.0 +/- 0.4 nm, and the zeta potential was -45.5 +/- 0.5 mV.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),m,45.5,195659,DB00864,Tacrolimus
,15032307,oral bioavailability,"Compared to Taxol, the oral bioavailability of paclitaxel SMEDDS increased by 28.6% to 52.7% at various doses.",Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),,52,195660,DB00864,Tacrolimus
,15032307,time above therapeutic level,There was a significant improvement in area under the curve (AUC) and time above therapeutic level (0.1 microM) of paclitaxel SMEDDS as compared to those of Taxol following coadministration of both formulations with 40 mg cyclosporin A (CsA)/kg.,Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15032307/),,0,195661,DB00864,Tacrolimus
,7690047,plasma clearance,"The plasma clearance ranged from 0.47 to 5.8 L/minute, and the half-life ranged from 4.5 hours to 33.1 hours.",Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690047/),[l] / [min],0.47 to 5.8,196807,DB00864,Tacrolimus
,7690047,half-life,"The plasma clearance ranged from 0.47 to 5.8 L/minute, and the half-life ranged from 4.5 hours to 33.1 hours.",Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690047/),h,4.5,196808,DB00864,Tacrolimus
,7690047,half-life,"The plasma clearance ranged from 0.47 to 5.8 L/minute, and the half-life ranged from 4.5 hours to 33.1 hours.",Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7690047/),h,33.1,196809,DB00864,Tacrolimus
,22660440,clearance (CL/F),"The estimated population mean values of clearance (CL/F) and volume of distribution (V/F) were 22.9 L/h and 716 L, respectively, and the k(a) was fixed to 4.5 h⁻¹.",Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660440/),[l] / [h],22.9,197279,DB00864,Tacrolimus
,22660440,volume of distribution (V/F),"The estimated population mean values of clearance (CL/F) and volume of distribution (V/F) were 22.9 L/h and 716 L, respectively, and the k(a) was fixed to 4.5 h⁻¹.",Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660440/),l,716,197280,DB00864,Tacrolimus
,22660440,k(a),"The estimated population mean values of clearance (CL/F) and volume of distribution (V/F) were 22.9 L/h and 716 L, respectively, and the k(a) was fixed to 4.5 h⁻¹.",Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22660440/),h⁻¹,4.5,197281,DB00864,Tacrolimus
,21440742,C0,"In fact, one patient who showed a low C0 (5.9 ng/mL) while receiving high doses of AVF (0.28 mg/kg), the AUC of 356 and 211 ng.h/mL performed on days 12 and 18 respectively showed exposure consistent with efficacy.",Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21440742/),[ng] / [ml],5.9,197621,DB00864,Tacrolimus
,21440742,AUC,"In fact, one patient who showed a low C0 (5.9 ng/mL) while receiving high doses of AVF (0.28 mg/kg), the AUC of 356 and 211 ng.h/mL performed on days 12 and 18 respectively showed exposure consistent with efficacy.",Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21440742/),[h·ng] / [ml],356,197622,DB00864,Tacrolimus
,21440742,AUC,"In fact, one patient who showed a low C0 (5.9 ng/mL) while receiving high doses of AVF (0.28 mg/kg), the AUC of 356 and 211 ng.h/mL performed on days 12 and 18 respectively showed exposure consistent with efficacy.",Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21440742/),[h·ng] / [ml],211,197623,DB00864,Tacrolimus
,27506258,C0,(C0 = 133; 26 patients).,Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27506258/),,133,198362,DB00864,Tacrolimus
,27506258,clearance,"In patients in the building set group, estimated clearance was 3.6 ± 0.57 L/h and estimated volume of distribution was 9.9 ± 1.14 L.",Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27506258/),[l] / [h],3.6,198363,DB00864,Tacrolimus
,27506258,volume of distribution,"In patients in the building set group, estimated clearance was 3.6 ± 0.57 L/h and estimated volume of distribution was 9.9 ± 1.14 L.",Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27506258/),l,9.9,198364,DB00864,Tacrolimus
,12835546,maximum concentration,The maximum concentration observed was 0.91 ng/ml and the maximum area under the concentration-time curve from 0-12 h post dose was 7.6 ng.h/ml.,"Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12835546/),[ng] / [ml],0.91,198393,DB00864,Tacrolimus
,12835546,maximum area under the concentration-time curve from 0-12 h,The maximum concentration observed was 0.91 ng/ml and the maximum area under the concentration-time curve from 0-12 h post dose was 7.6 ng.h/ml.,"Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12835546/),[h·ng] / [ml],7.6,198394,DB00864,Tacrolimus
,15285851,area under the blood concentration-time curve (AUC0-8),"Coadministration of lansoprazole significantly decreased the oral tacrolimus clearance, resulting in an increase in the area under the blood concentration-time curve (AUC0-8) (control vs with lansoprazole: 29.7 +/- 3.5 vs 44.1 +/- 5.0 ng h mL(-1), P < 0.05).",Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285851/),[h·ng] / [ml],29.7,198748,DB00864,Tacrolimus
,15285851,area under the blood concentration-time curve (AUC0-8),"Coadministration of lansoprazole significantly decreased the oral tacrolimus clearance, resulting in an increase in the area under the blood concentration-time curve (AUC0-8) (control vs with lansoprazole: 29.7 +/- 3.5 vs 44.1 +/- 5.0 ng h mL(-1), P < 0.05).",Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15285851/),[h·ng] / [ml],44.1,198749,DB00864,Tacrolimus
,16456831,C(max),"Mean daclizumab C(max) was 50.3 microg/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 microg/mL on days 3, 8, and 30, respectively.",A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16456831/),[μg] / [ml],50.3,198837,DB00864,Tacrolimus
,16456831,trough levels,"Mean daclizumab C(max) was 50.3 microg/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 microg/mL on days 3, 8, and 30, respectively.",A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16456831/),[μg] / [ml],21.8,198838,DB00864,Tacrolimus
,16456831,trough levels,"Mean daclizumab C(max) was 50.3 microg/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 microg/mL on days 3, 8, and 30, respectively.",A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16456831/),[μg] / [ml],25.7,198839,DB00864,Tacrolimus
,16456831,trough levels,"Mean daclizumab C(max) was 50.3 microg/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 microg/mL on days 3, 8, and 30, respectively.",A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16456831/),[μg] / [ml],9.9,198840,DB00864,Tacrolimus
,25681723,Z,"The obtained TAC-BSA-NPs, with 189.50±7.15 nm of diameter and -20.86±0.45 mV of Zeta potential determined by DLS, were spherical in shape observed by TEM.",Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25681723/),m,20.86,200246,DB00864,Tacrolimus
,25681723,encapsulation efficiency,"The drug loading content and encapsulation efficiency were (1.7±0.13)% and (85±3.0)%, respectively.",Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25681723/),%,85,200247,DB00864,Tacrolimus
,20335831,Cmin,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),[ng] / [ml],11.1,200282,DB00864,Tacrolimus
,20335831,Cmin,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),[ng] / [ml],9.4,200283,DB00864,Tacrolimus
,20335831,area under the curves,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),,162,200284,DB00864,Tacrolimus
,20335831,area under the curves,"A higher TAC Cmin was observed with EVL dose of 0.75 mg BID (TAC 11.1+/-6.4 group A vs. 9.4+/-5.0 ng/mL group B, P=0.03), with equivalent TAC area under the curves (162+/-61 vs. 171+/-75).",Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20335831/),,171,200285,DB00864,Tacrolimus
,19709321,peak,"In the following days, an increase in tacrolimus concentration was observed with a peak of 37 ng/mL.",Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19709321/),[ng] / [ml],37,200411,DB00864,Tacrolimus
,19709321,half-life,Tacrolimus half-life was 6.5 days and tacrolimus maintenance dose was 0.5 mg every 4 days.,Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19709321/),d,6.5,200412,DB00864,Tacrolimus
,7513355,Clearances,Clearances of MP were 0.45 liters/hr/kg after given alone and 0.48 liter/hr/kg after tracrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.45,200562,DB00864,Tacrolimus
,7513355,Clearances,Clearances of MP were 0.45 liters/hr/kg after given alone and 0.48 liter/hr/kg after tracrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.48,200563,DB00864,Tacrolimus
,7513355,plasma,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],2.18,200564,DB00864,Tacrolimus
,7513355,plasma,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.21,200565,DB00864,Tacrolimus
,7513355,plasma,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],2.35,200566,DB00864,Tacrolimus
,7513355,whole blood clearances,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.21,200567,DB00864,Tacrolimus
,7513355,whole blood clearances,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],2.35,200568,DB00864,Tacrolimus
,7513355,whole blood clearances,The plasma and whole blood clearances of tacrolimus were 2.18 and 0.21 and 2.35 and 0.19 liters/hr/kg after separate and joint administration with the steroid.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[l] / [h·kg],0.19,200569,DB00864,Tacrolimus
,7513355,IC50,MP and tacrolimus decreased the number of circulating helper-T cells with IC50 values of 23 ng/ml for MP and 6.7 ng/ml for tacrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],23,200570,DB00864,Tacrolimus
,7513355,IC50,MP and tacrolimus decreased the number of circulating helper-T cells with IC50 values of 23 ng/ml for MP and 6.7 ng/ml for tacrolimus.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],6.7,200571,DB00864,Tacrolimus
,7513355,IC50,The IC50 of tacrolimus for in vitro inhibition of lymphocyte proliferation was 0.39 ng/ml (0.47 nM) and 1.02 ng/ml (2.73 nM) for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],0.39,200572,DB00864,Tacrolimus
,7513355,IC50,The IC50 of tacrolimus for in vitro inhibition of lymphocyte proliferation was 0.39 ng/ml (0.47 nM) and 1.02 ng/ml (2.73 nM) for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),[ng] / [ml],1.02,200573,DB00864,Tacrolimus
,7513355,maximum percentage of inhibition,The maximum percentage of inhibition was 94.6% for tacrolimus and 64.9% for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),%,94.6,200574,DB00864,Tacrolimus
,7513355,maximum percentage of inhibition,The maximum percentage of inhibition was 94.6% for tacrolimus and 64.9% for MP.,Pharmacokinetic and pharmacodynamic effects of coadministration of methylprednisolone and tacrolimus in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7513355/),%,64.9,200575,DB00864,Tacrolimus
,31862313,Apparent clearance,"Apparent clearance and volume of distribution in the final linear model were 7.13 L/h and 142 L, respectively.",Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862313/),[l] / [h],7.13,201097,DB00864,Tacrolimus
,31862313,volume of distribution,"Apparent clearance and volume of distribution in the final linear model were 7.13 L/h and 142 L, respectively.",Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862313/),l,142,201098,DB00864,Tacrolimus
,31862313,maximal dose rate (Vmax),The maximal dose rate (Vmax) of the nonlinear MM model was 1.92 mg/day and the average concentration at steady-state at half-Vmax (Km) was 1.98 ng/mL.,Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862313/),[mg] / [d],1.92,201099,DB00864,Tacrolimus
,31862313,concentration at steady-state at half-Vmax (Km),The maximal dose rate (Vmax) of the nonlinear MM model was 1.92 mg/day and the average concentration at steady-state at half-Vmax (Km) was 1.98 ng/mL.,Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862313/),[ng] / [ml],1.98,201100,DB00864,Tacrolimus
,27793753,solubilisation,The in vitro lipolysis studies revealed significantly high solubilisation (***p<0.001) of TL-NLCs in aqueous phase (69.3%) in contrast to TL suspension (1.6%) and the results were very well corroborated with in vivo AUC values of the corresponding formulations (R2>0.99).,Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27793753/),%,69.3,201156,DB00864,Tacrolimus
,27793753,solubilisation,The in vitro lipolysis studies revealed significantly high solubilisation (***p<0.001) of TL-NLCs in aqueous phase (69.3%) in contrast to TL suspension (1.6%) and the results were very well corroborated with in vivo AUC values of the corresponding formulations (R2>0.99).,Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27793753/),%,1.6,201157,DB00864,Tacrolimus
,28552913,apparent oral clearance (CL/F),"The estimated apparent oral clearance (CL/F) and apparent oral volume of distribution (V/F) were 3.6 L/h and 1700 L, respectively, in the MG patients.",Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552913/),[l] / [h],3.6,201834,DB00864,Tacrolimus
,28552913,apparent oral volume of distribution (V/F),"The estimated apparent oral clearance (CL/F) and apparent oral volume of distribution (V/F) were 3.6 L/h and 1700 L, respectively, in the MG patients.",Population pharmacokinetic analysis of tacrolimus in Chinese myasthenia gravis patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28552913/),l,1700,201835,DB00864,Tacrolimus
,23382105,clearance (CL),"The median MPA clearance (CL) and volume of the central compartment were 24.2 L/hour and 36.4 L, respectively, for a 70 kg patient receiving tacrolimus with a serum albumin of 3.4 g/dL.",Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23382105/),[l] / [h],24.2,202474,DB00864,Tacrolimus
,23382105,volume of the central compartment,"The median MPA clearance (CL) and volume of the central compartment were 24.2 L/hour and 36.4 L, respectively, for a 70 kg patient receiving tacrolimus with a serum albumin of 3.4 g/dL.",Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23382105/),l,36.4,202475,DB00864,Tacrolimus
,8900327,area under the curve (AUC),"The area under the curve (AUC) of tacrolimus after the morning dose was significantly larger than after the evening dose (211+/-43 ng x hr/ml [morning] vs. 179+/-45 ng x hr/ml [evening], P=0.02).",Circadian variation of tacrolimus disposition in liver allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900327/),[h·ng] / [ml],211,202935,DB00864,Tacrolimus
,8900327,area under the curve (AUC),"The area under the curve (AUC) of tacrolimus after the morning dose was significantly larger than after the evening dose (211+/-43 ng x hr/ml [morning] vs. 179+/-45 ng x hr/ml [evening], P=0.02).",Circadian variation of tacrolimus disposition in liver allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900327/),[h·ng] / [ml],179,202936,DB00864,Tacrolimus
,8900327,time to peak (Tmax),"The time to peak (Tmax) was significantly shorter after the morning dose than after the evening dose (1.6+/-0.7 hr [morning] vs. 2.9+/-0.6 hr [evening], P=0.002).",Circadian variation of tacrolimus disposition in liver allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900327/),h,1.6,202937,DB00864,Tacrolimus
,8900327,time to peak (Tmax),"The time to peak (Tmax) was significantly shorter after the morning dose than after the evening dose (1.6+/-0.7 hr [morning] vs. 2.9+/-0.6 hr [evening], P=0.002).",Circadian variation of tacrolimus disposition in liver allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900327/),h,2.9,202938,DB00864,Tacrolimus
,8900327,peak (Cmax),"The peak (Cmax) was significantly higher after the morning dose than after the evening dose (32.2+/-10.2 ng/ml [morning] vs. 19.1+/-4.3 ng/ml [evening], P=0.003).",Circadian variation of tacrolimus disposition in liver allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900327/),[ng] / [ml],32.2,202939,DB00864,Tacrolimus
,8900327,peak (Cmax),"The peak (Cmax) was significantly higher after the morning dose than after the evening dose (32.2+/-10.2 ng/ml [morning] vs. 19.1+/-4.3 ng/ml [evening], P=0.003).",Circadian variation of tacrolimus disposition in liver allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900327/),[ng] / [ml],19.1,202940,DB00864,Tacrolimus
,8900327,trough (Cmin),"However, the trough (Cmin) was not significantly different between the morning dose and the evening dose (13.1+/-3.9 ng/ml [morning] vs. 13.3+/-4.4 ng/ml [evening], P=0.4).",Circadian variation of tacrolimus disposition in liver allograft recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900327/),[ng] / [ml],13.1,202941,DB00864,Tacrolimus
,8900327,trough (Cmin),"However, the trough (Cmin) was not significantly different between the morning dose and the evening dose (13.1+/-3.9 ng/ml [morning] vs. 13.3+/-4.4 ng/ml [evening], P=0.4).",Circadian variation of tacrolimus disposition in liver allograft recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900327/),[ng] / [ml],13.3,202942,DB00864,Tacrolimus
,21366650,area under the plasma concentration-time curve (AUC(0-12)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],45·2,204110,DB00864,Tacrolimus
,21366650,area under the plasma concentration-time curve (AUC(0-12)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],71·0,204111,DB00864,Tacrolimus
,21366650,area under the plasma concentration-time curve (AUC(0-12)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],74·5,204112,DB00864,Tacrolimus
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[ng] / [mg·ml],9·3,204113,DB00864,Tacrolimus
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],74·5,204114,DB00864,Tacrolimus
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[h·ng] / [mg·ml],52·4,204115,DB00864,Tacrolimus
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[ng] / [mg·ml],10·9,204116,DB00864,Tacrolimus
,21366650,maximum plasma concentration (C(max)),"There were no significant differences in the dose-adjusted area under the plasma concentration-time curve (AUC(0-12)) and maximum plasma concentration (C(max)) of tacrolimus between CYP2C19 genotype groups, but there were significant differences between CYP3A5 genotypes groups (*1/*1 + *1/*3 vs. *3/*3 = 45·2 ± 20·0 vs. 71·0 ± 34·1 ng·h/mL/mg, P < 0·0001 and 6·3 ± 2·6 vs. 9·3 ± 7·0 ng/mL/mg, P = 0·0017, respectively) and between co-administration with and without lansoprazole (74·5 ± 34·0 vs. 52·4 ± 27·4 ng·h/mL/mg, P = 0·0054 and 10·9 ± 8·8 vs. 6·7 ± 3·0 ng/mL/mg, P = 0·0024, respectively).",Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366650/),[ng] / [mg·ml],6·7,204117,DB00864,Tacrolimus
,28658202,dose-normalized area under the curve0-12h,"The primary end point, the dose-normalized area under the curve0-12h at month 1 posttransplant, was similar with TacHexal or Prograf; back-transformed geometric means of adjusted log-transformed values (analysis of variance) were 18.99 ng·h·L (TacHexal) and 20.48 ng·h·L (Prograf) (ratio, 1.08; 90% confidence interval, 0.84-1.38; P = 0.605).","Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28658202/),h·l·ng,18.99,205130,DB00864,Tacrolimus
,28658202,dose-normalized area under the curve0-12h,"The primary end point, the dose-normalized area under the curve0-12h at month 1 posttransplant, was similar with TacHexal or Prograf; back-transformed geometric means of adjusted log-transformed values (analysis of variance) were 18.99 ng·h·L (TacHexal) and 20.48 ng·h·L (Prograf) (ratio, 1.08; 90% confidence interval, 0.84-1.38; P = 0.605).","Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28658202/),h·l·ng,20.48,205131,DB00864,Tacrolimus
,17568575,C/D ratios,"Recipients with the capacity for low IL-10 production (-1082AA) carrying CYP3A5 non-expressor (CYP3A5()3/()3) liver had the highest C/D ratios (mean: 172.4, 161.7, 160.3 for 1, 2 and 3 weeks posttransplantation, respectively), whereas recipients with intermediate or high production of IL-10 (-1082GA or GG) engrafted with CYP3A5 expressor (CYP3A5()1 carrier) liver were found to have the lowest ratios (96.4, 78.0 and 75.4, respectively, P < 0.01).","Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17568575/),,172.4,205175,DB00864,Tacrolimus
,17568575,C/D ratios,"Recipients with the capacity for low IL-10 production (-1082AA) carrying CYP3A5 non-expressor (CYP3A5()3/()3) liver had the highest C/D ratios (mean: 172.4, 161.7, 160.3 for 1, 2 and 3 weeks posttransplantation, respectively), whereas recipients with intermediate or high production of IL-10 (-1082GA or GG) engrafted with CYP3A5 expressor (CYP3A5()1 carrier) liver were found to have the lowest ratios (96.4, 78.0 and 75.4, respectively, P < 0.01).","Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17568575/),,161.7,205176,DB00864,Tacrolimus
,17568575,C/D ratios,"Recipients with the capacity for low IL-10 production (-1082AA) carrying CYP3A5 non-expressor (CYP3A5()3/()3) liver had the highest C/D ratios (mean: 172.4, 161.7, 160.3 for 1, 2 and 3 weeks posttransplantation, respectively), whereas recipients with intermediate or high production of IL-10 (-1082GA or GG) engrafted with CYP3A5 expressor (CYP3A5()1 carrier) liver were found to have the lowest ratios (96.4, 78.0 and 75.4, respectively, P < 0.01).","Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17568575/),,160.3,205177,DB00864,Tacrolimus
,17139160,flow-rate,A flow-rate of 0.5 ml/min was used at ambient temperature and sample detection was carried out at 254 nm.,Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[ml] / [min],0.5,205472,DB00864,Tacrolimus
,17139160,time to reach the maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],11.7,205473,DB00864,Tacrolimus
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],4.5,205474,DB00864,Tacrolimus
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,2.6,205475,DB00864,Tacrolimus
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,9.0,205476,DB00864,Tacrolimus
,17139160,time to reach maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],10.5,205477,DB00864,Tacrolimus
,17139160,time to reach maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,4.0,205478,DB00864,Tacrolimus
,24089074,trough concentration,"The aims of this study were to develop a population pharmacokinetic model of tacrolimus in adult kidney transplant recipients, to use this model to compare cytochrome P450 3A5 (CYP3A5) genotype-based initial dosing of tacrolimus with standard per-kilogram-based dosing, and to predict the best starting dose of tacrolimus based on patient genotype to achieve a trough concentration between 6 and 10 µg/L by day 5 posttransplantation.",Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24089074/),[μg] / [l],6 and 10,206846,DB00864,Tacrolimus
,24089074,CL/F,"Typical population estimates for tacrolimus CL/F in CYP3A5*1 allele carriers and noncarriers were 40.8 and 25.5 L/h, respectively.",Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24089074/),[l] / [h],40.8,206847,DB00864,Tacrolimus
,24089074,CL/F,"Typical population estimates for tacrolimus CL/F in CYP3A5*1 allele carriers and noncarriers were 40.8 and 25.5 L/h, respectively.",Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24089074/),[l] / [h],25.5,206848,DB00864,Tacrolimus
below,24089074,trough,"In patients carrying the CYP3A5*1 allele, a per-kilogram dose of 0.075 mg/kg twice daily seemed too much low with approximately 65% of simulated subjects predicted to achieve a trough below 6 µg/L at day 5 posttransplantation.",Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24089074/),[μg] / [l],6,206849,DB00864,Tacrolimus
,30552703,absorption rate,"The mean absorption rate was 3.6 h-1 , clearance was 23.0 l h-1 (39% interindividual variability, IIV), central volume of distribution was 692 l (49% IIV) and the peripheral volume of distribution 5340 l (53% IIV).",A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30552703/),1/[h],3.6,206921,DB00864,Tacrolimus
,30552703,clearance,"The mean absorption rate was 3.6 h-1 , clearance was 23.0 l h-1 (39% interindividual variability, IIV), central volume of distribution was 692 l (49% IIV) and the peripheral volume of distribution 5340 l (53% IIV).",A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30552703/),[l] / [h],23.0,206922,DB00864,Tacrolimus
,30552703,central volume of distribution,"The mean absorption rate was 3.6 h-1 , clearance was 23.0 l h-1 (39% interindividual variability, IIV), central volume of distribution was 692 l (49% IIV) and the peripheral volume of distribution 5340 l (53% IIV).",A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30552703/),l,692,206923,DB00864,Tacrolimus
,30552703,peripheral volume of distribution,"The mean absorption rate was 3.6 h-1 , clearance was 23.0 l h-1 (39% interindividual variability, IIV), central volume of distribution was 692 l (49% IIV) and the peripheral volume of distribution 5340 l (53% IIV).",A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30552703/),l,5340,206924,DB00864,Tacrolimus
,15561258,AUC(0-12h),"When AUC(0-12h) was controlled in the range from 150 to 300 ng x h/mL (10 to 20 ng/mL trough levels), 17 of 18 patients (94.4%) did not show evidence of significant rejection (72.2% grade 0, 16.7% 1A, and 5.5% grade 1B).",Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561258/),[h·ng] / [ml],150 to 300,206999,DB00864,Tacrolimus
,15561258,AUC(0-12h),"When AUC(0-12h) was controlled in the range from 150 to 300 ng x h/mL (10 to 20 ng/mL trough levels), 17 of 18 patients (94.4%) did not show evidence of significant rejection (72.2% grade 0, 16.7% 1A, and 5.5% grade 1B).",Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561258/),[ng] / [ml],10 to 20,207000,DB00864,Tacrolimus
,15561258,trough levels,"When AUC(0-12h) was controlled in the range from 150 to 300 ng x h/mL (10 to 20 ng/mL trough levels), 17 of 18 patients (94.4%) did not show evidence of significant rejection (72.2% grade 0, 16.7% 1A, and 5.5% grade 1B).",Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561258/),[ng] / [ml],10 to 20,207001,DB00864,Tacrolimus
,15561258,AUC(0-12h),"Mean AUC(0-12h) values of Tac were significantly lower among patients who experienced acute rejection than those who remained rejection-free (89 vs 217 ng x h/mL, P = .023).",Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561258/),[h·ng] / [ml],89,207002,DB00864,Tacrolimus
,15561258,AUC(0-12h),"Mean AUC(0-12h) values of Tac were significantly lower among patients who experienced acute rejection than those who remained rejection-free (89 vs 217 ng x h/mL, P = .023).",Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561258/),[h·ng] / [ml],217,207003,DB00864,Tacrolimus
,15561258,trough levels,"To reduce the risk of rejection and renal toxicity, the trough levels should be controlled in range from 10 to 20 ng/mL in early stage after HT.",Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15561258/),[ng] / [ml],10 to 20,207004,DB00864,Tacrolimus
≥,33952179,trough level,"Within the sublingual group, it took a mean of 3.2 days to achieve a therapeutic tacrolimus trough level (≥8 ng/mL) compared with a mean of 3.8 days in the oral group (P = .175).",Safety and Efficacy of Perioperative Sublingual Tacrolimus in Pancreas Transplant Compared With Oral Tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33952179/),[ng] / [ml],8,207868,DB00864,Tacrolimus
,33952179,trough level,"Within the sublingual group, it took a mean of 3.2 days to achieve a therapeutic tacrolimus trough level (≥8 ng/mL) compared with a mean of 3.8 days in the oral group (P = .175).",Safety and Efficacy of Perioperative Sublingual Tacrolimus in Pancreas Transplant Compared With Oral Tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33952179/),d,3.8,207869,DB00864,Tacrolimus
,22759200,C(0),Mean (SD) C(0) was 7.3(1.8) ng/mL for generic tacrolimus versus 7.0(2.1) ng/mL for reference tacrolimus based on data from days 14 and 28.,A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22759200/),[ng] / [ml],7.3,208019,DB00864,Tacrolimus
,22759200,C(0),Mean (SD) C(0) was 7.3(1.8) ng/mL for generic tacrolimus versus 7.0(2.1) ng/mL for reference tacrolimus based on data from days 14 and 28.,A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22759200/),[ng] / [ml],7.0,208020,DB00864,Tacrolimus
,12000467,bioavailability,"Despite the lower bioavailability of OST when compared with TC, the rejection incidence was similar with both formulations (60% vs. 55%, respectively).",Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000467/),%,60,208341,DB00864,Tacrolimus
,12000467,bioavailability,"Despite the lower bioavailability of OST when compared with TC, the rejection incidence was similar with both formulations (60% vs. 55%, respectively).",Efficacy and pharmacokinetics of tacrolimus oral suspension in pediatric liver transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12000467/),%,55,208342,DB00864,Tacrolimus
,11269567,maximum MPA plasma concentration,The mean (+/- SD) maximum MPA plasma concentration of 10.6 (+/- 7.5) mg/ml was achieved within 0.5 to 5 hours.,Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269567/),[mg] / [ml],10.6,208347,DB00864,Tacrolimus
,11269567,steady-state area under the plasma concentration versus time curve (AUC(0-12)),The mean (+/- SD) steady-state area under the plasma concentration versus time curve (AUC(0-12)) was 40 (+/- 30.9) mg/ml/h.,Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269567/),[mg] / [h·ml],40,208348,DB00864,Tacrolimus
,11269567,half-life,The mean (+/- SD) half-life was 5.8 (+/- 3.8) hours.,Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269567/),h,5.8,208349,DB00864,Tacrolimus
,11269567,ratio of the AUC,"The mean (+/- SD) ratio of the AUC of mycophenolic acid glucuronide (MPAG) to MPA was 64 (+/- 84), which correlated significantly with serum creatinine (r = 0.72) but not with serum bilirubin concentrations (r = 0.309), indicating accumulation of MPAG in patients with renal dysfunction.",Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269567/),,64,208350,DB00864,Tacrolimus
<,11269567,trough plasma concentrations,"In 7 primary liver transplant patients on the same dose of MMF, the trough plasma concentrations of MPA during the first week of therapy ranged from < 0.3 to 1.5 microg/ml.",Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269567/),[μg] / [ml],0,208351,DB00864,Tacrolimus
,31888346,TAC,"Population estimates of TAC, CL/F, apparent central distribution volume (V2/F), rate of absorption (Ka), and apparent peripheral distribution volume (V3/F) were 18.1 L/h (12%), 72.7 L (34%), 0.163 h-1 (17%), and 412 L (21%), respectively.",Impact of Donor and Recipient CYP3A5*3 Genotype on Tacrolimus Population Pharmacokinetics in Chinese Adult Liver Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31888346/),[l] / [h],18.1,208923,DB00864,Tacrolimus
,31888346,apparent peripheral distribution volume (V3/F),"Population estimates of TAC, CL/F, apparent central distribution volume (V2/F), rate of absorption (Ka), and apparent peripheral distribution volume (V3/F) were 18.1 L/h (12%), 72.7 L (34%), 0.163 h-1 (17%), and 412 L (21%), respectively.",Impact of Donor and Recipient CYP3A5*3 Genotype on Tacrolimus Population Pharmacokinetics in Chinese Adult Liver Transplant Recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31888346/),l,412,208924,DB00864,Tacrolimus
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],44.40,209031,DB00864,Tacrolimus
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],158.01,209032,DB00864,Tacrolimus
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],92.23,209033,DB00864,Tacrolimus
,18721002,maximum plasma concentrations (C(max)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[ng] / [ml],9.31,209092,DB00864,Tacrolimus
,18721002,maximum plasma concentrations (C(max)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[ng] / [ml],9.76,209093,DB00864,Tacrolimus
,18721002,area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[h·ng] / [ml],24.1,209094,DB00864,Tacrolimus
,18721002,area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)),"Mean (standard deviation) midazolam maximum plasma concentrations (C(max)) and area under the plasma concentration-time curve from time zero to infinity (AUC(infinity)) were 9.31 (3.09) ng/mL and 24.1 (7.7) ng . h/mL, respectively, when administered in combination with cinacalcet, compared with 9.76 (2.81) ng/mL and 22.8 (6.1) ng . h/mL when administered alone.","Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18721002/),[h·ng] / [ml],22.8,209095,DB00864,Tacrolimus
,15816825,"apparent half-life of tacrolimus (t(1/2, z))","The mean apparent half-life of tacrolimus (t(1/2, z)) was 66+/-27 h (range 19-125 h).",A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15816825/),h,66,209487,DB00864,Tacrolimus
>,33246587,AUC0-12,All patients >60 years had MPA AUC0-12 >30 μg·h/mL within 22 to 114 days after transplantation.,Pharmacokinetics of Enteric-Coated Mycophenolate Sodium Metabolites in Patients Over 60 Years Old Within the First Year After Renal Transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246587/),[h·μg] / [ml],30,210103,DB00864,Tacrolimus
up to,15237382,elimination half-lives,"Under ritonavir-boosted HAART, cyclosporine A levels showed markedly altered absorption/elimination characteristics with more or less constant blood-levels throughout the dosing interval and prolonged elimination half-lives up to 38 hours.",Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15237382/),h,38,210328,DB00864,Tacrolimus
,32949050,AUC0-12 s,"The MPA AUC0-12 s in the no event, infection, and CLAD groups were 30.3 ± 6.5, 36.8 ± 10.7, and 20.6 ± 9.6 µg·h/mL, respectively (P = .0027), while the tacrolimus trough levels were similarly controlled in the groups.",Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),[h·μg] / [ml],30.3,210468,DB00864,Tacrolimus
,32949050,AUC0-12 s,"The MPA AUC0-12 s in the no event, infection, and CLAD groups were 30.3 ± 6.5, 36.8 ± 10.7, and 20.6 ± 9.6 µg·h/mL, respectively (P = .0027), while the tacrolimus trough levels were similarly controlled in the groups.",Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),[h·μg] / [ml],36.8,210469,DB00864,Tacrolimus
,32949050,AUC0-12 s,"The MPA AUC0-12 s in the no event, infection, and CLAD groups were 30.3 ± 6.5, 36.8 ± 10.7, and 20.6 ± 9.6 µg·h/mL, respectively (P = .0027), while the tacrolimus trough levels were similarly controlled in the groups.",Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),[h·μg] / [ml],20.6,210470,DB00864,Tacrolimus
,32949050,AUC0-12,"The thresholds of MPA AUC0-12 for the occurrence of infection and CLAD were 40.5 and 22.8 µg·h/mL, respectively.",Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),[h·μg] / [ml],40.5,210471,DB00864,Tacrolimus
,32949050,AUC0-12,"The thresholds of MPA AUC0-12 for the occurrence of infection and CLAD were 40.5 and 22.8 µg·h/mL, respectively.",Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),[h·μg] / [ml],22.8,210472,DB00864,Tacrolimus
,32949050,cumulative occurrence rate of adverse events,The cumulative occurrence rate of adverse events of adequate group (15.3%) was significantly lower than that of inadequate group (56.0%) (P = .0050).,Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),%,15.3,210473,DB00864,Tacrolimus
,32949050,cumulative occurrence rate of adverse events,The cumulative occurrence rate of adverse events of adequate group (15.3%) was significantly lower than that of inadequate group (56.0%) (P = .0050).,Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),%,56.0,210474,DB00864,Tacrolimus
,11958289,total area under the blood concentration-time curve from time zero to time infinity,"After intravenous infusion of tacrolimus, the total area under the blood concentration-time curve from time zero to time infinity was significantly greater in rats with U-ARF than that in control rats (35.8 versus 29.2 microg min mL(-1)) due to significantly slower total body clearance of tacrolimus (27.9 versus 34.3 mL min(-1) kg(-1)), and this could be due to significantly slower nonrenal clearance (because of impaired hepatic function).",Pharmacokinetic changes of intravenous tacrolimus in rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11958289/),[min·μg] / [ml],35.8,210942,DB00864,Tacrolimus
,11958289,total area under the blood concentration-time curve from time zero to time infinity,"After intravenous infusion of tacrolimus, the total area under the blood concentration-time curve from time zero to time infinity was significantly greater in rats with U-ARF than that in control rats (35.8 versus 29.2 microg min mL(-1)) due to significantly slower total body clearance of tacrolimus (27.9 versus 34.3 mL min(-1) kg(-1)), and this could be due to significantly slower nonrenal clearance (because of impaired hepatic function).",Pharmacokinetic changes of intravenous tacrolimus in rats with uranyl nitrate-induced acute renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11958289/),[min·μg] / [ml],29.2,210943,DB00864,Tacrolimus
,11958289,total body clearance,"After intravenous infusion of tacrolimus, the total area under the blood concentration-time curve from time zero to time infinity was significantly greater in rats with U-ARF than that in control rats (35.8 versus 29.2 microg min mL(-1)) due to significantly slower total body clearance of tacrolimus (27.9 versus 34.3 mL min(-1) kg(-1)), and this could be due to significantly slower nonrenal clearance (because of impaired hepatic function).",Pharmacokinetic changes of intravenous tacrolimus in rats with uranyl nitrate-induced acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11958289/),[ml] / [kg·min],27.9,210944,DB00864,Tacrolimus
,11958289,total body clearance,"After intravenous infusion of tacrolimus, the total area under the blood concentration-time curve from time zero to time infinity was significantly greater in rats with U-ARF than that in control rats (35.8 versus 29.2 microg min mL(-1)) due to significantly slower total body clearance of tacrolimus (27.9 versus 34.3 mL min(-1) kg(-1)), and this could be due to significantly slower nonrenal clearance (because of impaired hepatic function).",Pharmacokinetic changes of intravenous tacrolimus in rats with uranyl nitrate-induced acute renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11958289/),[ml] / [kg·min],34.3,210945,DB00864,Tacrolimus
,12099982,AUC,"Compared with W patients, NW patients showed higher variability in blood tacrolimus concentrations during dosing interval (37.40 +/- 5.64 vs. 56.95 +/- 11.49, p < 0.001) and lower drug exposures (AUC: 229.4 +/- 55.5 vs. 66.9 +/- 67.1 ng x h/mL, p=0.036).",The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099982/),[h·ng] / [ml],229.4,211327,DB00864,Tacrolimus
,12099982,AUC,"Compared with W patients, NW patients showed higher variability in blood tacrolimus concentrations during dosing interval (37.40 +/- 5.64 vs. 56.95 +/- 11.49, p < 0.001) and lower drug exposures (AUC: 229.4 +/- 55.5 vs. 66.9 +/- 67.1 ng x h/mL, p=0.036).",The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099982/),[h·ng] / [ml],66.9,211328,DB00864,Tacrolimus
,12099982,absorption,"Tacrolimus absorption increased from week 1-4 (1.1 +/- 0.53 vs. 1.73 +/- 0.97 nug/mL/mg, p < 0.0001) but was still showed high between- (41.6-70.4%) and within-subject (18.2-32.5%) variability, regardless of ethnicity, after stabilization.",The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099982/),[nug] / [mg·ml],1.1,211329,DB00864,Tacrolimus
,12099982,absorption,"Tacrolimus absorption increased from week 1-4 (1.1 +/- 0.53 vs. 1.73 +/- 0.97 nug/mL/mg, p < 0.0001) but was still showed high between- (41.6-70.4%) and within-subject (18.2-32.5%) variability, regardless of ethnicity, after stabilization.",The impact of ethnic miscegenation on tacrolimus clinical pharmacokinetics and therapeutic drug monitoring. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12099982/),[nug] / [mg·ml],1.73,211330,DB00864,Tacrolimus
,21166111,C2,"CsA was targeted to C2 of 700 to 1400 ng/mL, and Tac ER was targeted to C0 of 5 to 10 ng/mL.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ng] / [ml],700 to 1400,212609,DB00864,Tacrolimus
,21166111,C0,"CsA was targeted to C2 of 700 to 1400 ng/mL, and Tac ER was targeted to C0 of 5 to 10 ng/mL.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ng] / [ml],5 to 10,212610,DB00864,Tacrolimus
,21166111,C(o) Tac,"The achieved mean C(o) Tac and CsA were 6.4 +/- 1.16 and 201 +/- 57 ng/mL, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ng] / [ml],6.4,212611,DB00864,Tacrolimus
,21166111,C(o) Tac,"The achieved mean C(o) Tac and CsA were 6.4 +/- 1.16 and 201 +/- 57 ng/mL, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ng] / [ml],201,212612,DB00864,Tacrolimus
,21166111,AUC (PD 0-6) h,"The ERPF and GFR AUC (PD 0-6) hr were 3645 +/- 887 vs. 3210 +/- 582 mL/1.73 m2 (P=0.027) and 604 +/- 98 vs. 543+/- 79 mL/1.73 m2(P=0.023) for Tac ER versus CsA, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ml] / [1.73·m2],3645,212613,DB00864,Tacrolimus
,21166111,AUC (PD 0-6) h,"The ERPF and GFR AUC (PD 0-6) hr were 3645 +/- 887 vs. 3210 +/- 582 mL/1.73 m2 (P=0.027) and 604 +/- 98 vs. 543+/- 79 mL/1.73 m2(P=0.023) for Tac ER versus CsA, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ml] / [1.73·m2],3210,212614,DB00864,Tacrolimus
,21166111,AUC (PD 0-6) h,"The ERPF and GFR AUC (PD 0-6) hr were 3645 +/- 887 vs. 3210 +/- 582 mL/1.73 m2 (P=0.027) and 604 +/- 98 vs. 543+/- 79 mL/1.73 m2(P=0.023) for Tac ER versus CsA, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ml] / [1.73·m2],604,212615,DB00864,Tacrolimus
,21166111,AUC (PD 0-6) h,"The ERPF and GFR AUC (PD 0-6) hr were 3645 +/- 887 vs. 3210 +/- 582 mL/1.73 m2 (P=0.027) and 604 +/- 98 vs. 543+/- 79 mL/1.73 m2(P=0.023) for Tac ER versus CsA, respectively.",A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21166111/),[ml] / [1.73·m2],543,212616,DB00864,Tacrolimus
,27669677,AUC0-12h,A PK curve of tacrolimus recorded ≤3 weeks after transplantation has been standard of care in our institution and aided in adjusting the dose in each patient to attain a target AUC0-12h of 210 μg h/l early after transplantation.,A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669677/),[h·μg] / [l],210,212651,DB00864,Tacrolimus
,27669677,dose-corrected,Median dose-corrected AUCtau was 63 μg h/l. AUC target attainment was 37.5%.,A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669677/),[h·μg] / [l],63,212652,DB00864,Tacrolimus
,27669677,AUCtau,Median dose-corrected AUCtau was 63 μg h/l. AUC target attainment was 37.5%.,A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669677/),[h·μg] / [l],63,212653,DB00864,Tacrolimus
,27669677,AUC target attainment,Median dose-corrected AUCtau was 63 μg h/l. AUC target attainment was 37.5%.,A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669677/),%,37.5,212654,DB00864,Tacrolimus
>,28704257,C0,The percentage of patients with supratherapeutic Tac exposure (C0>15 ng/ml) was significantly higher in PM (43.5%) compared with EM (0%) at days 5-7 after transplantation (P=0.01).,The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28704257/),[ng] / [ml],15,212896,DB00864,Tacrolimus
<,28704257,C0,About 30% of EM had subtherapeutic exposure (C0<5 ng/ml) at days 5-7 after transplantation (P=0.001).,The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28704257/),[ng] / [ml],5,212897,DB00864,Tacrolimus
,11422824,trough level,"Until the time of intestinal perforation, the trough level of tacrolimus ranged from 13.0 to 19.6 ng/mL.",Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422824/),[ng] / [ml],13.0 to 19.6,213111,DB00864,Tacrolimus
,11422824,dose-normalized trough concentration (DNTC),The dose-normalized trough concentration (DNTC) of tacrolimus ranged from 130 to 196 ng.kg.day per mg.mL (control: 80-145 ng.kg.day per mg.mL).,Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422824/),[d·kg·ng] / [mg·ml],130 to 196,213112,DB00864,Tacrolimus
,11422824,dose-normalized trough concentration (DNTC),The dose-normalized trough concentration (DNTC) of tacrolimus ranged from 130 to 196 ng.kg.day per mg.mL (control: 80-145 ng.kg.day per mg.mL).,Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422824/),[d·kg·ng] / [mg·ml],80-145,213113,DB00864,Tacrolimus
,11422824,trough level,"For a 2-week period when the patient was septic, the tacrolimus dose was reduced to 0.05 mg/kg/day, with a subsequent trough level of 3.6-5.1 ng/mL (DNTC: 72-102 ng.kg.day per mg.mL).",Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422824/),[ng] / [ml],3.6-5.1,213114,DB00864,Tacrolimus
,11422824,trough level,"After 3 weeks, the dose was increased to 0.175 mg/kg/day with the disappearance of infection; the trough level ranged from 8.5 to 9.7 ng/mL with a peak level of 26.3 ng/mL (DNTC: 48.5-55.4 ng.kg.day per mg.mL).",Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422824/),[ng] / [ml],8.5 to 9.7,213115,DB00864,Tacrolimus
,11422824,peak level,"After 3 weeks, the dose was increased to 0.175 mg/kg/day with the disappearance of infection; the trough level ranged from 8.5 to 9.7 ng/mL with a peak level of 26.3 ng/mL (DNTC: 48.5-55.4 ng.kg.day per mg.mL).",Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422824/),[ng] / [ml],26.3,213116,DB00864,Tacrolimus
,11422824,DNTC,"After 3 weeks, the dose was increased to 0.175 mg/kg/day with the disappearance of infection; the trough level ranged from 8.5 to 9.7 ng/mL with a peak level of 26.3 ng/mL (DNTC: 48.5-55.4 ng.kg.day per mg.mL).",Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422824/),[d·kg·ng] / [mg·ml],48.5-55.4,213117,DB00864,Tacrolimus
,11422824,trough level,"After the initiation of oral feeding, the dose was slightly increased to 0.20 mg/kg/day with the trough level ranging from 8.1 to 9.8 ng/mL (DNTC: 40.5-49 ng.kg.day per mg.mL).",Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422824/),[ng] / [ml],8.1 to 9.8,213118,DB00864,Tacrolimus
,11422824,trough level,"After closure of the jejunostomy, the dose of tacrolimus was reduced to 0.075 mg/kg/day to maintain the same trough level (7.9-9.1 ng/mL) and the DNTC ranged from 105 to 121 ng.kg.day per mg.",Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422824/),[ng] / [ml],7.9-9.1,213119,DB00864,Tacrolimus
,11422824,DNTC,"After closure of the jejunostomy, the dose of tacrolimus was reduced to 0.075 mg/kg/day to maintain the same trough level (7.9-9.1 ng/mL) and the DNTC ranged from 105 to 121 ng.kg.day per mg.",Oral administration of tacrolimus in the presence of jejunostomy after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11422824/),[d·kg·ng] / [mg],105 to 121,213120,DB00864,Tacrolimus
,19681813,AUC(0-24),"Mean AUC(0-24) of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than Tacrolimus BID (232 and 361 ng.h/mL, respectively), but was comparable by day 4.","Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19681813/),[h·ng] / [ml],232,213277,DB00864,Tacrolimus
,19681813,AUC(0-24),"Mean AUC(0-24) of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than Tacrolimus BID (232 and 361 ng.h/mL, respectively), but was comparable by day 4.","Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19681813/),[h·ng] / [ml],361,213278,DB00864,Tacrolimus
,15073038,CR rate,The CR rate for 54 patients with active disease was 85%.,"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),%,85,213392,DB00864,Tacrolimus
,15073038,clearance,"Median busulfan clearance was 109 mL/min/m2 and median daily area-under-the-plasma-concentration-versus-time-curve was 4871 micromol-min, with negligible interdose variability in pharmacokinetic parameters.","Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),[ml] / [m2·min],109,213393,DB00864,Tacrolimus
,15073038,area-under-the-plasma-concentration-versus-time-curve,"Median busulfan clearance was 109 mL/min/m2 and median daily area-under-the-plasma-concentration-versus-time-curve was 4871 micromol-min, with negligible interdose variability in pharmacokinetic parameters.","Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15073038/),μmol-min,4871,213394,DB00864,Tacrolimus
,12352931,trough levels,"Co-medication with CsA demanded higher MPA mofetil (MMF) doses to achieve equivalent trough levels than Tac (362 vs. 178 mg per mg/L, P= 0.004).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l·mg],362,215557,DB00864,Tacrolimus
,12352931,trough levels,"Co-medication with CsA demanded higher MPA mofetil (MMF) doses to achieve equivalent trough levels than Tac (362 vs. 178 mg per mg/L, P= 0.004).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l·mg],178,215558,DB00864,Tacrolimus
,12352931,C(0),"Median MPA C(0) (range) was significantly lower during CsA co-therapy when corrected for MMF dose (2.8 vs. 5.6 mg MPA/L for Tac, P= 0.006).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[Mpa·mg] / [l],2.8,215559,DB00864,Tacrolimus
,12352931,C(0),"Median MPA C(0) (range) was significantly lower during CsA co-therapy when corrected for MMF dose (2.8 vs. 5.6 mg MPA/L for Tac, P= 0.006).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[Mpa·mg] / [l],5.6,215560,DB00864,Tacrolimus
,12352931,AUC,"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [h·l],229,215561,DB00864,Tacrolimus
,12352931,AUC,"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [h·l],94,215562,DB00864,Tacrolimus
,12352931,ratio at C(0),"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),,0.10,215563,DB00864,Tacrolimus
,12352931,ratio at C(0),"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),,0.14,215564,DB00864,Tacrolimus
,12352931,trough levels,"Children with elevated aspartate transaminase (AST; but with no evidence of rejection on liver biopsy, n = 7) had significantly lower MPA trough levels compared with those in whom AST was normal (0. 77 vs. 1.76 mg/L, P = 0.05), but there was no difference in the MMF dose per body weight.",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l],0. 77,215565,DB00864,Tacrolimus
,12352931,trough levels,"Children with elevated aspartate transaminase (AST; but with no evidence of rejection on liver biopsy, n = 7) had significantly lower MPA trough levels compared with those in whom AST was normal (0. 77 vs. 1.76 mg/L, P = 0.05), but there was no difference in the MMF dose per body weight.",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l],1.76,215566,DB00864,Tacrolimus
,23628674,maximum plasma concentration (C(max)),"Compared with administration of tacrolimus alone [maximum plasma concentration (C(max)), 18.87 ± 10.29 ng/ml; area under the plasma concentration-time curve from time zero to last sampling time (AUC(0→t)), 40.98 ± 37.07 ng h/ml], a single intragastric administered dose of WZC increased the pharmacokinetic parameters of tacrolimus (C(max), 59.42 ± 30.32 ng/ml; AUC(0→t), 239.71 ± 28.86 ng h/ml) by 5-fold in rat plasma.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[ng] / [ml],18.87,216308,DB00864,Tacrolimus
,23628674,area under the plasma concentration-time curve from time zero to last sampling time (AUC(0→t)),"Compared with administration of tacrolimus alone [maximum plasma concentration (C(max)), 18.87 ± 10.29 ng/ml; area under the plasma concentration-time curve from time zero to last sampling time (AUC(0→t)), 40.98 ± 37.07 ng h/ml], a single intragastric administered dose of WZC increased the pharmacokinetic parameters of tacrolimus (C(max), 59.42 ± 30.32 ng/ml; AUC(0→t), 239.71 ± 28.86 ng h/ml) by 5-fold in rat plasma.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[h·ng] / [ml],40.98,216309,DB00864,Tacrolimus
,23628674,C(max),"Compared with administration of tacrolimus alone [maximum plasma concentration (C(max)), 18.87 ± 10.29 ng/ml; area under the plasma concentration-time curve from time zero to last sampling time (AUC(0→t)), 40.98 ± 37.07 ng h/ml], a single intragastric administered dose of WZC increased the pharmacokinetic parameters of tacrolimus (C(max), 59.42 ± 30.32 ng/ml; AUC(0→t), 239.71 ± 28.86 ng h/ml) by 5-fold in rat plasma.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[ng] / [ml],59.42,216310,DB00864,Tacrolimus
,23628674,AUC(0→t),"Compared with administration of tacrolimus alone [maximum plasma concentration (C(max)), 18.87 ± 10.29 ng/ml; area under the plasma concentration-time curve from time zero to last sampling time (AUC(0→t)), 40.98 ± 37.07 ng h/ml], a single intragastric administered dose of WZC increased the pharmacokinetic parameters of tacrolimus (C(max), 59.42 ± 30.32 ng/ml; AUC(0→t), 239.71 ± 28.86 ng h/ml) by 5-fold in rat plasma.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[h·ng] / [ml],239.71,216311,DB00864,Tacrolimus
,23628674,AUC(0→t),"After pretreatment with WZC for 12 days, there were still significant increases in AUC(0→t) (from 40.98 ± 37.07 to 89.21 ± 26.39 ng h/ml; P < 0.05) and C(max) (from 18.87 ± 10.29 to 43.16 ± 10.61 ng/ml; P < 0.05) of tacrolimus, compared with oral of tacrolimus alone, suggesting that WZC increased the exposure of tacrolimus by one or more mechanisms.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[h·ng] / [ml],40.98,216312,DB00864,Tacrolimus
,23628674,AUC(0→t),"After pretreatment with WZC for 12 days, there were still significant increases in AUC(0→t) (from 40.98 ± 37.07 to 89.21 ± 26.39 ng h/ml; P < 0.05) and C(max) (from 18.87 ± 10.29 to 43.16 ± 10.61 ng/ml; P < 0.05) of tacrolimus, compared with oral of tacrolimus alone, suggesting that WZC increased the exposure of tacrolimus by one or more mechanisms.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[h·ng] / [ml],89.21,216313,DB00864,Tacrolimus
,23628674,C(max),"After pretreatment with WZC for 12 days, there were still significant increases in AUC(0→t) (from 40.98 ± 37.07 to 89.21 ± 26.39 ng h/ml; P < 0.05) and C(max) (from 18.87 ± 10.29 to 43.16 ± 10.61 ng/ml; P < 0.05) of tacrolimus, compared with oral of tacrolimus alone, suggesting that WZC increased the exposure of tacrolimus by one or more mechanisms.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[ng] / [ml],18.87,216314,DB00864,Tacrolimus
,23628674,C(max),"After pretreatment with WZC for 12 days, there were still significant increases in AUC(0→t) (from 40.98 ± 37.07 to 89.21 ± 26.39 ng h/ml; P < 0.05) and C(max) (from 18.87 ± 10.29 to 43.16 ± 10.61 ng/ml; P < 0.05) of tacrolimus, compared with oral of tacrolimus alone, suggesting that WZC increased the exposure of tacrolimus by one or more mechanisms.",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[ng] / [ml],43.16,216315,DB00864,Tacrolimus
,23628674,AUC(0→t),"The effect of WZC on tacrolimus AUC(0→t) also increased with dose, with a maximal effect observed at 450 mg/kg (825.34 ng h/ml).",Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23628674/),[h·ng] / [ml],825.34,216316,DB00864,Tacrolimus
,23097010,AUC0-24,"The mean tacrolimus AUC0-24, AUC0-∞ and Cmax for the POR 28 CC (n = 14) homozygotes in CYP3A5 expressers (CYP3A5 1/ 1 or 1/ 3 genotype) were 71.5 ± 38.9 h ng/mL, 94.3 ± 58.3 h ng/mL and 17.6 ± 9.8 ng/mL, which were much higher than the POR 28 CT heterozygotes (n = 17) of 46.7 ± 24.9 h ng/mL, 57.4 ± 33.9 h ng/mL and 11.2 ± 6.4 ng/mL (P < 0.05, respectively).",Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097010/),[h·ng] / [ml],71.5,216807,DB00864,Tacrolimus
,23097010,AUC0-∞,"The mean tacrolimus AUC0-24, AUC0-∞ and Cmax for the POR 28 CC (n = 14) homozygotes in CYP3A5 expressers (CYP3A5 1/ 1 or 1/ 3 genotype) were 71.5 ± 38.9 h ng/mL, 94.3 ± 58.3 h ng/mL and 17.6 ± 9.8 ng/mL, which were much higher than the POR 28 CT heterozygotes (n = 17) of 46.7 ± 24.9 h ng/mL, 57.4 ± 33.9 h ng/mL and 11.2 ± 6.4 ng/mL (P < 0.05, respectively).",Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097010/),[h·ng] / [ml],94.3,216808,DB00864,Tacrolimus
,23097010,AUC0-∞,"The mean tacrolimus AUC0-24, AUC0-∞ and Cmax for the POR 28 CC (n = 14) homozygotes in CYP3A5 expressers (CYP3A5 1/ 1 or 1/ 3 genotype) were 71.5 ± 38.9 h ng/mL, 94.3 ± 58.3 h ng/mL and 17.6 ± 9.8 ng/mL, which were much higher than the POR 28 CT heterozygotes (n = 17) of 46.7 ± 24.9 h ng/mL, 57.4 ± 33.9 h ng/mL and 11.2 ± 6.4 ng/mL (P < 0.05, respectively).",Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097010/),[h·ng] / [ml],57.4,216809,DB00864,Tacrolimus
,23097010,Cmax,"The mean tacrolimus AUC0-24, AUC0-∞ and Cmax for the POR 28 CC (n = 14) homozygotes in CYP3A5 expressers (CYP3A5 1/ 1 or 1/ 3 genotype) were 71.5 ± 38.9 h ng/mL, 94.3 ± 58.3 h ng/mL and 17.6 ± 9.8 ng/mL, which were much higher than the POR 28 CT heterozygotes (n = 17) of 46.7 ± 24.9 h ng/mL, 57.4 ± 33.9 h ng/mL and 11.2 ± 6.4 ng/mL (P < 0.05, respectively).",Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097010/),[ng] / [ml],17.6,216810,DB00864,Tacrolimus
,23097010,Cmax,"The mean tacrolimus AUC0-24, AUC0-∞ and Cmax for the POR 28 CC (n = 14) homozygotes in CYP3A5 expressers (CYP3A5 1/ 1 or 1/ 3 genotype) were 71.5 ± 38.9 h ng/mL, 94.3 ± 58.3 h ng/mL and 17.6 ± 9.8 ng/mL, which were much higher than the POR 28 CT heterozygotes (n = 17) of 46.7 ± 24.9 h ng/mL, 57.4 ± 33.9 h ng/mL and 11.2 ± 6.4 ng/mL (P < 0.05, respectively).",Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097010/),[h·ng] / [ml],46.7,216811,DB00864,Tacrolimus
,23097010,Cmax,"The mean tacrolimus AUC0-24, AUC0-∞ and Cmax for the POR 28 CC (n = 14) homozygotes in CYP3A5 expressers (CYP3A5 1/ 1 or 1/ 3 genotype) were 71.5 ± 38.9 h ng/mL, 94.3 ± 58.3 h ng/mL and 17.6 ± 9.8 ng/mL, which were much higher than the POR 28 CT heterozygotes (n = 17) of 46.7 ± 24.9 h ng/mL, 57.4 ± 33.9 h ng/mL and 11.2 ± 6.4 ng/mL (P < 0.05, respectively).",Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097010/),[h·ng] / [ml],57.4,216812,DB00864,Tacrolimus
,23097010,Cmax,"The mean tacrolimus AUC0-24, AUC0-∞ and Cmax for the POR 28 CC (n = 14) homozygotes in CYP3A5 expressers (CYP3A5 1/ 1 or 1/ 3 genotype) were 71.5 ± 38.9 h ng/mL, 94.3 ± 58.3 h ng/mL and 17.6 ± 9.8 ng/mL, which were much higher than the POR 28 CT heterozygotes (n = 17) of 46.7 ± 24.9 h ng/mL, 57.4 ± 33.9 h ng/mL and 11.2 ± 6.4 ng/mL (P < 0.05, respectively).",Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23097010/),[ng] / [ml],11.2,216813,DB00864,Tacrolimus
,12548506,CL/F,"Mean individual Bayesian estimates for CL/F and V/F were 26.5 +/- 8.2 (SD) L/hr and 399 +/- 185 L, respectively.",Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548506/),[l] / [h],26.5,216983,DB00864,Tacrolimus
,12548506,V/F,"Mean individual Bayesian estimates for CL/F and V/F were 26.5 +/- 8.2 (SD) L/hr and 399 +/- 185 L, respectively.",Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548506/),l,399,216984,DB00864,Tacrolimus
,12548506,steady-state trough concentration,"Based on the derived model, a 70-kg patient with an aspartate aminotransferase (AST) level less than 70 U/L would require a tacrolimus dose of 4.7 mg twice daily to achieve a steady-state trough concentration of 10 ng/mL.",Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12548506/),[ng] / [ml],10,216985,DB00864,Tacrolimus
>,33432012,GRWR,"Patients with a GRWR > 4% had a higher risk of acute rejection, observed in 20/49 (41%) patients.",Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33432012/),%,4,217089,DB00864,Tacrolimus
,7525661,distribution half life,"Mean +/- SD distribution half life was 0.9 +/- 0.2 hours, elimination half life (t1/2 beta) 33 +/- 8 hours, total body clearance (CL) 2.4 +/- 1.1 L/hour, and bioavailability 14 +/- 12%.",Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525661/),h,0.9,217329,DB00864,Tacrolimus
,7525661,elimination half life (t1/2 beta),"Mean +/- SD distribution half life was 0.9 +/- 0.2 hours, elimination half life (t1/2 beta) 33 +/- 8 hours, total body clearance (CL) 2.4 +/- 1.1 L/hour, and bioavailability 14 +/- 12%.",Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525661/),h,33,217330,DB00864,Tacrolimus
,7525661,total body clearance (CL),"Mean +/- SD distribution half life was 0.9 +/- 0.2 hours, elimination half life (t1/2 beta) 33 +/- 8 hours, total body clearance (CL) 2.4 +/- 1.1 L/hour, and bioavailability 14 +/- 12%.",Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525661/),[l] / [h],2.4,217331,DB00864,Tacrolimus
,7525661,bioavailability,"Mean +/- SD distribution half life was 0.9 +/- 0.2 hours, elimination half life (t1/2 beta) 33 +/- 8 hours, total body clearance (CL) 2.4 +/- 1.1 L/hour, and bioavailability 14 +/- 12%.",Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7525661/),%,14,217332,DB00864,Tacrolimus
,15518754,trough levels,"Oral tacrolimus was initiated at about 0.2 mg/kg/d, dose which was adjusted to achieve target trough levels of 10 to 20 ng/mL at 3 months and 5 to 10 ng/mL thereafter.",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[ng] / [ml],10 to 20,217652,DB00864,Tacrolimus
,15518754,trough levels,"Oral tacrolimus was initiated at about 0.2 mg/kg/d, dose which was adjusted to achieve target trough levels of 10 to 20 ng/mL at 3 months and 5 to 10 ng/mL thereafter.",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[ng] / [ml],5 to 10,217653,DB00864,Tacrolimus
,15518754,AUC,"Mean MPA AUC values at 1, 3, and 6 months were 40.5 +/- 9.4, 44.4 +/- 17.3, and 57.2 +/- 20.7 mug*h/mL, respectively (P = .0486, n = 7).",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[h·μg] / [ml],40.5,217654,DB00864,Tacrolimus
,15518754,AUC,"Mean MPA AUC values at 1, 3, and 6 months were 40.5 +/- 9.4, 44.4 +/- 17.3, and 57.2 +/- 20.7 mug*h/mL, respectively (P = .0486, n = 7).",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[h·μg] / [ml],44.4,217655,DB00864,Tacrolimus
,15518754,AUC,"Mean MPA AUC values at 1, 3, and 6 months were 40.5 +/- 9.4, 44.4 +/- 17.3, and 57.2 +/- 20.7 mug*h/mL, respectively (P = .0486, n = 7).",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[h·μg] / [ml],57.2,217656,DB00864,Tacrolimus
,17906856,area under the cuve (AUC)(6-12),"The dose-adjusted area under the cuve (AUC)(6-12) of MPA, an estimate of enterohepatic recirculation, was greater in SLCO1B3 T334G GG (or G699A AA) carriers than in TT carriers (or G699A GG) (40 vs. 25 ng h/mL per milligram, respectively, P = 0.0497).","Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17906856/),[h·ng] / [milligram·ml],40,218043,DB00864,Tacrolimus
,17906856,area under the cuve (AUC)(6-12),"The dose-adjusted area under the cuve (AUC)(6-12) of MPA, an estimate of enterohepatic recirculation, was greater in SLCO1B3 T334G GG (or G699A AA) carriers than in TT carriers (or G699A GG) (40 vs. 25 ng h/mL per milligram, respectively, P = 0.0497).","Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17906856/),[h·ng] / [milligram·ml],25,218044,DB00864,Tacrolimus
,17906856,oral clearance,"However, the oral clearance of MPA in recipients having both the SLCO1B3 T334G GG genotype and the ABCC2 C-24T T allele was significantly lower than in patients having both the SLCO1B3 T334G TT and ABCC2 C-24T CC genotypes (0.15 vs. 0.18 L/h per kilogram, respectively, P = 0.0010).","Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17906856/),[l] / [h·kg],0.15,218045,DB00864,Tacrolimus
,17906856,oral clearance,"However, the oral clearance of MPA in recipients having both the SLCO1B3 T334G GG genotype and the ABCC2 C-24T T allele was significantly lower than in patients having both the SLCO1B3 T334G TT and ABCC2 C-24T CC genotypes (0.15 vs. 0.18 L/h per kilogram, respectively, P = 0.0010).","Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17906856/),[l] / [h·kg],0.18,218046,DB00864,Tacrolimus
,12110798,survival,FK778 at 4 mg/kg prolonged median survival of the control animals from 10 days to 30.5 days.,"A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110798/),d,10,218966,DB00864,Tacrolimus
,12110798,trough levels,"In combined treatments, trough levels of FK778 at 4 mg/kg ranged between 40 microg/mL and 100 microg/mL after 1 month.","A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110798/),[μg] / [ml],40,218967,DB00864,Tacrolimus
,12110798,trough levels,"In combined treatments, trough levels of FK778 at 4 mg/kg ranged between 40 microg/mL and 100 microg/mL after 1 month.","A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12110798/),[μg] / [ml],100,218968,DB00864,Tacrolimus
,27310200,half maximal inhibitory concentration,"Cyclosporine predominantly inhibited CYP3A4 (half maximal inhibitory concentration = 0.71 µM) rather than CYP3A5 (>5 µM), whereas tacrolimus showed similar inhibition for CYP3A4 (0.29 µM) and CYP3A5 (0.41 µM).",Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310200/),μM,0.71,219176,DB00864,Tacrolimus
>,27310200,half maximal inhibitory concentration,"Cyclosporine predominantly inhibited CYP3A4 (half maximal inhibitory concentration = 0.71 µM) rather than CYP3A5 (>5 µM), whereas tacrolimus showed similar inhibition for CYP3A4 (0.29 µM) and CYP3A5 (0.41 µM).",Risk Assessment of Drug-Drug Interactions of Calcineurin Inhibitors Affecting Sirolimus Pharmacokinetics in Renal Transplant Patients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27310200/),,5,219177,DB00864,Tacrolimus
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),%,38,219180,DB00864,Tacrolimus
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),,13,219181,DB00864,Tacrolimus
,26556199,apparent clearance (CL/F),"The typical population values of tacrolimus for the pharmacokinetic parameters of apparent clearance (CL/F), apparent distribution volume of the central compartment (V 2/F), intercompartmental clearance (Q/F), apparent distribution volume of the peripheral compartment (V 3/F), and absorption rate (k a ) were 11.2 L/h, 406 L, 57.3 L/h, 503 L, and 0.723 h(-1), respectively.",The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556199/),[l] / [h],11.2,219395,DB00864,Tacrolimus
,26556199,apparent distribution volume of the central compartment (V 2/F),"The typical population values of tacrolimus for the pharmacokinetic parameters of apparent clearance (CL/F), apparent distribution volume of the central compartment (V 2/F), intercompartmental clearance (Q/F), apparent distribution volume of the peripheral compartment (V 3/F), and absorption rate (k a ) were 11.2 L/h, 406 L, 57.3 L/h, 503 L, and 0.723 h(-1), respectively.",The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556199/),l,406,219396,DB00864,Tacrolimus
,26556199,intercompartmental clearance (Q/F),"The typical population values of tacrolimus for the pharmacokinetic parameters of apparent clearance (CL/F), apparent distribution volume of the central compartment (V 2/F), intercompartmental clearance (Q/F), apparent distribution volume of the peripheral compartment (V 3/F), and absorption rate (k a ) were 11.2 L/h, 406 L, 57.3 L/h, 503 L, and 0.723 h(-1), respectively.",The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556199/),l,406,219397,DB00864,Tacrolimus
,26556199,intercompartmental clearance (Q/F),"The typical population values of tacrolimus for the pharmacokinetic parameters of apparent clearance (CL/F), apparent distribution volume of the central compartment (V 2/F), intercompartmental clearance (Q/F), apparent distribution volume of the peripheral compartment (V 3/F), and absorption rate (k a ) were 11.2 L/h, 406 L, 57.3 L/h, 503 L, and 0.723 h(-1), respectively.",The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556199/),[l] / [h],57.3,219398,DB00864,Tacrolimus
,26556199,apparent distribution volume of the peripheral compartment (V 3/F),"The typical population values of tacrolimus for the pharmacokinetic parameters of apparent clearance (CL/F), apparent distribution volume of the central compartment (V 2/F), intercompartmental clearance (Q/F), apparent distribution volume of the peripheral compartment (V 3/F), and absorption rate (k a ) were 11.2 L/h, 406 L, 57.3 L/h, 503 L, and 0.723 h(-1), respectively.",The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556199/),l,406,219399,DB00864,Tacrolimus
,26556199,apparent distribution volume of the peripheral compartment (V 3/F),"The typical population values of tacrolimus for the pharmacokinetic parameters of apparent clearance (CL/F), apparent distribution volume of the central compartment (V 2/F), intercompartmental clearance (Q/F), apparent distribution volume of the peripheral compartment (V 3/F), and absorption rate (k a ) were 11.2 L/h, 406 L, 57.3 L/h, 503 L, and 0.723 h(-1), respectively.",The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556199/),[l] / [h],57.3,219400,DB00864,Tacrolimus
,26556199,apparent distribution volume of the peripheral compartment (V 3/F),"The typical population values of tacrolimus for the pharmacokinetic parameters of apparent clearance (CL/F), apparent distribution volume of the central compartment (V 2/F), intercompartmental clearance (Q/F), apparent distribution volume of the peripheral compartment (V 3/F), and absorption rate (k a ) were 11.2 L/h, 406 L, 57.3 L/h, 503 L, and 0.723 h(-1), respectively.",The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556199/),l,503,219401,DB00864,Tacrolimus
,26556199,absorption rate (k a ),"The typical population values of tacrolimus for the pharmacokinetic parameters of apparent clearance (CL/F), apparent distribution volume of the central compartment (V 2/F), intercompartmental clearance (Q/F), apparent distribution volume of the peripheral compartment (V 3/F), and absorption rate (k a ) were 11.2 L/h, 406 L, 57.3 L/h, 503 L, and 0.723 h(-1), respectively.",The Population Pharmacokinetic Models of Tacrolimus in Chinese Adult Liver Transplantation Patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26556199/),1/[h],0.723,219402,DB00864,Tacrolimus
,10684355,plasma concentration of MPA at steady state,The mean plasma concentration of MPA at steady state was 4.7+/-1.3 microg/ml.,Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[μg] / [ml],4.7,220840,DB00864,Tacrolimus
,10684355,areas under the plasma concentration-time curves (AUCs) over 12 h,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[h·μg] / [ml],57.0,220841,DB00864,Tacrolimus
,10684355,areas under the plasma concentration-time curves (AUCs) over 12 h,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[h·μg] / [ml],"1,515",220842,DB00864,Tacrolimus
,10684355,apparent oral clearance,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[l] / [h],11.7,220843,DB00864,Tacrolimus
,10684355,apparent oral clearance,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[l] / [h],0.5,220844,DB00864,Tacrolimus
,10684355,concentration at steady state,"Assuming that the pharmacokinetics of MPA was dose dependent, the mean concentration at steady state and the AUC for MPA were calculated for the recommended dosage schedule of 600 mg/m(2) every 12 h and were 6.3+/-2.7 microg/ml and 75.2+/-32.9 microg.h/ml, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[μg] / [ml],6.3,220845,DB00864,Tacrolimus
,10684355,AUC,"Assuming that the pharmacokinetics of MPA was dose dependent, the mean concentration at steady state and the AUC for MPA were calculated for the recommended dosage schedule of 600 mg/m(2) every 12 h and were 6.3+/-2.7 microg/ml and 75.2+/-32.9 microg.h/ml, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[h·μg] / [ml],75.2,220846,DB00864,Tacrolimus
,31880588,time to first acute rejection,"Although the incidence of clinically suggested acute allograft rejection was significantly higher (OR = 0.365 [95% CI: 0.14 - 0.93]; P < .05) and median time to first acute rejection was sooner among CYP3A5 expressers compared with non-expressers (12.17 vs. 26.83 days, P < .05); however, estimated glomerular filtration rate, incidence of biopsy proven acute rejection and delayed graft function and 6-month patients' and grafts' survival did not differ between the two groups.",Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880588/),d,12.17,221660,DB00864,Tacrolimus
,31880588,time to first acute rejection,"Although the incidence of clinically suggested acute allograft rejection was significantly higher (OR = 0.365 [95% CI: 0.14 - 0.93]; P < .05) and median time to first acute rejection was sooner among CYP3A5 expressers compared with non-expressers (12.17 vs. 26.83 days, P < .05); however, estimated glomerular filtration rate, incidence of biopsy proven acute rejection and delayed graft function and 6-month patients' and grafts' survival did not differ between the two groups.",Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31880588/),d,26.83,221661,DB00864,Tacrolimus
,31055791,apparent oral clearance,"The apparent oral clearance estimate in the final model (population mean, relative standard error) was 2.87 L/h, 42.3%, which is lower than that reported for similar patients on corticosteroid-based regimens (11.9-26.3 L/h).",Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31055791/),[l] / [h],2.87,221761,DB00864,Tacrolimus
,31055791,apparent oral clearance,"The apparent oral clearance estimate in the final model (population mean, relative standard error) was 2.87 L/h, 42.3%, which is lower than that reported for similar patients on corticosteroid-based regimens (11.9-26.3 L/h).",Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31055791/),[l] / [h],11.9-26.3,221762,DB00864,Tacrolimus
,31055791,apparent oral clearance,Both mycophenolic acid-acyl-glucuronide trough concentration and the area under the concentration-time curve ratio were significant covariates that reduced mycophenolic acid apparent oral clearance from 16.5 (base model) to 2.87 L/h.,Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31055791/),[l] / [h],16.5,221763,DB00864,Tacrolimus
,31055791,apparent oral clearance,Both mycophenolic acid-acyl-glucuronide trough concentration and the area under the concentration-time curve ratio were significant covariates that reduced mycophenolic acid apparent oral clearance from 16.5 (base model) to 2.87 L/h.,Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31055791/),[l] / [h],2.87,221764,DB00864,Tacrolimus
,32621968,apparent clearance,"In CYP3A5*3/*3 70-kg patients with 30% hematocrit and voriconazole-free therapy, the mean estimated apparent clearance was 13.1 l h-1 with 20.1% between-subject variability, which was lower than that in Caucasian lung transplant patients (17.5-36.5 l h-1).",Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32621968/),[l] / [h],13.1,223018,DB00864,Tacrolimus
,32621968,trough concentration,"To achieve target trough concentration (10-15 ng ml-1) on the 8th day post-transplant, a higher initial dosage than the current regimen of 0.04 mg kg-1 every 12 h is recommended for CYP3A5*1/*3 patients without voriconazole concomitant therapy.",Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32621968/),[ng] / [ml],10-15,223019,DB00864,Tacrolimus
,15083070,Cmax,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[ng] / [ml],0.30,223833,DB00864,Tacrolimus
,15083070,Cmax,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[ng] / [ml],0.31,223834,DB00864,Tacrolimus
,15083070,Cmax,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[ng] / [ml],0.31,223835,DB00864,Tacrolimus
,15083070,Apparent clearance,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[l] / [h],122,223836,DB00864,Tacrolimus
,15083070,Apparent clearance,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[l] / [h],156,223837,DB00864,Tacrolimus
,15083070,Apparent clearance,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),[l] / [h],111,223838,DB00864,Tacrolimus
,15083070,t1/2,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),h,1.9,223839,DB00864,Tacrolimus
,15083070,t1/2,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),h,1.6,223840,DB00864,Tacrolimus
,15083070,t1/2,"No statistically significant differences were found in the calculated pharmacokinetic parameters between the three 3435 C >T genotypes (TT, CT and CC group, respectively: Cmax (mean +/- SD: 0.30 +/- 0.08 ng/ml, 0.31 +/- 0.09 ng/ml and 0.31 +/- 0.11 ng/ml; Apparent clearance: 122 +/- 29 l/h, 156 +/- 92 l/h and 111 +/- 35 l/h; t1/2: 1.9 +/- 1.1 h, 1.6 +/- 0.90 h and 1.7 +/- 0.7 h).",CYP3A activity measured by the midazolam test is not related to 3435 C >T polymorphism in the multiple drug resistance transporter gene. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083070/),h,1.7,223841,DB00864,Tacrolimus
,33502111,trough concentrations,A dosing simulation strategy based on observed trough concentrations (rather than model-based predictions) resulted in 12% more patients successfully achieving tacrolimus trough concentrations within the institutional target range (5-10 ng/ml).,Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33502111/),[ng] / [ml],5-10,223921,DB00864,Tacrolimus
,30471066,"area under the concentration-time curve at steady state from 0 to 24 h after dose administration (AUCss, 0-24)","After conversion, without diltiazem, the area under the concentration-time curve at steady state from 0 to 24 h after dose administration (AUCss, 0-24) was significantly reduced [median 224 (range 172-366) vs. 184 (104-347) ng·h/mL, p = 0.006, n = 26].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],224,224023,DB00864,Tacrolimus
,30471066,"area under the concentration-time curve at steady state from 0 to 24 h after dose administration (AUCss, 0-24)","After conversion, without diltiazem, the area under the concentration-time curve at steady state from 0 to 24 h after dose administration (AUCss, 0-24) was significantly reduced [median 224 (range 172-366) vs. 184 (104-347) ng·h/mL, p = 0.006, n = 26].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],184,224024,DB00864,Tacrolimus
,30471066,exposure,"A decrease in tacrolimus exposure (median 21%) was only evident among CYP3A5 expressors [227 (172-366) vs. 180 (104-347) ng·h/mL, p = 0.014, n = 18], not among non-expressors [215 (197-290) vs. 217 (129-281) ng·h/mL, p = 0.263, n = 8].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],227,224025,DB00864,Tacrolimus
,30471066,exposure,"A decrease in tacrolimus exposure (median 21%) was only evident among CYP3A5 expressors [227 (172-366) vs. 180 (104-347) ng·h/mL, p = 0.014, n = 18], not among non-expressors [215 (197-290) vs. 217 (129-281) ng·h/mL, p = 0.263, n = 8].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],180,224026,DB00864,Tacrolimus
,30471066,exposure,"A decrease in tacrolimus exposure (median 21%) was only evident among CYP3A5 expressors [227 (172-366) vs. 180 (104-347) ng·h/mL, p = 0.014, n = 18], not among non-expressors [215 (197-290) vs. 217 (129-281) ng·h/mL, p = 0.263, n = 8].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],215,224027,DB00864,Tacrolimus
,30471066,exposure,"A decrease in tacrolimus exposure (median 21%) was only evident among CYP3A5 expressors [227 (172-366) vs. 180 (104-347) ng·h/mL, p = 0.014, n = 18], not among non-expressors [215 (197-290) vs. 217 (129-281) ng·h/mL, p = 0.263, n = 8].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],217,224028,DB00864,Tacrolimus
,30471066,"AUCss, 0-24","In contrast, among CYP3A5 expressors receiving diltiazem, AUCss, 0-24 did not change significantly upon conversion [229 (170-296) vs. 221 (123-342) ng·h/mL, p = 0.575, n = 10].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],229,224029,DB00864,Tacrolimus
,30471066,"AUCss, 0-24","In contrast, among CYP3A5 expressors receiving diltiazem, AUCss, 0-24 did not change significantly upon conversion [229 (170-296) vs. 221 (123-342) ng·h/mL, p = 0.575, n = 10].",Conversion from Twice-Daily Prograf® to Once-Daily Advagraf® in Multi-ethnic Asian Adult Renal Transplant Recipients With or Without Concomitant Use of Diltiazem: Impact of CYP3A5 and MDR1 Genetic Polymorphisms on Tacrolimus Exposure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30471066/),[h·ng] / [ml],221,224030,DB00864,Tacrolimus
,12942457,trough blood concentration,"Patient 1, who was maintained on a 5 mg twice daily dose of tacrolimus with a trough blood concentration around 10.6 ng/mL, required only 0.5 mg of tacrolimus per week after addition of Kaletra to achieve similar tacrolimus blood concentrations, with a half-life of 10.6 days.",Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942457/),[ng] / [ml],10.6,225002,DB00864,Tacrolimus
,12942457,half-life,"Patient 1, who was maintained on a 5 mg twice daily dose of tacrolimus with a trough blood concentration around 10.6 ng/mL, required only 0.5 mg of tacrolimus per week after addition of Kaletra to achieve similar tacrolimus blood concentrations, with a half-life of 10.6 days.",Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942457/),d,10.6,225003,DB00864,Tacrolimus
,12942457,area under the blood concentration versus time curve,"In patient 2, the area under the blood concentration versus time curve for tacrolimus increased from 31 ng/mL/h to 301 ng/mL/h after addition of Kaletra, with a corresponding half-life of 20 days.",Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942457/),[ng] / [h·ml],31,225004,DB00864,Tacrolimus
,12942457,area under the blood concentration versus time curve,"In patient 2, the area under the blood concentration versus time curve for tacrolimus increased from 31 ng/mL/h to 301 ng/mL/h after addition of Kaletra, with a corresponding half-life of 20 days.",Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942457/),[ng] / [h·ml],301,225005,DB00864,Tacrolimus
,12942457,half-life,"In patient 2, the area under the blood concentration versus time curve for tacrolimus increased from 31 ng/mL/h to 301 ng/mL/h after addition of Kaletra, with a corresponding half-life of 20 days.",Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942457/),d,20,225006,DB00864,Tacrolimus
,12942457,half-life,"When the patient was subsequently switched to nelfinavir, the half-life decreased to 10.3 days.",Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12942457/),d,10.3,225007,DB00864,Tacrolimus
,19487492,trough level,"In the Bayesian group, the dose of tacrolimus during the first 3 and 4 weeks after surgery was adjusted with the Bayesian method using a population pharmacokinetic model, targeting a trough level of 5 to 12 ng/mL.",Prospective evaluation of the bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19487492/),[ng] / [ml],5 to 12,225058,DB00864,Tacrolimus
,29735215,peak concentration (Cmax),"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),[mg] / [l],7.0,225227,DB00864,Tacrolimus
,29735215,peak concentration (Cmax),"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),[mg] / [l],10.8,225228,DB00864,Tacrolimus
,29735215,time to peak concentration,"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),h,3.2,225229,DB00864,Tacrolimus
,29735215,time to peak concentration,"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),h,2.2,225230,DB00864,Tacrolimus
<,22466911,AUC,Cardiac rejection was associated with low MPA AUC values with a threshold of <36.2 mg×h/L during the first two post-transplant weeks.,Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[h·mg] / [l],36.2,225359,DB00864,Tacrolimus
,22466911,trough level,A threshold of 2-weeks average MPA trough level of 1.43 mg/L provided a sensitivity 82% and a specificity of 60%.<br />,Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[mg] / [l],1.43,225360,DB00864,Tacrolimus
,22466911,trough,"For patients with Cyclosporine co-immunosuppression, we propose an MPA trough of 1.4 mg/L and an MPA AUC of 36 mg × h/L as threshold values for dose adjustments.",Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[mg] / [l],1.4,225361,DB00864,Tacrolimus
,22466911,AUC,"For patients with Cyclosporine co-immunosuppression, we propose an MPA trough of 1.4 mg/L and an MPA AUC of 36 mg × h/L as threshold values for dose adjustments.",Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[h·mg] / [l],36,225362,DB00864,Tacrolimus
,15023155,AUC(0-12),"In phase I, the mean area under the blood concentration-time curve (AUC) was higher after the morning dose, AUC(0-12) 117 +/- 40 vs. AUC(12-24) 97 +/- 30 ng/h/mL, p=0.012.",Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023155/),[ng] / [h·ml],117,225377,DB00864,Tacrolimus
,15023155,AUC(12-24),"In phase I, the mean area under the blood concentration-time curve (AUC) was higher after the morning dose, AUC(0-12) 117 +/- 40 vs. AUC(12-24) 97 +/- 30 ng/h/mL, p=0.012.",Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023155/),[ng] / [h·ml],97,225378,DB00864,Tacrolimus
,15023155,AUC ratio,"In the 85% Group, the mean AUC ratio between twice and once daily was 1.0 (95% CI, 0.9-1.1) which predicted the best conversion ratio.",Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15023155/),,1.0,225379,DB00864,Tacrolimus
,9448208,area under the curve,Mean area under the curve (0.9 to 42.5 ng x hr/ml) was highly variable and appeared to be related to size of application area.,Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448208/),[h·ng] / [ml],0.9 to 42.5,225647,DB00864,Tacrolimus
less,9448208,absolute bioavailability,Comparison to historical intravenous data indicates that absolute bioavailability of topical tacrolimus was less than 0.5%.,Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448208/),%,0.5,225648,DB00864,Tacrolimus
,20926996,steady-state area under the concentration-time curve,"Based on individual estimates oral clearance from the population pharmacokinetic model, mean steady-state area under the concentration-time curve values for a mycophenolate mofetil dose of 1000 mg twice daily were 63 mg·hr/L (22%) and 59 mg·hr/L (36%) for the tasocitinib and tacrolimus groups, respectively.","Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926996/),[h·mg] / [l],63,225694,DB00864,Tacrolimus
,20926996,steady-state area under the concentration-time curve,"Based on individual estimates oral clearance from the population pharmacokinetic model, mean steady-state area under the concentration-time curve values for a mycophenolate mofetil dose of 1000 mg twice daily were 63 mg·hr/L (22%) and 59 mg·hr/L (36%) for the tasocitinib and tacrolimus groups, respectively.","Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926996/),[h·mg] / [l],59,225695,DB00864,Tacrolimus
,30854922,time to therapeutic tacrolimus concentration,"The median time to therapeutic tacrolimus concentration was significantly longer in patients who did not receive an empiric dose reduction (0% DR, 10d; 1-30% DR, 4d; 31-65% DR, 5d; >65% DR, 4d; p = 0.0395).",The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30854922/),%,0,227865,DB00864,Tacrolimus
,30854922,time to therapeutic tacrolimus concentration,"The median time to therapeutic tacrolimus concentration was significantly longer in patients who did not receive an empiric dose reduction (0% DR, 10d; 1-30% DR, 4d; 31-65% DR, 5d; >65% DR, 4d; p = 0.0395).",The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30854922/),%,1-30,227866,DB00864,Tacrolimus
,30854922,time to therapeutic tacrolimus concentration,"The median time to therapeutic tacrolimus concentration was significantly longer in patients who did not receive an empiric dose reduction (0% DR, 10d; 1-30% DR, 4d; 31-65% DR, 5d; >65% DR, 4d; p = 0.0395).",The impact of initiating posaconazole on tacrolimus pharmacokinetics in allogeneic stem cell transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30854922/),%,31-65,227867,DB00864,Tacrolimus
,30845890,trough level,A therapeutic tacrolimus concentration was defined as a trough level between 8 and 15 ng/mL for 2 consecutive days.,Prior Amiodarone Exposure Reduces Tacrolimus Dosing Requirements in Heart Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30845890/),[ng] / [ml],8 and 15,228865,DB00864,Tacrolimus
,22239105,steady-state trough levels,Mean tacrolimus whole blood trough levels were at the lower end of the recommended range during tacrolimus BID and QD; the difference between mean steady-state trough levels was statistically significant (7.5ng/ml vs. 6.5ng/ml; P<0.0001).,"Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239105/),[ng] / [ml],7.5,229411,DB00864,Tacrolimus
,22239105,steady-state trough levels,Mean tacrolimus whole blood trough levels were at the lower end of the recommended range during tacrolimus BID and QD; the difference between mean steady-state trough levels was statistically significant (7.5ng/ml vs. 6.5ng/ml; P<0.0001).,"Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239105/),[ng] / [ml],6.5,229412,DB00864,Tacrolimus
,22239105,trough levels,"Following conversion, mean tacrolimus trough levels were reduced by 15% (about 1ng/ml) without any cases of acute rejection, remained stable during the remainder of the study, and were more consistent, showing reduced between- and within-patient variability in trough levels.","Renal function, efficacy and safety postconversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22239105/),[ng] / [ml],1,229413,DB00864,Tacrolimus
,23266742,trough level before the dose (C0),"The mean ± SD sirolimus trough level before the dose (C0) was 8.0 ± 4.6 ng/mL (range, 1.8-21.6 ng/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],8.0,230288,DB00864,Tacrolimus
,23266742,peak concentration,"The peak concentration was 19.9 ± 11.8 ng/mL (range, 3.9-46.1 ng/mL), and the trough level 24 hours later (C24) was 9.1 ± 5.3 ng/mL (range, 1.0-19.1 ng/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],19.9,230289,DB00864,Tacrolimus
,23266742,trough level,"The peak concentration was 19.9 ± 11.8 ng/mL (range, 3.9-46.1 ng/mL), and the trough level 24 hours later (C24) was 9.1 ± 5.3 ng/mL (range, 1.0-19.1 ng/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],9.1,230290,DB00864,Tacrolimus
,23266742,C24),"The peak concentration was 19.9 ± 11.8 ng/mL (range, 3.9-46.1 ng/mL), and the trough level 24 hours later (C24) was 9.1 ± 5.3 ng/mL (range, 1.0-19.1 ng/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],9.1,230291,DB00864,Tacrolimus
,23266742,terminal disposition half-life (T1/2),"The terminal disposition half-life (T1/2) was 24.5 ± 11.2 hours (range, 5.8-53.2 hours), and the area under the concentration-versus-time curve (AUC0-24) was 401.1 ± 316.3 ng·h/mL (range, 20.7-1332.3 ng·h/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),h,24.5,230292,DB00864,Tacrolimus
,23266742,area under the concentration-versus-time curve (AUC0-24),"The terminal disposition half-life (T1/2) was 24.5 ± 11.2 hours (range, 5.8-53.2 hours), and the area under the concentration-versus-time curve (AUC0-24) was 401.1 ± 316.3 ng·h/mL (range, 20.7-1332.3 ng·h/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[h·ng] / [ml],401.1,230293,DB00864,Tacrolimus
,23266742,C24,C24 was significantly lower in patients (n = 10) who developed grade III-IV aGVHD (n = 10) than in those with grade 0-II aGVHD (n = 22) (6.1 ± 2.9 ng/mL versus 9.4 ± 5.5 ng/mL; P = .044).,Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],6.1,230294,DB00864,Tacrolimus
,23266742,C24,C24 was significantly lower in patients (n = 10) who developed grade III-IV aGVHD (n = 10) than in those with grade 0-II aGVHD (n = 22) (6.1 ± 2.9 ng/mL versus 9.4 ± 5.5 ng/mL; P = .044).,Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],9.4,230295,DB00864,Tacrolimus
,23266742,C0,"Dose-normalized sirolimus trough concentrations were significantly higher in patients receiving concomitant fluconazole therapy compared with those not receiving fluconazole (C0: 3.9 ± 2.5 versus 2.4 ± 1.5 ng/mL/mg, P = .030; C24: 4.8 ± 3.3 versus 2.5 ± 1.7 ng/mL/mg, P = .018).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [mg·ml],3.9,230296,DB00864,Tacrolimus
,23266742,C0,"Dose-normalized sirolimus trough concentrations were significantly higher in patients receiving concomitant fluconazole therapy compared with those not receiving fluconazole (C0: 3.9 ± 2.5 versus 2.4 ± 1.5 ng/mL/mg, P = .030; C24: 4.8 ± 3.3 versus 2.5 ± 1.7 ng/mL/mg, P = .018).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [mg·ml],2.4,230297,DB00864,Tacrolimus
,23266742,C24,"Dose-normalized sirolimus trough concentrations were significantly higher in patients receiving concomitant fluconazole therapy compared with those not receiving fluconazole (C0: 3.9 ± 2.5 versus 2.4 ± 1.5 ng/mL/mg, P = .030; C24: 4.8 ± 3.3 versus 2.5 ± 1.7 ng/mL/mg, P = .018).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [mg·ml],4.8,230298,DB00864,Tacrolimus
,23266742,C24,"Dose-normalized sirolimus trough concentrations were significantly higher in patients receiving concomitant fluconazole therapy compared with those not receiving fluconazole (C0: 3.9 ± 2.5 versus 2.4 ± 1.5 ng/mL/mg, P = .030; C24: 4.8 ± 3.3 versus 2.5 ± 1.7 ng/mL/mg, P = .018).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [mg·ml],2.5,230299,DB00864,Tacrolimus
,23266742,trough levels,"With therapeutic drug monitoring, the majority (79%) of sirolimus trough levels could be maintained within the target range (3-12 ng/mL).",Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23266742/),[ng] / [ml],3-12,230300,DB00864,Tacrolimus
,31062373,AUC0-12h,Mycophenolic acid AUC0-12h was 1.70-fold greater with tacrolimus (68.9 ± 30.9 mg·h/L) relative to cyclosporine (40.8 ± 17.6 mg·h/L); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[h·mg] / [l],68.9,230537,DB00864,Tacrolimus
,31062373,AUC0-12h,Mycophenolic acid AUC0-12h was 1.70-fold greater with tacrolimus (68.9 ± 30.9 mg·h/L) relative to cyclosporine (40.8 ± 17.6 mg·h/L); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[h·mg] / [l],40.8,230538,DB00864,Tacrolimus
,31062373,AUC0-12h,Target mycophenolic acid AUC0-12h of 30-60 mg·h/L was achieved in 56.3% on cyclosporine compared with 34.3% receiving tacrolimus (P < .001).,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[h·mg] / [l],30-60,230539,DB00864,Tacrolimus
,31062373,clearance,Mycophenolic acid clearance was 48% slower with tacrolimus (10.6 ± 4.7 L/h) relative to cyclosporine (20.5 ± 10.0 L/h); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[l] / [h],10.6,230540,DB00864,Tacrolimus
,31062373,clearance,Mycophenolic acid clearance was 48% slower with tacrolimus (10.6 ± 4.7 L/h) relative to cyclosporine (20.5 ± 10.0 L/h); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[l] / [h],20.5,230541,DB00864,Tacrolimus
,17645712,C(2),At conversion the mean C(2) was 969 ng/mL (95% CI: 684-1255; target 1700 ng/mL).,Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17645712/),[ng] / [ml],969,231081,DB00864,Tacrolimus
,17645712,C(2),At conversion the mean C(2) was 969 ng/mL (95% CI: 684-1255; target 1700 ng/mL).,Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17645712/),[ng] / [ml],1700,231082,DB00864,Tacrolimus
,17645712,acute,"Although not statistically significant, this group experienced an acute rejection rate of 33%, compared with 21% in the control group.",Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17645712/),%,33,231083,DB00864,Tacrolimus
,17645712,acute,"Although not statistically significant, this group experienced an acute rejection rate of 33%, compared with 21% in the control group.",Apparent low absorbers of cyclosporine microemulsion have higher requirements for tacrolimus in renal transplantation. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17645712/),,21,231084,DB00864,Tacrolimus
,21849516,oral clearance (CL/F),The mean estimate of oral clearance (CL/F) was 11.1 l/h.,Pharmacokinetic differences corroborate observed low tacrolimus dosage in Native American renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849516/),[l] / [h],11.1,231224,DB00864,Tacrolimus
,22369694,C(0) /dose,"Among CYP3A5*1 carriers, those also carrying the CYP3A4*1B allele showed the lowest C(0) /dose, as compared with CYP3A4*1/CYP3A5*3 carriers (54.28±26.45, 59.12±24.00, 62.43±41.12, and 57.01±17.34 vs. 112.37± 76.60, 123.21±59.57, 163.34±76.23, and 183.07±107.82 at 1 week, 1 month, 5 months, and 1 year after transplantation).",Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369694/),,54.28,231489,DB00864,Tacrolimus
,22369694,C(0) /dose,"Among CYP3A5*1 carriers, those also carrying the CYP3A4*1B allele showed the lowest C(0) /dose, as compared with CYP3A4*1/CYP3A5*3 carriers (54.28±26.45, 59.12±24.00, 62.43±41.12, and 57.01±17.34 vs. 112.37± 76.60, 123.21±59.57, 163.34±76.23, and 183.07±107.82 at 1 week, 1 month, 5 months, and 1 year after transplantation).",Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369694/),,59.12,231490,DB00864,Tacrolimus
,22369694,C(0) /dose,"Among CYP3A5*1 carriers, those also carrying the CYP3A4*1B allele showed the lowest C(0) /dose, as compared with CYP3A4*1/CYP3A5*3 carriers (54.28±26.45, 59.12±24.00, 62.43±41.12, and 57.01±17.34 vs. 112.37± 76.60, 123.21±59.57, 163.34±76.23, and 183.07±107.82 at 1 week, 1 month, 5 months, and 1 year after transplantation).",Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369694/),,62.43,231491,DB00864,Tacrolimus
,22369694,C(0) /dose,"Among CYP3A5*1 carriers, those also carrying the CYP3A4*1B allele showed the lowest C(0) /dose, as compared with CYP3A4*1/CYP3A5*3 carriers (54.28±26.45, 59.12±24.00, 62.43±41.12, and 57.01±17.34 vs. 112.37± 76.60, 123.21±59.57, 163.34±76.23, and 183.07±107.82 at 1 week, 1 month, 5 months, and 1 year after transplantation).",Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369694/),,57.01,231492,DB00864,Tacrolimus
,22369694,C(0) /dose,"Among CYP3A5*1 carriers, those also carrying the CYP3A4*1B allele showed the lowest C(0) /dose, as compared with CYP3A4*1/CYP3A5*3 carriers (54.28±26.45, 59.12±24.00, 62.43±41.12, and 57.01±17.34 vs. 112.37± 76.60, 123.21±59.57, 163.34±76.23, and 183.07±107.82 at 1 week, 1 month, 5 months, and 1 year after transplantation).",Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369694/),,112.37,231493,DB00864,Tacrolimus
,22369694,C(0) /dose,"Among CYP3A5*1 carriers, those also carrying the CYP3A4*1B allele showed the lowest C(0) /dose, as compared with CYP3A4*1/CYP3A5*3 carriers (54.28±26.45, 59.12±24.00, 62.43±41.12, and 57.01±17.34 vs. 112.37± 76.60, 123.21±59.57, 163.34±76.23, and 183.07±107.82 at 1 week, 1 month, 5 months, and 1 year after transplantation).",Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369694/),,123.21,231494,DB00864,Tacrolimus
,22369694,C(0) /dose,"Among CYP3A5*1 carriers, those also carrying the CYP3A4*1B allele showed the lowest C(0) /dose, as compared with CYP3A4*1/CYP3A5*3 carriers (54.28±26.45, 59.12±24.00, 62.43±41.12, and 57.01±17.34 vs. 112.37± 76.60, 123.21±59.57, 163.34±76.23, and 183.07±107.82 at 1 week, 1 month, 5 months, and 1 year after transplantation).",Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369694/),,163.34,231495,DB00864,Tacrolimus
,22369694,C(0) /dose,"Among CYP3A5*1 carriers, those also carrying the CYP3A4*1B allele showed the lowest C(0) /dose, as compared with CYP3A4*1/CYP3A5*3 carriers (54.28±26.45, 59.12±24.00, 62.43±41.12, and 57.01±17.34 vs. 112.37± 76.60, 123.21±59.57, 163.34±76.23, and 183.07±107.82 at 1 week, 1 month, 5 months, and 1 year after transplantation).",Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22369694/),,183.07,231496,DB00864,Tacrolimus
,19486291,elimination half-life,The median elimination half-life of tacrolimus was 14.47 and 12.59 h for Day 0 and Day 14 respectively.,Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19486291/),h,14.47,232208,DB00864,Tacrolimus
,19486291,elimination half-life,The median elimination half-life of tacrolimus was 14.47 and 12.59 h for Day 0 and Day 14 respectively.,Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19486291/),h,12.59,232209,DB00864,Tacrolimus
,11579300,CL/F,"Average parameter estimates were CL/F=5.75 L/h (cut-down liver), CL/F=44 L/h (whole liver), and V/F=617 L.",Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579300/),[l] / [h],5.75,232822,DB00864,Tacrolimus
,11579300,CL/F,"Average parameter estimates were CL/F=5.75 L/h (cut-down liver), CL/F=44 L/h (whole liver), and V/F=617 L.",Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579300/),[l] / [h],44,232823,DB00864,Tacrolimus
,11579300,V/F,"Average parameter estimates were CL/F=5.75 L/h (cut-down liver), CL/F=44 L/h (whole liver), and V/F=617 L.",Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11579300/),l,617,232824,DB00864,Tacrolimus
,12895195,trough concentrations,"Blood tacrolimus trough concentrations were not affected by cerivastatin (mean +/- SD 8.6 +/- 2.1 ng ml(-1) before, and 8.7 +/- 2.4 ng ml(-1) at day 90 of cerivastatin dosing, with a 95% confidence interval on the difference = 0.97, 1.08).",Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895195/),[ng] / [ml],8.6,232856,DB00864,Tacrolimus
,12895195,trough concentrations,"Blood tacrolimus trough concentrations were not affected by cerivastatin (mean +/- SD 8.6 +/- 2.1 ng ml(-1) before, and 8.7 +/- 2.4 ng ml(-1) at day 90 of cerivastatin dosing, with a 95% confidence interval on the difference = 0.97, 1.08).",Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895195/),[ng] / [ml],8.7,232857,DB00864,Tacrolimus
,12895195,"area under the blood concentration-time curve to 24 h (AUC(0,24 h))","The mean area under the blood concentration-time curve to 24 h (AUC(0,24 h)) for cerivastatin was 14.5 +/- 2.53 micro g l(-1) h(-1) at day 1 after starting treatment and 19.02 +/- 3.55 micro g l(-1) h(-1) (3 months later), resulting in a 35% higher (AUC(0,24 h)) compared with the first dose.",Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895195/),[μg] / [h·l],14.5,232858,DB00864,Tacrolimus
,12895195,"area under the blood concentration-time curve to 24 h (AUC(0,24 h))","The mean area under the blood concentration-time curve to 24 h (AUC(0,24 h)) for cerivastatin was 14.5 +/- 2.53 micro g l(-1) h(-1) at day 1 after starting treatment and 19.02 +/- 3.55 micro g l(-1) h(-1) (3 months later), resulting in a 35% higher (AUC(0,24 h)) compared with the first dose.",Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895195/),[μg] / [h·l],19.02,232859,DB00864,Tacrolimus
,28967706,t½,"Letermovir increased CsA and TAC Cmax by 37% and 70%, respectively, and exposure by 70% and 78%, respectively, compared with immunosuppressant alone; t½ was also increased from 10.7 to 17.9 hours for CsA.",Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967706/),h,10.7,233243,DB00864,Tacrolimus
,28967706,t½,"Letermovir increased CsA and TAC Cmax by 37% and 70%, respectively, and exposure by 70% and 78%, respectively, compared with immunosuppressant alone; t½ was also increased from 10.7 to 17.9 hours for CsA.",Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967706/),h,17.9,233244,DB00864,Tacrolimus
,28967706,t½,"CsA (50/200 mg) increased letermovir Cmax,ss (109%/167%) and AUCss,τ (126%/237%) and decreased t½ (4.33 to 3.68/3.04 hours) versus letermovir alone.",Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967706/),h,4.33,233245,DB00864,Tacrolimus
,28967706,t½,"CsA (50/200 mg) increased letermovir Cmax,ss (109%/167%) and AUCss,τ (126%/237%) and decreased t½ (4.33 to 3.68/3.04 hours) versus letermovir alone.",Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967706/),h,3.68,233246,DB00864,Tacrolimus
,28967706,t½,"CsA (50/200 mg) increased letermovir Cmax,ss (109%/167%) and AUCss,τ (126%/237%) and decreased t½ (4.33 to 3.68/3.04 hours) versus letermovir alone.",Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28967706/),h,3.04,233247,DB00864,Tacrolimus
,24977292,apparent clearance,"Typical apparent clearance and central volume of distribution were 12.1 l h(-1) and 31.3 l, respectively.",Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24977292/),[l] / [h],12.1,234430,DB00864,Tacrolimus
,24977292,central volume of distribution,"Typical apparent clearance and central volume of distribution were 12.1 l h(-1) and 31.3 l, respectively.",Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24977292/),l,31.3,234431,DB00864,Tacrolimus
,32438078,Ctrough,"In 8 renal transplant patients, rivaroxaban levels showed a predictable pharmacokinetic trend, both at Ctrough (30-61 μg/L) and at Cpeak (143-449 μg/L), with limited variability in the 25th-75th percentile range.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],30-61,235704,DB00864,Tacrolimus
,32438078,Cpeak,"In 8 renal transplant patients, rivaroxaban levels showed a predictable pharmacokinetic trend, both at Ctrough (30-61 μg/L) and at Cpeak (143-449 μg/L), with limited variability in the 25th-75th percentile range.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],143-449,235705,DB00864,Tacrolimus
,32438078,Ctrough,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-13,235706,DB00864,Tacrolimus
,32438078,Cpeak,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-16,235707,DB00864,Tacrolimus
,32438078,Ctrough,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],3-11,235708,DB00864,Tacrolimus
,32438078,Cpeak,"Tacrolimus (Ctrough 3-13 μg/L; Cpeak 3-16 μg/L), everolimus (Ctrough 3-11 μg/L; Cpeak 5-17 μg/L) and creatinine concentrations were stable as well.","Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32438078/),[μg] / [l],5-17,235709,DB00864,Tacrolimus
,33626199,area under the effect-time curve from 0 to 24 hours (AUE0-24h ),"Tac-LCP showed a statistically more maintained CNA inhibition between dose intervals (area under the effect-time curve from 0 to 24 hours (AUE0-24h )) compared with Tac-IR, in which CNA returned to predose levels after 4 hours of drug intake (373.8 vs. 290.5 pmol RII·h/min·mg prot, Tac-LCP vs. Tac-IR; P = 0.039).",Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33626199/),pM,373.8,235964,DB00864,Tacrolimus
,33626199,area under the effect-time curve from 0 to 24 hours (AUE0-24h ),"Tac-LCP showed a statistically more maintained CNA inhibition between dose intervals (area under the effect-time curve from 0 to 24 hours (AUE0-24h )) compared with Tac-IR, in which CNA returned to predose levels after 4 hours of drug intake (373.8 vs. 290.5 pmol RII·h/min·mg prot, Tac-LCP vs. Tac-IR; P = 0.039).",Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33626199/),pM,290.5,235965,DB00864,Tacrolimus
,33626199,half-maximal inhibitory concentration),"Moreover, Tac concentration to elicit a 50% of the maximum response (half-maximal inhibitory concentration) was 9.24 ng/mL.",Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33626199/),[ng] / [ml],9.24,235966,DB00864,Tacrolimus
,31003735,dose-normalized,"Model-predicted dose-normalized (6.0 mg/d) area under the TAC concentration-time curve over the dosing interval in groups A and B was similar (geometric mean, 235.6 ng/mL · h [95% CI, 139.6-598.7] vs 224.6 ng/mL · h [95% CI, 117.6-421.5], respectively; P = 0.94).",Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31003735/),[ng] / [h·ml],235.6,236880,DB00864,Tacrolimus
,31003735,area under the TAC concentration-time curve,"Model-predicted dose-normalized (6.0 mg/d) area under the TAC concentration-time curve over the dosing interval in groups A and B was similar (geometric mean, 235.6 ng/mL · h [95% CI, 139.6-598.7] vs 224.6 ng/mL · h [95% CI, 117.6-421.5], respectively; P = 0.94).",Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31003735/),[ng] / [h·ml],235.6,236881,DB00864,Tacrolimus
,31003735,area under the TAC concentration-time curve,"Model-predicted dose-normalized (6.0 mg/d) area under the TAC concentration-time curve over the dosing interval in groups A and B was similar (geometric mean, 235.6 ng/mL · h [95% CI, 139.6-598.7] vs 224.6 ng/mL · h [95% CI, 117.6-421.5], respectively; P = 0.94).",Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31003735/),[ng] / [h·ml],224.6,236882,DB00864,Tacrolimus
,31003735,Area under the CNA versus time curve,Area under the CNA versus time curve over the dosing interval did not differ between groups (4897 [3437] and 4079 [1008] pmol/min/106 cells; P = 0.50).,Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31003735/),[pM] / [106·cells·min],4897,236883,DB00864,Tacrolimus
,31003735,Area under the CNA versus time curve,Area under the CNA versus time curve over the dosing interval did not differ between groups (4897 [3437] and 4079 [1008] pmol/min/106 cells; P = 0.50).,Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31003735/),[pM] / [106·cells·min],4079,236884,DB00864,Tacrolimus
,31003735,trough CNA,"In group A, trough CNA at D14 posttransplantation was statistically higher than that measured just before the switch to PRT (ie, D7 posttransplantation) (198 [92] vs 124 [72] pmol/min/106cells, n = 8; P = 0.048); no statistical difference in TAC concentration was observed (P = 0.11).",Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31003735/),[pM] / [106cells·min],198,236885,DB00864,Tacrolimus
,31003735,trough CNA,"In group A, trough CNA at D14 posttransplantation was statistically higher than that measured just before the switch to PRT (ie, D7 posttransplantation) (198 [92] vs 124 [72] pmol/min/106cells, n = 8; P = 0.048); no statistical difference in TAC concentration was observed (P = 0.11).",Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31003735/),[pM] / [106cells·min],124,236886,DB00864,Tacrolimus
,31003735,trough CNA,"In group B, no statistical difference between D90 and D104 was observed in either trough CNA (149 [78] vs 172 [82] pmol/min/106 cells, n = 6; P = 0.18) or TAC (P = 0.17) concentration.",Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31003735/),[pM] / [106·cells·min],149,236887,DB00864,Tacrolimus
,31003735,trough CNA,"In group B, no statistical difference between D90 and D104 was observed in either trough CNA (149 [78] vs 172 [82] pmol/min/106 cells, n = 6; P = 0.18) or TAC (P = 0.17) concentration.",Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31003735/),[pM] / [106·cells·min],172,236888,DB00864,Tacrolimus
,20683390,steady-state predose blood concentrations,"Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively.",Overview of sotrastaurin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),[ng] / [ml],600,237179,DB00864,Tacrolimus
,20683390,steady-state predose blood concentrations,"Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively.",Overview of sotrastaurin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),[ng] / [ml],900,237180,DB00864,Tacrolimus
,20683390,elimination half-life,The elimination half-life of sotrastaurin averages 6 hours.,Overview of sotrastaurin clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),h,6,237181,DB00864,Tacrolimus
,24081207,Apparent volume of distribution,"Apparent volume of distribution and blood clearance estimates were 283 L and 10 L/h, respectively.",Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081207/),l,283,238173,DB00864,Tacrolimus
,24081207,blood clearance,"Apparent volume of distribution and blood clearance estimates were 283 L and 10 L/h, respectively.",Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081207/),[l] / [h],10,238174,DB00864,Tacrolimus
,24081207,first order rate,"The absorption was also considered to be a first order process, with a first order rate fixed to 4.45 hours.",Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081207/),h,4.45,238175,DB00864,Tacrolimus
≤,21040167,C(2),"The first postoperative tacrolimus dose was given either according to standard care (control group) or 0.15 mg/kg b.d. if the pre-transplant C(2) level was ≤20 ng/mL, 0.1 mg/kg b.d. if the C(2) level was 21-59 ng/mL or 0.05 mg/kg b.d. if the C(2) level was ≥60 ng/mL (T2 group).",Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],20,239026,DB00864,Tacrolimus
,21040167,C(2),"The first postoperative tacrolimus dose was given either according to standard care (control group) or 0.15 mg/kg b.d. if the pre-transplant C(2) level was ≤20 ng/mL, 0.1 mg/kg b.d. if the C(2) level was 21-59 ng/mL or 0.05 mg/kg b.d. if the C(2) level was ≥60 ng/mL (T2 group).",Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],21-59,239027,DB00864,Tacrolimus
≥,21040167,C(2),"The first postoperative tacrolimus dose was given either according to standard care (control group) or 0.15 mg/kg b.d. if the pre-transplant C(2) level was ≤20 ng/mL, 0.1 mg/kg b.d. if the C(2) level was 21-59 ng/mL or 0.05 mg/kg b.d. if the C(2) level was ≥60 ng/mL (T2 group).",Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],60,239028,DB00864,Tacrolimus
≥,21040167,trough levels,There was no difference in the proportion of subjects achieving tacrolimus trough levels ≥10 ng/mL (82.9% Control vs 93.0% T2; P=0.19) or between 10 and 15 ng/mL (41.5% Control vs 41.9% T2; P=0.97) at day 3 post transplant.,Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],10,239029,DB00864,Tacrolimus
,21040167,trough levels,There was no difference in the proportion of subjects achieving tacrolimus trough levels ≥10 ng/mL (82.9% Control vs 93.0% T2; P=0.19) or between 10 and 15 ng/mL (41.5% Control vs 41.9% T2; P=0.97) at day 3 post transplant.,Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],10 and 15,239030,DB00864,Tacrolimus
≥,21040167,trough levels,The T2 group achieved tacrolimus trough levels of ≥10 ng/mL significantly faster than the control group (100% achievement in 14 days (Control) versus 4 days (T2); P=0.01).,Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],10,239031,DB00864,Tacrolimus
,16359376,C2,"The acute rejection rate was lower (19% vs. 43%; P < 0.05) in patients achieving CsA C2 target range during the first week (1600-2000 microg/l), n = 26, compared with those who did not, n = 42.",Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359376/),[μg] / [l],1600-2000,239046,DB00864,Tacrolimus
,19606088,area under the curve (AUC),"After 500 mg MMF, the mean MPA area under the curve (AUC) was significantly lower in sirolimus-treated patients than in those treated with tacrolimus (35.4 +/- 32.3 vs. 77.1 +/- 67.5 mg/l).",Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19606088/),[mg] / [l],35.4,242878,DB00864,Tacrolimus
,19606088,area under the curve (AUC),"After 500 mg MMF, the mean MPA area under the curve (AUC) was significantly lower in sirolimus-treated patients than in those treated with tacrolimus (35.4 +/- 32.3 vs. 77.1 +/- 67.5 mg/l).",Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19606088/),[mg] / [l],77.1,242879,DB00864,Tacrolimus
,24189425,concentration/dose (C/D) ratio,"The concentration/dose (C/D) ratio of tacrolimus in patients carrying graft liver with CYP3A4*1/*1 was significantly higher during 7 d after surgery than in that with CYP3A4*1/*1G (214 vs. 157 [ng/mL]/[mg/kg/day], p<0.01).","Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24189425/),[ng] / [[mg·day·kg·ml]],214,243375,DB00864,Tacrolimus
,24189425,concentration/dose (C/D) ratio,"The concentration/dose (C/D) ratio of tacrolimus in patients carrying graft liver with CYP3A4*1/*1 was significantly higher during 7 d after surgery than in that with CYP3A4*1/*1G (214 vs. 157 [ng/mL]/[mg/kg/day], p<0.01).","Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24189425/),[ng] / [[mg·day·kg·ml]],157,243376,DB00864,Tacrolimus
,34284341,absorption rate constant (Ka),"The absorption rate constant (Ka) was set at 4.48 h-1 in the linear model, and the apparent clearance (CL/F) and volume of distribution (V/F) in the final linear model were 14.2 L/h and 172 L, respectively.",Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34284341/),1/[h],4.48,244676,DB00864,Tacrolimus
,34284341,apparent clearance (CL/F),"The absorption rate constant (Ka) was set at 4.48 h-1 in the linear model, and the apparent clearance (CL/F) and volume of distribution (V/F) in the final linear model were 14.2 L/h and 172 L, respectively.",Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34284341/),[l] / [h],14.2,244677,DB00864,Tacrolimus
,34284341,volume of distribution (V/F),"The absorption rate constant (Ka) was set at 4.48 h-1 in the linear model, and the apparent clearance (CL/F) and volume of distribution (V/F) in the final linear model were 14.2 L/h and 172 L, respectively.",Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34284341/),l,172,244678,DB00864,Tacrolimus
,34284341,maximal dose rate (Vmax),"The maximal dose rate (Vmax) and the average steady-state concentration at half-Vmax (Km) in the final nonlinear model were 2.15 mg/day and 0.845 ng/ml, respectively.",Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34284341/),[mg] / [d],2.15,244679,DB00864,Tacrolimus
,34284341,steady-state concentration at half-Vmax (Km),"The maximal dose rate (Vmax) and the average steady-state concentration at half-Vmax (Km) in the final nonlinear model were 2.15 mg/day and 0.845 ng/ml, respectively.",Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34284341/),[ng] / [ml],0.845,244680,DB00864,Tacrolimus
,12773068,concentrations,"The highest and mean concentrations of tacrolimus in milk were 0.57 and 0.429 ng/mL, respectively.",Milk transfer and neonatal safety of tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12773068/),[ng] / [ml],0.429,244786,DB00864,Tacrolimus
,12773068,milk-to-blood ratios,"The milk-to-blood ratios of tacrolimus at pre-dosing and 1-hour post-dosing concentrations were calculated to be 0.08 and 0.09, respectively.",Milk transfer and neonatal safety of tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12773068/),,0.08,244787,DB00864,Tacrolimus
,12773068,milk-to-blood ratios,"The milk-to-blood ratios of tacrolimus at pre-dosing and 1-hour post-dosing concentrations were calculated to be 0.08 and 0.09, respectively.",Milk transfer and neonatal safety of tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12773068/),,0.09,244788,DB00864,Tacrolimus
,24627339,AUC0-∞,The AUC0-∞ values were 145.92 (reference) and 140.49 ng h/mL (test).,Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24627339/),[h·ng] / [ml],145.92,245255,DB00864,Tacrolimus
,24627339,AUC0-∞,The AUC0-∞ values were 145.92 (reference) and 140.49 ng h/mL (test).,Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24627339/),[h·ng] / [ml],140.49,245256,DB00864,Tacrolimus
,24627339,Cmax,"The mean Cmax was 15.70 (reference) and 16.08 ng/mL (test) with Tmax values of 1.63 and 1.60 h, respectively.",Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24627339/),[ng] / [ml],15.70,245257,DB00864,Tacrolimus
,24627339,Cmax,"The mean Cmax was 15.70 (reference) and 16.08 ng/mL (test) with Tmax values of 1.63 and 1.60 h, respectively.",Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24627339/),[ng] / [ml],16.08,245258,DB00864,Tacrolimus
,24627339,Tmax,"The mean Cmax was 15.70 (reference) and 16.08 ng/mL (test) with Tmax values of 1.63 and 1.60 h, respectively.",Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24627339/),h,1.63,245259,DB00864,Tacrolimus
,24627339,Tmax,"The mean Cmax was 15.70 (reference) and 16.08 ng/mL (test) with Tmax values of 1.63 and 1.60 h, respectively.",Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24627339/),h,1.60,245260,DB00864,Tacrolimus
,24627339,t1/2,"The t1/2 for the reference and test formulations was 29.12 and 27.85 h, respectively.",Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24627339/),h,29.12,245261,DB00864,Tacrolimus
,24627339,t1/2,"The t1/2 for the reference and test formulations was 29.12 and 27.85 h, respectively.",Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24627339/),h,27.85,245262,DB00864,Tacrolimus
,24627339,Relative bioavailability,Relative bioavailability was calculated to be 96.28 %.,Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24627339/),%,96.28,245263,DB00864,Tacrolimus
,18347534,trough concentration,"Despite the lower doses used, mean trough concentration was significantly greater in LDLT as compared with DDLT (8.8+/-2.5 ng/mL vs. 6.79+/-1.5 ng/mL, respectively, P=0.013).",Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347534/),[ng] / [ml],8.8,245447,DB00864,Tacrolimus
,18347534,trough concentration,"Despite the lower doses used, mean trough concentration was significantly greater in LDLT as compared with DDLT (8.8+/-2.5 ng/mL vs. 6.79+/-1.5 ng/mL, respectively, P=0.013).",Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347534/),[ng] / [ml],6.79,245448,DB00864,Tacrolimus
,18347534,minimum Concentration (Cmin),"On the day of the pharmacokinetic study, minimum Concentration (Cmin), 12-hr postdose concentration (Clast), and average concentration (Cavg) were significantly greater in LDLT as compared with DDLT (LDLT: 6.6+/-2.4 ng/mL, 7.2+/-1.8 ng/mL, 8.9+/-3.0 ng/mL; DDLT: 4.3+/-1.0 ng/mL, 4.9+/-1.6 ng/mL, 5.9+/-1.4 ng/mL, P=0.02, 0.04, and 0.02, respectively).",Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347534/),[ng] / [ml],6.6,245449,DB00864,Tacrolimus
,18347534,postdose concentration (Clast),"On the day of the pharmacokinetic study, minimum Concentration (Cmin), 12-hr postdose concentration (Clast), and average concentration (Cavg) were significantly greater in LDLT as compared with DDLT (LDLT: 6.6+/-2.4 ng/mL, 7.2+/-1.8 ng/mL, 8.9+/-3.0 ng/mL; DDLT: 4.3+/-1.0 ng/mL, 4.9+/-1.6 ng/mL, 5.9+/-1.4 ng/mL, P=0.02, 0.04, and 0.02, respectively).",Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347534/),[ng] / [ml],7.2,245450,DB00864,Tacrolimus
,18347534,postdose concentration (Clast),"On the day of the pharmacokinetic study, minimum Concentration (Cmin), 12-hr postdose concentration (Clast), and average concentration (Cavg) were significantly greater in LDLT as compared with DDLT (LDLT: 6.6+/-2.4 ng/mL, 7.2+/-1.8 ng/mL, 8.9+/-3.0 ng/mL; DDLT: 4.3+/-1.0 ng/mL, 4.9+/-1.6 ng/mL, 5.9+/-1.4 ng/mL, P=0.02, 0.04, and 0.02, respectively).",Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347534/),[ng] / [ml],4.3,245451,DB00864,Tacrolimus
,18347534,average concentration (Cavg),"On the day of the pharmacokinetic study, minimum Concentration (Cmin), 12-hr postdose concentration (Clast), and average concentration (Cavg) were significantly greater in LDLT as compared with DDLT (LDLT: 6.6+/-2.4 ng/mL, 7.2+/-1.8 ng/mL, 8.9+/-3.0 ng/mL; DDLT: 4.3+/-1.0 ng/mL, 4.9+/-1.6 ng/mL, 5.9+/-1.4 ng/mL, P=0.02, 0.04, and 0.02, respectively).",Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347534/),[ng] / [ml],5.9,245452,DB00864,Tacrolimus
,10739787,AUC(12),"The FK AUC(12), trough, 2-hour, and 4-hour concentrations were 125 +/- 24 h.",Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10739787/),h,125,245624,DB00864,Tacrolimus
,29045960,maximum drug concentrations (Cmax/D),"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),[μg] / [l],1.7,245629,DB00864,Tacrolimus
,29045960,maximum drug concentrations (Cmax/D),"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),[μg] / [l],3.1,245630,DB00864,Tacrolimus
,29045960,maximum drug concentrations (Cmax/D),"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),[μg] / [l],8.0,245631,DB00864,Tacrolimus
,29045960,Areas under the drug concentration-time curve(AUC0-∞/D),"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),[h·μg] / [l],47.2,245632,DB00864,Tacrolimus
,29045960,Areas under the drug concentration-time curve(AUC0-∞/D),"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),[h·μg] / [l],84.0,245633,DB00864,Tacrolimus
,29045960,Areas under the drug concentration-time curve(AUC0-∞/D),"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),[h·μg] / [l],175.6,245634,DB00864,Tacrolimus
,29045960,Oral clearance rates,"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),[l] / [h·kg],0.8,245635,DB00864,Tacrolimus
,29045960,Oral clearance rates,"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),[l] / [h·kg],0.4,245636,DB00864,Tacrolimus
,29045960,Oral clearance rates,"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),[l] / [h·kg],1.9,245637,DB00864,Tacrolimus
,29045960,Body weight normalized distribution volumes,"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),[l] / [kg],7.0,245638,DB00864,Tacrolimus
,29045960,Body weight normalized distribution volumes,"Pharmacokinetic parameters of tacrolimus PR formulation in the 3 ascending doses groups (0.02 mg/kg,0.05 mg/kg and 0.10 mg/kg) were as follows: the maximum drug concentrations (Cmax/D) were (1.7±1.0) μg/L, (3.1±1.9) μg/L, (8.0±3.5) μg/L, respectively; Areas under the drug concentration-time curve(AUC0-∞/D) were (47.2±47.1) h×μg/L, (84.0±13.1) h×μg/L, (175.6±107.1) h×μg/L, respectively; Oral clearance rates were (0.8±0.9) L/(h×kg), (0.4±0.1) L/(h×kg), (1.9±1.3) L/(h×kg), respectively; Body weight normalized distribution volumes were (7.0±3.4) L/kg, (12.4±8.4) L/kg and (73.6±68.6) L/kg, respectively.",Pharmacokinetics of once daily prolonged-release formulation of tacrolimus in children with primary nephrotic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29045960/),,12.4,245639,DB00864,Tacrolimus
,32453306,peak blood concentration,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),[ng] / [ml],4.4,246189,DB00864,Tacrolimus
,32453306,peak blood concentration,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),[ng] / [ml],4.0,246190,DB00864,Tacrolimus
,32453306,area under the time-concentration curve (AUC) from time 0 to time of the last concentration,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),[ng] / [ml],89.1,246191,DB00864,Tacrolimus
,32453306,area under the time-concentration curve (AUC) from time 0 to time of the last concentration,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),[ng] / [ml],102.6,246192,DB00864,Tacrolimus
,32453306,AUC from time 0 to infinity,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),[h·ng] / [ml],99.7,246193,DB00864,Tacrolimus
,32453306,AUC from time 0 to infinity,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),[h·ng] / [ml],114.3,246194,DB00864,Tacrolimus
,32453306,AUC from 0 to 24 hours post-dose (AUC0-24,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),[h·ng] / [ml],49.4,246195,DB00864,Tacrolimus
,32453306,AUC from 0 to 24 hours post-dose (AUC0-24,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),[h·ng] / [ml],51.6,246196,DB00864,Tacrolimus
,32453306,time to reach maximum blood concentration,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),h,6.0,246197,DB00864,Tacrolimus
,32453306,total clearance,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),[l] / [h],21.5,246198,DB00864,Tacrolimus
,32453306,total clearance,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),[l] / [h],19.5,246199,DB00864,Tacrolimus
,32453306,terminal half-life,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),h,26.8,246200,DB00864,Tacrolimus
,32453306,terminal half-life,"No significant differences were observed between evening and morning dosing in peak blood concentration (4.4 versus 4.0 ng/mL; P = 0.27), area under the time-concentration curve (AUC) from time 0 to time of the last concentration (89.1 versus 102.6 ng/mL; P = 0.20), AUC from time 0 to infinity (99.7 versus 114.3 ng·h/mL; P = 0.18), AUC from 0 to 24 hours post-dose (AUC0-24; 49.4 versus 51.6 ng·h/mL; P = 0.56), time to reach maximum blood concentration (median, 6.0 versus 6.0 hours; P = 0.91), total clearance (arithmetic mean = 21.5 versus 19.5 L/h; P = 0.50), or terminal half-life (arithmetic mean = 26.8 versus 28.1 hours; P = 0.26).",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),h,28.1,246201,DB00864,Tacrolimus
,32453306,terminal half-life,"However, the terminal half-life did not differ between fasted and fed states (33.3 versus 34.8 hours; P = 0.16), implying that these differences occurred because of altered bioavailability rather than modified clearance.",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),h,33.3,246202,DB00864,Tacrolimus
,32453306,terminal half-life,"However, the terminal half-life did not differ between fasted and fed states (33.3 versus 34.8 hours; P = 0.16), implying that these differences occurred because of altered bioavailability rather than modified clearance.",Chronopharmacokinetics and Food Effects of Single-Dose LCP-Tacrolimus in Healthy Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32453306/),h,34.8,246203,DB00864,Tacrolimus
<,18315786,total area under the observed plasma concentration-time curve (AUC(0-12)),Acute rejection was over twice more common in recipients with a total area under the observed plasma concentration-time curve (AUC(0-12)) of MPA <70 microg x h/mL than in those with higher values AUC(0-12) values (17% vs. 7%).,No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18315786/),[h·μg] / [ml],70,246719,DB00864,Tacrolimus
<,18315786,C(0),"There were also no significant differences in the MPA pharmacokinetic parameters among three tacrolimus C(0) groups: 5 < or = C(0) < 10, 10 < or = C(0) < 15 and 15 < or =C(0) < 20 ng/mL.",No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18315786/),,10,246720,DB00864,Tacrolimus
<,18315786,C(0),"There were also no significant differences in the MPA pharmacokinetic parameters among three tacrolimus C(0) groups: 5 < or = C(0) < 10, 10 < or = C(0) < 15 and 15 < or =C(0) < 20 ng/mL.",No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18315786/),,15,246721,DB00864,Tacrolimus
<,18315786,C(0),"There were also no significant differences in the MPA pharmacokinetic parameters among three tacrolimus C(0) groups: 5 < or = C(0) < 10, 10 < or = C(0) < 15 and 15 < or =C(0) < 20 ng/mL.",No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18315786/),[ng] / [ml],20,246722,DB00864,Tacrolimus
,28377389,Bioavailability,Bioavailability was lower with suspension administered via a nasogastric tube versus intact capsules (17%; ratio 0.83; CI 0.76 to 0.92).,"Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28377389/),%,17,247024,DB00864,Tacrolimus
,12483452,CL/F,"Mean parameter estimates were CL/F (whole liver) = 16.3 l/h, CL/F (cut-down liver) = 8.5 l/h and V/F = 565 l in NONMEM, and CL/F = 8.3 l/h and V/F = 155 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),[l] / [h],16.3,248415,DB00864,Tacrolimus
,12483452,CL/F,"Mean parameter estimates were CL/F (whole liver) = 16.3 l/h, CL/F (cut-down liver) = 8.5 l/h and V/F = 565 l in NONMEM, and CL/F = 8.3 l/h and V/F = 155 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),[l] / [h],8.5,248416,DB00864,Tacrolimus
,12483452,V/F,"Mean parameter estimates were CL/F (whole liver) = 16.3 l/h, CL/F (cut-down liver) = 8.5 l/h and V/F = 565 l in NONMEM, and CL/F = 8.3 l/h and V/F = 155 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),l,565,248417,DB00864,Tacrolimus
,12483452,CL/F,"Mean parameter estimates were CL/F (whole liver) = 16.3 l/h, CL/F (cut-down liver) = 8.5 l/h and V/F = 565 l in NONMEM, and CL/F = 8.3 l/h and V/F = 155 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),[l] / [h],8.3,248418,DB00864,Tacrolimus
,12483452,V/F,"Mean parameter estimates were CL/F (whole liver) = 16.3 l/h, CL/F (cut-down liver) = 8.5 l/h and V/F = 565 l in NONMEM, and CL/F = 8.3 l/h and V/F = 155 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),l,155,248419,DB00864,Tacrolimus
,12483452,CL/F,"Individual Bayesian parameter estimates were CL/F (whole liver) = 17.9 +/- 8.8 l/h, CL/F (cut-down liver) = 11.6 +/- 8.8 l/h and V/F = 712 +/- 792 l in NONMEM, and CL/F (whole liver) = 12.8 +/- 3.5 l/h, CL/F (cut-down liver) = 8.2 +/- 3.4 l/h and V/F = 221 +/- 164 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),[l] / [h],17.9,248420,DB00864,Tacrolimus
,12483452,CL/F,"Individual Bayesian parameter estimates were CL/F (whole liver) = 17.9 +/- 8.8 l/h, CL/F (cut-down liver) = 11.6 +/- 8.8 l/h and V/F = 712 +/- 792 l in NONMEM, and CL/F (whole liver) = 12.8 +/- 3.5 l/h, CL/F (cut-down liver) = 8.2 +/- 3.4 l/h and V/F = 221 +/- 164 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),[l] / [h],11.6,248421,DB00864,Tacrolimus
,12483452,V/F,"Individual Bayesian parameter estimates were CL/F (whole liver) = 17.9 +/- 8.8 l/h, CL/F (cut-down liver) = 11.6 +/- 8.8 l/h and V/F = 712 +/- 792 l in NONMEM, and CL/F (whole liver) = 12.8 +/- 3.5 l/h, CL/F (cut-down liver) = 8.2 +/- 3.4 l/h and V/F = 221 +/- 164 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),l,712,248422,DB00864,Tacrolimus
,12483452,CL/F,"Individual Bayesian parameter estimates were CL/F (whole liver) = 17.9 +/- 8.8 l/h, CL/F (cut-down liver) = 11.6 +/- 8.8 l/h and V/F = 712 +/- 792 l in NONMEM, and CL/F (whole liver) = 12.8 +/- 3.5 l/h, CL/F (cut-down liver) = 8.2 +/- 3.4 l/h and V/F = 221 +/- 164 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),[l] / [h],12.8,248423,DB00864,Tacrolimus
,12483452,CL/F,"Individual Bayesian parameter estimates were CL/F (whole liver) = 17.9 +/- 8.8 l/h, CL/F (cut-down liver) = 11.6 +/- 8.8 l/h and V/F = 712 +/- 792 l in NONMEM, and CL/F (whole liver) = 12.8 +/- 3.5 l/h, CL/F (cut-down liver) = 8.2 +/- 3.4 l/h and V/F = 221 +/- 164 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),[l] / [h],8.2,248424,DB00864,Tacrolimus
,12483452,V/F,"Individual Bayesian parameter estimates were CL/F (whole liver) = 17.9 +/- 8.8 l/h, CL/F (cut-down liver) = 11.6 +/- 8.8 l/h and V/F = 712 +/- 792 l in NONMEM, and CL/F (whole liver) = 12.8 +/- 3.5 l/h, CL/F (cut-down liver) = 8.2 +/- 3.4 l/h and V/F = 221 +/- 164 l in P-PHARM.","Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12483452/),l,221,248425,DB00864,Tacrolimus
,28681225,apparent clearance,"Mean tacrolimus apparent clearance was 50.5 L/h, with an inter-patient variability of 25%.",A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus Following Pediatric Renal Transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28681225/),[l] / [h],50.5,248553,DB00864,Tacrolimus
,19881404,-,"The median MMF dose was 431 mg/m2 per day (range, 189-833 mg/m2 per day) leading to a median estimated MPA-AUC0-12h of 27 mg/h/L (range, 17-79 mg/h/L).",Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19881404/),[mg] / [h·l],27,248653,DB00864,Tacrolimus
,19881404,AUC0-12h,"The median MMF dose was 431 mg/m2 per day (range, 189-833 mg/m2 per day) leading to a median estimated MPA-AUC0-12h of 27 mg/h/L (range, 17-79 mg/h/L).",Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19881404/),[mg] / [h·l],27,248654,DB00864,Tacrolimus
,22377746,apparent clearance (CL/F),"The typical values (interindividual variability percent coefficient of variation) for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 20.9 L h (23.8%) and 808 l (70.4%), respectively.",The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377746/),h·l,20.9,248708,DB00864,Tacrolimus
,22377746,apparent volume of distribution (V/F),"The typical values (interindividual variability percent coefficient of variation) for apparent clearance (CL/F) and apparent volume of distribution (V/F) were 20.9 L h (23.8%) and 808 l (70.4%), respectively.",The impact of sulfonylureas on tacrolimus apparent clearance revealed by a population pharmacokinetics analysis in Chinese adult liver-transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22377746/),l,808,248709,DB00864,Tacrolimus
,24385281,AUC from 0 to 6 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],449,249174,DB00864,Tacrolimus
,24385281,AUC from 0 to 6 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],428,249175,DB00864,Tacrolimus
,24385281,AUC from 0 to 12 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],32,249176,DB00864,Tacrolimus
,24385281,AUC from 0 to 12 h,"No significant difference in mean dose-adjusted total prednisolone AUC from 0 to 6 h post-dose or mean dose-adjusted free prednisolone AUC from 0 to 12 h was observed between the cyclosporine and tacrolimus groups (449 versus 428 nmol·h/L/mg, p = 0.43, and 32 versus 30 nmol·h/L/mg, p = 0.51, respectively).",Comparison of the influence of cyclosporine and tacrolimus on the pharmacokinetics of prednisolone in adult male kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24385281/),[h·nM] / [l·mg],30,249177,DB00864,Tacrolimus
<,19545738,C(max)-C(0),"We investigated the pharmacokinetics of oral tacrolimus in 31 hematopoietic cell transplant recipients, identifying 2 subgroups based on the differences between C(0) (trough) and C(max) (maximal) levels: group A (n = 21; 68%) with a C(max)-C(0) value of <10 ng/mL, and group B (n = 10; 32%) with a C(max)-C(0) value of >or=10 ng/mL.",Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545738/),[ng] / [ml],10,249338,DB00864,Tacrolimus
>or=,19545738,C(max)-C(0),"We investigated the pharmacokinetics of oral tacrolimus in 31 hematopoietic cell transplant recipients, identifying 2 subgroups based on the differences between C(0) (trough) and C(max) (maximal) levels: group A (n = 21; 68%) with a C(max)-C(0) value of <10 ng/mL, and group B (n = 10; 32%) with a C(max)-C(0) value of >or=10 ng/mL.",Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545738/),[ng] / [ml],10,249339,DB00864,Tacrolimus
,19545738,area under the concentration curve for 12 hours (AUC(0-12)),"Although the C(0) and C(12) values were not significantly different between the 2 groups, the mean area under the concentration curve for 12 hours (AUC(0-12)) was significantly greater in group B than group A (200.9 +/- 36.3 vs 155.1 +/- 43.1 ng.h/mL; P < .05), and the mean half-life was significantly shorter in group B than group A (13.55 +/- 6.70 vs 18.17 +/- 6.30 hours; P < .05).",Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545738/),[h·ng] / [ml],200.9,249340,DB00864,Tacrolimus
,19545738,area under the concentration curve for 12 hours (AUC(0-12)),"Although the C(0) and C(12) values were not significantly different between the 2 groups, the mean area under the concentration curve for 12 hours (AUC(0-12)) was significantly greater in group B than group A (200.9 +/- 36.3 vs 155.1 +/- 43.1 ng.h/mL; P < .05), and the mean half-life was significantly shorter in group B than group A (13.55 +/- 6.70 vs 18.17 +/- 6.30 hours; P < .05).",Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545738/),[h·ng] / [ml],155.1,249341,DB00864,Tacrolimus
,19545738,half-life,"Although the C(0) and C(12) values were not significantly different between the 2 groups, the mean area under the concentration curve for 12 hours (AUC(0-12)) was significantly greater in group B than group A (200.9 +/- 36.3 vs 155.1 +/- 43.1 ng.h/mL; P < .05), and the mean half-life was significantly shorter in group B than group A (13.55 +/- 6.70 vs 18.17 +/- 6.30 hours; P < .05).",Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545738/),h,13.55,249342,DB00864,Tacrolimus
,19545738,half-life,"Although the C(0) and C(12) values were not significantly different between the 2 groups, the mean area under the concentration curve for 12 hours (AUC(0-12)) was significantly greater in group B than group A (200.9 +/- 36.3 vs 155.1 +/- 43.1 ng.h/mL; P < .05), and the mean half-life was significantly shorter in group B than group A (13.55 +/- 6.70 vs 18.17 +/- 6.30 hours; P < .05).",Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545738/),h,18.17,249343,DB00864,Tacrolimus
,19715905,area under-concentration time curve (AUC),The pharmacokinetics studies showed that carriers of T-275A and/or C-2152T displayed a smaller area under-concentration time curve (AUC): 57.8 +/- 4.3 vs 78.9 +/- 10.8 mg/L*h (P < .03).,The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715905/),[mg] / [h·l],57.8,249980,DB00864,Tacrolimus
,19715905,area under-concentration time curve (AUC),The pharmacokinetics studies showed that carriers of T-275A and/or C-2152T displayed a smaller area under-concentration time curve (AUC): 57.8 +/- 4.3 vs 78.9 +/- 10.8 mg/L*h (P < .03).,The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715905/),[mg] / [h·l],78.9,249981,DB00864,Tacrolimus
,11180035,maximum concentration,"After oral administration, the tacrolimus maximum concentration was significantly lower (P < .01) in the African American subjects (20.8 microg/L) than in the white subjects (37.8 microg/L) and Latin American subjects (33.0 microg/L).",The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180035/),[μg] / [l],20.8,250093,DB00864,Tacrolimus
,11180035,maximum concentration,"After oral administration, the tacrolimus maximum concentration was significantly lower (P < .01) in the African American subjects (20.8 microg/L) than in the white subjects (37.8 microg/L) and Latin American subjects (33.0 microg/L).",The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180035/),[μg] / [l],37.8,250094,DB00864,Tacrolimus
,11180035,maximum concentration,"After oral administration, the tacrolimus maximum concentration was significantly lower (P < .01) in the African American subjects (20.8 microg/L) than in the white subjects (37.8 microg/L) and Latin American subjects (33.0 microg/L).",The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180035/),[μg] / [l],33.0,250095,DB00864,Tacrolimus
,11180035,Absolute bioavailability,Absolute bioavailability was significantly lower (P = .01) in the African American subjects (11.9%) and in the Latin American subjects (14.4%) than in the white subjects (18.8%).,The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180035/),%,11.9,250096,DB00864,Tacrolimus
,11180035,Absolute bioavailability,Absolute bioavailability was significantly lower (P = .01) in the African American subjects (11.9%) and in the Latin American subjects (14.4%) than in the white subjects (18.8%).,The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180035/),%,14.4,250097,DB00864,Tacrolimus
,11180035,Absolute bioavailability,Absolute bioavailability was significantly lower (P = .01) in the African American subjects (11.9%) and in the Latin American subjects (14.4%) than in the white subjects (18.8%).,The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180035/),%,18.8,250098,DB00864,Tacrolimus
,11180035,area under the plasma concentration-time curve,"After the oral dose, the area under the plasma concentration-time curve was lower in the African American subjects (179 microg/L x h, geometric mean) than in the white (293 microg/L x h) and Latin American subjects (239 microg/L x h, differences not statistically significant).",The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180035/),[μg] / [h·l],179,250099,DB00864,Tacrolimus
,11180035,area under the plasma concentration-time curve,"After the oral dose, the area under the plasma concentration-time curve was lower in the African American subjects (179 microg/L x h, geometric mean) than in the white (293 microg/L x h) and Latin American subjects (239 microg/L x h, differences not statistically significant).",The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180035/),[μg] / [h·l],293,250100,DB00864,Tacrolimus
,11180035,area under the plasma concentration-time curve,"After the oral dose, the area under the plasma concentration-time curve was lower in the African American subjects (179 microg/L x h, geometric mean) than in the white (293 microg/L x h) and Latin American subjects (239 microg/L x h, differences not statistically significant).",The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180035/),[μg] / [h·l],239,250101,DB00864,Tacrolimus
<,15982304,Peak concentrations,"Peak concentrations after first ointment application were </=2.8 ng per mL, and the mean area under the concentration-time curve between 0 and 12 h using the trapezoidal rule (AUC(0-12)) values were 1.1, 1.6, and 4.8 ng h per mL for Groups 1, 2, and 3, respectively.",Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15982304/),[ng] / [ml],2.8,250630,DB00864,Tacrolimus
,15982304,area under the concentration-time curve between 0 and 12 h using the trapezoidal rule (AUC(0-12)),"Peak concentrations after first ointment application were </=2.8 ng per mL, and the mean area under the concentration-time curve between 0 and 12 h using the trapezoidal rule (AUC(0-12)) values were 1.1, 1.6, and 4.8 ng h per mL for Groups 1, 2, and 3, respectively.",Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15982304/),[h·ng] / [ml],1.1,250631,DB00864,Tacrolimus
,15982304,area under the concentration-time curve between 0 and 12 h using the trapezoidal rule (AUC(0-12)),"Peak concentrations after first ointment application were </=2.8 ng per mL, and the mean area under the concentration-time curve between 0 and 12 h using the trapezoidal rule (AUC(0-12)) values were 1.1, 1.6, and 4.8 ng h per mL for Groups 1, 2, and 3, respectively.",Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15982304/),[h·ng] / [ml],1.6,250632,DB00864,Tacrolimus
,15982304,area under the concentration-time curve between 0 and 12 h using the trapezoidal rule (AUC(0-12)),"Peak concentrations after first ointment application were </=2.8 ng per mL, and the mean area under the concentration-time curve between 0 and 12 h using the trapezoidal rule (AUC(0-12)) values were 1.1, 1.6, and 4.8 ng h per mL for Groups 1, 2, and 3, respectively.",Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15982304/),[h·ng] / [ml],4.8,250633,DB00864,Tacrolimus
,17587705,AUC(0-12 h) h,The MPA AUC(0-12 h) h values in the cyclosporine (CsA) and tacrolimus (FK) groups ranged from 13.11 to 50.98 mug .,Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients: comparison of cyclosporin and tacrolimus treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587705/),μg,13.11 to 50.98,251342,DB00864,Tacrolimus
,18695635,dose-adjusted AUC0-12,"On the other hand, the median dose-adjusted AUC0-12 of MPAG in SLCO1B1 1a/1a+1a/1b+1b+1b (n = 53) and 1a/*15 + 1b/*15+*15/*15 (n = 27) were 1549 and 1134 mg.h L g, respectively (P = 0.03004 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1549,251844,DB00864,Tacrolimus
,18695635,dose-adjusted AUC0-12,"On the other hand, the median dose-adjusted AUC0-12 of MPAG in SLCO1B1 1a/1a+1a/1b+1b+1b (n = 53) and 1a/*15 + 1b/*15+*15/*15 (n = 27) were 1549 and 1134 mg.h L g, respectively (P = 0.03004 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1134,251845,DB00864,Tacrolimus
,18695635,dose,"The median dose-adjusted AUC0-12 of MPAG in SLCO1B3 334T/T+T/G (699G/G+G/A, n = 46) and 334G/G (699A/A, n = 34) was 1191 and 1580 mg.h L g, respectively (P = 0.02792 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1191,251846,DB00864,Tacrolimus
,18695635,dose,"The median dose-adjusted AUC0-12 of MPAG in SLCO1B3 334T/T+T/G (699G/G+G/A, n = 46) and 334G/G (699A/A, n = 34) was 1191 and 1580 mg.h L g, respectively (P = 0.02792 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1580,251847,DB00864,Tacrolimus
,18695635,AUC0-12,"The median dose-adjusted AUC0-12 of MPAG in SLCO1B3 334T/T+T/G (699G/G+G/A, n = 46) and 334G/G (699A/A, n = 34) was 1191 and 1580 mg.h L g, respectively (P = 0.02792 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1191,251848,DB00864,Tacrolimus
,18695635,AUC0-12,"The median dose-adjusted AUC0-12 of MPAG in SLCO1B3 334T/T+T/G (699G/G+G/A, n = 46) and 334G/G (699A/A, n = 34) was 1191 and 1580 mg.h L g, respectively (P = 0.02792 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1580,251849,DB00864,Tacrolimus
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],3.88,252560,DB00864,Tacrolimus
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],4.54,252561,DB00864,Tacrolimus
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],4.94,252562,DB00864,Tacrolimus
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],2040,252563,DB00864,Tacrolimus
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],2757,252564,DB00864,Tacrolimus
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],3297,252565,DB00864,Tacrolimus
,21618566,terminal elimination half-life (t(½)),Coadministration with telaprevir increased the terminal elimination half-life (t(½)) of cyclosporine from a mean (standard deviation [SD]) of 12 (1.67) hours to 42.1 (11.3) hours and t(½) of tacrolimus from a mean (SD) of 40.7 (5.85) hours to 196 (159) hours.,Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618566/),h,12,254143,DB00864,Tacrolimus
,21618566,terminal elimination half-life (t(½)),Coadministration with telaprevir increased the terminal elimination half-life (t(½)) of cyclosporine from a mean (standard deviation [SD]) of 12 (1.67) hours to 42.1 (11.3) hours and t(½) of tacrolimus from a mean (SD) of 40.7 (5.85) hours to 196 (159) hours.,Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618566/),h,42.1,254144,DB00864,Tacrolimus
,21618566,t(½),Coadministration with telaprevir increased the terminal elimination half-life (t(½)) of cyclosporine from a mean (standard deviation [SD]) of 12 (1.67) hours to 42.1 (11.3) hours and t(½) of tacrolimus from a mean (SD) of 40.7 (5.85) hours to 196 (159) hours.,Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618566/),h,40.7,254145,DB00864,Tacrolimus
,21618566,t(½),Coadministration with telaprevir increased the terminal elimination half-life (t(½)) of cyclosporine from a mean (standard deviation [SD]) of 12 (1.67) hours to 42.1 (11.3) hours and t(½) of tacrolimus from a mean (SD) of 40.7 (5.85) hours to 196 (159) hours.,Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21618566/),h,196,254146,DB00864,Tacrolimus
,8605372,steady state,FK506 doses were adjusted to target a steady state or trough blood level between 10 to 30 ng/mL.,FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8605372/),[ng] / [ml],10 to 30,254585,DB00864,Tacrolimus
,8605372,trough blood level,FK506 doses were adjusted to target a steady state or trough blood level between 10 to 30 ng/mL.,FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8605372/),[ng] / [ml],10 to 30,254586,DB00864,Tacrolimus
,8605372,half-life,Whole blood pharmacokinetic parameters indicated a half-life of 18.2 +/- 12.1 hours; volume of distribution of 1.67 +/- 1.02 L/kg; clearance of 71 +/- 34 mL/h/kg; and bioavailability of 32 +/- 24%.,FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8605372/),h,18.2,254587,DB00864,Tacrolimus
,8605372,volume of distribution,Whole blood pharmacokinetic parameters indicated a half-life of 18.2 +/- 12.1 hours; volume of distribution of 1.67 +/- 1.02 L/kg; clearance of 71 +/- 34 mL/h/kg; and bioavailability of 32 +/- 24%.,FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8605372/),[l] / [kg],1.67,254588,DB00864,Tacrolimus
,8605372,clearance,Whole blood pharmacokinetic parameters indicated a half-life of 18.2 +/- 12.1 hours; volume of distribution of 1.67 +/- 1.02 L/kg; clearance of 71 +/- 34 mL/h/kg; and bioavailability of 32 +/- 24%.,FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8605372/),[ml] / [h·kg],71,254589,DB00864,Tacrolimus
,8605372,bioavailability,Whole blood pharmacokinetic parameters indicated a half-life of 18.2 +/- 12.1 hours; volume of distribution of 1.67 +/- 1.02 L/kg; clearance of 71 +/- 34 mL/h/kg; and bioavailability of 32 +/- 24%.,FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8605372/),%,32,254590,DB00864,Tacrolimus
,29691732,Apparent clearance,"Apparent clearance and dose/weight to reach the target trough concentration (C0) were significantly higher in the expresser group than in the non-expresser group (0.32 vs. 0.19 L/h/kg, p = 0.0003; 0.052 vs. 0.034 mg/kg/day, p = 0.0002); there were no significant differences in the area under the concentration-time curve from 0 to 12 h (AUC0-12) and concentrations at any sampling time point between the two groups.",Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691732/),[l] / [h·kg],0.32,254982,DB00864,Tacrolimus
,29691732,dose/weight to reach the target trough concentration (C0),"Apparent clearance and dose/weight to reach the target trough concentration (C0) were significantly higher in the expresser group than in the non-expresser group (0.32 vs. 0.19 L/h/kg, p = 0.0003; 0.052 vs. 0.034 mg/kg/day, p = 0.0002); there were no significant differences in the area under the concentration-time curve from 0 to 12 h (AUC0-12) and concentrations at any sampling time point between the two groups.",Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691732/),[l] / [h·kg],0.19,254983,DB00864,Tacrolimus
,29691732,dose/weight to reach the target trough concentration (C0),"Apparent clearance and dose/weight to reach the target trough concentration (C0) were significantly higher in the expresser group than in the non-expresser group (0.32 vs. 0.19 L/h/kg, p = 0.0003; 0.052 vs. 0.034 mg/kg/day, p = 0.0002); there were no significant differences in the area under the concentration-time curve from 0 to 12 h (AUC0-12) and concentrations at any sampling time point between the two groups.",Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29691732/),,0,254984,DB00864,Tacrolimus
,10348790,Cmax,"Tacrolimus was absorbed rapidly after oral dosing with a mean Cmax and Tmax of 42 ng/ml and 1 h, respectively.",The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348790/),[ng] / [ml],42,255362,DB00864,Tacrolimus
,10348790,Tmax,"Tacrolimus was absorbed rapidly after oral dosing with a mean Cmax and Tmax of 42 ng/ml and 1 h, respectively.",The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348790/),h,1,255363,DB00864,Tacrolimus
,10348790,oral bioavailability,The oral bioavailability was about 20%.,The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348790/),%,20,255364,DB00864,Tacrolimus
,10348790,total body clearance,The mean total body clearance at 37.5 ml/min was equivalent to about 3% of the liver blood flow.,The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348790/),[ml] / [min],37.5,255365,DB00864,Tacrolimus
,10348790,elimination half-life,The mean elimination half-life was 44 h.,The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10348790/),h,44,255366,DB00864,Tacrolimus
,23328499,50% inhibition concentration (IC50),"SN-38 glucuronidation in human and rat liver microsomes was inhibited dose-dependently by the presence of tacrolimus and the 50% inhibition concentration (IC50) values of tacrolimus in rat and human liver microsomes were 10.33 μM and 3.58 μM, respectively.","[Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328499/),μM,10.33,256392,DB00864,Tacrolimus
,23328499,50% inhibition concentration (IC50),"SN-38 glucuronidation in human and rat liver microsomes was inhibited dose-dependently by the presence of tacrolimus and the 50% inhibition concentration (IC50) values of tacrolimus in rat and human liver microsomes were 10.33 μM and 3.58 μM, respectively.","[Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328499/),μM,3.58,256393,DB00864,Tacrolimus
,23328499,inhibition constant (Ki),"When the inhibition type was determined by Lineweaver-Burk and Dixon plots, the inhibition was noncompetitive and the calculated inhibition constant (Ki) values for rat and human liver microsomes were 12.57 μM and 3.88 μM, respectively.","[Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328499/),μM,12.57,256394,DB00864,Tacrolimus
,23328499,inhibition constant (Ki),"When the inhibition type was determined by Lineweaver-Burk and Dixon plots, the inhibition was noncompetitive and the calculated inhibition constant (Ki) values for rat and human liver microsomes were 12.57 μM and 3.88 μM, respectively.","[Effect of tacrolimus on the pharmacokinetics and glucuronidation of SN-38, an active metabolite of irinotecan]. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23328499/),μM,3.88,256395,DB00864,Tacrolimus
,10468022,total clearance (CLtot),"The value of the total clearance (CLtot) for knockout mice (19.3 mL/min/kg) was about 1/3 of that for normal mice (55.8 mL/min/kg)(P < 0.001), although there was no significant difference in the distribution volume at the steady-state (Vd(ss)) (about 4.6 L/kg) between both types of mice.",P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468022/),[ml] / [kg·min],19.3,257263,DB00864,Tacrolimus
,10468022,total clearance (CLtot),"The value of the total clearance (CLtot) for knockout mice (19.3 mL/min/kg) was about 1/3 of that for normal mice (55.8 mL/min/kg)(P < 0.001), although there was no significant difference in the distribution volume at the steady-state (Vd(ss)) (about 4.6 L/kg) between both types of mice.",P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468022/),[ml] / [kg·min],55.8,257264,DB00864,Tacrolimus
,10468022,distribution volume at the steady-state (Vd(ss)),"The value of the total clearance (CLtot) for knockout mice (19.3 mL/min/kg) was about 1/3 of that for normal mice (55.8 mL/min/kg)(P < 0.001), although there was no significant difference in the distribution volume at the steady-state (Vd(ss)) (about 4.6 L/kg) between both types of mice.",P-glycoprotein-dependent disposition kinetics of tacrolimus: studies in mdr1a knockout mice. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10468022/),[l] / [kg],4.6,257265,DB00864,Tacrolimus
,17201457,Oral bioavailability,"Oral bioavailability of MPA, subsequent to mycophenolate mofetil administration, ranges from 80.7% to 94%.",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,80.7,258222,DB00864,Tacrolimus
,17201457,Oral bioavailability,"Oral bioavailability of MPA, subsequent to mycophenolate mofetil administration, ranges from 80.7% to 94%.",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,94,258223,DB00864,Tacrolimus
,17201457,absolute bioavailability,EC-mycophenolate sodium has an absolute bioavailability of MPA of approximately 72%.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,72,258224,DB00864,Tacrolimus
,17201457,lag time in absorption,EC-mycophenolate sodium exhibits a median lag time in absorption of MPA from 0.25 to 1.25 hours.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),h,0.25 to 1.25,258225,DB00864,Tacrolimus
,17201457,elimination half-life,The mean elimination half-life of MPA ranges from 9 to 17 hours.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),h,9 to 17,258226,DB00864,Tacrolimus
,17201457,CL/F,"In population pharmacokinetic studies, MPA CL/F in adults ranges from 14.1 to 34.9 L/h (ciclosporin co-therapy) and from 11.9 to 25.4 L/h (tacrolimus co-therapy).",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),[l] / [h],14.1 to 34.9,258227,DB00864,Tacrolimus
,17201457,CL/F,"In population pharmacokinetic studies, MPA CL/F in adults ranges from 14.1 to 34.9 L/h (ciclosporin co-therapy) and from 11.9 to 25.4 L/h (tacrolimus co-therapy).",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),[l] / [h],11.9 to 25.4,258228,DB00864,Tacrolimus
,17201457,AUC from 0 to 12 hours (AUC12),Targeting a total MPA AUC from 0 to 12 hours (AUC12) of 30-60 mg.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),mg,30-60,258229,DB00864,Tacrolimus
,23507258,Maximum concentrations,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),μ,6.2,258730,DB00864,Tacrolimus
,23507258,terminal half-lives,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),μ,6.2,258731,DB00864,Tacrolimus
,23507258,dose-normalized AUC,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),[dayg] / [ml],374,258732,DB00864,Tacrolimus
,23507258,dose-normalized AUC,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),[dayg] / [ml],508,258733,DB00864,Tacrolimus
<,23507258,Time to sub-therapeutic levels,"Time to sub-therapeutic levels (<1μg/mL) of active rATG was significantly shorter in Group 1 (18.75±6.9days versus 20±7.5days in Group 2, p<0.001).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),d,1,258734,DB00864,Tacrolimus
,23507258,Time to sub-therapeutic levels,"Time to sub-therapeutic levels (<1μg/mL) of active rATG was significantly shorter in Group 1 (18.75±6.9days versus 20±7.5days in Group 2, p<0.001).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),d,18.75,258735,DB00864,Tacrolimus
,23507258,Time to sub-therapeutic levels,"Time to sub-therapeutic levels (<1μg/mL) of active rATG was significantly shorter in Group 1 (18.75±6.9days versus 20±7.5days in Group 2, p<0.001).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),d,20,258736,DB00864,Tacrolimus
,30377942,apparent clearance,"The apparent clearance value for tacrolimus was 17.9 l/h (6.95% relative standard error) in our model, which is lower compared with similar subjects on corticosteroid-based therapy.",Population Pharmacokinetic Analysis of Immediate-Release Oral Tacrolimus Co-administered with Mycophenolate Mofetil in Corticosteroid-Free Adult Kidney Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30377942/),[l] / [h],17.9,259008,DB00864,Tacrolimus
,28025957,Hill coefficient H,The pharmacodynamic parameters of the action of tacrolimus were estimated with the Hill coefficient H at 1.5 and the CE50 at 6.7 ng/mL.,Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025957/),[ng] / [ml],1.5,259787,DB00864,Tacrolimus
,28025957,CE50,The pharmacodynamic parameters of the action of tacrolimus were estimated with the Hill coefficient H at 1.5 and the CE50 at 6.7 ng/mL.,Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients . ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025957/),[ng] / [ml],6.7,259788,DB00864,Tacrolimus
,28025957,ceiling concentration,"Accordingly, the pharmacodynamic threshold concentration was estimated at 0.9 ng/mL and the ceiling concentration at 48 ng/mL, indicating a wide span between target trough and peak levels.",Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025957/),[ng] / [ml],48,259789,DB00864,Tacrolimus
,23666572,C0/dose,"The dose-standardized exposure to TAC significantly and progressively increased in the months after transplantation: from month (M) 1 to M9 C0/dose increased from 2.33 to 3.44 mcg·L(1)·mg(1) and AUC/dose from 43.1 to 64.2 mcg·h(1)·L(1)·mg(1), respectively.",Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666572/),l(1)·mcg·mg(1,2,260235,DB00864,Tacrolimus
,23666572,C0/dose,"The dose-standardized exposure to TAC significantly and progressively increased in the months after transplantation: from month (M) 1 to M9 C0/dose increased from 2.33 to 3.44 mcg·L(1)·mg(1) and AUC/dose from 43.1 to 64.2 mcg·h(1)·L(1)·mg(1), respectively.",Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666572/),l(1)·mcg·mg(1,3,260236,DB00864,Tacrolimus
,23666572,AUC/dose,"The dose-standardized exposure to TAC significantly and progressively increased in the months after transplantation: from month (M) 1 to M9 C0/dose increased from 2.33 to 3.44 mcg·L(1)·mg(1) and AUC/dose from 43.1 to 64.2 mcg·h(1)·L(1)·mg(1), respectively.",Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666572/),h(1)·l(1)·mcg·mg,43.1,260237,DB00864,Tacrolimus
,23666572,AUC/dose,"The dose-standardized exposure to TAC significantly and progressively increased in the months after transplantation: from month (M) 1 to M9 C0/dose increased from 2.33 to 3.44 mcg·L(1)·mg(1) and AUC/dose from 43.1 to 64.2 mcg·h(1)·L(1)·mg(1), respectively.",Lessons from routine dose adjustment of tacrolimus in renal transplant patients based on global exposure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23666572/),h(1)·l(1)·mcg·mg,64.2,260238,DB00864,Tacrolimus
,24548445,AUC0-12 h,There were variable MPA AUC0-12 h levels between 14 and 67 mg×h/L (mean: 37 ± 14).,[Use of limited sampling strategy for estimating area under concentration-versus-time curve of mycophenolate sodium in renal allograft recipients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24548445/),,37,260384,DB00864,Tacrolimus
,18476801,C(max),"One (1) h after an instillation of the 1% suspension, ocular tissue concentrations, except the retina/choroid, vitreous body, and lens, were higher than the blood concentration (C(max): 2.7 ng/mL).",Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18476801/),[ng] / [ml],2.7,260766,DB00864,Tacrolimus
,18476801,AUC(0-24h),"In the i.v. dose study, AUC(0-24h) and T(1/2) were 1643 ng h/mL and 18.5 h, respectively.",Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18476801/),[h·ng] / [ml],1643,260767,DB00864,Tacrolimus
,18476801,T(1/2),"In the i.v. dose study, AUC(0-24h) and T(1/2) were 1643 ng h/mL and 18.5 h, respectively.",Pharmacokinetics and tissue distribution of tacrolimus (FK506) after a single or repeated ocular instillation in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18476801/),h,18.5,260768,DB00864,Tacrolimus
,22210422,C/Ds,The C/Ds were significantly lower in EX-R/EX-D (median: 122.3 at 2 weeks) than in NEX-R/NEX-D (389.6 at 2 weeks) until 12 months.,Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210422/),,122.3,260880,DB00864,Tacrolimus
,22210422,C/Ds,The C/Ds were significantly lower in EX-R/EX-D (median: 122.3 at 2 weeks) than in NEX-R/NEX-D (389.6 at 2 weeks) until 12 months.,Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210422/),,389.6,260881,DB00864,Tacrolimus
,22210422,C/Ds,The C/Ds in EX-R/NEX-D (163.2 at 2 weeks) have been significantly lower than those in NEX-R/NEX-D until 6 months.,Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22210422/),,163.2,260882,DB00864,Tacrolimus
,18502461,C(max),"The mean prednisolone C(max) for recipients (n=14) having both the ABCB1 3435CC genotype and the CYP3A5*3/*3 genotype was significantly higher than those (n=11) having both ABCB1 3435TT and CYP3A5*3/*3 genotypes (180ng/mL versus 129ng/mL, P=0.0392).","Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502461/),[ng] / [ml],180,261505,DB00864,Tacrolimus
,18502461,C(max),"The mean prednisolone C(max) for recipients (n=14) having both the ABCB1 3435CC genotype and the CYP3A5*3/*3 genotype was significantly higher than those (n=11) having both ABCB1 3435TT and CYP3A5*3/*3 genotypes (180ng/mL versus 129ng/mL, P=0.0392).","Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502461/),[ng] / [ml],129,261506,DB00864,Tacrolimus
,21574884,ma68,"Algorithm calculated and trapezoidal extrapolated AUC(0-12) values showed high correlation (r=0.995) and acceptable dispersion (ma68=0.71 μg·h/mL), median prediction error (6.6%) and median absolute prediction error (12.6%).",Diagnostic efficiency of truncated area under the curve from 0 to 2 h (AUC₀₋₂) of mycophenolic acid in kidney transplant recipients receiving mycophenolate mofetil and concomitant tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21574884/),[h·μg] / [ml],0.71,263267,DB00864,Tacrolimus
,21574884,ma68,"However, due to the high inter-individual variation of the drug absorption-rate, the dispersion between both pharmacokinetic variables (ma68=6.9 μg·h/mL) was unacceptable.",Diagnostic efficiency of truncated area under the curve from 0 to 2 h (AUC₀₋₂) of mycophenolic acid in kidney transplant recipients receiving mycophenolate mofetil and concomitant tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21574884/),[h·μg] / [ml],6.9,263268,DB00864,Tacrolimus
,17875118,trough blood concentration,The relative standard errors (%RSE) of the parameter estimation were lower than 30% and the residual variability of tacrolimus trough blood concentration was 2.81 ng/mL.,"Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17875118/),[ng] / [ml],2.81,263891,DB00864,Tacrolimus
,15919447,area under the concentration-time curve (AUC0-12),"The dose-adjusted area under the concentration-time curve (AUC0-12) was significantly lower among CYP3A5*1 carriers than those bearing CYP3A5*3/*3. (0.570 +/- 0.105 vs 0.865 +/- 0.343 ng.h/mL per mg/kg, P = .00322).",Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919447/),[h·ng] / [kg·mg·ml],0.570,264477,DB00864,Tacrolimus
,15919447,area under the concentration-time curve (AUC0-12),"The dose-adjusted area under the concentration-time curve (AUC0-12) was significantly lower among CYP3A5*1 carriers than those bearing CYP3A5*3/*3. (0.570 +/- 0.105 vs 0.865 +/- 0.343 ng.h/mL per mg/kg, P = .00322).",Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15919447/),[h·ng] / [kg·mg·ml],0.865,264478,DB00864,Tacrolimus
,16213338,area under the concentration-time curve (AUC),"There was no appreciable peak in tacrolimus concentration, and the area under the concentration-time curve (AUC) was 10.9 ng/mL/h.",Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213338/),[ng] / [h·ml],10.9,264613,DB00864,Tacrolimus
,16213338,AUC,"Furthermore, the AUC increased 90% to 20.7 ng/mL/h.",Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213338/),[ng] / [h·ml],20.7,264614,DB00864,Tacrolimus
,16044097,CL/F,"The population estimate of tacrolimus CL/F and apparent volume of distribution (V/F) were found to be 21.3 L/h (95% confidence interval, CI, 18.0-24.6 L/h) and 316.1 L (95% CI 133-495 L), respectively.",Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044097/),[l] / [h],21.3,264892,DB00864,Tacrolimus
,16044097,apparent volume of distribution (V/F),"The population estimate of tacrolimus CL/F and apparent volume of distribution (V/F) were found to be 21.3 L/h (95% confidence interval, CI, 18.0-24.6 L/h) and 316.1 L (95% CI 133-495 L), respectively.",Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044097/),l,316.1,264893,DB00864,Tacrolimus
,14749696,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[ng] / [ml],122.2,265126,DB00864,Tacrolimus
,14749696,area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)],"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[h·ng] / [ml],264.1,265127,DB00864,Tacrolimus
,14749696,time of peak concentration (t(max)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.1,265128,DB00864,Tacrolimus
,14749696,elimination half-life (t(1/2)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.2,265129,DB00864,Tacrolimus
,21796700,AUC(0-24h),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],280.8,265395,DB00864,Tacrolimus
,21796700,AUC(0-24h),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],543.5,265396,DB00864,Tacrolimus
,21796700,C(max),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[ng] / [ml],44.6,265397,DB00864,Tacrolimus
,21796700,C(max),"After pretreatment with WZ, there were significant increases in the AUC(0-24h) of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C(max) (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05).",Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[ng] / [ml],86.8,265398,DB00864,Tacrolimus
,21796700,AUC(0-24h),The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],163.6,265399,DB00864,Tacrolimus
,21796700,AUC(0-24h),The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[h·ng] / [ml],212.7,265400,DB00864,Tacrolimus
,21796700,clearance,The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[l] / [h·kg],3.2,265401,DB00864,Tacrolimus
,21796700,clearance,The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC(0-24h) (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05).,Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21796700/),[l] / [h·kg],2.2,265402,DB00864,Tacrolimus
,14703922,t(1/2),"There was no significant difference between concentrations of tacrolimus in blood sampled at inflow port and outflow port sites and t(1/2)-values of tacrolimus in the three recipients were 29.9, 63.6 and 28.8 h.",Influence of continuous venovenous haemodiafiltration on the pharmacokinetics of tacrolimus in liver transplant recipients with small-for-size grafts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703922/),h,29.9,265955,DB00864,Tacrolimus
,14703922,t(1/2),"There was no significant difference between concentrations of tacrolimus in blood sampled at inflow port and outflow port sites and t(1/2)-values of tacrolimus in the three recipients were 29.9, 63.6 and 28.8 h.",Influence of continuous venovenous haemodiafiltration on the pharmacokinetics of tacrolimus in liver transplant recipients with small-for-size grafts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703922/),h,63.6,265956,DB00864,Tacrolimus
,14703922,t(1/2),"There was no significant difference between concentrations of tacrolimus in blood sampled at inflow port and outflow port sites and t(1/2)-values of tacrolimus in the three recipients were 29.9, 63.6 and 28.8 h.",Influence of continuous venovenous haemodiafiltration on the pharmacokinetics of tacrolimus in liver transplant recipients with small-for-size grafts. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703922/),h,28.8,265957,DB00864,Tacrolimus
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],3145,266003,DB00864,Tacrolimus
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],384,266004,DB00864,Tacrolimus
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],4218,266005,DB00864,Tacrolimus
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],587,266006,DB00864,Tacrolimus
,17358097,R/S ratio,The mean R/S ratio for AUC of lansoprazole in each CYP3A5 genotype group was the same (12.6).,Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),,12.6,266007,DB00864,Tacrolimus
,18417431,recoveries,The recoveries of liquid-liquid extraction method were 58.3-62.6% for FK506 and 50.4-58.8% for DTZ.,Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: application to a clinical drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18417431/),%,58.3-62.6,266552,DB00864,Tacrolimus
,18417431,recoveries,The recoveries of liquid-liquid extraction method were 58.3-62.6% for FK506 and 50.4-58.8% for DTZ.,Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: application to a clinical drug-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18417431/),%,50.4-58.8,266553,DB00864,Tacrolimus
,22500920,AUC((0-6h)),Estimates for AUC((0-6h)) were 0.923 (0.865; 0.984) h*μg/ml and 0.985 (0.877; 1.106) μg/ml for C(min).,Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500920/),[h·μg] / [ml],0.923,267057,DB00864,Tacrolimus
,22500920,C(min),Estimates for AUC((0-6h)) were 0.923 (0.865; 0.984) h*μg/ml and 0.985 (0.877; 1.106) μg/ml for C(min).,Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500920/),[μg] / [ml],0.985,267058,DB00864,Tacrolimus
,28030534,-,"Patients off steroids had a higher dose-adjusted MPA-AUC (0.18 mg·h/L per mg/m, 0.012-0.27) compared with patients on steroids (0.12 mg·h·L·mg, 0.09-0.19; P = 0.04).",Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28030534/),[h·mg] / [l·m·mg],0.18,267154,DB00864,Tacrolimus
,28030534,AUC,"Patients off steroids had a higher dose-adjusted MPA-AUC (0.18 mg·h/L per mg/m, 0.012-0.27) compared with patients on steroids (0.12 mg·h·L·mg, 0.09-0.19; P = 0.04).",Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28030534/),[h·mg] / [l·m·mg],0.18,267155,DB00864,Tacrolimus
,28030534,AUC,"Patients off steroids had a higher dose-adjusted MPA-AUC (0.18 mg·h/L per mg/m, 0.012-0.27) compared with patients on steroids (0.12 mg·h·L·mg, 0.09-0.19; P = 0.04).",Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28030534/),h·l·mg·mg,0.12,267156,DB00864,Tacrolimus
less,32250458,ki,All three compounds showed a strong reversible inhibition on CYP2C8 enzyme with ki of less than 0.5 μmol L-1 .,"Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),[μM] / [l],0.5,267402,DB00864,Tacrolimus
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.0,267403,DB00864,Tacrolimus
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.1,267404,DB00864,Tacrolimus
,32250458,AUC ratio,"The verified PBPK models were able to describe the increase in systemic exposure of midazolam and tacrolimus due to co-administration of S. sphenanthera, consistent with the reported changes in the corresponding clinical interaction study (AUC ratio of 2.0 vs 2.1 and 2.4 vs 2.1, respectively).","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,2.4,267405,DB00864,Tacrolimus
,32250458,AUC ratio,"The PBPK simulation predicted that at recommended dosing regimens of S. sphenanthera, co-administration would result in an increase in bosutinib exposure (AUC ratio 3.0) but not in imatinib exposure.","Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32250458/),,3.0,267406,DB00864,Tacrolimus
,20832577,concentration-dose ratio,"The mean (SD) concentration-dose ratio of tacrolimus in all patients at 1, 4, 8, and 24 hours after concomitant administration of micafungin was 607 ± 306, 653 ± 328, 699 ± 340 and 671 ± 403 (ng/mL)/(mg/kg/d), respectively, and without micafungin was 756 ± 314 (ng/mL)/(mg/kg/d).",Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20832577/),[ml·ng] / [d·kg·mg],607,268560,DB00864,Tacrolimus
,20832577,concentration-dose ratio,"The mean (SD) concentration-dose ratio of tacrolimus in all patients at 1, 4, 8, and 24 hours after concomitant administration of micafungin was 607 ± 306, 653 ± 328, 699 ± 340 and 671 ± 403 (ng/mL)/(mg/kg/d), respectively, and without micafungin was 756 ± 314 (ng/mL)/(mg/kg/d).",Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20832577/),[ml·ng] / [d·kg·mg],653,268561,DB00864,Tacrolimus
,20832577,concentration-dose ratio,"The mean (SD) concentration-dose ratio of tacrolimus in all patients at 1, 4, 8, and 24 hours after concomitant administration of micafungin was 607 ± 306, 653 ± 328, 699 ± 340 and 671 ± 403 (ng/mL)/(mg/kg/d), respectively, and without micafungin was 756 ± 314 (ng/mL)/(mg/kg/d).",Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20832577/),[ml·ng] / [d·kg·mg],699,268562,DB00864,Tacrolimus
,20832577,concentration-dose ratio,"The mean (SD) concentration-dose ratio of tacrolimus in all patients at 1, 4, 8, and 24 hours after concomitant administration of micafungin was 607 ± 306, 653 ± 328, 699 ± 340 and 671 ± 403 (ng/mL)/(mg/kg/d), respectively, and without micafungin was 756 ± 314 (ng/mL)/(mg/kg/d).",Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20832577/),[ml·ng] / [d·kg·mg],671,268563,DB00864,Tacrolimus
,20832577,concentration-dose ratio,"The mean (SD) concentration-dose ratio of tacrolimus in all patients at 1, 4, 8, and 24 hours after concomitant administration of micafungin was 607 ± 306, 653 ± 328, 699 ± 340 and 671 ± 403 (ng/mL)/(mg/kg/d), respectively, and without micafungin was 756 ± 314 (ng/mL)/(mg/kg/d).",Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20832577/),[ml·ng] / [d·kg·mg],756,268564,DB00864,Tacrolimus
,23588560,Apparent volumes of the central compartment,"Apparent volumes of the central compartment, intercomparmental clearance and maximum blood clearance estimates were 253 L, 115 L/day and 314 L/day, respectively.",Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23588560/),l,253,269332,DB00864,Tacrolimus
,23588560,maximum blood clearance,"Apparent volumes of the central compartment, intercomparmental clearance and maximum blood clearance estimates were 253 L, 115 L/day and 314 L/day, respectively.",Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23588560/),[l] / [d],314,269333,DB00864,Tacrolimus
,23588560,absorption first-order rate,"The absorption first-order rate and volume of peripheral compartment were fixed to 4.5 h(-1) and 100 L, respectively.",Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23588560/),1/[h],4.5,269334,DB00864,Tacrolimus
,23588560,volume of peripheral compartment,"The absorption first-order rate and volume of peripheral compartment were fixed to 4.5 h(-1) and 100 L, respectively.",Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23588560/),l,100,269335,DB00864,Tacrolimus
,31745812,apparent clearance,"The typical value of the apparent clearance was 19.6 L/h (95% CI 16.2-22.9), and the apparent distribution volumes of central and peripheral compartments, V1 and V2, were 231 L (95% CI 199-267) and 521 L (95% CI 441-634), respectively.",High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31745812/),[l] / [h],19.6,270068,DB00864,Tacrolimus
,31745812,V1,"The typical value of the apparent clearance was 19.6 L/h (95% CI 16.2-22.9), and the apparent distribution volumes of central and peripheral compartments, V1 and V2, were 231 L (95% CI 199-267) and 521 L (95% CI 441-634), respectively.",High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31745812/),l,231,270069,DB00864,Tacrolimus
,31745812,V2,"The typical value of the apparent clearance was 19.6 L/h (95% CI 16.2-22.9), and the apparent distribution volumes of central and peripheral compartments, V1 and V2, were 231 L (95% CI 199-267) and 521 L (95% CI 441-634), respectively.",High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31745812/),l,521,270070,DB00864,Tacrolimus
,31745812,relative bioavailability,"Inter-occasion (dose-to-dose) variability far exceeded the interindividual variability (IIV), with an estimated variability in relative bioavailability of 55% (95% CI 48.5-64.4).",High Variability of Whole-Blood Tacrolimus Pharmacokinetics Early After Thoracic Organ Transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31745812/),%,55,270071,DB00864,Tacrolimus
<,29574974,trough levels,"In transplant patients, the approved dose of 0.75-1 mg twice daily (BID) results in subtherapeutic trough levels (<6 μg l-1 ) and that a higher starting dose of 2.25-3 mg BID is required.",A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29574974/),[μg] / [l],6,274094,DB00864,Tacrolimus
